CLINICAL STUDY PROTOCOL  
 
 
NCT Number:   N CT02386839  
 Study Title:  Long -term Outcome of Children Enrolled in Study ROPP -2008- 01 
Previously Treated with rhIGF -1/rhIGFBP -3 for the Prevention of 
Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal 
Care  
  Study Number:  SHP607- 201 
 
Protocol Version and Dat e: 
Original Protocol:  27 Aug  2014 
Amendment 1:  19 Feb 2016  
Amendment 2:  21 Feb 2017  
Amendment 3:  11 May 2017  
Amendment 4: 09 Apr 2018  
 
For non-commercial use only
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 3Visual acuity as assessed by an age appropriate method
Ocular alignment and ocular motor examination in primary gaze and in as many of 
9positions of gaze as poss ible as assessed by corneal light reflex and by the cover test
Assessment of nystagmus by observation
Refraction as assessed by retinoscopy with cycloplegia
Stereoacuity as assessed with the Lang Stereotest
The secondary efficacy endpoints of this study ar e:
Growth parameters including body weight, body length (or height), and head 
circumference
Cognitive development as assessed by the following standardized, age- appropriate 
tools:
oBayley Scales of Infant and Toddler Development, Third E dition (BSID -III)
oWechsler Preschool and Primary Scale of Inte lligence, Fourth Edition 
(WPPSI- IV)
Physical development as assessed by standardized, age appropriate tools including 
physical exam, neurological examination for assessment of cerebral palsy, and hearing 
assessment
Child behavior as assessed by the following:
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
oChild Behavior Checklist (CBCL; 1 ½ to 5)
oAttention Deficit/Hyperactivity Disorder Rating Scale -fourth edition (ADHD 
RS-IV) for the assessment of symptom s of attention deficit/hyperactivity 
disorder (ADHD)
oSocial Communication Questionnaire (SCQ) for screening of Autism 
Spectrum Disorder (ASD)
Pulmonary morbidity data (eg, hospitalizations, emergency room [ER] visits, 
pulmonary medications)
Survival as assessed by death during the study due to any cause
The health economic outcome research endpoints of this study are:
Health- related quality of l ife (HRQoL) will be assessed by the Pediatric Quality of Life 
Inventory (PedsQL™) Scales appropriate for the child's age of development with the 
Total Scale Score and 5 domains within Physical Health (Physical Functioning and 
Physical Symptoms) and Psychosocial Health Scores (Emotional, Social, and 
Cognitive Functioning, respectively)
Health status (eg, health u tility) will be measured by the Health Status Classification 
System -Preschool (HSCS- PS) 
Resource use associated with inpatient visits, outpatient visits, medical utilization and  
pharmacy utilization will be assessed 
The safety endpoints of this study are:
Physical examination including tonsil examination
For non-commercial use only
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 5Continuous variables will be summarized using descriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categori cal variables will be summarized using frequencies and percentages.
As referred to in descriptions of summary statistics, treatment groups refer to the 2 possible 
treatment assignments in the antecedent study, ROPP -2008- 01, Section D (rhIGF -1/rhI GFBP -3 or 
standard neonatal care).
For analysis purposes, baseline is defined as the first assessment either in the antecedent study 
(ROPP-2008- 01) or in this study (SHP -607-201). As necessary , relevant data from Study 
ROPP -2008- 01 may be summarized with the data fr om this study (SHP -607- 201).
Date of Original Protocol :  27August 2014
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 6TABLE OF  CONTENTS
SYNOPSI S.................................................................................................................................2
LIST OF IN -TEXT TABLES ..................................................................................................10
LIST OF IN -TEXT FIGURES .................................................................................................10
LIST OF ABBREVIATION S..................................................................................................11
1 INTRODUCTION ...........................................................................................................13
2 STUDY OBJECTIVES ....................................................................................................15
2.1 Primary  Objectives .................................................................................................15
2.2 Secondary  Objectiv es.............................................................................................15
2.3 Exploratory  Objective ................................
............................................................15
3 STUDY ENDPOINTS .....................................................................................................16
3.1 Efficac y Endpoints .................................................................................................16
3.1.1 Primary  Efficacy  Endpoints .........................................................................16
3.1.2 Secondary  Efficacy  Endpoints .....................................................................16
3.2 Health Economic Outcome Research Endpoints ...................................................17
3.3 Safety  Endpoints ....................................................................................................17
3.4 Exploratory  Endpoints ...........................................................................................17
4 INVESTIGATIONAL PLAN ..........................................................................................18
4.1 Overall Study  Design and Plan ..............................................................................18
4.2 Ratio nale for Study  Design ....................................................................................19
4.3 Study  Duration .......................................................................................................20
5 STUDY POPUL ATION SEL ECTION ...........................................................................21
5.1 Study  Population ....................................................................................................21
5.2 Inclusion Criteria ................................
...................................................................21
5.3 Exclusion Criteria ..................................................................................................21
6 STUDY TREATMENT ...................................................................................................22
6.1 Description of Treatment .......................................................................................22
6.2 Treatments Administered .......................................................................................22
6.3 Selection and Timing of Dose for Each Subject ................................ .................... 22
6.4 Method of Assigning Subjects to Treatment Groups ................................ ............. 22
6.5 Masking ................................ ................................ ................................ .................. 22
6.6 Medications ................................ ................................ ................................ ............ 22
6.7 Restrictions ............................................................................................................22
6.7.1 Prior Therap y ...............................................................................................22
6.7.2 Other Restrictions ................................ ................................ ........................ 22
6.7.3 Treatment Compliance ................................ ................................ ................. 22
6.7.4 Packaging and Labeling ................................ ................................ ............... 22
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 76.8 Storage and Accountability ................................ ................................ .................... 23
7 STUDY PROCEDURES .................................................................................................24
7.1 Informed Consent ...................................................................................................24
7.2 Study  Entrance Criteria and Eligibility ..................................................................24
7.3 Study  Enrollment ...................................................................................................24
7.4 Demographics ........................................................................................................24
7.5 Growth Parameters:  Length (and Height), Weight, and Head Circumference.....24
7.5.1 Length and Height ........................................................................................24
7.5.2 Body Weight ................................................................................................25
7.5.3 Head Circumference ....................................................................................25
7.6 Efficacy  Assessments .............................................................................................25
7.6.1 Visual Assessments ......................................................................................25
7.6.1.1 Visual Acuity .....................................................................................25
7.6.1.2 Corrective Lens Determination..........................................................26
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility ) .............26
7.6.1.4 Refraction with C ycloplegia ..............................................................
27
7.6.1.5 Stereoacuit y........................................................................................27
7.6.1.6
7.6.2 Hearing Assessment History ........................................................................28
7.6.3 Behavioral Assessments ...............................................................................28
7.6.3.1 Bayley Scales of Infant and Toddler Development, Third Edition....28
7.6.3.2 Wechsler Preschool and Primary  Scale of Intelligence, Fourth 
Edition (WPPSI -IV)...........................................................................28
7.6.3.3 Child Behavior Checklist (CBCL)
.....................................................29
7.6.3.4 Vineland Adaptive Behavior Scales, Second Edition
........................29
7.6.3.5 Attention- Deficit/Hy peractivity  Disorder Rating Scale -Fourth 
Edition ................................
................................................................29
7.6.3.6 Social Communication Questionnaire –Lifetime Form ....................30
7.6.4 Cerebral Pals y Assessment ..........................................................................30
7.6.5 Pulmonary  Morbidit y Assessment ................................ ............................... 30
7.6.6 Survival Assessment ....................................................................................30
7.6.7 Health Economic Outcome Research Assessments.....................................30
7.6.7.1 Health Related Quality  of L ife...........................................................30
7.6.8 Health Care Resource Use ...........................................................................31
7.6.8.1 Health Status Classification Sy stem -Preschool .................................31
7.7
Safety  Assessments ................................ ................................ ................................ 32
7.7.1 Abdominal ultrasound................................ ................................ .................. 32
7.7.2 Echocardiogram ................................ ................................ ........................... 32
7.7.3 Physical Examination ................................ ................................ ................... 32
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 87.8 Medication Assessment ................................ ................................ ......................... 33
7.9 Adverse Events Assessments .................................................................................33
7.9.1 Definitions of Adverse Events, Serious Adverse Events, and Suspected 
Unexpected Serious Adverse Reactions ......................................................33
7.9.1.1 Adverse Event ....................................................................................33
7.9.1.2 Serious Adverse Event .......................................................................34
7.9.1.3 Suspected Unexpected Serious Adverse Reaction.............................35
7.9.1.4 Targeted Medical Events ...................................................................35
7.9.2 Classification of Adverse Events and Serious Adverse Events ...................35
7.9.3 Clarification be tween Serious and Severe ...................................................35
7.9.4 Relatedness of Adverse Events and Serious Adverse Events ......................36
7.9.5 Procedures for Recording and R eporting Adverse Events ..........................36
7.9.5.1 Adverse Event Monitoring and Period of Observation......................36
7.9.5.2 Reporting Serious Adverse Events ....................................................37
7.9.5.3 Regulatory  Agency , Institutional Review Board, Ethics Committee, 
and Site Reporting................................
..............................................38
7.10 Removal of Subjects from the Trial .......................................................................38
7.11 Other Study  Procedures ................................
.........................................................39
7.11.1 Participation in Other Clinical Studies ........................................................39
7.12 Appropriateness of Measurements .........................................................................39
8 STUDY ACTIVIT IES.....................................................................................................40
8.1 Initial Study  Visit (40 weeks CA [term equivalent]) .............................................40
8.2 Study  Visits ................................
............................................................................40
8.2.1 Outcome Assessment Visits Conducted by
 Telephone ...............................40
8.2.2 Clinical Site Visits .......................................................................................41
8.2.2.1 Outcome Assessment Site Visits .......................................................41
8.2.2.2 Visits Dedicated to Cor rective Lens Determination ..........................44
8.3 Assessments upon Discontinuation .......................................................................44
9 QUALITY CONTROL AND ASSURANCE .................................................................45
10 STATI STICAL ANALYSES ..........................................................................................46
10.1 General Methodology ................................ ................................ ............................ 46
10.2 Determination of Sample Size ................................ ................................ ............... 46
10.3 Method of Assigning Study  Subjects to Treatment Groups ..................................46
10.4 Population Description...........................................................................................46
10.4.1 Analy sis Populations ................................ ................................ .................... 46
10.4.2 Subject Disposition ................................ ................................ ...................... 46
10.4.3 Protocol Violations and Deviations ................................ ............................. 47
10.4.4 Demographics and Baseline Characteristics................................ ................ 47
10.5 Efficacy  Anal ysis................................ ................................ ................................ ...47
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 910.5.1 Primary  Efficacy  Anal ysis................................ ................................ ........... 47
10.5.2 Secondary  Efficacy  Analy sis.......................................................................48
10.5.3 Subset Analy ses...........................................................................................49
10.5.4 Exploratory  Anal yses...................................................................................49
10.6 Health Economics and Outcomes Research Anal yses...........................................49
10.7 Analy sis of Safet y..................................................................................................49
10.8 Statistical/Analy tical Issues ...................................................................................50
10.8.1 Adjustment for Covariates ...........................................................................50
10.8.2 Handling of Dropouts or Missing Data ........................................................50
10.8.3 Interim Anal yses and Data Monitoring........................................................50
10.8.4 Multiple Comparisons/Multiplicity .............................................................50
10.8.5 Sensitivity  Anal yses.....................................................................................50
11 ADMINISTRATIVE CONSI DERATIONS................................
....................................51
11.1 Investigators and Study  Administrative Structure .................................................51
11.2 Institutional Review Board or Independent Ethics Committee Approval .............51
11.3 Ethical Conduct of the Study .................................................................................51
11.4 Subject I nformation and Consent ...........................................................................51
11.5 Subject Confidentiality ................................
..........................................................52
11.6 Study  Monitoring ...................................................................................................52
11.7 Case Report Forms and Study  Records ................................
.................................53
11.7.1 Case Report Forms .......................................................................................53
11.7.2 Critical Documents ................................
......................................................53
11.8 Data Monitoring Committee ..................................................................................54
11.9 Protocol Violations/Deviations ................................
..............................................54
11.10 Premature Closure of the Study .............................................................................54
11.11 Access to Source Documentation ..........................................................................55
11.12 Data Generation and Analy sis...............................................................................55
11.13 Retention of Data ...................................................................................................55
11.14 Financial Disclosure ...............................................................................................55
11.15 Publication and Disclosure Policy ................................ ................................ ......... 55
12 LIST OF REFER ENCES ................................ ................................ ................................ .57
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 10LIST OF IN -TEXT TABLES
Table 7-1 Summary  of Visual Acuity  Assessments ................................ ................... 26
Table 7-2 Assessments for Phy sical Examinations ....................................................33
Table 7-3 Adverse Event Severit y..............................................................................35
Table 12-1 Summary  of Visual Acuity  Assessments ...................................................62
LIST OF 
IN-TEXT FIGURES
Figure 4-1 Overview of Study  Design, Study  SHP -607-201.......................................19
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 11LIST OF ABBREVIATIONS
Abbreviation Definition
AAO Americ an Academy of Ophthalmology
ADHD attention -deficit hyperactivity disorder
ADHD -RS-IV Attention -Deficit/ Hypera ctivity Disorder Rating Scale -fourth edition
AE adverse event
ASD Autism Spectrum Disorder
BSID -III Bayley Scales of Infant and Toddler Develo pment, Third Edition
CBCL Child Behavior Checklist (1 ½ to 5)
CFR Code of Federal Regulations
CA corrected age
CI confidence interval
CRF case report form (electronic)
CRO contract research organization
DMC data monitoring committee
eCRF electronic case report form
EOS end of study
ETDRS Early Treatment of Diabetic Retinopathy Study
ER emergency room
EU European Union
FDA Food and Drug Administration
GCP Good Clinical Practice
GH grow th horm one
HRQoL health -related quality of l ife
HSCS -PS Health Status Classification System -Preschool
ICH International Conference on Harmonisation
IEC independent ethics committee
IGF insulin -like growth factor
IGFBP -3 insulin -like growth factor binding protein -3
IND Investigational New Drug application
IRB institutional review board
LV left ventricle
MedDRA Medical Dictionary for Regulatory Activities 
OD right eye
OS left eye
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 12Abbreviation Definition
OU both eyes
PedsQL Pediatric Quality of Life Inventory 
REB research ethics board
ROP retinopathy of prematurity
SAE serious adverse event
SAP statistical analysis plan
SAS Statistical Analysis System©
SCQ Social Communication Questionnaire
SD standard deviation
SOE schedule of events
SUSAR suspected unexpected serious adverse reactio n
UK United Kingdom
US United States
VABS -II Vineland Adaptive Behavior Scales, Second Edition
VLBW very low birth weight
WHO World Health Organization
WHO -DD World Health Organization Drug Dictionary
WPPSI -IV Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 131 INTRODUCTION
Retinopathy  of prematurity  (ROP) is a rare disorder of the developing retinal blood vessels and 
retinal neurons of the preterm infant and is one of the leading causes of preventable blindness in 
children.1
Visual acuity  is decreased in infants with a history  of ROP.2In addition to acuity, other aspects 
of ey e health are also significantly  impacted by  ROP . Strabismus and my opia are clearly  
increased in pat ients with a history  of ROP.3-6  Additionally , more than half of patients at 6 to 
10years of age with a history  of Stage 1 and Stage 2 ROP were reported to have ongoing visual 
issues.7
When preterm infants are deprived of their natural intrauterine environment, they  lose important 
factors normally  found in utero, such as proteins, growth factors and cy tokines . It has been 
demonstrated that IGF -1 is one such factor . During fetal life, IGF -1 is availa ble through placental 
absorption and ingestion from amniotic fluid .8Deprivation of such factors is likely  to cause 
inhibition or improper stimulation of important pathway s, which in the ey e may  cause abnormal 
retinal vascular development, the hallmark of ROP.
The finding in both a mouse model of ROP and preterm infants that development of ROP is 
associated with low levels of IGF -1 after premature birth, indicates a possible role for 
replacement of IGF -1 to levels found in utero as a strategy  to potentiall y decrease abnormal 
retinal vascularization and abnormal retinal neural development, and ultimately , ROP . 
Mecasermin rinfabate (rhIGF -1/rhIGFBP -3) is the human recombinant form of the naturall y 
occurring protein complex of I GF-1 and insulin- like growth fa ctor binding protein -3 (IGFBP -3). 
rhIGF -1/rhIGFBP -3 was developed to enhance the sy stemic exposure of administered rhIGF -
1 
and to improve the safety profile of rhIGF -1 therapy . rhIGF-1/rhIGFBP -3 was approved by  the 
Food and Drug Administration ( FDA )in 200 5 for the treatment of growth failure in children 
with severe primary  IGF-1 deficiency  or with growth hormone (GH) gene deletion who have 
developed neutralizing antibodies to GH . 
The pharmacokinetics and safet y of rh IGF-1/rhIGFBP -3 have been evaluated in a Phase I stud y 
(ROPP -2005- 01) and pharmacokinetics, safet y, and efficacy are being evaluated in the ongoing 
phase II stud y (ROPP -2008 -01)
. Sections A -C of the ROPP -2008- 01 study  are complete . 
Section D of the ROPP -
2008 -01 study  is currentl y being conducte d to assess pharmacokinetics, 
safet y and efficacy of rhIGF -1/rhIGFBP -3 for the prevention of ROP in premature infants (up to 
a corrected age [CA] of 40 weeks [± 4 day s]). Subjects in Study  ROPP -2008- 01are randoml y 
assigned to receive rhIGF -1/rhIGFBP -3 or s tandard neonatal care . The target dose of 
rhIGF -1/rhIGFBP -3 for Study  Section D is 250 μg/kg/24 hours to be administered via 
continuous infusion starting on Study  Day  0 (day  of birth) and continuing through postmenstrual 
age (gestational age + time elapsed from birth) 29 weeks + 6 day s.
Although the rh IGF-1/rhIGFBP -3 therap y in Section D of the Phase II study (Stud y 
ROPP -2008- 01) represents a short -term exposure (< 2 months for each subject), 
rhIGF -1/rhIGFBP -3 may have long -lasting effects on visual outcome s as well as other potential 
outcomes related to complications of prematurit y such as neurodevelopment, pulmonary  
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 14function, and growth . In addition, it is critical to understand an y long term safety effects from 
short term exposure to rhIGF -1/rhIGFBP -3. 
The long
-term outcomes assessed in this study  will require utilization of different assessment 
tools than are utilized in the Phase II stud y, ROPP -2008- 01 Section D, given the changes in 
physical and cognitive development that will occur in the subjects as they age during their 
participation in this study . 
Please refer to the current edition of the I nvestigator’s Brochure for further information 
concerning the safet y and clinical development of rhIGF -1/rhIGFBP -3.
For non-commercial use only
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 163 STUDY E NDPOINTS
3.1 Efficacy Endpoints
3.1.1 Primary Efficacy Endpoints
Visual acuity  as assessed by  an age -appropriate method
Ocular alignment and ocular motor examination in primary  gaze and in as many  of 
9positions of gaze as possible a s assessed b y corneal light reflex and b y the cover test
Assessment of n ystagmus by  observation
Refraction as assessed b y retinoscop y with cycloplegia
Stereoacuit y as assessed with the Lang Stereotest
3.1.2 Secondary Efficacy Endpoints
Growth parameters including bod y weight, bod y length (or height), and head 
circumference
Cognitive development as assessed b y the following standardized, age -appropriate 
tools:
oBayley Scales of Infant and Toddler Development, Third Edition (BSID- III)
oWechsler Preschool and Primary Scale of Intelligence, Fourth Edition 
(WPPSI -IV)
Physical development as assessed by  standardized, age appropriate tools including 
physical exam ination , neurological examination for assessment of cerebral palsy , and 
hearing assessment
Child behavior as assessed by  the following:
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
oChild Behavior Checklist (CBCL ;1 ½ to 5)
oAttention- Deficit/ Hyperactivity  Disorder Rating Scale -fourth edition 
(ADHD -RS-IV) for the assessment of sy mptoms of 
attention -deficit/hyperactivity  disorder (ADHD)
oSocial Communication Questionnaire (SCQ) for screening of Autism Spectrum 
Disorder (ASD)
Pulmonary  morbidity  data (eg, hospitalizations, emergency  room [ER] visits, 
pulmonary  medications)
Survival as assessed b y death dur ing the study  due to any  cause
For non-commercial use only
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 184 INVESTIGATIONAL PLAN
4.1 Overall Study Design and Plan
This is a Phase II, multicenter, long- term developmental outcome study  enrolling subjects who 
were randomized in Section D of Study  ROPP -2008-01 to receive eithe rrhIGF -1/rhIGFBP -3
(treated) or standard neonatal care (control) . Enrolled subjects in this study  will be followed 
through age 5 years CA . This study  will enroll both subjects who were in the treated (received 
rhIGF -1/rhIGFBP -3) and control (received standard neonatal care) groups of Study  
ROPP -2008-01 (Section D) to enable assessment of rhIGF- 1/rhIGFBP -3 long -term efficacy  and 
safet y outcomes versus standard neonatal care. No investigational product will be administered 
in this study . 
In this stud y, the Initial Visit will occur at 40 weeks CA (ie, term equivalent) or upon 
discontinuation from Study  ROPP -2008- 01 or may  occur any  time u p to the visit at 3 months 
CA. Subjects in Study  ROPP -
2008- 01 are premature infants enrolling at gestational age of 
23week s + 0 day s to 27 weeks + 6 days.
Time points for assessments have been chosen based on standard premature infant follow -
up 
periods and represent important developmental ages for premature infant follow -up. Both 
telephone and clinical site visits are included to help maintain contact with subjects throughout 
the 5- year duration of the study .
Subjects will be evaluated at appropriate follow
-up site locations with expertise in the 
assessment of the developmental outcomes of premature infants . Pediatric ophthal mology  
expertise will also be required
. 
See Appendix 1for the Study  Schedule of Events t able.
The overall study  design is outlined in Figure 4
-1.
For non-commercial use only
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 20Insulin -like growth fa ctor-1 (IGF -1) mediates its primary  actions b y binding to its specific 
receptor, the insulin- like growth factor 1 receptor (IGF -1R), which is present on many  cell ty pes 
in many  tissues . Binding to its receptor initiates intracellular signaling including vi a the AKT 
signaling pathway . This pathway  is involved in stimulation of cell division, growth and 
differentiation and inhibits programmed cell death. Specificall y regarding premature infants, 
IGF-1 is an important mediator of fetal growth and has been show n to play  a role in earl y 
postnatal growth following pre -term delivery .9, 10
Insulin -like growth factor -1 (IGF -1) has also been shown to play  a role in pulmonary  
development11and neural development.12, 13Given the potential role for IGF-1 in the 
development of multiple sy stems, this study  has been designed to evaluate the long -term effects 
of rhIGF -1/rhIGFBP -3, both from a safety  and efficacy  perspective, on the development of the 
premature infant.
4.3 Study Duration
Duration for an individual subject’s participation in the study will vary  depending upon age at 
enrollment, but subjects will not be followed beyond age 5.5 years CA .
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 215 STUDY POPULATION SEL ECTION
5.1 Study Populatio n
Subjects randomized in Study  ROPP -2008- 01, Section D are eligible to enroll in this study ; 
completion of Study  ROPP -2008- 01 Section D is not required. Subjects in Study  ROPP - 2008-01 
are premature infants (gestational age of 23 weeks + 0 day s to 27 weeks + 6 day s) who are 
randomized to receive either treatment with rhIGF- 1/rhIGFBP -3 or standard neonatal care. Up to 
120 subjects are planned to be randomized in Study ROPP -2008- 01 Section D.
5.2 Inclusion Criteria
Each subject must meet the following criteria to be enrolled in this study .
1.Subje ct was randomized in Study  ROPP -2008- 01, Section D
2.Subject’s parent or legally  authorized representative(s) must provide written informed 
consent prior to performing an y stud y-related activities. Study -related activities are any 
procedures that would not have been performed during normal management of the subject.
5.3 Exclusion Criteria
Subjects who meet an y of the following criteria will be excluded from the study.
1.Any other condition or therapy  that, in the Investigator’s opinion, may  pose a risk to the 
subject or interfere with the subject’s ability  to be compliant with this protocol or interfere 
with the interpretation of results
2.The subject or subject’s parent or legally  authorized representative(s) is unable to comply  
with the protocol as determined by  the Investigator
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 226 STUDY TREATMENT
6.1 Description of Treatment
No investigational product will be administered in this study .
6.2 Treatments Administered
Not applicable.
6.3 Selection and Timing of Dose for Each Subject
Not applicable.
6.4 Method of Assigning Subjects to Treatment Groups
Not applicable.
6.5 Masking
Not applicable.
6.6 Medications
Any medications administered to the subjects will be collected from the time of informed 
consent through the 5 -year CA visit (or until the subject withdraws or is discontinued). Any  
investigational product received b y subjects will be recorded separatel y as part of an assessment 
of subjects’ participation in other clinical studies (Section 7.11.1).
6.7 Restrictions 
6.7.1 Prior Therapy
There are no restrictions related to prior therap y.
6.7.2 Other Restrictions
There are no restrictions related to fluid or food intake, or subject activity .
6.7.3 Treatment Compliance
Not applicable.
6.7.4 Packaging and Labeling
Not applicable.
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 236.8 Storage and Accoun tability
Not applicable
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 247 STUDY PROCEDURES
Detailed descriptions of subject procedures and evaluations required for this protocol are 
described in this section . These evaluations will be performed during the indicated day s and 
weeks of the stud y (see Schedul e of Events in Appendix 1). 
All data collected are to be recorded on the subject’s appropriate eCRF . 
Details for stud y procedures are described in the Operations Manual for this study.
7.1 Informed Consent
Prior to c onducting an y study -related procedures, written informed consent must be obtained 
from the subject’s parent(s) or legall y authorized representative(s).
The nature, scope, and possible consequences, including risks and benefits, of the study will be 
explain ed to the subject, the subject’s parent(s), or the subject’s legall y authorized representative 
by the Investigator or designee in accordance with the guidelines described in Section 11.4. 
Documentation and filin g of informed consent documents should be completed according to 
Section 11.4.
7.2 Study Entrance Criteria and Eligibility
At the I nitial Visit , each subject will be reviewed for eligibility  against the study  entrance 
criteria . Subjects who do not meet the study  entrance criteria will not be allowed to participate in 
the study . The reason(s) for the subject’s ineligibility  for the stud y will be documented . No 
exemptions will be allowed.
7.3 Study Enrollment
Subjects will be considered enrolled in the stud y once written informed consent has been 
obtained from the subject’s parent(s) or legally  authorized representative(s).
7.4 Demographics
Subject demographic information including gender, date of birth , and race will be record ed.
7.5 Growth Parameters :  Length (and Height), Weight, and Head Circumference
7.5.1 Length and Height
Body length (supine measurement) will be collected when subjects are 24 -months CA or 
younger . 
For the length measurement, the subject will be placed on his or he r back so that the 
subject is ly ing straight and the shoulders and buttocks are flat against the measuring surface. 
The subject's ey es should be looking straight up and care should be taken that the head is in a 
neutral position (neither being flexed nor e xtended at the neck). Both legs should be fully  
extended and the toes should be pointing upward with feet perpendicular to the measuring 
surface.
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 25Height (standing measure) will be collected when subjects are older than 24 -months CA. A 
stadiometer should be utilized for measurement of height. The subject should remove shoes.
For the measurement of standing height, the child is instructed to stand erect (stand up straight 
and look straight ahead) with the child’s head positioned in a horizontal plane . The moveable 
headpiece is brought onto the upper most (superior) point on the head with sufficient pressure to 
compress the hair. 
For height and length, 2 measures should take place and both will be recorded . If the 2 measures 
are discrepant b y >2 cm, the measur es should be repeated. All measures should be recorded in 
metric units and measurement should be recorded to the nearest tenth centimeter (0.1 cm). 
7.5.2 Body Weight
Body weight will be collected . Calibrated scales should be utilized for body  weight measures 
(type of scale will depend upon subject’s age) . Care should be taken to remove any  extraneous 
clothing prior to measures and shoes should be removed.
The measure should be recorded to the nearest 0.1 kg.
7.5.3 Head Circumference
Head circumference will be measured for all subjects. An accurate head circumference 
measure ment is obtained with a “lasso” -type, non -stretchable measuring tape such as the Lasso-o 
tape. Head circumference or occipital frontal circumference is measured over the occiput and just 
above the su
praorbital ridge, which is the largest circumference of the head.
7.6 Efficacy Assessments
7.6.1 Visual Assessments
After corrective lens determination has occurred (Section 7.6.1.2), all visual assessments should 
be cond ucted with best -corrected vision, ie, with corrective lenses in place (if required); this 
applies to 24
-month and 5- year visits.
7.6.1.1 Visual Acuity
Visual acuity  is a measure of how well a subject sees at different distances . It will be assessed by  
the methods summarized in Table 7-1; the method employ ed will be selected based on the 
subject’s age (CA) at the time of the study  visit . Visual acuity  measurements will be measured 
and recorded for the left (OS), right (OD) e ye, and both ey es (OU).
At ages 6 months and 12 months CA, visual acuity will be assessed with Teller acuit y cards . At 
ages 24 months and 5 years CA an attempt should be made to assess visual acuity  by the LEA 
Symbols Test and LEA Sy mbols Chart, respective ly. If during this attempt, the examiner 
determines that it will not be possible to perform an accurate assessment with the relevant LEA 
tool, visual acuity  should be assessed with the Teller acuit y cards. 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 26The visual acuity assessments should be performed by an optometrist or ophthalmologist trained 
in pediatrics. 
Table 7-1 Summary of Visual Acuity Assessments 
Visual Acuity 
Assessment ToolDescription Unit of Measure Applicable 
Age/Study 
Visit (CA)
Teller a cuity cardsResolution acuity –
discrimination of a grating 
optotype from a background with 
the same mean luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity -tests 
recognition of 4 optotypesSnellen fraction
(eg, 20/20)24 monthsa
LEA Symbols 
(ETDRS -style) chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be ma de to assess visual acuity by the LEA 
Symbols Test and LEA Symbols Chart, respectively . If during this attempt, the examiner determines 
that it will not be possible to perform an accurate assessment w ith the relevant LEA tool, visual acuity 
should be assessed with the Teller acuity cards.
7.6.1.2 Corrective Lens Determination
An assessment to determine if the subject requires vision correction with corrective lenses will 
be performed. This is being performed to ensure the accuracy  of subjects’ subsequent visual 
acuity  assessments (at the 24-month and 5- year visits) . The corrective lens determination will be 
performed according to the guidelines published by the American Academy of Ophthalmology  
(AAO).14
This assessment should be perfor med by an optometrist or ophthalmologist trained in pediatrics . 
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility)
Ocular alignment will be assessed in primary  gaze by  comparing the position of the corneal light 
reflection in OS and OD (corneal light reflection assessment). Presence or absence of strabismus 
will be recorded in primary  gaze and in as many  of the 9 positions of gaze as feasible with the 
cover test assessment of refixation mo vement. Extraocular muscle over -action or deficiency  will 
be rec orded. The assessment will be performed according to the AAO guidelines .14
Presence or absence of ny stagmus as observed during the ocular alignment assessments will also 
be recorded.
The assessment will be performed b y a pediat ric ophthalmologist or an ophthalmologist trained 
in the care of pediatric subjects with a history of premature birth . Degree of adherence to the 
AAO guidelines will be at the discretion of the examining phy sician in consideration of the need 
for patient c ooperation. 
For non-commercial use only
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 287.6.2 Hearing Assessment History
Results of previously  completed hearing assessments will be recorded; hearing tests are not 
being performed as part of this study . 
7.6.3 Behavioral Assess ments
7.6.3.1 Bayley Scales of Infant and Toddler Development, Third Edition
The BSID -III will be used to assess cognitive, motor, and language skills, and is applicable to 
children aged 1 to 42 months. 
The BSID-IIIis an assessment tool designed to measure a y oung child's skills in the 3 core areas 
of development :  cognitive, language, and motor. There are 5 subscales, the cognitive subscale 
stands alone while the 2 language subscales (expressive and receptive) combine to make a total 
language score and the 2 mot or subtests (fine and gross motor) form a combined motor scale. 
The tool is engaging, with colorful props and visual stimuli that capture the attention of the child. 
The individual test items are short, limiting the amount of attention required for each i tem. The 
test administration is flexible in that items can be administered out of order, provided the 
assessor adheres to the specific guide lines in the examiner's manual.
The BSID -III will be administered to the subject ,with participation of the subject’ sparent(s) or 
legally  authorized representative(s) ,by a trained professional. Scores to be recorded are detailed 
in the Study  Operations Manual.
7.6.3.2 Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition 
(WPPSI -IV)
The WPPSI -IV is a measure of general cognitive development in children that has components 
of both verbal and nonverbal tasks.19  It is applicable to preschoolers and young children aged 
2years + 6 months to 7 years + 7 months, and is a direct assessment o f a child’s cognitive skills.
It is composed of the following 5 scales:
Verbal
Performance
Processing Speed
Full Scale
Language
It not onl y applies to healthy children, but in the course of the scale’s standardization20special
group validity  studies were performed, including, but not limited to, groups of children with 
developmental risk factors, autistic disorder, and intellectual disability . Scores may  be 
interpreted in the context of provided norms, which reflect inclusion o f the special groups.
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 29The WPPSI -IV will be administered to the subject by  a trained professional . Scores to be 
recorded are detailed in the Study Operations Manual.
7.6.3.3 Child Behavior Checklist (CBCL)
The CBCL (1 ½ to 5) is a parent -reported outcome measure used to assess behavioral, emotional, 
and social functioning of toddlers and preschool children aged 18 to 60 months.21It is composed 
of 99 items that are rated on a L ikert scale and includes the following 7 s yndrome scales 
arranged under 2 domains (ie, Internalizing and Externalizing Problems) :22
Internalizing Problems
Emotionally  Reactive
Anxious/Depressed
Somatic Complaints
Withdrawn
Sleep Problems
Attention Problems
Aggressive Behavior
The questionnaire is widely  used and has been employ ed to assess long- term behavioral 
outcomes in children born prematurel y, aged similarly to the subjects expected in this study  
population.22 -24It is associated with well- established n ormative data ;25norms may  be selected 
to aid in interpretation of the scale scores.
The CBCL (1 ½ to 5) is a questionnaire that will be administered to the subject’s parent(s) or 
legally  authorized representative(s) by  a traine d professional. Scores to be recorded are detailed 
in the Study  Operations Manual.
7.6.3.4 Vineland Adaptive Behavior Scales, Second Edition
The VABS -II Expanded Interview Form will be used to measure the personal and social skills of 
subjects seriall y over time; these scales are organized within a 3- domain structure :  
Communication, Daily  Living, and Socialization. In addition, the VABS -II offers a Motor Skills 
Domain and an optional Maladaptive Be havior Index. The VABS -II Expanded Interview Form 
assesses what a subject actually  does, rather than what he or she is able to do. 
The VAB S-II Expanded Interview Form will be administered to the subject’s parent(s) or legall y 
authorized representative(s) b y a trained professional . Scores to be recorded are detailed in th e 
Study  Operations Manual.
7.6.3.5 Attention -Deficit/Hyperactivity Disorder Rating Scale -Fourth Edition
The ADHD -RS-IV was developed to measure the behaviors of children with ADHD. The 
ADHD -RS-IV consists of 18 items designed to reflect current symptomatology  of A DHD based 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 30on DSM -IV criteria. Each item is scored from a range of 0 (reflecting no s ymptoms) to 
3(reflecting severe s ymptoms) with total scores ranging from 0- 54. The 18 items are grouped 
into 2 subscales:  hyperactivity -impulsivity  (even numbered items 2- 18) and inattention 
(“inattentivene ss”) (odd numbered items 1 -17).
The ADHD -RS-IV,26will be completed b y the subject’s parent(s) or legally  authorized 
representat ive(s) . Scores to be recorded are detailed in the Study  Operati ons Manual.
7.6.3.6 Social Communication Questionnaire – Lifetime Form
The SCQ is a brief instrument that helps evaluate communication skills and social functioning in 
children27that can be used for screening for autism or autism spect rum disorders in the general 
population .28
The SCQ will be completed by  the subject’s parent(s) or legall y authorized representative(s). The 
investigator or designee should review the assessment for completeness and to confirm a ll 
responses . Scores to be recorded are detailed in the Study  Operations Manual.
7.6.4 Cerebral Palsy Assessment
Comprehensive neurological examination for the diagnosis of cerebral palsy (CP) will be 
conducted . The Amiel -Tison neurological examination framework29will be utilized for this 
assessment and conducted by  trained medical professionals.
7.6.5 Pulmonary Morbidity Assessment
Pulmonary  morbidity  will be assessed with questions related to famil y history and smoking 
status as well as d iagnosis of select pulmonary  symptoms, conditions and related 
hospitalizations
. The questionnaire will be administered to the subject’s parent(s) or legally 
authorized representative(s). 
7.6.6 Survival Assessment
Survival status will be assessed and recorded.
7.6.7 Health Economic Outcome Research Assessments
7.6.7.1 Health Related Quality of Life
Health-related qualit y of l ife (HRQoL) is an important outcome towards improving the health 
care of pediatric patients as it is that part of a person’s overall qualit y of life that is determined 
primarily  by their health status and which can be influenced by  clinical interventions . It is an 
important concept, which is also used in determining the value of health care services in this 
population.30, 31  Itis a multidimensional construct whose content is guided by  the World Health 
Organization32; minimally it includes ph ysical, psy chological (including emotional and 
cognitive), and social health dimensions .
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 31In this stud y, HRQoL will be assessed via the validated Pediatric Quality  of L ife Inventory  
(PedsQL™) Scales appropriate for the child’s age of development.33 -35The development of the 
PedsQL  was based on the delineations of the World Health Organizat ion (WHO )and is a 
modular approach to assessing HRQoL in the pediatric population. Initially , the PedsQL  Generic 
Scales were developed and continue to be used in children aged 2 to 18 years. More recently  
Infant Scales have been developed that appl y to ag es 1 to 24 months.34
The following scales will be used in this study :
Infant Scale for ages 1 -12 months (36 I tems)
Infant Scale for ages 13 –24 months (45 I tems)
Toddler Scale for 2 -4 years of age (21 Items)
Young Child Scale f or 5-7 years of age (23 Items)
The PedsQL will be administered to the subject’s parent and may  be conducted via telephone 
through a call center . The scale(s) to be administered at each visit will be specified in the Study  
Operations Manual.
7.6.8 Health Care Re source Use
To understand the value of the investigational product administered in Study  ROPP -2008-01 
(Section D), the resource use associated with inpatient visits, outpatient visits, and medical and 
pharmacy utilization in this study  will be recorded. 
This assessment may  be conducted via telephone through a call center.
7.6.8.1 Health Status Classification System -Preschool
Health status (eg, health u tility ) will be measured by  the Health Status Classification 
System -Preschool (HSCS -PS), which is a validated instr ument adapted for use via parent prox y 
within the pediatric population age 2.5 to 5 (adapted from the validated Health Utilities I ndex 
Mark 2 and 3 [HUI 2/3]).36Validity  of the HSCS -PS concepts has not been established for a ges 
younger than 2.5 y ears.
The HSCS- PS was developed to provide a consistent measure of health status in preschool- aged 
children who had been born prematurely .3
6The sy stem is applicable to children with special 
needs as ma y be included in this study ; validation cohorts for the s ystem included children with 
very low birth weight (VLBW), which is congruent with this study  population.
The instrument is composed of 12 dimensions (Vision, Hearing, Speech, Mobility , Dexterity , 
Self-care, Emotion, Learn/remember, Think/problem solve, Pain, General Health, and Behavior) 
intended to provide a comprehensive assessment of a child’s health status as it pertains to 
health- related quality  of life . The individual domains of the instrument will be scored as a mean 
score, representing the overall state for each concept individually . The global score will be 
recorded as well as the scores for each of the dimensions.
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 32The HSCS- PS is a questionnaire that will be administered to the subject’s pare nt(s) or legall y 
authorized representative(s) and may  be conducted via telephone through a call center.
7.7 Safety Assessments
7.7.1 Abdominal ultrasound
An abdominal ultrasound will be performed to assess the size of the spleen and kidney s. The 
spleen will be measu red in the coronal longitudinal plane and the longest longitudinal length will 
be measured for each kidney  (left and right) .37Ultrasound results will be assessed by a central 
reader.
Organ size will be interpreted in the co ntext of reference values established for children.37, 38
7.7.2 Echocardiogram
Echocardiographic examination (conventional M- mode recording of the left ventricle [L V] 
parasternal long axis view) will be performed for the evaluation of cardiac size, assessed by  
measuring the following:
interventricular septal thickness (during end diastole)
LV posterior wall thickness
LV intracavit y volume (both in end diastole and end systole)
Echocardiogram results will be assessed by a central re ader.
7.7.3 Physical Examination
Physical examinations will include a review of the subject’s general appearance, neurological 
examination, as well as a tonsillar examination ( Table 7-2). An y abnormal change in findings 
will b e recorded as an AE
. 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 33Table 7-2 Assessments for Physical Examinations
Assessment Assessment
General appearance Endocrine
Head and neck Cardiovascular
Eyes Abdomen
Ears Genitourinary
Nose Skin
Thro at Musculoskeletal
Chest and lungs Neurological
Tonsils
7.8 Medication Assessment
All medications received by  study  subjects will be collected from the time of enrollment through 
the 5- year CA visit (or upon discontinuation) . Any investigational product r eceived b y subjects 
will be recorded separately  as part of an assessment of subjects’ participation in other clinical 
studies (Section 7.11.1).
7.9 Adverse Events Assessments
7.9.1 Defin itions of Adverse Events, Serious A dverse Events, and Suspected 
Unexpected Serious Adverse Reactions
7.9.1.1 Adverse Event
An AE is an y noxious, pathologic, or unintended change in anatomical, physiologic, or 
metabolic function as indicated b y physical signs, sy mptoms, or laboratory  changes occurri ng in 
any phase of a clinical study , whether or not considered investigational product-related. This 
includes an exacerbation of a pre -existing condition . 
In this long -term outcome study  in follow -up to Study  ROPP -2008- 01 (Section D), no 
investigational p roduct is being administered. However, the relationship to the investigational 
product (rhIGF -1/rhIGFBP -3) as administered in Study  ROPP -2008- 01 (Section D) will be 
assessed . 
Adverse events collected in this study  will be the following :  
those considered related to investigational product (rhIGF- 1/rhIGFBP -3 as 
administered in Study  ROPP -2008- 01, Section D)
those considered related to procedures performed in this study  (Study  SHP -
607-201)
specified targeted medical events (Section 7.9.1.3) regardless of causality
fatal SAEs regardless of causality
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 34Adverse events include:
Worsening (change in nature, severit y, or frequency) of conditions present at the onset 
of the study
Intercurrent illnesses
Drug interactions
Events related to or possibly  related to concomitant medications
Abnormal laboratory values (this includes significant shifts from baseline within the 
range of normal that the Investigator considers to be clinically  important)
Clinically  significant abnorm alities in phy sical examination, vital signs, and weight
Throughout the stud y, the Investigator must record AEs on the AE electronic case report form 
(eCRF), regardless of the severit y. The Investigator should treat subjects with AEs appropriatel y 
and obs erve them at suitable intervals until the events stabilize or resolve . Adverse events may  
be discovered through observation or examination of the subject, questioning of the subject, 
complaint by  the subject, or by  abnormal clinical laboratory  values.
In addition, AEs may  also include laboratory
 values that become significantly  out of range . In 
the event of an out -of-range value, the laboratory  test should be repeated until it returns to 
normal or can be explained and the subject’s safety is not at risk. 
Additional illnesses present at the time when informed consent is given are regarded as AEs and 
will be documented on the appropriate pages of the eCRF . Illnesses first occurring or detected 
during the stud y, and worsening of a concomitant illness during th e stud y, are to be regarded as 
AEs and must be documented as such in the eCRF.
7.9.1.2 Serious Adverse Event
An SAE is any  AE that results in any  of the following outcomes:
Death
Is life -threatening
Requires hospitalization
Requires prolongation of existing hospit alization
A persistent or significant disability  or incapacity  
A congenital anomal y or birth defect
Important medical events that may  not result in death, be life -threatening, or require 
hospitalization may  be considered an SAE when, based upon appropria te medical judgment, they  
may jeopardize the subject and may  require medical or surgical intervention to prevent one of the 
outcomes listed in this definition . A life -threatening AE is defined as an AE that placed the 
subject, in the view of the initial re porter, at immediate risk of death from the AE as it occurred 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 35(ie, it does not include an AE that, had it occurred in a more severe form, might have caused 
death).
7.9.1.3 Suspected Unexpected Serious Adverse Reaction
Suspected unexpected serious adverse reactions (SUSAR) are suspected adverse reactions related 
to an investigational product (investigational products and comparators [if applicable]), which 
occur in the concerned study , and that are both serious and unexpected according to the current 
Investigator’s Brochure .
7.9.1.4 Targeted Medical Events
If it is determined that any of the following targeted medical events have been experienced b y a 
subject, they will be recorded as AEs or SAEs, as appropriate, regardless of relationship to 
investigational product ( rhIGF-1/rhIGFBP -3 as administered in Study  ROPP -2008-01, 
Section D):
intracranial hy pertension
any abnormalit y of glucose metabolism (eg, h ypogl ycemia, h ypergl ycemia, and 
diabetes)
tonsillar hy pertrophy  (based on tonsil exam [part of the phy sical exam])
increased kidney  size 
increased cardiac size
increased spleen size
7.9.2 Classification of Adverse Events and Serious Adverse Events
The severit y of AEs will be assessed b y the Investigator based on the definition indicated in 
Table 7-3. The severit y of all AEs/SAEs should be recorded on the appropriate eCRF page to a 
severit y of mild, moderate, or severe.
Table 7-3 Adverse Event Severity
Severity Definition
Mild No limitation of usual activities.
Moderate Some limitation of usual activities.
Severe Inability to carry out usual activities.
7.9.3 Clarification between Serious and Severe
The term “severe” is often used to describe the intensity  (severit y) of a specific event (as in mild, 
moderate, or severe m yocardial infarction); the event itself, however, may  be of relatively  minor 
medical significance (such as severe headache) . This is not the same as “serious,” which is based 
on the outcome or action criteria usuall y associated with events that pose a threat to life or 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 36functioning. Seriousness (not severity) and causality serve as a guide for defining regulatory 
reporting obligations.
7.9.4 Relatedness of Adverse Events and Serious Adverse Events
Relationship of an AE or SAE to investigati onal product (rhIGF -1/rhIGFBP -3 as administered in 
Study  ROPP -2008- 01, Section D) is to be determined by  the Investigator based on the following 
definitions (See Table 7-4).
Table 7-4 Adverse Event Relatedness
Relationship to Product Definition
Not Related Unrelated to investigational product
Possibly Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, but which could 
also be explained by concurrent disease or other drugs or chemicals.
Probably Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, unlikely to be 
attributable to concurrent disease or other drugs and chemicals and 
which follows a clinically reasonable response on de -challenge . The 
association of the clinical event or laboratory abnormality must also 
have some biologic plausibility, at least on theoretica l grounds.
Definitely related The event follows a reasonable temporal sequence from administration 
of the investigational product, follows a known or suspected response 
pattern to the investigational product, is confirmed by improvement 
upon stopping the investigational product (de- challenge), and 
reappears upon repeated exposure (re -challenge) . Note that this is not 
to be construed as requiring re -exposure of the subject to 
investigational product; however, the determination of definitely 
related can only be used when recurrence of event is observed.
7.9.5 Procedures for Recording and Reporting Adverse Events
7.9.5.1 Adverse Event Monitoring and Period of Observation
Adverse events will be monitored throughout the study . 
For the purposes of this study , the period of observation extends from the time at which the 
subject’s parent(s) or legally  authorized representative(s) gives informed consent until the 
subject’s final evaluation of the study . For safet y purposes, the final evaluation will be defined as 
the last study visit when the subject is 5 y ears-old in CA.
If the Investigator considers it necessary  to report an AE in a stud y subject after the end of the 
safet y observation period, he or she should contact the Sponsor to determine how the AE should 
be documented an d reported.
For non-commercial use only
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 387.9.5.3 Regulatory Agency, Ins titutional Review Board, Ethics Committee, and Site 
Reporting
The Sponsor and the CRO are responsible for notify ing the relevant regulatory authorities/US 
central IRBs/E uropean U nion (EU) central ECs of related, unexpected SAEs.
For some European regulator y authorities, these reports are submitted directly  to Eudravigilance. 
In case of deaths or life -threatening SUSARs, these must be reported to the relevant regulatory  
authorities before 7 day s have elapsed from that the initial SAE report has reached the S ponsor 
or its representatives. A full report has to be submitted within another 8 days. For other SUSARs 
the timelines for reporting are 15 day s.
In addition, the CRO is responsible for notify ing active sites of all related, unexpected SAEs 
occurring durin g all interventional studies across the rhIGF -1/rhIGFBP -3 program at Shire .
The investigator is responsible for notify
ing the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
7.10 Removal of Subjects from the Trial
A subject’s participation in the study  may  be discontinued at any  time at the discretion of the 
Investigator . The following may  be justifiable reasons for the Investigator to remove a subject 
from the study :
Non-compliance, includin g failure to appear at one or more stud y visits
The subject was erroneously  included in the study
The subject develops an exclusion criterion 
The study
 is terminated by  the Sponsor
The subject, the subject’s parent(s), or the subject’s legall y authorized representative acting on 
behalf of the subject is free to withdraw consent and discontinue participation in the study  at an y 
time without prejudice to further treatment.
If a subject or the subject’s parent(s) or the subject’s legally  authorized represent ative(s) acting 
on behalf of the subject, discontinues participation in the study , or the subject is discontinued by  
the Investigator, reasonable efforts will be made to follow the subject through the end of study  
assessments . The reason for refusal will be documented on the eCRF. An y AEs experienced up 
to the point of discontinuation must be documented on the AE eCRF . If AEs are present when 
the subject withdraws from the study , the subject will be re -evaluated within 30 day s of 
withdrawal . 
All ongoing SAE s at the time of withdrawal will be followed until resolution.
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 397.11 Other Study Procedures
7.11.1 Participation in Other Clinical Studies
Following enrollment, subjects in this study  will not be restricted from enrolling in another 
clinical study  that involves the use of investigational product . The status of a subject’s 
participation in such studies will be re corded (ie, yes/no) . If a subject is enrolled in such a study, 
additional parameters will be recorded, including the masking status of the study , the identity  of
the investigational product being evaluated in the study, and the subject’s treatment assignment 
in the study  (if possible) . 
7.12 Appropriateness of Measurements
Overall, the primary  and secondary  efficacy  and safet y measures being employed in this study 
are considered appropriate for the follow-up of preterm infants. The validated tools being used to 
assess neurodevelopment, phy sical development, and health economic research outcomes in this 
pediatric population are widely used and recognized.
In some cases t ools were designed specifically  for use in this study . These are the pulmonary  
morbidity  assessment and the cerebral palsy  assessment . In these cases, the tools are either based 
on validated tools or the current state of knowledge in the literature . For ex ample, the cerebral 
palsy  assessment is based on the Amiel -Tison neurological examination framework29and the 
pulmonary  assessment is based on published research in a similar pediatric population .39, 40
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 408 STUDY ACTIVITIES
The timing of the visits in this study  is based on subjects’ corrected age (CA). 
8.1 Initial Study Visit (40 weeks CA [term equivalent])
The Initial Visit will occur at 40 weeks CA (ie, term equi valent) or upon discontinuation from 
Study  ROPP -2008- 01, Section D or any  time up to the visit at 3 months CA . 
At the I nitial Visit, informed consent will be obtained followed by  an assessment of study  
eligibility  criteria and collection of demographic da ta.
The following AE d ata, collected as part of Study  ROPP -2008- 01 (Section D) will also be 
recorded :
Ongoing targeted medical events regardless of causality
Ongoing stud y drug -related AEs, including SAEs
8.2 Study Visits
Study  visits for follow -up outcome as sessments will take place at the following time points in 
CA:
3 months (±2 weeks) –conducted by  telephone
6 months (±1 month) –clinical site visit
12 months (±3 months) –clinical site visit
24 months (±3 months) –clinical site visit
3 years (±3 months) –conducted by  telephone
4 years (±3 month) – conducted by  telephone
5 years (+6 months) –clinical site visit
In addition, there will be 2 visits that must occur at least 1 month prior to the 24 -month and 
5-year CA stud y visits to assess the need for co rrective lenses . The timing of these 2 visits 
(20months [ -1 month] and 4.75 y ears [
-1 month]) was set to ensure that any  prescribed 
corrective lenses would be worn for at least 1 month prior to the visual assessments at the 
24-month and 5- year study visit s CA.
The activities at the study  visits are described in Sections 8.2.1 and 8.2.2.
8.2.1 Outcome Assessment Visits Conducted by Telephone
Visits at 3 months, 3 y ears, and 4 y ears CA will be conducted by  telephone . The following 
outcome assessments will be conducted at each of these 3 visits, unless otherwise indicated:
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 41HRQoL  
HCRU
HSCS -PS (3- year and 4 -year visits only )
Medications
Survival assessment
Assessment of particip ation in other clinical studies
Adverse events (including targeted medical events)
8.2.2 Clinical Site Visits
8.2.2.1 Outcome Assessment Site Visits
The following clinical site visits (in CA) to capture follow- up outcome data will occur at the 
clinical site:
6 months ( ±1 month)
12 months (±3 months) 
24 months (±3 months)
5 years (+6 months)
The following assessments will be performed at the 6 -month visit:
Visual acuity
Refraction with cy cloplegia
Length
Weight
Head circumference
VABS -II
Physical examination (including tonsil examination)
Hearing Assessment History  (Historical hearing test data may  be recorded at any  time prior 
to the 6- month visit) 
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints dur
ing this clinical site 
visit)
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 42HCRU (may  be performed by  telephone if there are time constraints during this clinical site 
visit)
Abdominal ultrasound
Echocardiogram
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at the 12 -month visit:
Visual acuity
Corrective lens determination
Ocular alignment and motility
Refraction with cy cloplegia
Length
Weight
Head circumference
BSID-III
VABS -II
Physical e xamination (including tonsil examination)
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this clinical site 
visit)
HCRU (may  be performed by  telephone if there are time constrain ts during this clinical site 
visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at the 24 -month visit:
Visual acuity
Ocular alignment and motility
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 43Refraction with cy cloplegia
Length
Weight
Head circumference
BSID-III
CBCL
VABS -II
Physical examination (including tonsil examination)
Cerebral Pals y assessment
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by telephon e if there are time constraints during this clinical site 
visit)
HCRU (may  be performed by  telephone if there are time constraints during this clinical site 
visit)
HSCS -PS (may  be performed by  telephone if there are time constraints during this clinical 
site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at the 5 -year visit:
Visual acuity
Ocular alignment and motility
Refraction with cy cloplegia
Stereoacuit y
Height
Weight
WPPSI -IV
CBCL
VABS -II
ADHD -RS-IV
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 44SCQ
Physical examination (including tonsil examination)
Pulmonary  morbidity  assessment
Survival assessment

HRQoL  (may  be performed by  telephone if there are time constraints during th is clinical site 
visit)
HCRU (may  be performed by  telephone if there are time constraints during this clinical site 
visit)
HSCS -PS (may  be performed by  telephone if there are time constraints during this clinical 
site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
8.2.2.2 Visits Dedicated to Corrective Lens Determination
The following clinical site visits are dedicated solely  to corrective lens determination in 
preparation for the outcome assessment visits at 24
-months and 5- years CA:
20months ( -1 month) 
4.75 y ears (- 1 month) 
At these visits, the following will be performed:
Visual acuity
Refraction with cy cloplegia
Corrective lens determination
The 20- month visit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 month prior 
to the 24-month and 5- year visits, respectivel y. Any prescribed corrective lenses must be worn 
for at least 1 month prior to the 24 month and 5 y ear assessments.
8.3 Assessments upon Discontinuation
If a subject discontinues prior to the 5 -year CA visit, every attempt will be made to complete the 
assessments scheduled for the subject’s next visit. 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 459 QUALITY CONTROL AND ASSURANCE
Training will occur at an Investigator meeting or at the site initiation visi t or both, and instruction 
manuals will be provided to aid consistency  in data collection and reporting across sites.
Clinical sites will be monitored by  the Sponsor or its designee to ensure the accuracy  of data 
against source documents. The required data will be captured in a validated clinical data 
management s ystem that is compliant with the FDA 21 Code of Federal Regulations ( CFR )Part 
11 Guidance . The clinical trial database will include an audit trail to document any  evidence of 
data processing or ac tivity  on each data field by  each user . Users will be trained and given 
restricted access, based on their role(s) in the study, through a password -protected environment.
Data entered in the s ystem will be reviewed manually  for validity  and completeness aga inst the 
source documents by  a clinical monitor from the Sponsor or its designee . If necessary , the study  
site will be contacted for corrections or clarifications; all missing data will be accounted for.
Serious adverse event information captured in the cl
inical trial database will be reconciled with 
the information captured in the Pharmacovigilance and Risk Management database.
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 4610 STATISTICAL AN ALYSES
10.1 General Methodology
Details regarding the statistical methods and definitions will be provided in the Statist ical 
Analy sis Plan (SAP) . The SAP will be finalized prior to database lock. All statistical analy ses 
will be performed b y the Biometrics department at Shire. Statistical analy ses will be performed 
using Version 9.1 or higher of SAS®(SAS Institute, Cary , N
C 27513).
Continuous variables will be summarized using descriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categorical variables will be summarized using frequencies and percenta ges.
As referred to in descriptions of summary  statistics, t reatment groups refer to the 2 possible 
treatment assignments in the antecedent study ,ROPP-2008- 01, Section D ( rhIGF-1/rhIGFBP -3
or standard neonatal care) .
For analy sis purposes, baseline is defined as the first assessment either in the antecedent study  
(ROPP -2008- 01) or in this study  (SHP -607-201). As necessary , relevant data from Study  
ROPP -2008- 01 may  be summarized with the data from this study  (SHP -607-201).
10.2
Determination of Sample Size
No fo rmal sample size calculation wasperformed for this study  because this is a follow -up study  
to Section D of Study  ROPP -2008- 01. Any  subjects enrolled in Study  ROPP -2008- 01 are 
eligible to enroll in this study . There are up to 120 subjects who will be eligi ble to enroll in this 
long-term developmental outcome study .
10.3 Method of Assigning Study Subjects to Treatment Groups
Not applicable.
10.4 Population Description
10.4.1 Analysis Populations
Enrolled Population - the Enrolled Population will consist of all subjects for wh om written 
informed consent has been provided for this study . 
Safety  Population- the Safety  Population will consist of the subjects in the Enrolled 
Population who have safety  follow -up data in this long -term outcome study .
10.4.2 Subject Disposition
Subjects who complete the study  and subjects who prematurel y discontinue from the stud y will 
be summarized by  treatment group using descriptive statistics. I n addition, for subjects who 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 47prematurel y discontinue from the study, the reasons for discontinuation will be s ummarized by  
treatment group.
10.4.3 Protocol Violations and Deviations
Protocol violations and deviations will be listed. Details of the criteria for deviations and 
violations will be provided in the SAP.
10.4.4 Demographics and Baseline Characteristics
Descriptive summaries of demographic and baseline characteristics will be presented b y 
treatment group for the Enrolled Population . 
Demographics and baseline characteristics will be exami ned to assess the comparability  of the 
treatment group s. Continuous variables such as age (including corrected age) , weight, and 
length/height will be summarized using number of observations, mean, standard deviation, 
median, minimum and maximum values. Categorical variables, like gender and race, will be 
summarized using number of obse rvations and percentages.
Medical history ,including maternal and perinatal history , (as obtained from the antecedent 
study , ROPP -2008- 01) will be summarized by  treatment group using the number of observations 
and percentages of subjects reporting each cat egory .
10.5 Efficacy Analysis
All efficacy  analy ses will be performed using the Enrolled Population .
10.5.1 Primary Efficacy Analysis
The primary  efficacy  endpoints consist of the following:
Visual Acuity :  Visual acuity  will be categorized as the following: 
onormal (measurable acuity ≥20/40), 
obelow normal (20/200≤ measurable acuit y <20/40), 
opoor (measurable acuity ≤20/200)
oblind/low vision (onl y the ability  to detec t the 2.2 cm wide stripes on the low -
vision Teller acuit y card and at an y location in the visual field). 
The number and proportion of patients within each category  listed above will be 
summarized by  treatment group and visit. I n addition, a cuity  results in the normal and 
below normal categories will be classified as favorable outcomes, and acuity  results in 
the poor and blind/low- vision categories will be classified as unfavorable outcomes. 
Tabular summaries b y trea tment group and visit will include the frequency  and the 
percentage for each visual acuity  category . In addition, shift tables of favorable 
outcomes from baseline (first assessment during this study ) to each of the subsequent 
assessments, including the last assessment , will be presented bytreatment group .
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 48Ocular Alignment and Oculomotor Exam (Motility) :  Findings from the ocular 
motility  assessment will be either presence or absence of strabismus (esotropia, 
exotropia, hy pertropia, or hy potropia). Tabular summaries by treatment group and 
visit will include the frequency  and the percentage in each category . In addition, shift 
tables from baseline (first assessment during this study ) to the last assessment will be 
provided b y treatment group.
Nystagmus :  Presence or absence of ny stagmus will be summarized by  treatment 
group and visit
Refraction with C ycloplegia :  Findings from the refraction wit h cycloplegia will be 
summarized by  treatment group and visit
Stereoacuit y:  Presence or absence of stereopsis will be sum marized by  treatment 
group and visit
10.5.2 Secondary Efficacy Analysis
Growth Parameters (b ody weight, body  length [and height], and head circ umference) :  
A standard Z- score, utilizing WHO child growth standards, will be calculated for each 
assessment by  adjusting age -and sex - matched means and standard deviations (norm). 
The descriptive statistics of the Z -score for each of these parameters will be 
summarized at each assessment and the corresponding change from baseline. When 
appropriate, a 95% CI for the corresponding mean change within each group and the 
difference in the mean change between the 2 treatment groups and the corresponding 
95% CI will be presented as appropriate. If the parametric assumption for the 
distribution of the above endpoints cannot be justified, a non -parametric approach will 
be utilized to estimate the treatment difference (ie, median difference or 
Hodges -Lehmann estimator and the corr esponding confidence intervals)
BSID-III and WPPSI -IV:  The raw score for each domain within each questionnaire 
will be summarized by  treatment group and visit using descriptive statistics.
ADHD -RS-IV:  ADHD -RS-IV total score and subscales (Hyperactivity /Impulsivity  
and Inattentiveness) will be summarized by treatment group and visit using descriptive 
statistics.
SCQ :  The SCQ subscales (communication and social) will be summarized by  
treatment group and visit using descriptive statistics
VABS -II:  The raw score for each domain of the scale will be summarized by  
treatment group and visit using descriptive statistics.
CBCL :  The raw score and change from baseline for each domain of the scale will be 
summarized by  treatment group and visit usi ng descriptive statistics.
Pulmonary  morbidity  questionnaire :  The binary  response of each question will be by  
treatment group and visit using descriptive statistics.
Survival :  For subjects who have an event (ie, death), the event time will be calculated 
as the length of time from the subject’s date of birth to death during the study  due to 
any cause . Subjects who do not have an event (ie, death) during the stud y will be 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 49censored at the end of the study . The survival endpoint will be analy zed by treatment 
group using Kaplan
-Meier methods.
10.5.3 Subset Analyses
Subgroup anal yses may  be explored based on factors that may  have influence on the efficacy  or 
safet y endpoints. Subgroup anal yses will be specified in the SAP.
10.5.4 Exploratory Analyses
10.6 Health Economics and Outcomes Research Analyses
For PedsQL, descriptive statistics will be provided for summary  scores by  treatment group and at 
each time point.
The HUI 2/3 s ystem contains a number of attributes/domains to classify  the level of health status. 
Each attribute or domain (eg, mobility , cognition, emotion or pain) is rated on a 5- point ordinal 
scale to indicate the severity  level, ranging from 1 to 5 (higher numbers indicating a more severe
level). Summary  statistics will be provided by  treatment group and at each time point.
For HCRU the utilization for each resource -item (eg, hospital day s, phy sician visits) reported at 
each time point will be reported descriptivel y by treatment group.
10.7 Analysis of Safety
Safety  summaries will be based on all assessments post -baseline. The safet y data will be 
assessed b y AE monitoring, change in cardiac size, and kidney  and spleen size over time. 
Adverse events will be summarized by  system organ class and p referred term for each treatment 
group and overall, the number and percentage of subjects having an y AE, having an AE in each 
body  system and having each individual AE. In addition, those events which resulted in death, or 
were otherwise classified as serious will be presented in a separate listing. In addition, the 
summary  of AEs will be presented by  severit y and relationship to trial medication. 
The change in cardiac size, and size of kidney  and spleen will be assessed at the 6 -month CA 
visit via echocar diogram and abdominal ultrasound, respectivel y.  These data will be anal yzed as 
a binary  response (ie, normal/abnormal) and summarized using frequency  count.  The number 
and proportion of patients with each category  (ie, normal/abnormal) for each of these safet y 
endpoints will be summarized by  treatment group.  I n addition, the 2 -sided 95% CI  for the 
proportion of patients with a normal status for each of the endpoints will be estimated by 
treatment group.
Physical examinations findings will be summarized d escriptivel y. 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 5010.8 Statistical/Analytical Issues
10.8.1 Adjustment for Covariates
If any baseline data are imbalanced and are considered to be clinically relevant, between -group 
comparisons for efficacy  outcomes will be adjusted for covariates and detailed in the SAP . 
10.8.2 Handling of Dropouts or Missing Data
Handling of missing data rules will be described in the SAP.
10.8.3 Interim Analyses and Data Monitoring
Aninterim anal ysis will be performed after all data from all enrolled subjects in this study  have 
either completed 2 -year follow -up (24- month visit) assessments or have prematurely  withdrawn 
from the study  (before completing 2 y ears of follow -up) has been entered i nto the database, 
queried and discrepancies resolved . A full 2- year study  report based on these data, including 
efficacy  and safet y endpoint analy ses,will be completed.
Additionally , descriptive anal yses of the data at other time points before study  completion may  
be performed for safet y monitoring, regulatory  reporting or general planning purposes.
10.8.4 Multiple C omparisons/Multiplicity
Not applicable.
10.8.5 Sensitivity Analyses
Sensitivity  analy ses for the efficacy  outcomes will be detailed in the SAP, as necessary .
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 5111 ADMINISTRATIVE CONSIDERATIONS
11.1 Investigators and Study Administrative Structure
Before initiation of the study , the Investigators must provide the Sponsor with a completed Form 
FDA 1572 and Investigator Agreement . Curriculum vitae must be provided for the Investigators 
and sub
-investigators listed on Form FDA 1572 or I nvestigator Agreement . 
The Investigator should ensure that all persons assisting with the study  are adequatel y informed 
about the protocol, an y amendments to the protocol, and their study related duties and functions . 
The Investigator must maintain a list of sub -investigators and other appropria tely qualified 
persons to whom he or she has delegated significant study  related duties.
11.2 Institutional Review Board or Independent Ethics Committee Approval
Before initiation of the study , the Investigator must provide the Sponsor with a copy  of the 
writte n IRB/IEC/REB approval of the protocol and the informed consent form . This approval 
must refer to the informed consent form and to the study  title, study  number, and version and 
date of issue of the stud y protocol, as given b y the Sponsor on the cover page of the protocol.
Status reports must be submitted to the I RB/IEC/REB at least once per year. The IRB/IEC/REB 
must be notified of completion of the study . Within 3 months of study  completion or termination, 
a final report must be provided to the I RB/IECREB . A cop y of these reports will be sent to the 
study  clinical monitor . The Investigators must maintain an accurate and complete record of all 
submissions made to the IRB/IEC, including a list of all reports and documents submitted . AEs 
which are reported to the US (FDA or other Regulatory
 agencies (Safet y Reports) must be 
submitted promptly  to the I RB/IEC/REB.
11.3 Ethical Conduct of the Study
The procedures set out in this study  protocol, pertaining to the conduct, evaluation, and 
documentation of this study , are designed to ensure that the Sponsor and Investigators abide by  
good clinical practice (GCP) as described in the 21 CFR Parts 50, 56, and 312 and the 
International Conference on Harmonization (I CH) GCP Guidelines Compliance with these 
regulations and guid elines also constitutes compliance with the ethical principles described in the 
Declaration of Helsinki.
11.4 Subject Information and Consent
Before enrolling in the clinical study , the subject or the subject’s parent(s) or legally  authorized 
representative(s) must consent to participate after the nature, scope, and possible consequences 
of the clinical stud y have been explained in a form understandable to him or her.
An informed consent form (assent form if applicable) that includes information about the study  
will be prepared and given to the subject or the subject’s parent(s) or legally authorized 
representative(s) . This document will contain all FDA and ICH -required elements . The informed 
consent (or assent) form must be in a language understandable to the su bject or the subject’s 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 52parent(s) or legall y authorized representative(s) and must specify who informed the subject, the 
subject’s parent(s), or the subject’s legall y authorized representative(s).
After reading the informed consent document, the subject or the subject’s parent(s) or legall y 
authorized representative(s) must give consent in writing. Consent must be confirmed at the time 
of consent b y the personally  dated signature of the subject, the subject’s parent(s) or the subject’s 
legally  authorized rep resentative(s) and by  the personally  dated signature of the person 
conducting the informed consent discussions.
If the subject or the subject’s parent(s) or legally  authorized representative(s) is unable to read, 
oral presentation and explanation of the wr itten informed consent form and information to be 
supplied must take place in the presence of an impartial witness . Consent must be confirmed at 
the time of consent orall y and by the personally dated signature of the subject or by a local 
legally  recognize d alternative (eg, the subject’s thumbprint or mark) or by  the personall y dated 
signature of the subject’s parent(s) or the subject’s legally  authorized representative . The witness 
and the person conducting the informed consent discussions must also sign a nd personall y date 
the informed consent document . It should also be recorded and dated in the source document that 
consent was given.
A cop y of the signed and dated consent document(s) must be given to the subject or the subject’s 
parent(s) or legal repres entative(s) . The original signed and dated consent document will be 
retained b y the Investigator.
The Investigator will not undertake any  measures specificall y required solely for the clinical 
study  until valid consent has been obtained.
A model of the inf ormed consent form to be used in this study  will be provided to the sites 
separately  from this protocol.
11.5 Subject Confidentiality
Subject names will not be supplied to the Sponsor . Only  the subject number and subject initials 
will be recorded in the eCRF, a nd if the subject name appears on an y other document, it must be 
obliterated before a cop y of the document is supplied to the Sponsor
. Study  findings stored on a 
computer will be stored in accordance with local data protection laws . The subjects will be told 
that representatives of the Sponsor, a designated CRO, the I RB/IEC/REB, or regulatory  
authorities may  inspect their medical records to verify  the information collected, and that all 
personal information made available for inspection will be handled in s trictest confidence and in 
accordance with local data protection laws . The Investigator will maintain a personal subject 
identification list (subject numbers with the corresponding subject names) to enable records to be 
identified.
11.6 Study Monitoring
Monitor ing procedures that comply  with current Good Clinical Practice (GCP) guidelines will be 
followed
. Review of the eCRFs for completeness and clarit y, cross -checking with source 
documents, and clarification of administrative matters will be performed.
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 53The study  will be monitored by  the Sponsor or its designee . Monitoring will be performed by  a 
representative of the Sponsor (Clinical Study  Monitor) who will review the eCRFs and source 
documents . 
The site monitor will ensure that the investigation is conducted a ccording to protocol 
design and regulatory  requirements by  frequent site visits and communications (letter, telephone, 
and facsimile).
11.7 Case Report Forms and Study Records
11.7.1 Case Report Forms
Electronic case report forms (eCRFs) are provided for each subject .All forms must be filled out 
by authorized study  personnel. All corrections to the original eCRF entry  must indicate the 
reason for change . The Investigator is required to sign the eCRF after all data have been captured 
for each subject . If corrections ar e made after review and signature b y the Investigator, he or she 
must be made aware of the changes, and his or her awareness documented by  resigning the 
eCRF.
11.7.2 Critical Documents
Before the Sponsor initiates the trial (ie, obtains informed consent from the first subject), it is the 
responsibility  of the Investigator to ensure that the following documents are available to Sponsor 
or their designee:
Completed FDA Form 1572 (Statement of Investigator), signed, dated, and accurate
Curricula vitae of Investigator and sub
-investigator(s) (current, dated and signed 
within 12 months of study initiation)
Copy  of Investigator and sub -investigator(s) current medical license (indicating 
license number and expiration date)
Signed and dated agreement of the final protocol
Signed and dated agreement of an y amendment(s), if applicable
Approval/favorable opinion from the IRB/IEC/REB clearl y identifying the documents 
reviewed b y name, number and date of approval or re approval :  protocol, any  
amendments, Subject Information/I nformed Consent Form, and any  other written 
information to be provided regarding subject recruitment procedures
Copy  of IRB/IEC/REB approved Subject Information/I nformed Consent Form/any  
other written information/advertisement (with IRB approval stamp and d ate of 
approval)
Current list of I RB/IEC/REB Committee members/constitution (dated within 
12months prior to study  initiation)
Financial Disclosure Form signed b y Investigator and sub- investigator(s)
Current laboratory  reference ranges (if applicable)
Certification/QA scheme/other documentation (if applicable)
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 54Regulatory  approval and notification as required must also be available; these are the 
responsibility  of Shire.
11.8 Data Monitoring Committee
Given that an y long -term safet y signal observed in this study  could impact the safet y profile of 
rhIGF -1/rhIGFBP -3 as administered in premature neonates being enrolled in the antecedent 
study  (ROPP -2008- 01, Section D), the Data Monitoring Committee (DMC) for Study  
ROPP -2008- 01 will review safet y data from this long - term outcome study .
11.9 Protocol Violations/Deviations
The Investigator will conduct the study  in compliance with the protocol. The protocol will not be 
initiated until the I RB/IEC/REB and the appropriate regulatory  authorities, where applicable, 
have given app roval/favorable opinion . Modifications to the protocol will not be made without 
agreement of the Sponsor . Changes to the protocol will require written IRB/I EC/REB 
approval/favorable opinion prior to implementation, except when the modification is needed to
eliminate an immediate hazard(s) to subjects . The IRB/IEC/REB may  provide, if applicable 
regulatory  authorities permit, expedited review and approval/favorable opinion for minor 
change(s) in ongoing studies that have the approval/favorable opinion of the IRB/IEC/REB . The 
Sponsor will submit all protocol modifications to the regulatory  authorities, where applicable, in 
accordance with the governing regulations.
A record of subjects screened, but not entered into the study , is also to be maintained . No 
proto
col exemption will be granted for this study .
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to 
subjects, the Investigator will contact the Sponsor or its designee, if circumstances permit, to 
discuss the planned course of action. An y departures from the protocol must be fully documented 
as a protocol deviation. Protocol deviations will need to be reviewed b y the medical monitor and 
may also be required to be submitted to the I RB/IEC/REB.
Protocol modifications wi ll only  be initiated by  the Sponsor and must be approved by  the 
IRB/IEC/REB and submitted to the FDA or other applicable international regulatory  authorit y 
before initiation, if applicable.
11.10 Premature Closure of the Study
If the Sponsor, Investigator, or re gulatory  authorities discover conditions arising during the stud y 
which indicate that the clinical investigation should be halted due to an unacceptable subject risk, 
the study  may  be terminated after appropriate consultation between the Sponsor and the 
Investigator(s) . In addition, a decision on the part of the Sponsor to suspend or discontinue 
development of the investigational product may  be made at any  time . Conditions that may  
warrant termination of the study
 or site include, but are not limited to:
The discovery  of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the study
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 55Failure of the Investigator to comply  with pertinent global regulations
Submission of knowingly  false information from the study  site to the Sponsor or ot her 
pertinent regulatory  authorities
Insufficient adherence b y the I nvestigator to protocol requirements
11.11 Access to Source Documentation
Regulatory  authorities, the I RB/IEC/REB, or the Sponsor may  request access to all source 
documents, eCRFs, and other st udy documentation for onsite audit or inspection. Direct access to 
these documents must be guaranteed b y the Investigator, who must provide support at all times 
for these activities. Monitoring and auditing procedures that compl y with current GCP guideline s 
will be followed . On-site review of the eCRFs for completeness and clarit y, crosschecking with 
source documents, and clarification of administrative matters may  be performed.
11.12 Data Generation and Analysis
The clinical database will be developed and mainta ined b y a contract research organization or an 
electronic data capture technology  provider as designated by  the Sponsor . The Sponsor or its 
designee will be responsible for performing study  data management activities. 
Adverse events will be coded using Me dical Dictionary  for Regulatory  Activities (MedDRA) . 
Concomitant medication will be coded using WHO
-Drug Dictionary  (WHO -DD). Central reads 
will be employ ed as described in the study  manual to aid in consistent measurement of 
abdominal ultrasound and echoc ardiogram parameters. 
11.13 Retention of Data
Essential documents should be retained until at least 2 y ears after the last approval of a 
marketing application and until there are no pending or contemplated marketing applications or 
at least 2 y ears have elapsed since the formal discontinuation of clinical development of the 
investigational product. The Sponsor will notify  the Investigator if these documents must be 
retained for a longer period of time . It is the responsibility  of the Sponsor to inform the 
Invest igator or institution as to when these documents no longer need to be retained.
11.14 Financial Disclosure
The Investigator should disclose an y financial interests in the Sponsor as described in 21 CFR 
Part 54 prior to beginning this study . The appropriate form will be provided to the I nvestigator 
by the Sponsor, which will be signed and dated b y the Investigator, prior to the start of the study . 
11.15 Publication and Disclosure Policy
All information concerning the stud y material, such as patent applications, manufac turing 
processes, basic scientific data, and formulation information supplied by  the Sponsor and not 
previously  published are considered confidential and will remain the sole propert y of the 
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 56Sponsor . The Investigator agrees to use this information only  in accomplishing this study  and 
will not use it for other purposes.
It is understood by  the Investigator that the information developed in the clinical study  may  be 
disclosed as required to the authorized regulatory  authorities and governmental agencies . In 
order to allow for the use of the information derived from the clinical studies, it is understood 
that there is an obligation to provide the Sponsor with complete test results and all data 
developed in the stud y in a timely manner.
The Investigator and an y other clinical personnel associated with this study  will not publish the 
results of the study , in whole or in part, at an y time, unless they  have consulted with the Sponsor, 
provided the Sponsor a copy  of the draft document intended for publication, and ob
tained the 
Sponsor’s written consent for such publication . All information obtained during the conduct of 
this study  will be regarded as confidential
. 
For non-commercial use only
For non-commercial use only
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27August 14
Shire Confidential 5933.Varni JW, L imbers CA. The pediatric quality  of life inventory :  measuring pediatri c health -
related qualit y of life from the perspective of children and their parents. Pediatr Clin North 
Am 2009;56:843-63.
34.Varni JW, L imbers CA, Neighbors K, et al. The PedsQL Infant Scales :  feasibility , internal 
consistency  reliability , and validity  in health y and ill infants. Quality  of life research :  an 
international journal of quality  of life aspects of treatment, care and rehabilitation 
2011;20:45-55.
35.Varni JW, Seid M, Kurtin PS. PedsQL  4.0:  reliability  and validity  of the Pediatric Qualit y of 
Life Inventory  version 4.0 generic core scales in healthy  and patient populations. Medical 
care 2001;39:800-12.
36. Saigal S, Rosenbaum P, Stoskopf B, et al. Development, reliability  and validity  of a new 
measure of overall health for pre -school children. Quality  of life research :  an international 
journal of quality  of life aspects of treatment, care and rehabilitation 2005;14:243 -57.
37. Rosenbaum DM, Korngold E, Teele RL. Sonographic assessment of renal length in normal 
children. Am J Roentgenol 1984;142:467 -9.
38.Rosenberg HK, Markowitz RI , Kolberg H, Park C, Hubbard A, Bellah RD. Normal splenic 
size in infants and children :  sonographic measurements. Am J Roentgenol 1991;157:119-21.
39.Stevens TP, Finer NN, Carlo WA, et al. Respiratory  Outcomes of the Surfactant Positiv e 
Pressure and Oximetry  Randomized Trial (SUPPORT). J Pediatr 2014;165:240- 9.e4.
40.Zivanovic S, Peacock J, Alcazar -Paris M, et al. Late outcomes of a randomized trial of high -
frequency  oscillation in neonates. N Engl J Med 2014;370:1121 -30.
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27 August 2014 
Shire Confidential 60Appendix 1 Study Schedule of Events
ProceduresInitial Study 
Visite Months (CA) Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 wks6 
± 1mth12
± 3 m ths20 
-1 mthg24
± 3mth3f
± 3mths4f
± 3mths4.75
-1 mthg5
+ 6 m ths
Informed Cons ent •
Eligibility Criteria •
Dem ographics •
Visual acuitya• • • • • •
Corrective lens determination • •g•g
Ocular alignment and motility • • •
Refraction with cycloplegia • • • • • •
Stereoacuity •
Length • • •
Height •
Weight • • • •
Head Circumference • • •
BSID -III • •
WPPSI -IV •
CBCL • •
VABS -II • • • •
ADHD -RS-IV •
SCQ •
Physical Exam ination includi ng tonsil 
examination • • • •
Cerebral Palsy Assessment •
Hearing Assessment Historyb•
Pulmonary Morbidity Assessment • • • •
Survival assessment • • • • • • •
HRQoLc• •h•h•h• • •h
HCRU • •h•h•h• • •h
HSCS -PS •h• • •h
Abdominal Ultrasound •
Echocardiogram •
Assessment of Participation in Other Clinical 
Studies• • • • • • •
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27 August 2014 
Shire Confidential 61ProceduresInitial Study 
Visite Months (CA) Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 wks6 
± 1mth12
± 3 m ths20 
-1 mthg24
± 3mth3f
± 3mths4f
± 3mths4.75
-1 mthg5
+ 6 m ths
Medications • • • • • • •
Adverse eventsd•i• • • • • • •
Abbreviati ons:  ADHD -RS-IV= Attention- Deficit/ Hyperactivity Disorder Rating Scale -fourth edition ; BSID -III=Bayley Scales of In fant and Toddler 
Development -Third Edition , CBCL =Child Behavior Checkli st; CA =corrected age; HCRU = health care resource use; HRQoL = health -related quality of l ife; 
HSCS -PS = Health Status Classification System; mth(s) =months; ; PedsQL =Pediatric Quality of Life Inventory; 
SCQ =Social Communication Questionnaire; VABS -II=Vineland Adaptive Behavio r Scales, Second Edition; wks=weeks; WPPSI -IV=Wechsler Preschool 
and Primary Scale of Intelligence, Fourth Edition
aThe tools used to assess visual acuity will change as the subject ages during their participation in the study . The tools that w ill be used in this study and are 
summarized by applicable study visit in Table 12-1.
bHistorical hearing test data may be recorded at any time during the study prior to the 6 -month visit.
cHRQoL will be assessed via the vali dated PedsQL™  scales appropriate for the child’s age of development as specified in the Study Operations Manual
dAdverse event collection will include an assessment of the specified targeted medical events 
eThe Initial Visit  may be performed prior to 40 weeks CA for any subject who discontinued from Study ROPP -2008- 01 and, for all subjects,  any time after 
40 w eeks CA, up to the study visit to occur at 3 months CA.
fVisits at 3 months, 3 years, and 4 years CA will be conducted by telephone.
gThe 20 -month vi sit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 month prior to the 24 -month and 5 -year visits, respectively. Any 
prescribed corrective lenses must be w orn for at least 1 month prior to the 24 -month and 5 -year assessments.
hThe HRQoL, HCRU, and HSCS -PS assessments for the 6 -month, 12 -month, 24 -month and 5 -year visits may be performed through a call center if there are 
time constraints during the on -site visit. At the 3 -month, 3 -year, and 4 -year visits, these assessments will be performed through a call center and may be 
performed at any time within the visit window .
iThe follow ing,collected as part of the ROPP -2008- 01 study ,will be used as part of this study (SHP -607-201):  any ongoing targeted medical events 
regardless of causality and any ongoing study dru g-related AEs, including SAEs.
For non-commercial use only
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3
Clinical Trial Protocol:  SHP -607-201 27 August 2014 
Shire Confidential 62Table 12-1 Summary of Visual Acuity Assessments 
Visual Acuity 
Assessment ToolDescription Unit of Measure Applicable 
Age/Study 
Visit (CA)
Teller acuity cardsResolution acuity –
discrimination of a grating 
optotype from a background with 
the same mean luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity -tests 
recognition of 4 optotypesSnellen fraction
(eg, 20/20)24 mon thsa
LEA Symbols 
(ETDRS -style) chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be made to assess visual acuity by the LEA 
Symbols Test and LEA Symbols Chart, respectively . If during this attempt, the examiner determines 
that it will not be possible to perform an accurate assessment w ith the relevant LEA tool, visual acuity 
should be assessed w ith the Teller acuity cards.
For non-commercial use only
For non-commercial use only
For non-commercial use only
  
     y 
SYNOPSIS
Sponsor:
Premacure AB, A Member of the Shire Group of Companies
Name of Finished Product:
Mecasermin rinfabate (rhIGF -1/rhIGFB P-3)
Study Title:
Long- term Outcome of Children Enrolled in Study ROPP -2008- 01 Previously Treated with 
rhIGF -1/rhI GFBP -3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received 
Standard Neonatal Care
Study Number:
SHP-607-201
Study Phase :  II
Investigational Product, Dose, and Mode of Administration:
Not applicable.
Primary Objectives
The primary objectives of this study are:
To evaluate the long -term efficacy outcomes following short -term exposure to 
rhIGF -1/rhI GFBP -3 versus stan dard neonatal care in Study ROPP -2008- 01 (Section D) 
as assessed by ROP associated visual outcomes
To evaluate the long -term safety outcomes following short -term exposure to 
rhIGF -1/rhI GFBP -3 versus standard neonatal care in Study ROPP -2008- 01 (Section D)
Secondary Objectives
The secondary objectives of this study are to evaluate the effect following short- term exposure to 
rhIGF -1/rhI GFBP -3 versus standard neonatal care in Study ROPP -2008- 01 (Section D) on:
Growth parameters
Cognitive development
Physical development
Child behavior
Pulmonary morbidity
Survival
Health -related quality of l ife (HRQoL)
Health u tility
Health care resource u se (HCRU)
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 2 of 68-
For non-commercial use only
For non-commercial use only
For non-commercial use only
  
     y 
Efficacy Assessments:
Efficacy will be assessed by visual outcomes, growth parameters, cognitive development, physical 
development, child behavior, p ulmonary morbidity, and survival.
Safety Assessments:
Safety will be assessed by physical examination (including tonsil examination), AEs (as
specified ), echocardiogram, and abdominal ultrasound.
Statistical Methods
Details regarding the statistical methods and definitions will be provided in the Statistical Analysis 
Plan (SAP) . The SAP will be finalized prior to database lock. All statistical analyses will be 
performed by the sponsor or CRO after the database is locked . Statistical analyses will be 
performed using Version 9.1 or higher of SAS®(SAS Institute, Cary, NC 27513).
Continuous variables will be summarized using d escriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categorical variables will be summarized using frequencies and percentages.
As referred to in descriptions of summary statistics , treatment groups refer to the 2 possible 
treatment assignments in the antecedent study, ROPP -2008- 01, Section D (rhIGF -1/rhI GFBP -3 or 
standard neonatal care).
For analysis purposes, baseline is defined as the first assessment either in the antecedent stu dy 
(ROPP-2008- 01) or in this study (SHP -607-201). As necessary , relevant data from Study 
ROPP -2008- 01 may be summarized with the data from this study (SHP -
607-201).
Date of Original Protocol :  27August 2014
Date of Amendment 1: 19 February 2016
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 5 of 68
For non-commercial use only
  
     y 
TABLE OF CONTENTS
SYNOPSI S.................................................................................................................................2
LIST OF IN -TEXT TABLES ..................................................................................................10
LIST OF IN -TEXT FIGURES .................................................................................................10
LIST OF ABBREVIATION S..................................................................................................11
1 INTRODUCTION ...........................................................................................................13
2 STUDY OBJECTIVES ....................................................................................................15
2.1 Primary  Objectives .................................................................................................15
2.2 Secondary  Objectives .............................................................................................15
2.3 Exploratory  Objective ............................................................................................15
3 STUDY ENDPOINTS ................................................................
.....................................16
3.1 Efficacy  Endpoints .................................................................................................16
3.1.1 Primary  Efficacy  Endpoints .........................................................................16
3.1.2 Secondary  Efficacy  Endpoints .....................................................................16
3.2 Health Economic Outcome Research Endpoints ...................................................17
3.3 Safety  Endpoints ....................................................................................................17
3.4 Exploratory  Endpoints ...........................................................................................17
4 INVESTIGATIONAL PLAN ..........................................................................................18
4.1 Overall Study  Design and Plan ..............................................................................18
4.2 Rationale for Study  Design ....................................................................................19
4.3 Study  Duration .......................................................................................................20
5 STUDY POPUL ATION SEL ECTION ...........................................................................21
5.1 Study  Population ....................................................................................................21
5.2 Inclusion Criteria ...................................................................................................21
5.3 Exclusion Criteria ................................
..................................................................21
6 STUDY TREATMENT ...................................................................................................22
6.1 Description of Treatment .......................................................................................22
6.2 Treatments Administered .......................................................................................22
6.3 Selection and Timing of Dose for Each Subject ....................................................22
6.4 Method of Assigning Subjects to Treatment Groups .............................................22
6.5
Masking ................................ ................................ ................................ .................. 22
6.6 Medications ............................................................................................................22
6.7 Restrictions ............................................................................................................22
6.7.1 Prior Therap y ...............................................................................................22
6.7.2 Other Restrictions ........................................................................................22
6.7.3 Treatment Compliance .................................................................................22
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 6 of 68
For non-commercial use only
  
     y 
6.7.4 Packaging and Labeling ................................ ................................ ............... 22
6.8 Storage and Accountability ....................................................................................23
7 STUDY PROCEDURES .................................................................................................24
7.1 Informed Consent ...................................................................................................24
7.2 Study  Entrance Criteria and Eligibility ..................................................................24
7.3 Study  Enrollment ...................................................................................................24
7.4 Demographics ........................................................................................................24
7.5 Growth Parameters:  Length (and Height), Weight, and Head Circumference.....24
7.5.1 Length and Height ................................ ........................................................24
7.5.2 Body Weight ................................
................................................................25
7.5.3 Head Circumference ....................................................................................25
7.6 Efficacy  Assessments .............................................................................................25
7.6.1 Visual Assessments ......................................................................................25
7.6.1.1 Visual Acuity .....................................................................................25
7.6.1.2 Corrective Lens Determination..........................................................26
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility ) .............26
7.6.1.4 Refraction with C ycloplegia ..............................................................27
7.6.1.5 Stereoacuit y
........................................................................................27
7.6.1.6
7.6.2 Hearing Assessment History ........................................................................28
7.6.3 Behavioral Assessments ...............................................................................28
7.6.3.1 Bayley Scales of Infant and Toddler Development, Third Edition....28
7.6.3.2 Wechsler Preschool and Primary  
Scale of Intelligence, Fourth 
Edition (WPPSI -IV)...........................................................................28
7.6.3.3 Child Behavior Checklist (CBCL)
.....................................................29
7.6.3.4 Vineland Adaptive Behavior Scales, Second Edition........................29
7.6.3.5 Attention
-Deficit/Hy peractivity  Disorder Rating Scale -Fourth 
Edition ................................................................................................30
7.6.3.6 Social Communication Questionnaire –Lifetime Form ....................30
7.6.4 Cerebral Pals y Assessment ................................
..........................................30
7.6.5 Pulmonary  Morbidit y Assessment ...............................................................30
7.6.6 Survival Assessment ................................
....................................................30
7.6.7 Health Economic Outcome Research Assessments.....................................31
7.6.7.1 Health Related Quality  of L ife...........................................................31
7.6.8 Health Care Resource Use ...........................................................................31
7.6.8.1 Health Status Classification Sy stem -Preschool .................................31
7.7 Safety  Assessments ................................ ................................ ................................ 32
7.7.1 Abdominal ultrasound................................ ................................ .................. 32
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 7 of 68
For non-commercial use only
  
     y 
7.7.2 Echocardiogram ................................ ................................ ........................... 32
7.7.3 Physical Examination ...................................................................................32
7.8 Medication Assessment .........................................................................................33
7.9 Adverse Events Assessments .................................................................................33
7.9.1 Definitions of Adverse Events, Serious Adverse Events, and Suspected 
Unexpected Serious Adverse Reactions ......................................................33
7.9.1.1 Adverse Event ....................................................................................33
7.9.1.2 Serious Adverse Event .......................................................................34
7.9.1.3 Suspected Unexpected Serious Adverse Reaction.............................35
7.9.1.4 Targeted Medical Events ...................................................................35
7.9.2 Classification of Adverse Events and Serious Adverse Events ...................35
7.9.3 Clarification between Serious and Severe ...................................................36
7.9.4 Relatedness of Adverse Events and Serious Adverse Event s......................36
7.9.5 Procedures for Recording and Reporting Adverse Events ..........................37
7.9.5.1 Adverse Event Monitoring and Period of Observation......................37
7.9.5.2 Reporting Serious Adverse Events ....................................................37
7.9.5.3 Regulatory  Agency , Institutional Review Board, Ethics Committee, 
and Site Reporting..............................................................................38
7.10 Removal of Subjects from the Trial .......................................................................39
7.11 Other Study  Procedures ................................
.........................................................39
7.11.1 Participation in Other Clinical Studies ........................................................39
7.12 Appropriateness of Measurements .........................................................................39
8 STUDY ACTIVIT IES................................................................
.....................................41
8.1 Initial Study  Visit (40 weeks CA [term equivalent]) .............................................41
8.2 Study  Visits ............................................................................................................41
8.2.1 Outcome Assessment Visits Conducted by
 Telephone ...............................42
8.2.2 Clinical Site Visits .......................................................................................42
8.2.2.1
Outcome Assessment Site Visits .......................................................42
8.2.2.2 Visits Dedicated to Corrective Lens Determination ..........................45
8.3 Assessments upon Discontinuation ................................ ................................ .......46
9 QUALITY CONTROL AND ASSURANCE .................................................................47
10 STATI STICAL ANALYSES ..........................................................................................48
10.1 General Methodology ............................................................................................48
10.2 Determination of Sample Size ...............................................................................48
10.3 Method of Assigning Study  Subjects to Treatment Groups ..................................48
10.4
Population Description ................................ ................................ ........................... 48
10.4.1 Analy sis Populations ................................ ................................ .................... 48
10.4.2 Subject Disposition ................................ ................................ ...................... 48
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 8 of 68
For non-commercial use only
  
     y 
10.4.3 Protocol Violations and Deviations ................................ ............................. 49
10.4.4 Demographics and Baseline Characteristics ................................................49
10.5 Efficacy  Anal ysis...................................................................................................49
10.5.1 Primary  Efficacy  Anal ysis...........................................................................49
10.5.2 Secondary  Efficacy  Analy sis.......................................................................50
10.5.3 Subset Analy ses...........................................................................................51
10.5.4 Exploratory  Anal yses...................................................................................51
10.6 Health Economics and Outcomes Research Anal yses...........................................51
10.7 Analy sis of Safet y..................................................................................................51
10.8 Statistical/Analy tical Issues ...................................................................................52
10.8.1 Adjustment for Covariates ...........................................................................52
10.8.2 Handling of Dropouts or Missing Data ........................................................52
10.8.3 Interim Anal yses and Data Monitoring........................................................52
10.8.4 Multiple Comparisons/Multiplicity .............................................................52
10.8.5 Sensitivity  
Anal yses.....................................................................................52
11 ADMINISTRATIVE CONSI DERATIONS....................................................................53
11.1 Investigators and Study  Administrative Structure .................................................53
11.2
Institutional Review Board or Independent Ethics Committee Approval .............53
11.3 Ethical Conduct of th e Study .................................................................................53
11.4 Subject I nformation and Consent ...........................................................................53
11.5 Subject Confidentiality ..........................................................................................54
11.6 Study  Monitoring ................................
...................................................................54
11.7 Case Report Forms and Study  Records .................................................................55
11.7.1 Case Report Forms .......................................................................................55
11.7.2 Critical Documents ................................
......................................................55
11.8 Data Monitoring Committee ..................................................................................56
11.9 Protocol Violations/Deviations ................................
..............................................56
11.10 Premature Closure of the Study .............................................................................56
11.11
Access to Source Documentation ..........................................................................57
11.12 Data Generation and Analy sis................................ ................................ ............... 57
11.13 Retention of Data ................................ ................................ ................................ ...57
11.14 Financial Disclosure ...............................................................................................57
11.15 Publication and Disclosure Policy .........................................................................58
12 LIST OF REFERENCES .................................................................................................59
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 9 of 68
For non-commercial use only
  
     y 
LIST OF IN -TEXT TABLES
Table 7-1 Summary  of Visual Acuity  Assessments ...................................................26
Table 7-2 Assessments for Phy sical Examinations ....................................................33
Table 7-3 Adverse Event Severit y..............................................................................35
Table 12-1 Summary  of Visual Acuity  Assessments ...................................................64
LIST OF IN -TEXT FIGURES
Figure 4-1 Overview of Study  Design, Study  SHP -607-
201.......................................19
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 10 of 68
For non-commercial use only
  
     y 
LIST OF ABBREVIATIONS
Abbreviation Definition
AAO American Academy of Ophthalmology
ADHD attention -deficit hyperactivity disorder
ADHD -RS-IV Attention -Deficit/ Hypera ctivity Disorder Rating Scale -fourth edition
AE adverse event
ASD Autism Spectrum Disorder
BSID -III Bayley Scales of Infant and Toddler Development, Third Edition
CBCL Child Behavior Checklist (1 ½ to 5)
CFR Code of Federal Regulations
CA corrected age
CI confidence interval
CRF case report form (electronic)
CRO contract research organization
DMC data monitoring committee
eCRF electronic case report form
EOS end of study
ETDRS Early Treatment of Diabetic Retinopathy Study
ER emergency room
EU European Union
FDA Food and Drug Administration
GCP Good Clinical Practice
GH grow th horm one
HRQoL health -related quality of l ife
HSCS -PS Health Status Classification System -Preschool
ICH International Conference on Harmonisation
IEC independent ethics committee
IGF insulin -like growth factor
IGFBP -3 insulin -like growth factor binding protein -3
IND Investigational New Drug application
IRB institutional review board
LV left ventricle
MedDRA Medical Dictionary for Regulatory Activities 
OD right eye
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 11 of 68
For non-commercial use only
  
     y 
Abbreviation Definition
OS left eye
OU both eyes
PedsQL Pediatric Quality of Life Inventory 
REB research ethics board
ROP retinopathy of prematurity
SAE serious adverse event
SAP statistical analysis plan
SAS Statistical Analysis System©
SCQ Social Communication Questionnaire
SD standard deviation
SOE schedule of events
SUSAR suspected unexpected serious adverse reaction
UK United Kingdom
US United States
VABS -II Vineland Adaptive Behavior Scales, Second Edition
VLBW very low birth weight
WHO World Health Organization
WHO -DD World Health Organization Drug Dictionary
WPPSI -IV Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 12 of 68
For non-commercial use only
  
     y 
1 INTRODUCTION
Retinopathy  of prematurity  (ROP) is a rare disorder of the developing retinal blood vessels and 
retinal neurons of the preterm infant and is one of the leading causes of preventable blindness in 
children.1
Visual acuity  is decreased in infants with a history  of ROP.2In addition to acuity, other aspects 
of ey e health are also significantly  impacted by  ROP . Strabismus and my opia are clearly  
increased in patients with a history  of ROP.3-6  Additionally , more than half of patients at 6 to 
10years of age with a history  of Stage 1 and Stage 2 ROP were reported to have ongoing visual 
issues.7
When preterm infants are deprived of their natural intrauterine environment, they  lose important 
factors normally  found in utero, such as proteins, growth factors and cy tokines . It has been 
demonstrated that IGF -1 is one such factor . During fetal life, IGF -1 is available through placental 
absorption and ingestion from amniotic fluid .8Deprivation of such factors is likely  to cause 
inhibition or improper stimulation of important pathway s, which in the ey e may  cause abnormal 
retinal vascul ar development, the hallmark of ROP.
The finding in both a mouse model of ROP and preterm infants that development of ROP is 
associated with low levels of IGF -1 after premature birth, indicates a possible role for 
replacement of IGF -1 to levels found in ut ero as a strategy  to potentially  decrease abnormal 
retinal vascularization and abnormal retinal neural development, and ultimately , ROP . 
Mecasermin rinfabate (rhIGF -1/rhIGFBP -3) is the human recombinant form of the naturall y 
occurring protein complex of I GF-1 and insulin-like growth factor binding protein- 3 (IGFBP -3). 
rhIGF -1/rhIGFBP -3 was developed to enhance the sy stemic exposure of administered rhIGF -1 
and to improve the safety profile of rhIGF -1 therapy . 
rhIGF-1/rhIGFBP -3 was approved by  the 
Food and D rug Administration ( FDA ) in 2005 for the treatment of growth failure in children 
with severe primary  IGF-1 deficiency  or with growth hormone (GH) gene deletion who have 
developed neutralizing antibodies to GH . 
The pharmacokinetics and safet y of rh IGF-1/rhIGFBP-3 have been evaluated in a Phase I study  
(ROPP -2005- 01) and pharmacokinetics, safet y, and efficacy are being evaluated in the ongoing 
phase II stud y (ROPP -2008 -
01). Sections A -C of the ROPP -2008- 01 study  are complete . 
Section D of the ROPP -2008- 01 st udy is currentl y being conducted to assess pharmacokinetics, 
safet y and efficacy of rhIGF -1/rhIGFBP -
3 for the prevention of ROP in premature infants (up to 
a corrected age [CA] of 40 weeks [± 4 day s]). Subjects in Study  ROPP -2008- 01are randoml y 
assigned to receive rhIGF -1/rhIGFBP -3 or standard neonatal care . The target dose of 
rhIGF -1/rhIGFBP -3 for Study  Section D is 250 μg/kg/24 hours to be administered via 
continuous infusion starting on Study  Day  0 (day  of birth) and continuing through postmenstrual 
age (gestational age + time elapsed from birth) 29 weeks + 6 day s.
Although the rh IGF-1/rhIGFBP -3 therap y in Section D of the Phase II study (Stud y 
ROPP -2008- 01) represents a short -term exposure (< 2 months for each subject), 
rhIGF -1/rhIGFBP -3 may have long -lasting effects on visual outcomes as well as other potential 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 13 of 68
For non-commercial use only
  
     y 
outcomes related to complications of prematurit y such as neurodevelopment, pulmonary  
function, and growth . In addition, it is critical to understand an y long term safety effects from 
short term exposure to rhIGF -1/rhIGFBP -3. 
The long- term outcomes assessed in this study  will require utilization of different assessment 
tools than are utilized in the Phase II stud y, ROPP -2008- 01 Section D, given the changes in 
physical and cognitive development th at will occur in the subjects as they  age during their 
participation in this study . 
Please refer to the current edition of the I nvestigator’s Brochure for further information 
concerning the safet y and clinical development of rhIGF -1/rhIGFBP -3.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 14 of 68
For non-commercial use only
For non-commercial use only
  
     y 
3 STUDY E NDPOINTS
3.1 Efficacy Endpoints
3.1.1 Primary Efficacy Endpoints
Visual acuity  as assessed by  an age -appropriate method
Ocular alignment and ocular motor examination in primary  gaze and in as many of 
9positions of gaze as possible as assessed b y corneal light reflex and b y the cover test
Assessment of n ystagmus by  observation
Refraction as assessed b y retinoscop y with cycloplegia
Stereoacuit y as assessed with the Lang Stereotest
3.1.2 Secondary Efficac y Endpoints
Growth parameters including bod y weight, bod y length (or height), and head 
circumference
Cognitive development as assessed b y the following standardized, age -appropriate 
tools:
oBayley Scales of Infant and Toddler Development, Third Edition (BSID- III)
oWechsler Preschool and Primary  Scale of Intelligence, Fourth Edition 
(WPPSI -IV)
Physical development as assessed by  standardized, age appropriate tools including 
physical exam ination , neurological examination for assessment of cerebral palsy , and 
hearing assessment
Child behavior as assessed by  the following:
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
oChild Behavior Checklist (CBCL ;1 ½ to 5)
oAttention- Deficit/ Hyperactivity  Disorder Rating Scale -fourth edition 
(ADHD -RS-IV) for the assessment of sy mptoms of 
attention -deficit/ hyperactivity  disorder (ADHD)
oSocial Communication Questionnaire (SCQ) for screening of Autism Spectrum 
Disorder (ASD)
Pulmonary  morbidity  data (eg, hospitalizations, emergency  room [ER] visits, 
pulmonary  medications)
Survival as assessed b y death during the study  due to any  cause
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 16 of 68
For non-commercial use only
For non-commercial use only
  
     y 
4 INVESTIGATIONAL PLAN
4.1 Overall Study Design and Plan
This is a Phase II, multicenter, long- term developmental outcome study  enrolling subjects who 
were randomized in Section D of Study  ROPP -2008-01 to receive either rhIGF -1/rhIGFBP -3
(treated) or standard neonatal care (control) . Enrolled subjects in this study  will be followed 
through age 5 years CA . This study  will enroll both subjects who were in the treated (received 
rhIGF -1/rhIGFBP -3) and control (received standard neonatal care) groups of Study  
ROPP -2008-01 (Section D) to enable assessment of rhIGF- 1/rhIGFBP -3 long -term efficacy  and 
safety outcomes versus standard neonatal care. No investigational product will be administered 
in this study . 
In this stud y, the Initial Visit will occur at 40 weeks CA (ie, term equivalent) or upon 
discontinuation from Study  ROPP -2008- 01 or may  occur any  time up to the visit at 3 months 
CA. Subjects in Study  ROPP -2008- 01 are premature infants enrolling at gestational age of 
23weeks + 0 day s to 27 weeks + 6 day
s.
Time points for assessments have been chosen based on standard premature infant follow -up 
perio ds and represent important developmental ages for premature infant follow -
up. Both 
telephone and clinical site visits are included to help maintain contact with subjects throughout 
the 5- year duration of the study .
Subjects will be evaluated at appropriate follow -up site locations with expertise in the 
assessment of the developmental outcomes of premature infants . Pediatric ophthalmology  
expertise will also be required. 
See Appendix 1for the Study  Schedule of Events 
table.
The overall study  design is outlined in Figure 4-
1.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 18 of 68
For non-commercial use only
For non-commercial use only
  
     y 
Insulin -like growth factor -1 (IGF -1) mediates its primary  actions b y binding to its specific 
receptor, the insulin- like growth factor 1 receptor (IGF -1R), which is present on many  cell ty pes 
in many  tissues . Binding to its rec eptor initiates intracellular signaling including via the AKT 
signaling pathway . This pathway  is involved in stimulation of cell division, growth and 
differentiation and inhibits programmed cell death. Specificall y regarding premature infants, 
IGF-1 is an important mediator of fetal growth and has been shown to play  a role in earl y 
postnatal growth following pre -term delivery .9,10
Insulin -like growth factor -1 (IGF -1) has also been shown to play  a role in pulmonary  
development11and neural development.12,13Given the potential role for IGF-1 in the 
development of multiple sy stems, this study  has been designed to evaluate the long -term effects 
of rhIGF -1/rhIGFBP -3, both from a safety  and efficacy  perspective, on the development of the 
premature infant.
4.3 Study Duration
Duration for an individual subject’s participation in the study will vary  depending upon age at 
enrollment, but subjects will not be followed beyond age 5.5 years CA .
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 20 of 68
For non-commercial use only
  
     y 
5 STU DY POPULATION SELECT ION
5.1 Study Population
Subjects randomized in Study  ROPP -2008- 01, Section D are eligible to enroll in this study ; 
completion of Study  ROPP -2008- 01 Section D is not required. Subjects in Study  ROPP -2008-01 
are premature infants (gestational age of 23 weeks + 0 day s to 27 weeks + 6 day s) who are 
randomized to receive either treatment with rhIGF- 1/rhIGFBP -3 or standard neonatal care. Up to 
120 subjects are planned to be randomized in Study ROPP -2008- 01 Section D.
5.2 Inclusion Criteria
Each subject must meet the following criteria to be enrolled in this study .
1.Subje ct was randomized in Study  ROPP -2008- 01, Section D
2.Subject’s parent or legally  authorized representative(s) must provide written informed 
consent prior to performing an y stud y-related activities. Study -related activities are an y 
procedures that would not have been performed during normal management of the subject.
5.3 Exclusion Criteria
Subjects who meet an y of the following criteria will be excluded from the study.
1.Any other condition or therapy  that, in the Investigator’s opinion, may  pose a risk to the 
subject or interfere with the subject’s ability  to be compliant with this protocol or interfere 
with the interpretation of results
2.The subject or subject’s parent or legally  authorized representative(s) is unable to comply  
with the protocol as determined by  the Investigator
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 21 of 68
For non-commercial use only
  
     y 
6 STUDY TREATMENT
6.1 Description of Treatment
No investigational product will be administered in this study .
6.2 Treatments Administered
Not applicable.
6.3 Selection and Timing of Dose for Each Subject
Not applicable.
6.4 Method of Assigning Subjects to Treatment Groups
Not applicable.
6.5 Masking
Not applicable.
6.6 Medications
Any medications administered to the subjects will be collected from the time of informed 
consent through the 5- year CA visit (or until the subject withdraws or is discontinued). An y 
investigational product received b y subjects will be recorded separatel y as part of an assessment 
of subjects’ participation in other clinical studies (Section 7.11.1).
6.7 Restricti ons 
6.7.1 Prior Therapy
There are no restrictions related to prior therap y.
6.7.2 Other Restrictions
There are no restrictions related to fluid or food intake, or subject activity .
6.7.3 Treatment Compliance
Not applicable.
6.7.4 Packaging and Labeling
Not applicable.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 22 of 68
For non-commercial use only
  
     y 
6.8 Storage and Accountability
Not applicable
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 23 of 68
For non-commercial use only
  
     y 
7 STUDY PROCEDURES
Detailed descriptions of subject procedures and evaluations required for this protocol are 
described in this section . These evaluations will be performed during the indicated day s and 
weeks of the stud y (see Schedule of Events in Appendix 1). 
All data collected are to be recorded on the subject’s appropriate eCRF. 
Details for stud y procedures are described in the Operations Manual for this study.
7.1 Informed Consent
Prior to conducting an y study -related procedures, written informed consent must be obtained 
from the subject’s parent(s) or legall y authorized representative(s).
The nature, scope, and possible consequences, including risks and benefits, of the study will be 
explained to the subject, the subje ct’s parent(s), or the subject’s legall y authorized representative 
by the Investigator or designee in accordance with the guidelines described in Section 11.4. 
Documentation and filing of informed consent documents should be completed according to 
Section 11.4.
7.2 Study Entrance Criteria and Eligibility
At the I nitial Visit , each subject will be reviewed for eligibility  against the study  entrance 
criteria . Subjects who do not meet the study  entrance criteria will not be allowed to participate in 
the study . The reason(s) for the subject’s ineligibility  for the stud y will be documented . No 
exemptions will be allowed.
7.3 Study Enrollment
Subjects will be considered enrolled in the stud y once written informed consent has been 
obtained from the subject’s parent(s) or l egally  authorized representative(s).
7.4 Demographics
Subject demographic information including gender, date of birth , and race will be recorded.
7.5 Growth Parameters :  Length (and Height), Weight, and Head Circumference
7.5.1 Length and Height
Body length (supine mea surement) will be collected when subjects are 24 -months CA or 
younger . For the length measurement, the subject will be placed on his or her back so that the 
subject is ly ing straight and the shoulders and buttocks are flat against the measuring surface. 
The subject's ey es should be looking straight up and care should be taken that the head is in a 
neutral position (neither being flexed nor extended at the neck). Both legs should be fully  
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 24 of 68
For non-commercial use only
  
     y 
extended and the toes should be pointing upward with feet perpendicula r to the measuring 
surface.
Height (standing measure) will be collected when subjects are older than 24 -months CA. A 
stadiometer should be utilized for measurement of height . The subject should remove shoes.
For the measurement of standing height, the child is instructed to stand erect (stand up straight 
and look straight ahead) with the child’s head positioned in a horizontal plane . The moveable 
headpiece is brought onto the upper most (superior) point on the head with sufficient pressure to 
compress t he hair. 
For height and length, 2 measures should take place and both will be recorded . If the 2 measures 
are discrepant b y >2 cm, the measures should be repeated. All measures should be recorded in 
metric units and measurement should be recorded to the nearest tenth centimeter (0.1 cm). 
7.5.2 Body Weight
Body weight will be collected . Calibrated scales should be utilized for body  weight measures 
(type of scale will depend upon subject’s age) . Care should be taken to remove any  extraneous 
clothing prior to meas ures and shoes should be removed.
The measure should be recorded to the nearest 0.1 kg.
7.5.3 Head Circumference
Head circumference will be measured for all subjects. An accurate head circumference 
measure ment is obtained with a “lasso” -type, non -stretchable measuring tape such as the Lasso -o 
tape. Head circumference or occipital frontal circumference is measured over the occiput and just 
above the supraorbital ridge, which is the largest circumference of the head.
7.6 Efficacy Assessments
7.6.1 Visual Assessments
After corrective lens determination has occurred (Section 7.6.1.2), all visual assessments should 
be conducted with best -corrected vision, ie, with corrective lenses in place (if required); this 
applies to 24-month and 5- year visits.
7.6.1.1 Visual Acuity
Visual acuity is a measure of how well a subject sees at different distances . It will be assessed by  
the methods summarized in Table 7-1; the method employ ed will be selected based on the 
subject’s age (CA) at the time of the study  visit . 
Visual acuity  measurements wil l be measured 
and recorded for the left (OS), right (OD) ey e, and both ey es (OU).
At ages 6 months and 12 months CA, visual acuity will be assessed with Teller acuit y cards . At 
ages 24 months and 5 years CA an attempt should be made to assess visual acuit y by the LEA 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 25 of 68
For non-commercial use only
  
     y 
Symbols Test and LEA Sy mbols Chart, respectively . If during this attempt, the examiner 
determines that it will not be possible to perform an accurate assessment with the relevant LEA 
tool, visual acuity  should be assessed with the Teller acuit y cards. 
The visual acuit y assessments should be performed by an optometrist or ophthalmologist trained 
in pediatrics. 
Table 7-1 Summary of Visual Acuity Assessments 
Visual Acuity 
Assessment ToolDescription Unit of Measure Applicable 
Age/Study 
Visit (CA)
Teller acuity cardsResolution acuity –
discrimination of a grating 
optotype from a background with 
the same mean luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity - tests 
recognition of 4 optotypesSnellen fraction
(eg, 20/20)24 monthsa
LEA Symbols 
(ETDRS -style) chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be made to assess visual acuity by the LEA 
Symbols Test and LEA Symbols Chart, respectively . If during this attempt, the examiner determines 
that it will not be possible to perform an acc urate assessment w ith the relevant LEA tool, visual acuity 
should be assessed with the Teller acuity cards.
7.6.1.2 Corrective Lens Determination
An assessment to determine if the subject requires vision correction with corrective lenses will 
be performed. This is being performed to ensure the accuracy  of subjects’ subsequent visual 
acuity  assessments (at the 24-month and 5- year visits) . The corrective lens determination will be 
performed according to the guidelines published by the American Academy of Ophthalmol ogy 
(AAO).14
This assessment should be performed b y an optometrist or ophthalmologist trained in pediatrics . 
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility)
Ocular alignment will be assessed in primary  gaze by  comparing the position of the corneal ligh t 
reflection in OS and OD (corneal light reflection assessment). Presence or absence of strabismus 
will be recorded in primary  gaze and in as many  of the 9 positions of gaze as feasible with the 
cover test assessment of refixation mo vement. Extraocular mus cle over- action or deficiency  will 
be recorded. The assessment will be performed according to the AAO guidelines .14
Presence or absence of ny stagmus as observed during the ocular alignment assessments will also 
berecorded.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 26 of 68
For non-commercial use only
For non-commercial use only
For non-commercial use only
  
     y 
It not onl y applies to healthy children, but in the course of the scale’s standardization20special 
group validity  studies were performed, including, but not limited to, groups of children with 
developmental risk factors, autistic disorder, and intellectual disability . Scores may  be 
interpreted in the context of provided norms, which reflect inclusion of the special groups.
The WPPSI -IV will be administered to the s ubject by  a trained professional . Scores to be 
recorded are detailed in the Study Operations Manual.
7.6.3.3 Child Behavior Checklist (CBCL)
The CBCL (1 ½ to 5) is a parent -reported outcome measure used to assess behavioral, emotional, 
and social functioning of toddlers and preschool children aged 18 to 60 months .21It is compos ed 
of 99 items that are rated on a L ikert scale and includes the following 7 s yndrome scales 
arranged under 2 domains (ie, Internalizing and Externalizing Problems) :22
Internalizing Problems
Emotionally  Reactive
Anxious/Depressed
Somatic Complaints
Withdrawn
Sleep Problems
Attention Problems
Aggressive Behavior
The questionnaire is widely  used and has been employ ed to assess long- term behavioral 
outcomes in children born prematurel y, aged similarly to the subjects expected in this study  
population.22-24It is associated with well -established normative data;25norms may  be selected to 
aid in interpretation of the scale scores.
The CBCL (1 ½ to 5) is a questionnaire t hat will be administered to the subject’s parent(s) or 
legally  authorized representative(s) by  a trained professional. Scores to be recorded are detailed 
in the Study  Operations Manual.
7.6.3.4 Vineland Adaptive Behavior Scales, Second Edition
The VABS -II Expanded Interview Form will be used to measure the personal and social skills of 
subjects seriall y over time; these scales are organized within a 3 -domain structure :  
Communication, Daily  Living, and Socialization. In addition, the VABS -II offers a Motor Skills 
Domain and an optional Maladaptive Be havior Index. The VABS -II Expanded Interview Form 
assesses what a subject actually does, rather than what he or she is able to do. 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 29 of 68
For non-commercial use only
  
     y 
The VAB S-II Expanded Interview Form will be administered to the subject’s parent(s) or l egall y 
authorized representative(s) b y a trained professional . Scores to be recorded are detailed in the 
Study  Operations Manual.
7.6.3.5 Attention -Deficit/Hyperactivity Disorder Rating Scale -Fourth Edition
The ADHD -RS-IV was developed to measure the behaviors of children with ADHD. The 
ADHD -RS-IV consists of 18 items designed to reflect current symptomatology  of ADHD based 
on DSM -IV criteria. Each item is scored from a range of 0 (reflecting no s ymptoms) to 
3(reflecting severe s ymptoms) with total scores ranging from 0 -54. The 18 items are grouped 
into 2 subscales:  hyperactivity -impulsivity  (even numbered items 2- 18) and inattention 
(“inattentivene ss”) (odd numbered items 1 -17).
The ADHD -RS-IV,26will be completed b y the subject’s parent(s) or legally  authorized 
representat ive(s). Scores to be recorded are detailed in the Study  Operations Manual.
7.6.3.6 Social Communication Questionnaire – Lifetime Form
The SCQ is a brief instrument that helps evaluate communication skills and social functioning in 
children27that can be used for screening for autism or autism spectrum disorders in the general 
population .28
The SCQ will be completed by  the subject’s parent(s) or legall y authorized representative(s). The 
investigator or designee should review the assessment for completeness and to confirm all 
responses . Scores to be recorded are detailed in the Study  Operations Manual.
7.6.4 Cerebral Palsy Assessment
Comprehensive neurological examination for the diagnosis of cerebral palsy (CP) will be 
conducted . The Amiel -Tison neurological examination framework29will be utilized for this 
assessment and conducte d by trained medical professionals.
7.6.5 Pulmonary Morbidity Assessment
Pulmonary  morbidity  will be assessed with questions related to famil y history and smoking 
status as well as diagnosis of select pulmonary  symptoms, conditions and related 
hospitalizations. The assessment will be administered to the subject’s parent(s) or legall y 
authorized representative(s). 
7.6.6 Survival Assessment
Survival status will be assessed and recorded.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 30 of 68
For non-commercial use only
  
     y 
7.6.7 Health Economic Outcome Research Assessments
7.6.7.1 Health Related Quality of Life
Health-r elated qualit y of l ife (HRQoL) is an important outcome towards improving the health 
care of pediatric patients as it is that part of a person’s overall qualit y of life that is determined 
primarily  by their health status and which can be influenced by  clini cal interventions . It is an 
important concept, which is also used in determining the value of health care services in this 
population.30,31It is a multidimensional construct whose content is guided by the World Health 
Organization;32minimally it includes ph ysical, psy chological (including emotional and 
cognitive), and social health dimensions .
In this stud y, HRQoL will be assessed via the validated Pedia tric Quality  of L ife Inventory  
(PedsQL™) Scales appropriate for the child’s age of development.33-35  The development of the 
PedsQL  was based on the delineations of the World Health Organization ( WHO )and is a 
modular approach to assessing HRQoL in the pediatric population. Initially , the PedsQL  Generic 
Scales were developed an d continue to be used in children aged 2 to 18 years. More recently  
Infant Scales have been developed that appl y to ages 1 to 24 months.34
The following scales will be used in this study :
Infant Scale for ages 1 -12 months (36 I tems)
Infant Scale for ages 13 –24 months (45 I tems)
Toddler Scale for 2 -4 years of age (21 Items)
Young Child Scale for 5 -7 years of age (23 Items)
The PedsQL will be administered to the subject’s parent and may  be conducted via telephone by 
clinical site staff . The scale(s) to be administered at each visit will be specified in the Study  
Operations Manual.
7.6.8 Health Care Resource Use
To understand the value of the investigational product administered in Study  ROPP -2008-01 
(Section D), the resource use associated with inpatient visits, outpatient visits, and medical and 
pharmacy utilization in this study  will be recorded. 
This assessment may be conducted via telephone by clinical site staff .
7.6.8.1 Health Status Classification System -Preschool
Health status (eg, health u tility ) will be measured by  the Health Status Classification 
System -Preschool (HSCS -PS), which is a validated instrument adapted for use via parent prox y 
within the pediatric population age 2.5 to 5 (adapted from the validated Health Utilities I ndex 
Mark 2 and 3 [HUI 2/3]).36  Validity  of the HSCS -PS concepts has not been established for ages 
younger than 2.5 y ears.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 31 of 68
For non-commercial use only
  
     y 
The HSCS- PS was developed to provide a consistent measure of health status in preschool -aged 
children who had been born prematurely .36The sy stem is applicable to children with special 
needs as may  be included in this study ; validation cohor ts for the s ystem included children with 
very low birth weight (VLBW), which is congruent with this study  population.
The instrument is composed of 12 dimensions (Vision, Hearing, Speech, Mobility , Dexterity , 
Self-care, Emotion, Learn/remember, Think/problem solve, Pain, General Health, and Behavior) 
intended to provide a comprehensive assessment of a child’s health status as it pertains to 
health- related quality  of life . The individual domains of the instrument will be scored as a mean 
score, representing the overall state for each concept individually . The global score will be 
recorded as well as the scores for each of the dimensions.
The HSCS- PS is a questionnaire that will be administered to the subject’s parent(s) or legall y 
authorized representative(s) and may  be conducted via telephone by clinical site staff .
7.7 Safety Assessments
7.7.1 Abdominal ultrasound
An abdominal ultrasound will be performed to assess the size of the spleen and kidney s. The 
spleen will be measured in the coronal longitudinal plane and th e longest longitudinal length will 
be measured for each kidney  (left and right) .37Ultrasound results will be assessed by a central 
reader.
Organ size will be interpreted in the context of reference values established for children .37,38
7.7.2 Echocardiogram
Echocardiographic examination (conventional M- mode recording of the left ventricle [L V] 
parasternal long axis view) will be performed for the evaluation of cardiac size, assesse d by 
measuring the following:
interventricular septal thickness (during end diastole)
LV posterior wall thickness
LV intracavit y volume (both in end diastole and end systole)
Echocardiogram results will be assessed by a central reader.
7.7.3 Physical Examination
Physical examinations will include a review of the subject’s general appearance, neurological 
examination, as well as a tonsillar examination ( Table 7-2). An y abnormal change in findings 
will b e recorded as an AE
. 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 32 of 68
For non-commercial use only
  
     y 
Table 7-2 Assessments for Physical Examinations
Assessment Assessment
General appearance Endocrine
Head and neck Cardiovascular
Eyes Abdomen
Ears Genitourinary
Nose Skin
Throat Musculoskeletal
Chest and lungs Neurological
Tonsils
7.8 Medication Assessment
All medications received by  study  subjects will be collected from the time of enrollment through 
the 5- year CA visit (or upon discontinuation) . Any investigational product received b y subjects 
will be recorded separately  as part of an assessment of subjects’ participation in other clinical 
studies (Section 7.11.1).
7.9 Adverse Events Assessments
7.9.1 Defin itions of Adverse Events, Serious Adverse Events , and Suspected 
Unexpected Serious Adverse Reactions
7.9.1.1 Adverse Event
An AE is an y noxious, path ologic, or unintended change in anatomical, phy siologic, or 
metabolic function as indicated b y physical signs, sy mptoms, or laboratory  changes occurring in 
any phase of a clinical study , whether or not considered investigational product-related. This 
includes an exacerbation of a pre -existing condition . 
Adverse events include:
Worsening (change in nature, severit y, or frequency) of conditions present at the onset 
of the study
Intercurrent illnesses
Drug interactions
Events related to or possibly  related to concomitant medications
Abnormal laboratory values (this includes significant shifts from baseline within the 
range of normal that the Investigator considers to be clinically  important)
Clinically  significant abnormalities in phy sical examination, vital s igns, and weight
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 33 of 68
For non-commercial use only
  
     y 
In this long -term outcome study  in follow -up to Study  ROPP -2008- 01 (Section D), no 
investigational product is being administered. However, the relationship to the investigational 
product (rhIGF -1/rhIGFBP -3) as administered in Study  ROPP -2008- 01 (Section D) will be 
assessed . 
For the purposes of this study  only the following a dverse events will be collected:  
those considered related to investigational product (rhIGF- 1/rhIGFBP -3 as 
administered in Study  ROPP -2008- 01, Section D)
those considered related to procedures performed in this study  (Study  SHP -607-201)
specified targeted medical events (Section 7.9.1.3) regardless of causality
Throughout the stud y, the Investigator must record AEs on the AE electronic case report form 
(eCRF), regardless of the severit y. The Investigator should treat subjects with AEs appropriatel y 
and observe them at suitable intervals until the events stabilize or resolve . Adverse events may  
be discovered through observation or examination of the subject, ques tioning of the subject, 
complaint by  the subject, or by  abnormal clinical laboratory  values.
In addition, AEs may  also include laboratory values that become significantly  out of range . In 
the event of an out -
of-range value, the laboratory  test should be re peated until it returns to 
normal or can be explained and the subject’s safety is not at risk. 
Additional illnesses present at the time when informed consent is given are regarded as AEs and 
will be documented on the appropriate pages of the eCRF . Illness es first occurring or detected 
during the stud y, and worsening of a concomitant illness during the stud y, are to be regarded as 
AEs and must be documented as such in the eCRF.
7.9.1.2 Serious Adverse Event
An SAE is any  AE that results in any  of the following outc omes:
Death
Is life -threatening
Requires hospitalization
Requires prolongation of existing hospitalization
A persistent or significant disability  or incapacity  
A congenital anomal y or birth defect
Important medical events that may  not result in death, be life-threatening, or require 
hospitalization may  be considered an SAE when, based upon appropriate medical judgment, they  
may jeopardize the subject and may  require medical or surgical intervention to prevent one of the 
outcomes listed in this definition .A life -threatening AE is defined as an AE that placed the 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 34 of 68
For non-commercial use only
  
     y 
subject, in the view of the initial reporter, at immediate risk of death from the AE as it occurred 
(ie, it does not include an AE that, had it occurred in a more severe form, might have caused 
death).
For the purposes of this study  only SAE listed in the following will be collected:
fatal SAEs regardless of causality
SAEs related to ROP
SAEs related to congenital malformations not identified at birth which may impact 
neurocognitive development 
7.9.1.3 Suspected Unexpected Serious Adverse Reaction
Suspected unexpected serious adverse reactions (SUSAR) are suspected adverse reactions related 
to an investigational product (investigational products and comparators [if applicable]), which 
occur in the concerned study , and that are both serious and unexpected according to the current 
Investigator’s Brochure .
7.9.1.4 Targeted Medical Events
If it is determined that any of the following targeted medical events have been experienced b y a 
subject , they  will be recorded as AEs or SAEs, as appropriate, regardless of relationship to 
investigational product ( rhIGF-1/rhIGFBP -3 as administered in Study  ROPP -2008-01, 
Section D):
intracranial hy pertension
any abnormalit y of glucose metabolism (eg, hypoglycemia, h ypergl ycemia, and 
diabetes)
tonsillar hy pertrophy  (based on tonsil exam [part of the phy sical exam])
increased kidney  size 
increased cardiac size
increased spleen size
7.9.2 Classification of Adverse Events and Serious Adverse Events
The severit y of AEs will be assessed b y the Investigator based on the definition indicated in 
Table 7-3. The severit y of all AEs/SAEs should be recorded on the appropriate eCRF page to a 
severit y of mild, moderate, or severe.
Table 7-3 Adverse Event Severity
Severity Definition
Mild No limitation of usual activities.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 35 of 68
For non-commercial use only
  
     y 
Table 7-3 Adverse Event Severity
Severity Definition
Moderate Some limitation of usual activities.
Severe Inability to carry out usual activities.
7.9.3 Clarification between Serious and Severe
The term “severe” is often used to describe the intensity  (severit y) of a specific event (as in mild, 
moderate, or severe m yocardial infarction); the event itself, however, may  be of relatively  minor 
medical significance (such as severe headache) . This is not the same as “serious,” which is based 
on the outcome or action criteria usually associated with events that pose a threat to life or 
functioning. Seriousness (not severity) and causality serve as a guide for defining regulatory 
reporting obligations.
7.9.4 Relatednes s of Adverse Events and Serious Adverse Events
Relationship of an AE or SAE to investigational product (rhIGF- 1/rhIGFBP -3 as administered in 
Study  ROPP -2008- 01, Section D) is to be determined by  the Investigator based on the following 
definitions (See Table 7-4).
Table 7-4 Adverse Event Relatedness
Relationship to Product Definition
Not Related Unrelated to investigational product
Possibly Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, but which could 
also be explained by concurrent disease or other drugs or chemicals.
Probably Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, unlikely to be 
attributable to concurrent disease or other drugs and chemicals and 
which follows a clinically reasonable response on de -challenge . The 
association of the clinical event or laboratory abnormality must also 
have so me biologic plausibility, at least on theoretical grounds.
Definitely related The event follows a reasonable temporal sequence from administration 
of the investigational product, follows a known or suspected response 
pattern to the investigational product, is confirmed by improvement 
upon stopping the investigational product (de -challenge), and 
reappears upon repeated exposure (re -challenge) . Note that this is not 
to be construed as requiring re -exposure of the subject to 
investigational product; ho wever, the determination of definitely 
related can only be used when recurrence of event is observed.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 36 of 68
For non-commercial use only
For non-commercial use only
For non-commercial use only
  
     y 
7.10 Removal of Subjects from the Trial
A subject’s participation in the study  may  be discontinued at any  time at the discretion of the 
Investigator . The following may  be justifiable reasons for the Investigator to remove a subject 
from the study :
Non-compliance, including failure to appear at one or more stud y visits
The subject was erroneously  included in the study
The subject develops an exclusion criterion 
The study is terminated by  the Sponsor
The subject, the subject’s parent(s), or the subject’s legall y authorized representative acting on 
behalf of the subject is free to withdraw consent and discontinue partic ipation in the study  at an y 
time without prejudice to further treatment.
If a subject or the subject’s parent(s) or the subject’s legally  authorized representative(s) acting 
on behalf of the subject, discontinues participation in the study , or the subject is discontinued by  
the Investigator, reasonable efforts will be made to follow the subject through the end of study  
assessments . The reason for refusal will be documented on the eCRF. An y AEs experienced up 
to the point of discontinuation must be documente d on the AE eCRF . If AEs are present when 
the subject withdraws from the study , the subject will be re -evaluated within 30 day s of 
withdrawal . All ongoing SAEs at the time of withdrawal will be followed until resolution.
7.11 Other Study Procedures
7.11.1 Participatio n in Other Clinical Studies
Following enrollment, subjects in this study  will not be restricted from enrolling in another 
clinical study  that involves the use of investigational product . The status of a subject’s 
participation in such studies will be re corded (ie, yes/no) . If a subject is enrolled in such a study, 
additional parameters will be recorded, including the masking status of the study , the identity  of 
the investigational product being evaluated in the study, and the subject’s treatment assignme nt 
in the study  (if possible) . 
7.12 Appropriateness of Measurements
Overall, the primary  and secondary  efficacy  and safet y measures being employed in this study 
are considered appropriate for the follow -up of preterm infants. The validated tools being used to 
assess neurodevelopment, phy sical development, and health economic research outcomes in this 
pediatric population are widely used and recognized.
In some cases tools were designed specifically  for use in this study . These are the pulmonary  
morbidity  assess ment and the cerebral palsy  assessment . In these cases, the tools are either based 
on validated tools or the current state of knowledge in the literature . For example, the cerebral 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 39 of 68
For non-commercial use only
  
     y 
palsy  assessment is based on the Amiel -Tison neurological examination frame work29and the 
pulmonary  assessment is based on published rese arch in a similar pediatric population39,40.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 40 of 68
For non-commercial use only
  
     y 
8 STUDY ACTIVITIES
The timing of the visits in this study  is based on subjec ts’ corrected age (CA). 
8.1 Initial Study Visit (40 weeks CA [term equivalent])
The Initial Visit will occur at 40 weeks CA (ie, term equivalent) or upon discontinuation from 
Study  ROPP -2008- 01, Section D or any  time up to the visit at 3 months CA . 
At the I nitial Visit, informed consent will be obtained followed by  an assessment of study  
eligibility  criteria and collection of demographic data.
The following AE d ata, collected as part of Study  ROPP -2008- 01 (Section D) will be recorded :
Ongoing targeted medical events regardless of causality
Ongoing stud y drug -related AEs, including SAEs
SAEs , as outlined in Section 7.9.1.1 and Section 7.9.1.2, that the subject experiences between the 
ROPP -2008- 01 end-of- study  visit and the time of informed consent for the SHI P-607- 201 study  
will be reported b y the Investigator ,pending permission for subject’s parent or legally  authorized 
representative(s) ,as documented on the informed consent form.
8.2 Study Visits
Study  visits for follow -up outcome assessments will take place at the following time points in 
CA:
3 months (±2 weeks) –conducted by  telephone
6 months (±1 month) –clinical site visit
12 months (±3 months) – clinical site visit
20 month ( -1 months) 
–clinical site visit
24 months (±3 months) –clinical site visit
3 years (±3 months) – conducted by  telephone
4 years (±3 month) – conducted by  telephone
4.75 y ears (
-1 months) – clinical site visit
5 years(+6 months) – clinical site visit
In addition, there will be 2 visits that must occur at least 1 month prior to the 24 -month and 
5-year CA stud y visits to assess the need for corrective lenses . The timing of these 2 visits 
(20months [ -1 month] and 4.75 years [-1 month]) was set to ensure that any  prescribed 
corrective lenses would be worn for at least 1 month prior to the visual assessments at the 
24-
month and 5- year study visits CA.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 41 of 68
For non-commercial use only
  
     y 
The activities at the study  visits are described in Sections 8.2.1 and 8.2.2.
8.2.1 Outcome Assessment Visits Conducted by Telephone
Visits at 3 months, 3 y ears, and 4 y ears CA will be conducted by  telephone . The following 
outcome assessments will be conducted at each of these 3 visits, unless otherwise indicated:
HRQoL  
HCRU
HSCS -PS (3- year and 4 -year visits only )
Medications
Survival assessment
Assessment of participation in other clinical studies
Adverse events (including targeted medical events)
8.2.2 Clinical Site Visits
8.2.2.1 Outcome Assessment Site Visits
The following clinical site vis its (in CA) to capture follow -up outcome data will occur at the 
clinical site:
6 months (±1 month)
12 months (±3 months) 
20 months ( -1 month)
24 months (±3 months)
4.75 y ears (- 1 months)
5 years (+6 months)
The following assessments will be performed at the 6- month visit:
Visual acuity
Refraction with cy cloplegia
Length
Weight
Head circumference
VABS -II
Physical examination (including tonsil examination)
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 42 of 68
For non-commercial use only
  
     y 
Hearing Assessment History  (Historical hearing test data may  be recorded at any  time 
prior to the 6- month visit) 
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Abdominal ultrasound
Echocardiogram
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at the 12 -month visit:
Visual acuity
Corrective le ns determination (including refraction with cy cloplegia)
Ocular alignment and motility
Length
Weight
Head circumference
BSID-III
VABS -II
Physical examination (including tonsil examination)
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be pe rformed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 43 of 68
For non-commercial use only
  
     y 
The following assessments will be performed at the 20 -month visit:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
Assessment of participation in other clinical studies
The following assessments will be performed at the 24- month visit:
Visual acuity
Ocular alignment and motility
Length
Weight
Head circumference
BSID-III
CBCL
VABS -II
Physical examination (including tonsil examination)
Cerebral Pals y assessment
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HSCS -PS (may  be perfor med by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at 4.75- year visit:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
The following assessments will be performed at the 5 -year visit:
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 44 of 68
For non-commercial use only
  
     y 
Visual acuity
Ocular alignment and motility
Stereoacuit y
Height
Weight
WPPSI -IV
CBCL
VABS -II
ADHD -RS- IV
SCQ
Physical examination (including tonsil examination)
Pulmonary  morbidity  assessment
Survival assessment

HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HSCS -PS (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
8.2.2.2 Visits Dedicated to Corrective Lens Determination
The following clinical site visits are dedicated solely  to corrective lens determination in 
preparation for the outcome assessment visits at 24- months and 5- years CA:
20months ( -1month) 
4.75 y ears (- 1 month) 
At these visits, the following will be performed:
Visual acuity
Corrective lens determination (includes refraction with cy cloplegia)
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 45 of 68
For non-commercial use only
  
     y 
The 20- month visit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 mont h prior 
to the 24-month and 5- year visits, respectivel y. Any prescribed corrective lenses must be worn 
for at least 1 month prior to the 24 month and 5 y ear assessments.
8.3 Assessments upon Discontinuation
If a subject discontinues prior to the 5 -year CA visi t, every  attempt will be made to complete the 
assessments scheduled for the subject’s next visit. 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 46 of 68
For non-commercial use only
  
     y 
9 QUALITY CONTROL AND ASSURANCE
Training will occur at an Investigator meeting or at the site initiation visit or both, and instruction 
manuals will be provide d to aid consistency  in data collection and reporting across sites.
Clinical sites will be monitored by  the Sponsor or its designee to ensure the accuracy  of data 
against source documents. The required data will be captured in a validated clinical data 
management s ystem that is compliant with the FDA 21 Code of Federal Regulations ( CFR )Part 
11 Guidance . The clinical trial database will include an audit trail to document any  evidence of 
data processing or activity  on each data field by  each user . Users will be trained and given 
restricted access, based on their role(s) in the study, through a password -protected environment.
Data entered in the s ystem will be reviewed manually  for validity  and completeness against the 
source documents by  a clinical monitor fr om the Sponsor or its designee. If necessary , the study  
site will be contacted for corrections or clarifications; all missing data will be accounted for.
Serious adverse event information captured in the clinical trial database will be reconciled with 
the information captured in the Pharmacovigilance and Risk Management database.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 47 of 68
For non-commercial use only
  
     y 
10 STATISTICAL AN ALYSES
10.1 General Methodology
Details regarding the statistical methods and definitions will be provided in the Statistical 
Analy sis Plan (SAP) . The SAP will be finalize d prior to database lock. All statistical analy ses 
will be performed b y the Biometrics department at Shire. Statistical analy ses will be performed 
using Version 9.1 or higher of SAS®(SAS Institute, Cary , NC 27513).
Continuous variables will be summarized using descriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categorical variables will be summarized using frequencies and percentages.
As referred to in descriptions of summary  statistics, treat ment groups refer to the 2 possible 
treatment assignments in the antecedent study ,ROPP-2008- 01, Section D ( rhIGF-1/rhIGFBP -3
or standard neonatal care) .
For analy sis purposes, baseline is defined as the first assessment either in the antecedent stud y 
(ROPP -2008- 01) or in this study  (SHP -607-201). As necessary , relevant data from Study  
ROPP -2008- 01 may  be summarized with the data from this study  (SHP -607-201).
10.2 Determination of Sample Size
No formal sample size calculation wasperformed for this study  because this is a follow -up study  
to Section D of Study  ROPP -2008- 01. Any  subjects enrolled in Study  ROPP -
2008- 01 are 
eligible to enroll in this study . There are up to 120 subjects who will be eligible to enroll in this 
long-term development al outcome study .
10.3 Method of Assigning Study Subjects to Treatment Groups
Not applicable.
10.4 Population Description
10.4.1 Analysis Populations
Enrolled Population - the Enrolled Population will consist of all subjects for whom written 
informed consent has been provid ed for this study . 
Safety  Population- the Safety  Population will consist of 
the subjects in the Enrolled Population
who have safet y follow- up data in this long -term outcome study .
10.4.2 Subject Disposition
Subjects who complete the study  and subjects who prematurel y discontinue from the stud y will 
be summarized by  treatment group using descriptive statistics. I n addition, for subjects who 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 48 of 68
For non-commercial use only
  
     y 
prematurel y discontinue from the study, the reasons for discontinuation will be summarized by 
treatment group.
10.4.3 Protoco l Violations and Deviations
Protocol violations and deviations will be listed. Details of the criteria for deviations and 
violations will be provided in the SAP.
10.4.4 Demographics and Baseline Characteristics
Descriptive summaries of demographic and baseline characteristics will be presented b y 
treatment group for the Enrolled Population . 
Demographics and baseline characteristics will be exami ned to assess the comparability  of the 
treatment group s. Continuous variables such as age (including corrected age) , wei ght, and 
length/height will be summarized using number of observations, mean, standard deviation, 
median, minimum and maximum values. Categorical variables, like gender and race, will be 
summarized using number of observations and percentages.
Medical hist ory,including maternal and perinatal history , (as obtained from the antecedent 
study , ROPP -2008- 01) will be summarized by  treatment group using the number of observations 
and percentages of subjects reporting each category .
10.5 Efficacy Analysis
All efficacy analy ses will be performed using the Enrolled Population .
10.5.1 Primary Efficacy Analysis
The primary  efficacy  endpoints consist of the following:
Visual Acuity :  Visual acuity  will be categorized as the following: 
onormal (measurable acuity ≥20/40), 
obelow normal (20/200≤ measurable acuit y <20/40), 
opoor (measurable acuity ≤20/200)
oblind/low vision (onl y the ability  to detec t the 2.2 cm wide stripes on the low -
vision Teller acuit y card and at an y location in the visual field). 
The number and proportion of patients within each category  listed above will be 
summarized by  treatment group and visit. I n addition, a cuity  results in the normal and 
below normal categories will be classified as favorable outcomes, and acuity  results in 
the poor and blind/low- vision categories will be classified as unfavorable outcomes. 
Tabular summaries b y trea tment group and visit will include the frequency  and the 
percentage for each visual acuity  category . In addition, shift tables of favorable 
outcomes from baseline (first assess ment during this study ) to each of the subsequent 
assessments, including the last assessment , will be presented bytreatment group .
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 49 of 68
For non-commercial use only
  
     y 
Ocular Alignment and Oculomotor Exam (Motility) :  Findings from the ocular 
motility  assessmen t will be either presence or ab sence of strabismus (esotropia, 
exotropia, hy pertropia, or hy potropia). Tabular summaries by treatment group and 
visit will include the frequency  and the percentage in each category . In addition, shift 
tables from baseline (first assessment during this study ) to the last assessment will be 
provided b y treatment group.
Nystagmus :  Presence or absence of ny stagmus will be summarized by  treatment 
group and visit
Refraction with C ycloplegia :  Findings from the refraction wit h cycloplegia will be 
summarized by  treatment group and visit
Stereoacuit y:  Presence or absence of stereopsis will be sum marized by  treatment 
group and visit
10.5.2 Secondary Efficacy Analysis
Growth Parameters (b ody weight, body  length [and height], and head circumference) :  
A standard Z-score, utilizing WHO child growth standards, will be calculated for each 
assessment by  adjusting age -and sex - matched means and standard deviations (norm). 
The descriptive statistics of the Z -score for each of these parameters will be 
summarized at each assessme nt and the corresponding change from baseline. When 
appropriate, a 95% CI for the corresponding mean change within each group and the 
difference in the mean change between the 2 treatment grou ps and the corresponding 
95% CI  will be presented as appropriate . If the parametric assumption for the 
distribution of the above endpoints cannot be justified, a non -parametric approach will 
be utilized to estimate the treatment difference (ie, median difference or 
Hodges -Lehmann estimator and the corr esponding confide nce intervals)
BSID-III and WPPSI -IV:  The raw score for each domain within each questionnaire 
will be summarized by  treatment group and visit using descriptive statistics.
ADHD -RS-IV:  ADHD -RS-IV total score and subscales (Hy peractivity /Impulsivity  
and I nattentiveness) will be summarized by  treatment group and visit using descriptive 
statistics.
SCQ :  The SCQ subscales (communication and social) will be summarized by  
treatment group and visit using descriptive statistics
VABS -II:  The raw score for each d omain of the scale will be summarized by  
treatment group and visit using descriptive statistics.
CBCL :  The raw score and change from baseline for each domain of the scale will be 
summarized by  treatment group and visit using descriptive statistics.
Pulmon ary morbidity  assessment :  The binary  response of each question will be by  
treatment group and visit using descriptive statistics.
Survival :  For subjects who have an event (ie, death), the event time will be calculated 
as the length of time from the subject’s date of birth to death during the study  due to 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 50 of 68
For non-commercial use only
  
     y 
any cause . Subjects who do not have an event (ie, death) during the stud y will be 
censored at the end of the study . The survival endpoint will be analy zed by treatment 
group using Kaplan- Meier methods.
10.5.3 Subset Analyses
Subgroup anal yses may  be explored based on factors that may  have influence on the efficacy  or 
safet y endpoints. Subgroup anal yses will be specified in the SAP.
10.5.4 Exploratory Analyses
10.6 Health Economics and Outcomes Research Analyses
For PedsQL, descriptive statistics will be provided for summary  scores by  treatment group and at 
each time point.
The HUI 2/3 s ystem contains a number of attributes/domains to classify  thelevel of health status. 
Each attribute or domain (eg, mobility , cognition, emotion or pain) is rated on a 5- point ordinal 
scale to indicate the severity  level, ranging from 1 to 5 (higher numbers indicating a more severe 
level). Summary  statistics will be provided by treatment group and at each time point.
For HCRU the utilization for each resource -item (eg, hospital day s, phy sician visits) reported at 
each time point will be reported descriptivel y by treatment group.
10.7 Analysis of Safety
Safety  summaries wi ll be based on all assessments post -baseline. The safet y data will be 
assessed b y AE monitoring, change in cardiac size, and kidney  and spleen size over time. 
Adverse events will be summarized by  system organ class and preferred term for each treatment 
group and overall, the number and percentage of subjects having any  AE, having an AE in each 
body  system and having each individual AE. In addition, those events which resulted in death, or 
were otherwise classified as serious will be presented in a separate listing. In addition, the 
summary  of AEs will be presented by  severit y and relationship to trial medication. 
The change in cardiac size, and size of kidney  and spleen will be assessed at the 6 -month CA 
visit via echocardiogram and abdominal ultrasound, r espectivel y.  These data will be anal yzed as 
a binary  response (ie, normal/abnormal) and summarized using frequency  count.  The number 
and proportion of patients with each category (ie, normal/abnormal) for each of these safet y 
endpoints will be summarized by treatment group.  I n addition, the 2 -sided 95% CI  for the 
proportion of patients with a normal status for each of the endpoints will be estimated by 
treatment group.
Physical examinations findings will be summarized descriptivel y. 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 51 of 68
For non-commercial use only
  
     y 
10.8 Statistical/Analytic al Issues
10.8.1 Adjustment for Covariates
If any baseline data are imbalanced and are considered to be clinically relevant, between -group 
comparisons for efficacy  outcomes will be adjusted for covariates and detailed in the SAP. 
10.8.2 Handling of Dropouts or Missing Data
Handling of missing data rules will be described in the SAP.
10.8.3 Interim Analyses and Data Monitoring
Aninterim anal ysis will be performed after all data from all enrolled subjects in this study  have 
either completed 2 -year follow -up (24- month visit) ass essments or have prematurely  withdrawn 
from the study  (before completing 2 y ears of follow -up) has been entered i nto the database, 
queried and discrepancies resolved . A full 2- year study  report based on these data, including 
efficacy  and safet y endpoint analy ses,will be completed.
Additionally , descriptive anal yses of the data at other time points before study  completion may  
be performed for safet y monitoring, regulatory  reporting or general planning purposes.
10.8.4 Multiple Comparisons/Multiplicity
Not applic able.
10.8.5 Sensitivity Analyses
Sensitivity  analy ses for the efficacy  outcomes will be detailed in the SAP, as necessary .
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 52 of 68
For non-commercial use only
  
     y 
11 ADMINISTRATIVE CONSIDERATIONS
11.1 Investigators and Study Administrative Structure
Before initiation of the study , the Investigators must provide the Sponsor with a completed Form 
FDA 1572 and Investigator Agreement . Curriculum vitae must be provided for the Investigators 
and sub- investigators listed on Form FDA 1572 or I nvestigator Agreement . 
The Investigator should ensure that all persons ass isting with the study  are adequatel y informed 
about the protocol, an y amendments to the protocol, and their study related duties and functions . 
The Investigator must maintain a list of sub -investigators and other appropriately  qualified 
persons to whom he or she has delegated significant study  related duties.
11.2 Institutional Review Board or Independent Ethics Committee Approval
Before initiation of the study , the Investigator must provide the Sponsor with a copy  of the 
written I RB/IEC/REB approval of the prot ocol and the informed consent form . This approval 
must refer to the informed consent form and to the study  title, study  number, and version and 
date of issue of the stud y protocol, as given by the Sponsor on the cover page of the protocol.
Status reports m ust be submitted to the I RB/IEC/REB at least once per year. The IRB/IEC/REB 
must be notified of completion of the study . Within 3 months of study  completion or termination, 
a final report must be provided to the I RB/IECREB . A cop y of these reports will be sent to the 
study  clinical monitor . The Investigators must maintain an accurate and complete record of all 
submissions made to the IRB/IEC, including a list of all reports and documents submitted . AEs 
which are reported to the US (FDA or other Regulatory  agencies (Safet y Reports) must be 
submitted promptly  to the I RB/IEC/REB.
11.3 Ethical Conduct of the Study
The procedures set out in this study  protocol, pertaining to the conduct, evaluation, and 
documentation of this study , are designed to ensure that the Sponsor and Investigators abide b y 
good clinical practice (GCP) as described in the 21 CFR Parts 50, 56, and 312 and the 
International Conference on Harmonization (I CH) GCP Guidelines Compliance with these 
regulations and guidelines also constitutes compliance with the ethical principles described in the 
Declaration of Helsinki.
11.4 Subject Information and Consent
Before enrolling in the clinical study , the subject or the subject’s parent(s) or legally  authorized 
representative(s) must consent to participate af ter the nature, scope, and possible consequences 
of the clinical stud y have been explained in a form understandable to him or her.
An informed consent form (assent form if applicable) that includes information about the study  
will be prepared and given to the subject or the subject’s parent(s) or legally authorized 
representative(s) . This document will contain all FDA and ICH -required elements. 
The informed 
consent (or assent) form must be in a language understandable to the subject or the subject’s 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 53 of 68
For non-commercial use only
  
     y 
parent( s) or legall y authorized representative(s) and must specify who informed the subject, the 
subject’s parent(s), or the subject’s legall y authorized representative(s).
After reading the informed consent document, the subject or the subject’s parent(s) or leg ally 
authorized representative(s) must give consent in writing. Consent must be confirmed at the time 
of consent b y the personally  dated signature of the subject, the subject’s parent(s) or the subject’s 
legally  authorized representative(s) and by  the pers onally  dated signature of the person 
conducting the informed consent discussions.
If the subject or the subject’s parent(s) or legally  authorized representative(s) is unable to read, 
oral presentation and explanation of the written informed consent form an d information to be 
supplied must take place in the presence of an impartial witness . Consent must be confirmed at 
the time of consent orall y and by the personally dated signature of the subject or by a local 
legally  recognized alternative (eg, the subject’s thumbprint or mark) or by  the personall y dated 
signature of the subject’s parent(s) or the subject’s legally  authorized representative . The witness 
and the person conducting the informed consent discussions must also sign and personall y date 
the informe d consent document . It should also be recorded and dated in the source document that 
consent was given.
A cop y of the signed and dated consent document(s) must be given to the subject or the subject’s 
parent(s) or legal representative(s). The original signed and dated consent document will be 
retained b y the Investigator.
The Investigator will not undertake any  measures specificall y required solely for the clinical 
study  until valid consent has been obtained.
A model of the informed consent form to be u sed in this study  will be provided to the sites 
separately  from this protocol.
11.5 Subject Confidentiality
Subject names will not be supplied to the Sponsor . Only  the subject number - will be recorded in 
the eCRF, and if the subject name appears on an y other document, it must be obliterated before a 
copy  of the document is supplied to the Sponsor . Study  findings stored on a computer will be 
stored in accordance with local data protection laws . The subjects will be told that 
representatives of the Sponsor, a des ignated CRO, the I RB/IEC/REB, or regulatory  authorities 
may inspect their medical records to verify  the information collected, and that all personal 
information made available for inspection will be handled in strictest confidence and in 
accordance with lo cal data protection laws . The Investigator will maintain a personal subject 
identification list (subject numbers with the corresponding subject names) to enable records to be 
identified.
11.6 Study Monitoring
Monitoring procedures that comply  with current Good Clinical Practice (GCP) guidelines will be 
followed. Review of the eCRFs for completeness and clarit y, cross -checking with source 
documents, and clarification of administrative matters will be performed.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 54 of 68
For non-commercial use only
  
     y 
The study  will be monitored by  the Sponsor or its de signee . Monitoring will be performed by  a 
representative of the Sponsor (Clinical Study  Monitor) who will review the eCRFs and source 
documents . The site monitor will ensure that the investigation is conducted according to protocol 
design and regulatory  requirements by  frequent site visits and communications (letter, telephone, 
and facsimile).
11.7 Case Report Forms and Study Records
11.7.1 Case Report Forms
Electronic case report forms (eCRFs) are provided for each subject . All forms must be filled out 
by authorized study  personnel. All corrections to the original eCRF entry  must indicate the 
reason for change . The Investigator is required to sign the eCRF after all data have been captured 
for each subject . If corrections are made after review and signature b y the Inve stigator, he or she 
must be made aware of the changes, and his or her awareness documented by  resigning the 
eCRF.
11.7.2 Critical Documents
Before the Sponsor initiates the trial (ie, obtains informed consent from the first subject), it is the 
responsibility  of the Investigator to ensure that the following documents are available to Sponsor 
or their designee:
Completed FDA Form 1572 (Statement of Investigator), signed, dated, and accurate
Curricula vitae of Investigator and sub-investigator(s) (current, dated and signed 
within 12 months of study initiation)
Copy  of Investigator and sub -investigator(s) current medical license (indicating 
license number and expiration date)
Signed and dated agreement of the final protocol
Signed and dated agreement of an y amendment(s ), if applicable
Approval/favorable opinion from the IRB/IEC/REB clearl y identifying the documents 
reviewed b y name, number and date of approval or re approval :  protocol, any  
amendments, Subject Information/I nformed Consent Form, and any  other written 
information to be provided regarding subject recruitment procedures
Copy  of IRB/IEC/REB approved Subject Information/I nformed Consent Form/any  
other written information/advertisement (with IRB approval stamp and date of 
approval)
Current list of I RB/IEC/REB Committee members/constitution (dated within 
12months prior to study  initiation)
Financial Disclosure Form signed b y Investigator and sub- investigator(s)
Current laboratory  reference ranges (if applicable)
Certification/QA scheme/other documentation (if applicable)
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 55 of 68
For non-commercial use only
  
     y 
Regulatory  approval and notification as required must also be available; these are the 
responsibility  of Shire.
11.8 Data Monitoring Committee
Given that an y long -term safet y signal observed in this study  could impact the safet y profile of 
rhIGF -1/rhIGFBP -3 as administered in premature neonates being enrolled in the antecedent 
study  (ROPP -2008- 01, Section D), the Data Monitoring Committee (DMC) for Study  
ROPP -2008- 01 will review safet y data from this long -term outcome study .
11.9 Protocol Violations/De viations
The Investigator will conduct the study  in compliance with the protocol. The protocol will not be 
initiated until the I RB/IEC/REB and the appropriate regulatory  authorities, where applicable, 
have given approval/favorable opinion . Modifications to the protocol will not be made without 
agreement of the Sponsor . Changes to the protocol will require written IRB/I EC/REB 
approval/favorable opinion prior to implementation, except when the modification is needed to 
eliminate an immediate hazard(s) to subj ects. The IRB/IEC/REB may  provide, if applicable 
regulatory  authorities permit, expedited review and approval/favorable opinion for minor 
change(s) in ongoing studies that have the approval/favorable opinion of the I RB/IEC/REB . The 
Sponsor will submit all protocol modifications to the regulatory authorities, where applicable, in 
accordance with the governing regulations.
A record of subjects screened, but not entered into the study , is also to be maintained . No 
protocol exemption will be granted for this st udy.
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to 
subjects, the Investigator will contact the Sponsor or its designee, if circumstances permit, to 
discuss the planned course of action . Any departures from the protocol must be fully  documented 
as a protocol deviation. Protocol deviations will need to be reviewed b y the medical monitor and 
may also be required to be submitted to the I RB/IEC/REB.
Protocol modifications will only  be initiated by  the Sponsor and m ust be approved b y the 
IRB/IEC/REB and submitted to the FDA or other applicable international regulatory  authorit y 
before initiation, if applicable.
11.10 Premature Closure of the Study
If the Sponsor, Investigator, or regulatory  authorities discover conditions arising during the stud y 
which indicate that the clinical investigation should be halted due to an unacceptable subject risk, 
the study  may  be terminated after appropriate consultation between the Sponsor and the 
Investigator(s) . In addition, a decision on the part of the Sponsor to suspend or discontinue 
development of the investigational product may  be made at any  time . 
Conditions that may  
warrant termination of the study or site include, but are not limited to:
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 56 of 68
For non-commercial use only
  
     y 
The discovery  of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the study
Failure of the Investigator to comply  with pertinent global regulations
Submission of knowingly  false information from the study  site to the Sponsor or other 
pertinent regulatory  authorities
Insufficient adherence b y the I nvestigator to protocol requirements
11.11 Access to Source Documentation
Regulatory  authorities, the I RB/IEC/REB, or the Sponsor may  request access to all source 
documents, eCRFs, and other study documentation for onsite audit or ins pection . Direct access to 
these documents must be guaranteed b y the Investigator, who must provide support at all times 
for these activities. Monitoring and auditing procedures that compl y with current GCP guidelines 
will be followed . On-site review of the eCRFs for completeness and clarit y, crosschecking with 
source documents, and clarification of administrative matters may  be performed.
11.12 Data Generation and Analysis
The clinical database will be developed and maintained b y a contract research organization or an 
electronic data capture technology  provider as designated by  the Sponsor . The Sponsor or its 
designee will be responsible for performing study  data management activities. 
Adverse events will be coded using Medical Dictionary  for Regulatory  Activities (MedDRA) . 
Concomitant medication will be coded using WHO- Drug Dictionary  (WHO -DD). Central reads 
will be employ ed as described in the study  manual to aid in consistent measurement of 
abdominal ultrasound and echocardiogram parameters . 
11.13 Retention of Data
Essential documents should be retained until at least 2 y ears after the last approval of a 
marketing application and until there are no pending or contemplated marketing applications or 
at least 2 years have elapsed since the formal discontinuatio n of clinical development of the 
investigational product. The Sponsor will notify  the Investigator if these documents must be 
retained for a longer period of time . It is the responsibility  of the Sponsor to inform the 
Investigator or institution as to when these documents no longer need to be retained.
11.14
Financial Disclosure
The Investigator should disclose an y financial interests in the Sponsor as described in 21 CFR 
Part 54 prior to beginning this study . The appropriate form will be provided to the Investigator 
by the Sponsor, which will be signed and dated b y the Investigator, prior to the start of the study . 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 57 of 68
For non-commercial use only
  
     y 
11.15 Publication and Disclosure Policy
All information concerning the stud y material, such as patent applications, manufacturing 
processes, basic scientific data, and formulation information supplied by  the Sponsor and not 
previously  published are considered confidential and will remain the sole propert y of the 
Sponsor . The Investigator agrees to use this information only  in accomplishing this study and 
will not use it for other purposes.
It is understood by  the Investigator that the information developed in the clinical study  may  be 
disclosed as required to the authorized regulatory  authorities and governmental agencies . In 
order to allow for the us e of the information derived from the clinical studies, it is understood 
that there is an obligation to provide the Sponsor with complete test results and all data 
developed in the stud y in a timely manner.
The Investigator and an y other clinical personnel associated with this study  will not publish the 
results of the study , in whole or in part, at an y time, unless they  have consulted with the Sponsor, 
provided the Sponsor a copy  of the draft document intended for publication, and obtained the 
Sponsor’s wri tten consent for such publication. All information obtained during the conduct of 
this study  will be regarded as confidential. 
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 58 of 68
For non-commercial use only
For non-commercial use only
For non-commercial use only
  
     y 
32.Constitution of the World Health Organization:  basic document. Geneva, Switzerland :  
World Health Organization; 1948.
33.Varni JW, L imbers CA. The pediatric quality  of life inventory :  measuring pediatric health -
related qualit y of life from the perspective of children and their parents. Pediatr Clin North 
Am 2009;56:843-63.
34.Varni JW, L imbers CA, Neighbors K, et al. The PedsQL Infant Scales :  feasibility , internal 
consistency  reliability , and validity  in health y and ill infa nts. Quality  of life research :  an 
international journal of quality  of life aspects of treatment, care and rehabilitation 
2011;20:45-55.
35.Varni JW, Seid M, Kurtin PS. PedsQL  4.0:  reliability  and validity  of the Pediatric Qualit y of 
Life Inventory  version 4.0 generic core scales in healthy  and patient populations. Medical 
care 2001;39:800-12.
36. Saigal S, Rosenbaum P, Stoskopf B, et al. Development, reliability  and validity  of a new 
measure of overall health for pre -school children. Quality  of life research : an international 
journal of quality  of life aspects of treatment, care and rehabilitation 2005;14:243 -57.
37. Rosenbaum DM, Korngold E, Teele RL. Sonographic assessment of renal length in normal 
children. Am J Roentgenol 1984;142:467 -9.
38.Rosenberg HK, Markowitz RI , Kolberg H, Park C, Hubbard A, Bellah RD. Normal splenic 
size in infants and children :  sonographic measurements. Am J Roentgenol 1991;157:119-21.
39.Stevens TP, Finer NN, Carlo WA, et al. Respiratory  Outcomes of the Surfactant Positive 
Pressure and Oximetry  Randomized Trial (SUPPORT). J Pediatr 2014;165:240- 9.e4.
40.Zivanovic S, Peacock J, Alcazar -Paris M, et al. Late outcomes of a randomized trial of high -
frequency  oscillation in neonates. N Engl J Med 2014;370:1121 -30.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 61 of 68
For non-commercial use only
    
Appendix 1 Study Schedule of Events
ProceduresInitial Study 
Visite Months (CA) Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 wks6 
± 1mth12
± 3 m ths20 
-1 mthg24
± 3mth3f
± 3mths4f
± 3mths4.75
-1 mthg5
+ 6 m ths
Informed Consent •
Eligibility Criteria •
Dem ographics •
Visual acuitya• • • • • •
Corrective lens determinationh• •g•g
Ocular alignment and motility • • •
Refraction with cycloplegiah•
Stereoacuity •
Length • • •
Height •
Weight • • • •
Head Circumference • • •
BSID -III • •
WPPSI -IV •
CBCL • •
VABS -II • • • •
ADHD -RS-IV •
SCQ •
Physical Exam ination including tonsil 
examination • • • •
Cerebral Palsy Assessment •
Hearing Assessment Historyb•
Pulmonary Morbidity Assessment • • • •
Survival assessment • • • • • • •
HRQoLc• •i•i•i• • •i
HCRU • •i•i•i• • •i
HSCS -PS •i• • •i
Abdominal Ultrasound •
Echocardiogram •
Assessment of Participation in Other Clinical 
Studies• • • • • • •
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 62 of 68
For non-commercial use only
    
ProceduresInitial Study 
Visite Months (CA) Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 wks6 
± 1mth12
± 3 m ths20 
-1 mthg24
± 3mth3f
± 3mths4f
± 3mths4.75
-1 mthg5
+ 6 m ths
Medications • • • • • • •
Adverse eventsd•j• • • • • • •
Abbreviations :  ADHD -RS-IV= Attention- Deficit/ Hyperactivity Disorder Rating Scale -fourth edition ; BSID -III=Bayley Scales of In fant and Toddler 
Development -Third Edition , CBCL =Child Behavior Checkli st; CA =corrected age; HCRU = health care resource us e; HRQoL = health -related quality of l ife; 
HSCS -PS = Health Status Classification System; mth(s) =months; ; PedsQL =Pediatric Quality of Life Inventory; 
SCQ =Social Communication Questionnaire; VABS -II=Vineland Adapti ve Behavior Scales, Second Edition; wks=weeks; WPPSI -IV=Wechsler Preschool 
and Primary Scale of Intelligence, Fourth Edition
aThe tools used to assess visual acuity will change as the subject ages during their participation in the study . The tools that will be used in this study and are 
summarized by applicable study visit in Table 12-1.
bHistorical hearing test data may be recorded at any time during the study prior to the 6 -month visit.
cHRQoL will be assessed via the validated PedsQL™  scales appropriate for the child’s age of development as specified in the Study Operations Manual
dAdverse event collection will include an assessment of the specified targeted medical events 
eThe Initial Visit may be performed prior to 40 w eeks CA for any subject who discontinued from Study ROPP -2008- 01 and, for all subjects, any time after 
40 w eeks CA, up to the study visit to occur at 3 months CA.
fVisits at 3 months, 3 years, and 4 years CA will be conducted by telephone.
gThe 20 -month visit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 month prior to the 24 -month and 5 -year visits, respectively. Any 
prescribed corrective lenses must be w orn for at least 1 month prior to the 24 -month and 5 -year assessments.
hRefraction with cycloplegia wi ll be performed as part of the corrective lens determination procedure.
iThe HRQoL, HCRU, and HSCS -PS assessments for the 6 -month, 12 -month, 24 -month and 5 -year vi sits may be performed through clinical site staff ifthere 
are time constraints during the on -site visit. At the 3 -month, 3 -year, and 4 -year visits, these assessme nts will be performed through clinical site staff and 
may be performed at any time within the visit window .
jThe follow ing,collected as part of the ROPP -2008- 01 study ,will be used as par t of this study (SHP -607-201):  any ongoing targeted medical events 
regardless of causality and any ongoing study dru g-related AEs, including SAEs.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 63 of 68
For non-commercial use only
  
      
Table 12-1 Summary of Visual Acuity Assessments 
Visual Acuity 
Assessment ToolDescription Unit of Measure Applicable 
Age/Study 
Visit (CA)
Teller acuity cardsResolution acuity –
discrimination of a grating 
optotype from a background with 
the same mean luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity -tests 
recognition of 4 optotypesSnellen fraction
(eg, 20/20)24 monthsa
LEA Symbols 
(ETDRS -style) chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be made to assess visual acuity by the LEA 
Symbols Test and LEA Symbols Chart, respectively . If during this attempt, the examiner determines 
that it will not be possible to perform an accurate assessment w ith the relevant LEA tool, visual acuity 
should be assesse d with the Teller acuity cards.
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 64 of 68
For non-commercial use only
  
      
Appendix 2Summary of Changes
Description ofChange Section(s)
Eliminate repetitive study procedures –the Refraction with Cy cloplegia 
assessment is completed as part of the corrective lens determination that 
occurs at the 20 month and the 4.75 year visits. This procedure is 
removed from the 24 month and the 5y ear visits. Added visual acuit y to 
20 month visit and 4.75 y ear visit. Added assessment of participation in 
other clin ical studies to 20 month visit .
Removed “Refraction with cy cloplegia” from assessment performed at 
the 20 month and the 4.75 y ears visits.Section 4.1–  
Figure 4-1
Section 8.2
Section 8.2.2.1
Section 8.2.2.2
Appendix 1
The 20 month visit was added with the following assessments:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
Assessment of participation in other clinical studies
The 4.75 year visit was added with the following assessments:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)Section 8.2.2
Clarify  by using the term “Pulmonary  Morbidity  Assessment” throughout 
the protocol for consistency .
Replaced “Questionnaire” with “Assessment” Section 7.6.5
Section 10.5.2
All phone contacts are performed b y site staff, no call center was set up 
for the stud y.
Replace “call center” to “by  clinical site staff”Section 7.6.7.1
Section 7.6.8
Section 7.6.8.1
Appendix 1
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 65 of 68
For non-commercial use only
  
      
Description ofChange Section(s)
The overall list of Target Medical Events to be captured in the study  was 
reassessed and updated to ensure all an y events with a potential impact to 
the primary  and secondary  endpoint are tracked.
For this study  only the following AEs will be collected:  
those consi dered related to investigational product (rhIGF-
1/rhIGFBP -3 as administered in Study  ROPP  2008 01, Section 
D)
those considered related to procedures performed in this study  
(Study  SHP 607 201)
specified targeted medical events (Section 7.9.1.3) regardless of 
causality
Only  the following SAEs will be collected:
Fatal SAEs regardless of causality
SAEs related to ROP
SAEs related to congenital malformations not identified at birth 
which may  impact neurocognitive developmentSection 7.9.1.1
Section 7.9.1.2
Capture SAE from the end -of–study  visit in ROPP -2008- 01 Section D 
and the start of the SHP -607- 201 study for safety  purpose.
Added “When possible, subject’s parents or legally  authorized 
representative(s) should be consented at the end of study  visit for the 
ROPP -2008- 01.However, Serious Adverse Events that the subject 
experiences between ROPP -2008- 001 end-of- study  visit and the start of 
the SHP-607- 201, will be reported b y the Investigator.” in Section 7.9.5.1
Added “SAEs that the subject experiences bet ween ROPP -2008- 001 end-
of-study  visit and the start of the SHP -
607-201 will be reported b y the 
Investigator.” in Section 8.1Section 7.9.5.1
Section 8.1
Shire  
SHP607-201 Protocol & Amendment 1
CONFIDENTIAL 
Version 1.0,  Final
19 February 2016 
Page 66 of 68
For non-commercial use only
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire  CONFIDENTIAL Page 2 
Clinical Trial Protocol: SHP-607-201 
Mecasermin rinfabate (rhIGF-1/rhIGFBP-3)  21 Feb 2017 
 
 SYNOPSIS 
Sponsor: 
Premacure AB, A Member of the Shire Group of Companies 
Name of Finished Product: 
Mecasermin rinfabate (rhIGF-1/rhIGFBP-3)  
Study Title: 
Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with 
rhIGF-1/rhIGFBP-3 for the Prevention of Reti nopathy of Prematurity (ROP) or Who Received 
Standard Neonatal Care  
Study Number: 
SHP-607-201 
Study Phase:  II 
Investigational Product, Dose, and Mode of Administration: 
Not applicable. 
Primary Objectives  
The primary objectives of this study are: 
 To evaluate the long-term efficacy ou tcomes following short-term exposure to 
rhIGF-1/rhIGFBP-3 versus standard neonatal care  in Study ROPP-2008-01 (Section D) 
as assessed by ROP associated visual outcomes 
 To evaluate the long-term safety outcomes following short-term exposure to 
rhIGF-1/rhIGFBP-3 versus standard neon atal care in Study ROPP-2008-01 (Section D) 
Secondary Objectives 
The secondary objectives of this study are to evalua te the effect following short-term exposure to 
rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (Section D) on: 
 Growth parameters 
 Cognitive development 
 Physical development 
 Child behavior 
 Pulmonary morbidity 
 Survival 
 Health-related quality of life (HRQoL) 
 Health utility 
 Health care resource use (HCRU) 
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 5
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Efficacy Assessments:
Efficacy will be assessed by visual outcomes, growth parameters, cognitive development, physical 
development, child behavior, p ulmonary morbidity, and survival.
Safety Assessments:
Safety will be assessed by physical examination (including tonsil examination), AEs (as
specified ), echocardiogram, and abdominal ultrasound.
Statistical Methods
Details regarding the statistical methods and definitions will be provided in the Statistical Analysis 
Plan (SAP) . The SAP will be finalized prior to database lock. All statistical analyses will be 
performed by the sponsor or CRO after the database is locked . Statistical analyses will be 
performed using Version 9.1 or higher of SAS®(SAS Institute, Cary, NC 27513).
Continuous variables will be summarized using descriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categorical variables will be summarized using frequencies and percentages.
As referred to in descriptions of summary statistics, treatment groups refer to the 2 possible 
treatment assignments in the antecedent study, ROPP -2008- 01, Section D (rhIGF -1/rhI GFBP -3 or 
standard neonatal care).
For analysis purposes, baseline is defined as the first assessment either in the antecedent study 
(ROPP-2008- 01) or in this study (SHP -607-
201). 
As necessary , relevant data from 
Study ROPP -2008- 01 may be summarized with the data from this study (SHP -
607-201).
Date of Original Protocol :  27August 2014
Date of Amendment 1: 19 February 2016
Date of Amendment 2: 21 February 2017
For non-commercial use only
Shire CONFIDENTIAL Page 6
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
TABLE OF CONTENTS
SYNOPSI S.......................................................................................................................................2
TABLE OF CONTENTS .................................................................................................................6
LIST OF IN -TEXT TABLES ........................................................................................................10
LIST O F IN-TEXT FIGURES .......................................................................................................10
LIST OF APPENDICES ................................................................
................................................10
LIST OF ABBREVIATION S........................................................................................................11
1INTRODUCTION ..................................................................................................................13
2STUDY OBJECTIVES ..........................................................................................................15
2.1 Primary  Objectives ...................................................................................................15
2.2 Secondary  Objectives ...............................................................................................15
2.3 Exploratory  Objective ................................
..............................................................15
3STUDY ENDPOINTS ............................................................................................................16
3.1 Efficacy  Endpoints ...................................................................................................16
3.1.1 Primary  Efficacy  Endpoints ...................................................................................16
3.1.2 Secondary  Efficacy  Endpoints ...............................................................................16
3.2 Health Economic Outcome Research Endpoints ......................................................16
3.3 Safety  Endpoints ......................................................................................................17
3.4 Exploratory  Endpoints ..............................................................................................17
4INVESTIGATIONAL PLAN .................................................................................................18
4.1 Overall Study  Design and Plan ................................................................................18
4.2 Rationale for Study  Design ......................................................................................19
4.3 Study  Duration .........................................................................................................20
5STUDY POPUL ATION SEL ECTION ..................................................................................21
5.1 Study  Population ......................................................................................................21
5.2 Inclusion Criteria................................
......................................................................21
5.3 Exclusion Criteria .....................................................................................................21
6STUDY TREATMENT ..........................................................................................................22
6.1 Description of Treatment ................................ ................................ ......................... 22
6.2 Treatments Administered ................................ ................................ ......................... 22
6.3 Selection and Timing of Dose for Each Subject ......................................................22
6.4 Method of Assigning Subjects to Treatment Groups ...............................................22
6.5 Masking....................................................................................................................22
6.6 Medications ..............................................................................................................22
6.7 Restrictions ...............................................................................................................22
6.7.1 Prior Therap y
................................ ................................ ................................ ......... 22
For non-commercial use only
Shire CONFIDENTIAL Page 7
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
6.7.2 Other Restrictions ..................................................................................................22
6.7.3 Treatment Compliance ...........................................................................................22
6.7.4 Packaging and Labeling .........................................................................................22
6.8 Storage and Accountability ......................................................................................22
7 STUDY PROCEDURES........................................................................................................23
7.1 Informed Consent .....................................................................................................23
7.2 Study  Entrance Criteria and Eligibility ....................................................................23
7.3 Study  Enrollment ......................................................................................................23
7.4 Demographics ...........................................................................................................23
7.5 Growth Parameters:  Length (and Height), Weight, and Head Circumference .......23
7.5.1 Length and Height ................................
..................................................................23
7.5.2 Body Weight ..........................................................................................................24
7.5.3 Head Circumference ..............................................................................................24
7.6 Efficacy  Assessments ...............................................................................................24
7.6.1 Visual Assessments ................................................................................................24
7.6.1.1 Visual Acuity ..........................................................................................24
7.6.1.2
Corrective Lens Determination ..............................................................25
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility )..................25
7.6.1.4 Refraction with C ycloplegia ...................................................................26
7.6.1.5 Stereoacuit y............................................................................................26
7.6.1.6
7.6.2 Hearing Assessment History ..................................................................................27
7.6.3 Behavioral Assessments .........................................................................................27
7.6.3.1 Bayley Scales of Infant and Toddler Development, Third Edition ........27
7.6.3.2 Wechsler Preschool and Primary  Scale of Intelligence (WPPSI ) ..........27
7.6.3.3 Child Behavior Checklist (CBCL) .........................................................28
7.6.3.4
Vineland Adaptive Behavior Scales, Second Edition ............................28
7.6.3.5 Attention- Deficit/Hy peractivity  Disorder Rating Scale .........................28
7.6.3.6 Social Communication Ques
tionnaire –Lifetime Form ........................29
7.6.4 Cerebral Pals y Assessment ....................................................................................29
7.6.5 Pulmonary  Morbidit y Assessment ................................
.........................................29
7.6.6 Cerebral Magnetic Resonance Imaging .................................................................29
7.6.7 Survival Assessment ..............................................................................................29
7.6.8
Health Economic Outcome Research Assessments................................ ............... 29
7.6.8.1 Health Related Quality  of L ife................................ ............................... 29
7.6.9 Health Care Resource Use ................................ ................................ ..................... 30
7.6.9.1 Health Status Classification Sy stem -Preschool ................................ ......30
7.7 Safety  Assessments ................................ ................................ ................................ ..31
For non-commercial use only
Shire CONFIDENTIAL Page 8
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
7.7.1 Abdominal ultrasound............................................................................................31
7.7.2 Echocardiogram .....................................................................................................31
7.7.3 Physical Examination .............................................................................................31
7.7.4 Blood Pressure, Heart Rate, and Respiratory  Rate ................................................32
7.8 Medication Assessment ............................................................................................32
7.9 Adverse Events Assessments ...................................................................................32
7.9.1 Definitions of Adverse Events, Serious Adverse Events, and Suspected 
Unexpected Serious Adverse Reactions ................................
................................32
7.9.1.1 Adverse Event ........................................................................................32
7.9.1.2 Serious Adverse Event ...........................................................................33
7.9.1.3 Suspected Unexpected Serious Adverse Reaction .................................34
7.9.1.4 Targeted Medical Events ........................................................................34
7.9.2 Classification of Adverse Events and Serious Adverse Events .............................34
7.9.3 Clarification between Serious and Severe .............................................................35
7.9.4 Relatedness of Adverse Events and Serious Adverse Events ................................35
7.9.5 Procedures for Recording and Reporting Adverse Events ....................................35
7.9.5.1
Adverse Event Monitoring and Period of Observation..........................35
7.9.5.2 Reporting Serious Adverse Events .........................................................36
7.9.5.3 Regulatory  Agency , Institutional Review Board, Ethics Committee, 
and Site Reporting................................
..................................................37
7.10 Removal of Subj ects from the Trial .........................................................................37
7.11 Other Study  Procedures ............................................................................................38
7.11.1 Participation in Other Clinical Studies ..................................................................38
7.12 Appropriateness of Measurements ................................
...........................................38
8STUDY ACTIVIT IES............................................................................................................39
8.1 Initial Study  Visit (40 weeks CA [term equivalent]) ...............................................39
8.2 Study  Visits ................................
..............................................................................39
8.2.1 Outcome Assessment 
Visits Conducted by  Telephone .........................................40
8.2.2 Clinical Site Visits ................................................................
.................................40
8.2.2.1 Outcome Assessment Site Visits............................................................40
8.2.2.2 Visits Dedicated to Corrective Lens Determin ation...............................44
8.3 Assessments upon Discontinuation ..........................................................................44
9QUALITY CONTROL AND ASSURANCE ........................................................................45
10STATI STICAL ANALYSES .................................................................................................46
10.1 General Methodology ...............................................................................................46
10.2 Determination of Sample Size ................................ ................................ .................. 46
10.3 Method of Assigning Study  Subjects to Treatment Groups ................................ .....46
10.4 Population Description................................ ................................ ............................. 46
For non-commercial use only
Shire CONFIDENTIAL Page 9
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
10.4.1 Analy sis Populations ..............................................................................................46
10.4.2 Subject Disposition ................................................................................................47
10.4.3 Protocol Violations and Deviations .......................................................................47
10.4.4 Demographics and Baseline Characteristics..........................................................47
10.5 Efficacy  Anal ysis.....................................................................................................47
10.5.1 Primary  Efficacy  Anal ysis.....................................................................................47
10.5.2 Secondary  Efficacy  Analy sis.................................................................................48
10.5.3 Subset Analy ses.....................................................................................................49
10.5.4 Exploratory  Anal yses.............................................................................................49
10.6 Health Economics and Outcomes Research Anal yses.............................................49
10.7 Analy sisof Safet
y ................................................................
....................................49
10.8 Statistical/Analy tical Issues ......................................................................................50
10.8.1 Adjustment for Covariates .....................................................................................50
10.8.2 Handling of Dropouts or Missing Data ..................................................................50
10.8.3 Interim Anal yses and Data Monitoring..................................................................50
10.8.4 Multiple Comparisons/Multiplicity ................................
.......................................50
10.8.5 Sensitivity  Anal yses...............................................................................................50
11ADMINISTRATIVE CONSI DERATIONS ..........................................................................51
11.1 Investigators and Study  Administrative Structure ...................................................51
11.2
Institutional Review Board or Independent Ethics Committee Approval................51
11.3 Ethical Conduct of the Study ...................................................................................51
11.4 Subject I nformation and Consent ................................
.............................................51
11.5 Subject Confidentiality .............................................................................................52
11.6 Study  Monitoring .....................................................................................................52
11.7 Case Report Forms and Study  Records ....................................................................53
11.7.1 Case Report Forms ................................
.................................................................53
11.7.2 Critical Documents ................................
................................................................53
11.8 Data Monitoring Committee ....................................................................................54
11.9 Protocol Violations/Deviations ................................................................................54
11.10 Premature Closure of the Study ...............................................................................54
11.11
Access to Source Documentation.............................................................................55
11.12 D ata Generation and Analy sis..................................................................................55
11.13 Retention of Data .....................................................................................................55
11.14 Financial Disclosure .................................................................................................55
11.15 Publication and Disclosure Policy ............................................................................56
12LIST OF REFERENCES ........................................................................................................57
13APPENDI CES ................................ ................................ ................................ ........................ 61
For non-commercial use only
Shire CONFIDENTIAL Page 10
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
LIST OF IN -TEXT TABLES
Table 7-1 Summary  of Visual Acuity  Assessments ...........................................................25
Table 7-2 Assessments for Phy sical Examinations ............................................................31
Table 7-3 Adverse Event Severit y......................................................................................34
Table 13-1 Summary  of Visual Acuity  Assessments ...........................................................65
LIST OF IN -TEXT FIGURES
Figure 4-1 Overview of Study  Design, Study  SHP -607
-201...............................................19
LIST OF APPENDICES
Appendix 1 Study  Schedule of Events ................................
...................................................62
Appendix 2 Pulmonary  Morbidit y Assessment (Clinical Site Visits at 6 and 12 
Months CA) ........................................................................................................66
Appendix 3 Pulmonary  Morbidit y Assessment 2 (Clinical Site Visits at 24 Months 
and 5 Years CA) .................................................................................................67
Appendix 4 Pulmonary  Morbidit y Assessment (Phone Interviews at 30 Months, 3 
Years, 3.5 Years, 4 Years, and 4.5 Years CA)
...................................................73
Appendix 5 Summary  of Changes .........................................................................................75
Appe ndix 6 Protocol Signature Page
.....................................................................................77
For non-commercial use only
Shire CONFIDENTIAL Page 11
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
LIST OF ABBREVIATIONS
Abbreviation Definition
AAO American Academy of Ophthalmology
ADHD attention -deficit hyperactivity disorder
ADHD -RS Attention -Deficit/ Hypera ctivity Disorder Rating Scale
AE adverse event
ASD Autism Spectrum Disorder
BSID -III Bayley Scales of Infant and Toddler Development, Third Edition
CBCL Child Behavior Checklist (1 ½ to 5)
CFR Code of Federal Regulations
CA corrected age
CI confidence interval
CRF case report form (electronic)
CRO contract research organization
DMC data monitoring committee
eCRF electronic case report form
EOS end of study
ETDRS Early Treatment of Diabetic Retinopathy Study
ER emergency room
EU European Union
FDA Food and Drug Administration
GCP Good Clinical Practice
GH grow th horm one
HRQoL health -related quality of l ife
HSCS -PS Health Status Classification System -Preschool
ICH International Conference on Harmonisation
IEC independent ethics committee
IGF insulin -like growth factor
IGFBP -3 insulin -like growth factor binding protein -3
IND Investigational New Drug application
IRB institutional review board
LV left ventricle
MedDRA Medical Dictionary for Regulatory Activities 
MRI magnetic resonance imaging
For non-commercial use only
Shire CONFIDENTIAL Page 12
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Abbreviation Definition
OD right eye
OS left eye
OU both eyes
PedsQL Pediatric Quality of Life Inventory 
REB research ethics board
ROP retinopathy of prematurity
SAE serious adverse event
SAP statistical analysis plan
SAS Statistical Analysis System©
SCQ Social Communication Questionnaire
SD standard deviation
SOE schedule of events
SUSAR suspected unexpected serious adverse reaction
UK United Kingdom
US United States
VABS -II Vineland Adaptive Behavior Scales, Second Edition
VLBW very low birth weight
WHO World Health Organization
WHO -DD World Health Organization Drug Dictionary
WPPSI Wechsler Preschool and Primary Scale of Intelligence
For non-commercial use only
Shire CONFIDENTIAL Page 13
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
1 INTRODUCTION
Retinopathy  of prematurity  (ROP) is a rare disorder of the developing retinal blood vessels and 
retinal neurons of the preterm infant and is one of the leading causes of preventable blindness in 
children.1
Visual acuity  is decreased in infants with a history  of ROP.2In addition to acuity, other aspects 
of ey e health are also significantly  impacted by  ROP . Strabismus and my opia are clearly  
increased in patients with a history  of ROP.3-6  Additionally , more than half of patients at 6 to 
10years of age with a history  of Stage 1 and Stage 2 ROP were reported to have ongoing visual 
issues.7
When preterm infants are deprived of their natural intrauterine environment, they  lose important 
factors normally  found in utero, such as proteins, growth factors and cy tokines . It has been 
demonstrated that IGF -1 is one such factor . During fetal life, IGF -1 is available through placental 
absorption and ingestion from amniotic fluid .8Deprivation of such factors is likely  to cause 
inhibition or improper stimulation of important pathway s, which in the ey e may  cause abnormal 
retinal vascular development, the hallmark of ROP.
The finding in both a mouse model of ROP and preterm infants that development of ROP is 
associated with low levels of IGF -1 after premature birth, indicates a possible role for 
replacement of IGF -1 to leve ls found in utero as a strategy  to potentially  decrease abnormal 
retinal vascularization and abnormal retinal neural development, and ultimately , ROP . 
Mecasermin rinfabate (rhIGF -1/rhIGFBP -3) is the human recombinant form of the naturall y 
occurring protei n complex of I GF-1 and insulin-like growth factor binding protein- 3 (IGFBP -3)
. 
rhIGF -1/rhIGFBP -3 was developed to enhance the sy stemic exposure of administered rhIGF -1 
and to improve the safety profile of rhIGF -1 therapy . rhIGF-1/rhIGFBP -3 was approved by  
the 
Food and Drug Administration ( FDA ) in 2005 for the treatment of growth failure in children 
with severe primary  IGF-1 deficiency  or with growth hormone (GH) gene deletion who have 
developed neutralizing antibodies to GH . 
The pharmacokinetics and safet yof rh IGF
-1/rhIGFBP -3 have been evaluated in a Phase I study  
(ROPP -2005- 01) and pharmacokinetics, safet y, and efficacy are being evaluated in the ongoing 
phase II stud y (ROPP -2008 -01). Sections A -C of the ROPP -2008- 01 study  are complete . 
Section D of the R OPP-2008- 01 study  is currentl y being conducted to assess pharmacokinetics, 
safet y and efficacy of rhIGF -1/rhIGFBP -
3 for the prevention of ROP in premature infants (up to 
a corrected age [CA] of 40 weeks [± 4 day s]). Subjects in Study  ROPP -2008- 01are random ly 
assigned to receive rhIGF -1/rhIGFBP -3 or standard neonatal care . The target dose of 
rhIGF -1/rhIGFBP -3 for Study  Section D is 250 μg/kg/24 hours to be administered via 
continuous infusion starting on Study  Day  0 (day  of birth) and continuing through post menstrual 
age (gestational age + time elapsed from birth) 29 weeks + 6 day s.
Although the rh IGF-1/rhIGFBP -3 therap y in Section D of the Phase II study 
(Study ROPP -2008- 01) represents a short -term exposure (< 2 months for each subject), 
rhIGF -1/rhIGFBP -3 ma y have long -lasting effects on visual outcomes as well as other potential 
For non-commercial use only
Shire CONFIDENTIAL Page 14
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
outcomes related to complications of prematurit y such as neurodevelopment, pulmonary  
function, and growth . In addition, it is critical to understand an y long term safet y effects from
short term exposure to rhIGF -1/rhIGFBP -3. 
The long- term outcomes assessed in this study  will require utilization of different assessment 
tools than are utilized in the Phase II stud y, ROPP -2008- 01 Section D, given the changes in 
physical and cognitive development that will occur in the subjects as they  age during their 
participation in this study . 
Please refer to the current edition of the I nvestigator’s Brochure for further information 
concerning the safet y and clinical development of rhIGF -1/rhIGFBP -3.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 16
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
3 STUDY E NDPOINTS
3.1 Efficacy Endpoints
3.1.1 Primary Efficacy Endpoints
Visual acuity  as assessed by  an age -appropriate method
Ocular alignment and ocular motor examination in primary  gaze and in as many  of 
9positions of gaze as possible as assessed b y corneal light reflex and b y the cover test
Assessment of n ystagmus by  observation
Refraction as assessed b y retinoscop y with cycloplegia
Stereoacuit y as assessed with the Lang Stereotest
3.1.2 Secondary Efficacy Endpoints
Growth parameters including bod y weight, bod y length (or height), and head 
circumference
Cognitive development as assessed b y the following standardized, age -appropriate 
tools:
oBayley Scales of Infant and Toddler Development, Third Edition (BSID -III)
oWechsler Preschool and Primary  Scale of Intelligence (WPPSI )
Physical development as assessed by  standardized, age appropriate tools including 
physical exam ination , neurological examination for assessment of cerebral palsy , and 
hearing assessment
Child behavior as assessed by  the following:
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
oChild Behavior Checklist (CBCL ;1 ½ to 5)
oAttention- Deficit/ Hyperactivity  Disorder Rating Scale (ADHD -RS) for the 
assessment of s ymptoms of attention -deficit/ hyperactivity  disorder (ADHD)
oSocial Communication Questionnaire (SCQ) for screening of Autism Spectrum 
Disorder (ASD)
Pulmonary  morbidity  data (eg, hospitalizations, emergency  room [ER] visits, 
pulmonary  medications)
Survival as assessed by death during the study  due to any  cause
3.2 Health Economic Outcome Research Endpoints
Health Related Quality  of L ife (HRQoL) will be assessed by  the Pediatric Quality  of 
Life Inventory  (PedsQL™) Scales appropriate for the child’s age of development with 
the Total Scale Score and 5 domains within Phy sical Health (Phy sical Functioning and 
Physical S ymptoms) and Psy chosocial Health Scores (Emotional, Social, and 
Cognitive Functioning, respectivel y)
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 18
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
4 INVESTIGATIONAL PLAN
4.1 Overall Study Design and Plan
This is a Phase II, multicenter, long- term developmental outcome study  enro lling subjects who 
were randomized in Section D of Study  ROPP -2008-01 to receive either rhIGF -1/rhIGFBP -3
(treated) or standard neonatal care (control) . Enrolled subjects in this study  will be followed 
through age 5 years CA . This study  will enroll both su bjects who were in the treated (received 
rhIGF -1/rhIGFBP -3) and control (received standard neonatal care) groups of Study  
ROPP -2008-01 (Section D) to enable assessment of rhIGF- 1/rhIGFBP -3 long -term efficacy  and 
safet y outcomes versus standard neonatal care
. No investigational product will be administered 
in this study . 
In this stud y, the Initial Visit will occur at 40 weeks CA (ie, term equivalent) or upon 
discontinuation from Study  ROPP -2008- 01 or may  occur any  time u p to the visit at 3 months 
CA. Subjects in Study  ROPP -2008- 01 are premature infants enrolling at gestational age of 
23weeks + 0 day s to 27 weeks + 6 day
s.
Time points for assessments have been chosen based on standard premature infant follow -up 
periods and represent important developmental ages for premature infant follow -
up. 
Both telephone and clinical site visits are included to help maintain contact with subjects 
throughout the 5- year duration of the study .
Subjects will be evaluated at appropriate follow- up site locations w ith expertise in the 
assessment of the developmental outcomes of premature infants . Pediatric ophthalmology  
expertise will also be required
. 
See Appendix 1for the Study  Schedule of Events t able.
The overall study  design is outlined in Figure 4-
1.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 20
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Insulin -like growth factor -1 (IGF -1) mediates its primary  actions b y binding to its specific 
receptor, the insulin- like growth factor 1 receptor (IGF -1R), which is present on many  cell ty pes 
in many  tissues . Binding to its receptor initiates intracellular signaling including via the AKT 
signaling pathway . This pathway  is involved in stimulation of cell division, growth and 
differentiation and inhibits programmed cell death. Specificall y regarding premature infants, 
IGF-1 is an important mediator of fetal growth and has been shown to play  a role in earl y 
postnatal growth following pre -term delivery .9,10
Insulin -like growth factor -1 (IGF -1) has also been shown to play  a role in pulmonary  
development11and neural development.12,13Given the potential role for IGF-1 in the 
development of multiple sy stems, this study  has been designed to evaluate the long -term effects 
of rhIGF -1/rhIGFBP -3, both from a safety  and efficacy  perspective, on the development of the 
premature infant.
4.3 Study Duration
Duration for an individual subject’s participation in the study 
will vary  depending upon age at 
enrollment, but subjects will not be followed beyond age 5.5 years CA .
For non-commercial use only
Shire CONFIDENTIAL Page 21
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
5 STUDY POPULATION SEL ECTION
5.1 Study Population
Subjects randomized in Study ROPP -2008- 01, Section D are eligible to enroll in this study ; 
completion of Study  ROPP -2008- 01 Section D is not required. Subjects in Study  ROPP -2008-01 
are premature infants (gestational age of 23 weeks + 0 day s to 27 weeks + 6 day s) who ar e 
randomized to receive either treatment with rhIGF- 1/rhIGFBP -3 or standard neonatal care. Up to 
120 subjects are planned to be randomized in Study ROPP -2008- 01 Section D.
5.2 Inclusion Criteria
Each subject must meet the following criteria to be enrolled in this study .
1.Subje ct was randomized in Study  ROPP -
2008- 01, Section D
2.Subject’s parent or legally  authorized representative(s) must provide written informed 
consent prior to performing an y stud y-related activities. Study -related activities are an y 
procedures that would not have been performed during normal management of the subject.
5.3 Exclusion Criteria
Subjects who meet an y of the following criteria will be excluded from the study.
1.Any other condition or therapy  that, in the Investigator’s opinion, may  pose a risk to the 
subject or interfere with the subject’s ability  to be compliant with this protocol or interfere 
with the interpretation of results
2.The subject or subject’s parent or legally  authorized representative(s) is unable to comply  
with the protocol as determined by
 the Investigator
For non-commercial use only
Shire CONFIDENTIAL Page 22
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
6 STUDY TREATMENT
6.1 Description of Treatment
No investigational product will be administered in this study .
6.2 Treatments Administered
Not applicable.
6.3 Selection and Timing of Dose for Each Subject
Not applicable.
6.4 Method of Assigni ng Subjects to Treatment Groups
Not applicable.
6.5 Masking
Not applicable.
6.6 Medications
Any medications administered to the subjects will be collected from the time of informed 
consent through the 5 -year CA visit (or until the subject withdraws or is discontin ued). An y 
investigational product received b y subjects will be recorded separatel y as part of an assessment 
of subjects’ participation in other clinical studies (Section 7.11.1).
6.7 Restrictions 
6.7.1 Prior Therapy
There are no restrictions related to prior therap y.
6.7.2 Other Restrictions
There are no restrictions related to fluid or food intake, or subject activity .
6.7.3 Treatment Compliance
Not applicable.
6.7.4 Packaging and Labeling
Not applicable.
6.8 Storage and Accountability
Not applicable
For non-commercial use only
Shire CONFIDENTIAL Page 23
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
7 STUDY PROCEDURES
Detailed descriptions of subject procedures and evaluations required for this protocol are 
described in this section . These evaluations will be performed during the indicated day s and 
weeks of the stud y (see Schedule of Events in Appendix 1). 
All data collected ar e to be recorded on the subject’s appropriate eCRF . 
Details for stud y procedures are described in the Operations Manual for this study.
7.1 Informed Consent
Prior to conducting an y study -related procedures, written informed consent must be obtained 
from the s ubject’s parent(s) or legall y authorized representative(s).
The nature, scope, and possible consequences, including risks and benefits, of the study will be 
explained to the subject, the subject’s parent(s), or the subject’s legall y authorized representati ve 
by the Investigator or designee in accordance with the guidelines described in Section 11.4. 
Documentation and filing of informed consent documents should be completed according to 
Section 11.4.
7.2 Study Entrance Criteria and Eligibility
At the I nitial Visit, each subject will be reviewed for eligibility  against the study  entrance 
criteria . Subjects who do not meet the study  entrance criteria will not be allowed to participate in 
the study . The reason(s) for the subject’s ineligibility  for the stud y will be documented . No 
exemptions will be allowed.
If informed consent is not obtained at or before the 3 -month visit in Study  ROPP -
2008- 01 for 
inclusion in this study  (SHP607 -201), the subject may  still be enrolled until they  turn 2 years CA
+3 months . Subjects are no longer eligible to participate in this study  after they  turn 2 y ears CA
+3 months. 
7.3 Study Enrollment
Subjects will be considered enrolled in the stud y once written informed consent has been 
obtained from the subject’s parent(s) or legally  authorized representative(s).
7.4 Demographics
Subject demographic information including gender, date of birth , and race will be recorded.
7.5 Growth Parameters :  Length (and Height), Weight, and Head Circumference
7.5.1 Length and Height
Body length (supine measurement) will be collected when subjects are 24 -months CA or 
younger . 
For the length measurement, the subject will be placed on his or her back so that the 
For non-commercial use only
Shire CONFIDENTIAL Page 24
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
subject is ly ing straight and the shoulders and buttocks are flat against the measuring surface. 
The subject's ey es should be looking straight up and care should be taken that the head is in a 
neutral position (neither being flexed nor extended at the neck). Both legs should be fully  
extended and the toes should be pointing upward with feet perpendicular to the measurin g 
surface.
Height (standing measure) will be collected when subjects are older than 24 -months CA. A 
stadiometer should be utilized for measurement of height . The subject should remove shoes.
For the measurement of standing height, the child is instructed to stand erect (stand up straight 
and look straight ahead) with the child’s head positioned in a horizontal plane . The moveable 
headpiece is brought onto the upper most (superior) point on the head with sufficient pressure to 
compress the hair. 
For height and length, 2 measures should take place and both will be recorded . If the 2 measures 
are discrepant b y >2 cm, the measures should be repeated. All measures should be recorded in 
metric units and measurement should be recorded to the nearest tenth centime ter (0.1 cm). 
7.5.2 Body Weight
Body weight will be collected . Calibrated scales should be utilized for body  weight measures 
(type of scale will depend upon subject’s age) . Care should be taken to remove any  extraneous 
clothing prior to measures and shoes should be removed.
The measure should be recorded to the nearest 0.1 kg.
7.5.3 Head Circumference
Head circumference will be measured for all subjects. An accurate head circumference 
measure ment is obtained with a “lasso” -type, non -stretchable measuring tape suc h as the Lasso -o 
tape. Head circumference or occipital frontal circumference is measured over the occiput and just 
above the supraorbital ridge, which is the largest circumference of the head.
7.6 Efficacy Assessments
7.6.1 Visual Assessments
After corrective lens d etermination has occurred (Section 7.6.1.2), all visual assessments should 
be conducted with best -corrected vision, ie, with corrective lenses in place (if required); this 
applies to 24-month and 5- year visits.
7.6.1.1 Visual Acuity
Visual acuity  is a measure of h ow well a subject sees at different distances . It will be assessed by  
the methods summarized in Table 7-1; the method employ ed will be selected based on the 
subject’s age (CA) at the time of the study  visit . 
Visual acuity  measurements will be measured 
and recorded for the left (OS), right (OD) ey e, and both ey es (OU).
For non-commercial use only
Shire CONFIDENTIAL Page 25
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
At ages 6 months and 12 months CA, visual acuity will be assessed with Teller acuit y cards . At 
ages 24 months and 5 years CA an attempt should be made to assess visual acuity  by the LEA 
Symbol s Test and LEA Sy mbols Chart, respectively . If during this attempt, the examiner 
determines that it will not be possible to perform an accurate assessment with the relevant LEA 
tool, visual acuity  should be assessed with the Teller acuit y cards. 
The visua l acuit y assessments should be performed by an optometrist or ophthalmologist trained 
in pediatrics. 
Table 7-1 Summary of Visual Acuity Assessments 
Visual Acuity 
Assessment ToolDescription Unit of Measure Applicable 
Age/Study 
Visit (CA)
Teller acuity cardsResolution acuity –
discrimination of a grating 
optotype from a background with 
the same mean luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity -tests 
recognition of 4optotypesSnellen fraction
(eg, 20/20)24 monthsa
LEA Symbols 
(ETDRS -style) chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be made to assess visual acuity by the LEA 
Symbols Test and LEA Symbols Chart, respectively . If during this attempt, the examiner determines 
that it will not be possible to perform an accurate assessment w ith the rel evant LEA tool, visual acuity 
should be assessed with the Teller acuity cards.
7.6.1.2 Corrective Lens Determination
An assessment to determine if the subject requires vision correction with corrective lenses will 
be performed. This is being performed to ensure the accuracy  of subjects’ subsequent visual 
acuity  assessments (at the 24-month and 5- year visits) . The corrective lens determination will be 
performed according to the guidelines published by the American Academy of Ophthalmology  
(AAO).14
This assessment should be performed b y an optometrist or ophthalmologist trained in pediatrics . 
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility)
Ocular alignment will be assessed in primary  gaze by  comparing the position of the corneal light 
reflection in OS and OD (corneal light reflection assessment). Presence or absence of strabismus 
will be recorded in primary  gaze and in as many  of the 9 positions of gaze as feasible with the 
cover test assessment of refixation mo vement. Ext raocular muscle over -action or deficiency  will 
be recorded. The assessment will be performed according to the AAO guidelines .14
Presence or absence of ny stagmus as observed during the ocular alignment assessments will also
be recorded.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 27
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
7.6.2 Hearing Assessment History
Results of previously  completed hearing assessments will be recorded at the 5 -year CA visit;
hearing tests are not being performed as p art of this study . 
7.6.3 Behavioral Assessments
7.6.3.1 Bayley Scales of Infant and Toddler Development, Third Edition
The BSID -III will be used to assess cognitive, motor, and language skills, and is applicable to 
children aged 1 to 42 months. 
The BSID-IIIis an assessment tool designed to measure a y oung child's skills in the 3 core areas 
of development :  cognitive, language, and motor. There are 5 subscales, the cognitive subscale 
stands alone while the 2 language subscales (expressive and receptive) comb ine to make a total 
language score and the 2 motor subtests (fine and gross motor) form a combined motor scale. 
The tool is engaging, with colorful props and visual stimuli that capture the attention of the child. 
The individual test items are short, limiting the amount of attention required for each item. The 
test administration is flexible in that items can be administered out of order, provided the 
assessor adheres to the specific guide lines in the examiner's manual.
The BSID -III will be administered to the subject ,with participation of the subject’s parent(s) or 
legally  authorized representative(s) ,by a trained professional. Scores to be recorded are detailed 
in the Study  Operations Manual.
7.6.3.2 Wechsler Preschool and Primary Scale of Intelligence (WPPSI)
The WPPSI is a measure of general cognitive development in children that has components of 
both verbal and nonverbal tasks.19  It is applicable to preschoolers and young children aged 
2years + 6 months to 7 years + 7 months, and is a direct assessment of a child’s cognitive skills.
It is composed of the following 5 scales:
Verbal
Performance
Processing Speed
Full Scale
Language
It not onl y applies to healthy children, but in the course of the scale’s standardization20special 
group validity  
studies were performed, including, but not limited to, groups of children with 
developmental risk factors, autistic disorder, and intellectual disability . Scores may  be 
interpreted in the context of provided norms, which reflect inclu sion of the special groups.
The WPPSI will be administered to the subject by a trained professional. 
Scores to be recorded 
are detailed in the Study  Operations Manual.
For non-commercial use only
Shire CONFIDENTIAL Page 28
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
7.6.3.3 Child Behavior Checklist (CBCL)
The CBCL (1 ½ to 5) is a parent -reported outcome measure used to assess behavioral, emotional, 
and social functioning of toddlers and preschool children aged 18 to 60 months.21It is composed 
of 99 items that are rated on a L ikert scale and includes the following 7 s yndrome scales 
arranged under 2 domains (ie, Internalizing and Ext ernalizing Problems) :22
Internalizing Problems
Emotionally  Reactive
Anxious/Depressed
Somatic Complaints
Withdrawn
Sleep Problems
Attention Problems
Aggressive Behavior
The questionnaire is widely  used and has been employ ed to assess long- term behavioral 
outcomes in children born prematurel y, aged similarly to the subjects expected in this study  
population.22-24It is associated with well -established normative d ata;25norms may  be selected to 
aid in interpretation of the scale scores.
The CBCL (1 ½ to 5) is a questionnaire that will be administered to the subject’s parent(s) or 
legally  authorized representative(s) by  a trained professional. Scores to be recorded are detailed 
in the Study  Operations Manual.
7.6.3.4 Vineland Adaptive Behavior Scales, Second Edition
The VABS -II Expanded Interview Form will be used to measure the personal and social skills of 
subjects seriall y over time; these scales are organized within a 3 -domain structure :  
Communication, Daily  Living, and Socialization. In addition, the VABS -II offers a Motor Skills 
Domain and an optional Maladaptive Be havior Index. The VABS -II Expanded Interview Form 
assesses what a subject actually does, rather than what he or she is able to do. 
The VAB S-II Expanded Interview Form will be administered to the sub ject’s parent(s) or legall y 
authorized representative(s) b y a trained professional . Scores to be recorded are detailed in the 
Study  Operations Manual.
7.6.3.5 Attention -Deficit/Hyperactivity Disorder Rating Scale
The ADHD -RS was developed to measure the behaviors of children with ADHD. The 
ADHD -
RS consists of 18 items designed to reflect current s ymptomatology of ADHD based on 
DSM -IV criteria. Each item is scored from a range of 0 (reflecting no s ymptoms) to 3 (reflecting 
severe s ymptoms) with total scores ranging from 0 -54. 
For non-commercial use only
Shire CONFIDENTIAL Page 29
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
The18items aregrouped into2subscales :  hyperactivity -impulsivity  (even numbered items 
2-18) and inattention (“inattentivene ss”) (odd numbered items 1 -17).
The ADHD -RS,26will be completed b y the subject’s parent(s) or legally  authorized 
representat ive(s) . Scores to be recorded are detailed in the Study  Operations Manual.
7.6.3.6 Social Communication Questionnaire – Lifetime Form
The SCQ is a brief instrument that helps evaluate communication skills and social funct ioning in 
children27that can b e used for screening for autism or autism spectrum disorders in the general 
population .28
The SCQ will be completed by  the subject ’s parent(s) or legall y authorized representative(s). The 
investigator or designee should review the assessment for completeness and to confirm all 
responses . Scores to be recorded are detailed in the Study  Operations Manual.
7.6.4 Cerebral Palsy Assessment
Comp rehensive neurological examination for the diagnosis of cerebral palsy (CP) will be 
conducted . The Amiel -Tison neurological examination framework29will be utilized for this 
assessment and conducted by  trained medical professionals.
7.6.5 Pulmonary Morbidity Assessment
Pulmonary  morbidity  will be assessed with questions related to famil y history and smoking 
status as well as diagnosis of select pulmonary  symptoms, conditions and related 
hospitalizations. The assessment will be administered to the subject’s parent(s) or l egall y 
authorized representative(s). Assessments will be performed as outlined in the Schedule of 
Events (see Appendix 1).Questionnaires that will be used for these assessments at clinic al site
visits are provided in Appendix 2for the 6-month and 12- month CA visits and Appendix 3for 
the 24-
month and 5- year CA visits .The q uestionnaire that will be used for these assessments 
during phone interviews at the 30-month, 3 -year, 3.5 -year, 4-year, and 4.5 -year CA visits is
provided in Appendix 4
.
7.6.6 Cerebral M agnetic R esonance I
maging
Magnetic resonance imaging ( MRI )of the brain will be performed. The MRI  should be 
performed without sedation. If the scan is unsucce ssful, a second attempt should be made . 
Volumetric anal yses of the cortical gray  matter, cortical white matter, corpus callosum, frontal 
lobes , cerebellum, and total volume
will be analy zed for the purposes of this study .     
7.6.7 Survival Assessment
Survival status will be assessed and recorded.
7.6.8 Health Economic Outcome Research Assessments
7.6.8.1 Health Related Quality of Life
Health-related qualit y of l ife (HRQoL) is an important outcome towards improving the health 
care of pediatric patients as it is that part of a person’s overall qualit y of life that is determined 
For non-commercial use only
Shire CONFIDENTIAL Page 30
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
primarily  by their health status and which can be influenced by  clinical interventions . It is an 
important concept, which is also used in determining the value of health care services in this 
population.30,31It is a multidimensional construct whose content is guided by the World Health 
Organization;32minimally it includes ph ysical, psy chological (including emotional and 
cognitive), and social health dimensions .
In this stud y, HRQoL will be assessed via the validated Pediatric Quality of L ife In ventory  
(PedsQL™) Scales appropriate for the child’s age of development.33-35  The development of the 
PedsQL  was based on the delineations of the World Health Organization ( WHO )and is a 
modular approach to assessing HRQoL in the pediatric population. Initially , the PedsQL  Generic 
Scales were developed and continue to be used in children aged 2 to 18 years. More recently  
Infant Scales have been developed that appl y to ages 1 to 24 months.34
The following scales will be used in this study :
Infant Scale for ages 1 -12 months (36 I tems)
Infant Scale for ages 13 –24 months (45 I tems)
Toddler Scale for 2 -4 years of age (21 Items)
Young Child Scale for 5 -7 years of age (23 Items)
The PedsQL will be administered to the subject’s parent and may  be conducted via telephone by 
clinical site staff . The scale(s) to be administered at each visit will be specified in the 
Study Operations Manual.
7.6.9 Health Care Resource Use
To understand the value of the investigational product administered in Study  ROPP -
2008-01 
(Section D), the resource use associated with inpatient visits, outpatient visits, and medical and 
pharmacy utilization in this study  will be recorded. 
This assessment may be conducted via telephone by clinical site staff .
7.6.9.1 Health Status Classification System -Preschool
Health status (eg, health u tility ) will be measured by  the Health Status Classification 
System -Preschool (HSCS -PS), which is a validated instrument adapted for use via parent prox y 
within the pediatric population age 2.5 to 5 (adapted from the validated Health Utilities I ndex 
Mark 2 and 3 [HUI 2/3]).36  Validity  of the HSCS -PS concepts has not been established for ages 
younger than 2.5 y ears.
The HSCS- PS was developed to provide a consistent measure of health status in preschool
-aged 
children who had been born prematurely .36The sy stem is applicable to children with special 
needs as may  be included in this study ; validation cohorts for the s ystem included children with 
very low birth weight (VLBW), which is congruent with this study  population.
For non-commercial use only
Shire CONFIDENTIAL Page 31
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
The instrument is composed of 12 dimensions (Vision, Hearing, Speech, Mobility , Dexterity , 
Self-care, Emotion, Learn/remember, Think /problem solve, Pain, General Health, and Behavior) 
intended to provide a comprehensive assessment of a child’s health status as it pertains to 
health- related quality  of life . The individual domains of the instrument will be scored as a mean 
score, represe nting the overall state for each concept individually . The global score will be 
recorded as well as the scores for each of the dimensions.
The HSCS- PS is a questionnaire that will be administered to the subject’s parent(s) or legall y 
authorized representat ive(s) and may  be conducted via telephone by clinical site staff .
7.7 Safety Assessments
7.7.1 Abdominal ultrasound
An abdominal ultrasound will be performed to assess the size of the spleen and kidney s. The 
spleen will be measured in the coronal longitudinal plane and the longest longitudinal length will 
be measured for each kidney  (left and right) .37Ultrasound results will be assessed by a central 
reader.
Organ size will be interpreted in the context of reference values established for children .37,38
7.7.2 Echocardiogram
Echocardiographic examination (conventional M- mode recording of the left ventricle [L V] 
parasternal long axis view) will be performed for the evaluation of cardiac size, assessed by  
measuring the following:
interventricular septal thickness (during end diastole)
LV posterior wall thickness
LV intracavit y volume (both in end diastole and end systole)
Echocardiogram results will be assessed by a central reader.
7.7.3 Physical Examination
Physical examinations will include a review of the subject’s general appearance, neurological 
examination, as well as a tonsillar examination ( Table 7-2
). An y abnormal change in findings 
will b e recorded as an AE
. 
Table 7-2 Assessments for Physical Examinations
Assessment Assessment
General appearance Endocrine
Head and neck Cardiovascular
Eyes Abdomen
Ears Genitourinary
Nose Skin
For non-commercial use only
Shire CONFIDENTIAL Page 32
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Table 7-2 Assessments for Physical Examinations
Assessment Assessment
Throat Musculoskeletal
Chest and lungs Neurological
Tonsils
7.7.4 Blood Pressure , Heart Rate , and Respiratory Rate
Blood pressure ,heart rate , and respiratory will be measured at the 5- year CA visit.
7.8 Medication Assessment
All medications received by  study  subjects will be collected from the time of enrollment through 
the 5- year CA visit (or upon discontinuation) . Any investigational product received b y subjects 
will be recorded separately  as part of an assessment of subjects’ participation in other clinical 
studies (Section 7.11.1).
7.9 Adverse Events Assessments
7.9.1 Defin itions of Adverse Events, Serious Adverse Events , and Suspected 
Unexpected Serious Adverse Reactions
7.9.1.1 Adverse Event
An AE is an y noxious, pathologic, or unintended change in anatomical, physiologic, or 
metabolic function as indicated b y physical signs, symptoms, or laboratory  changes occurring in 
any phase of a clinical study , whether or not considered investigational product-related. This 
includes an exacerbation of a pre -existing condition . 
Adverse events include:
Worsening (change in nature, severit y, or frequency) of conditions present at the onset 
of the study
Intercurrent illnesses
Drug interactions
Events related to or possibly  related to concomitant medications
Abnormal laboratory  values (this includes significant shifts from baseline within the
range of normal that the Investigator considers to be clinically  important)
Clinically  significant abnormalities in phy sical examination, vital signs, and weight
In this long -term outcome study  in follow -up to Study  ROPP -2008- 01 (Section D), no 
investigational product is being administered. However, the relationship to the investigational 
product (rhIGF -1/rhIGFBP -3) as administered in Study  ROPP -2008- 01 (Section D) will be 
assessed . 
For non-commercial use only
Shire CONFIDENTIAL Page 33
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
For the purposes of this study  only the following a dverse event swill be collected:  
those considered related to investigational product (rhIGF- 1/rhIGFBP -3 as 
administered in Study  ROPP -2008- 01, Section D)
those considered related to procedures performed in this study  (Study  SHP -607-201)
specified targeted medical e vents (Section 7.9.1.3) regardless of causality
Throughout the stud y, the Investigator must record AEs on the AE electronic case report form 
(eCRF), regardless of the severit y. The Investigator should treat subjects with AEs appropriatel y 
and observe them at suitable intervals until the events stabilize or resolve . Adverse events may  
be discovered through observation or examination of the subject, questioning of the subject, 
complaint by  the subject, or by  abnormal clinical laboratory  values.
In addition, AEs may  also include laboratory values that become significantly  out of range . In 
the event of an out -of
-range value, the laboratory  test should be repeated until it returns to 
normal or can be explained and the subject’s safety is not at risk. 
Additional illnesses present at the time when informed consent is given are regarded as AEs and 
will be documented on the appropriate pages of the eCRF . Illnesses first occurring or detected 
during the stud y, and worsening of a concomitant illness during the stud y, are to be regarded as 
AEs and must be documented as such in the eCRF.
7.9.1.2 Serious Adverse Event
An SAE is any  AE that results in any  of the following outcomes:
Death
Is life -threatening
Requires hospitalization
Requires prolongation of existing hospitalization
A persistent or significant disability  or incapacity  
A congenital anomal y or birth defect
Important medical events that may  not result in death, be life -threatening, or require 
hospitalization may  be considered an SAE when, based upon appropriate medica l judgment, they  
may jeopardize the subject and may  require medical or surgical intervention to prevent one of the 
outcomes listed in this definition . A life -threatening AE is defined as an AE that placed the 
subject, in the view of the initial reporter, a t immediate risk of death from the AE as it occurred 
(ie, it does not include an AE that, had it occurred in a more severe form, might have caused 
death).
For non-commercial use only
Shire CONFIDENTIAL Page 34
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
For the purposes of this study  only SAE listed in the following will be collected:
fatal SAEs regardl ess of causality
SAEs related to ROP
SAEs related to congenital malformations not identified at birth which may impact 
neurocognitive development 
7.9.1.3 Suspected Unexpected Serious Adverse Reaction
Suspected unexpected serious adverse reactions (SUSAR) are suspected adverse reaction s related 
to an investigational product (investigational products and comparators [if applicable]), which 
occur in the concerned study , and that are both serious and unexpected according to the current 
Investigator’s Brochure .
7.9.1.4 Targeted Medical Events
If it is determined that any of the following targeted medical events have been experienced b y a 
subject, they will be recorded as AEs or SAEs, as appropriate, regardless of relationship to 
investigational product ( rhIGF-1/rhIGFBP -3as administered in Study  ROPP -2008-01, 
Section D):
intracranial hy pertension
any abnormalit y of glucose metabolism (eg, h ypogl ycemia, h ypergl ycemia, and 
diabetes)
tonsillar hy pertrophy  (based on tonsil exam [part of the phy sical exam])
increased kidney  size 
increased cardiac size
increased spleen size
7.9.2 Classification of Adverse Events and Serious Adverse Events
The severit y of AEs will be assessed b y the Investigator based on the definition indicated in 
Table 7-3. The severit y of all AEs/SAEs should be recorded on the appropriate eCRF page to a 
severit y of mild, moderate, or severe.
Table 7-
3 Adverse Event Severity
Severity Definition
Mild No limitation of usual activities.
Moderate Some limitation of usual activities.
Severe Inability to carry out usual activities.
For non-commercial use only
Shire CONFIDENTIAL Page 35
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
7.9.3 Clarification between Serious and Severe
The term “severe” is often used to describe the intensity  (severit y) of a specific event (as in mild, 
moderate, or severe m yocardial infarction); the event itself, however, may  be of relatively  minor 
medical significance (such as severe headache) . This is not the same as “serious,” which is based 
on the outcome or action criteria usually associated with events that pose a threat to life or 
functioni ng. Seriousness (not severity) and causality serve as a guide for defining regulatory 
reporting obligations.
7.9.4 Relatedness of Adverse Events and Serious Adverse Events
Relationship of an AE or SAE to investigational product (rhIGF- 1/rhIGFBP -3 as administered in 
Study  ROPP -2008- 01, Section D) is to be determined by  the Investigator based on the following 
definitions (See Table 7-4).
Table 7-4 Adverse Event Relatedness
Relationship to Product Definition
Not Related Unrelated to investigational product
Possibly Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, but which could 
also be explained by concurrent disease or other drugs or chemicals.
Probably Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, unlikely to be 
attributable to concurrent disease or other drugs and chemicals and 
which follows a clin ically reasonable response on de -challenge . The 
association of the clinical event or laboratory abnormality must also 
have some biologic plausibility, at least on theoretical grounds.
Definitely related The event follows a reasonable temporal sequence fro m administration 
of the investigational product, follows a known or suspected response 
pattern to the investigational product, is confirmed by improvement 
upon stopping the investigational product (de -challenge), and 
reappears upon repeated exposure (re -challenge) . Note that this is not 
to be construed as requiring re -exposure of the subject to 
investigational product; however, the determination of definitely 
related can only be used when recurrence of event is observed.
7.9.5 Procedures for Recording and Repor ting Adverse Events
7.9.5.1 Adverse Event Monitoring and Period of Observation
Adverse events will be monitored throughout the study . 
For the purposes of this study , the period of observation begin s from the time at which the 
subject’s parent(s) or legally  authorized representative(s) gives informed consent until the 
subject’s final evaluation of the study .When possible, subject’s parents or legally  authorized 
representative(s) should be consented a t the end of study  visit for the ROPP -2008-01. However ,
if this is not possible, subject’s parents or legall y authorized representative(s) will be asked to 
provide consent for an y Serious Adverse Events that the subject experiences between 
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 38
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
If a subject or the subject’s parent(s) or the subject’s legally  authorized representative(s) acting 
on behalf of the subject, discontinues participation in the study , or the subject is discontinued by  
the Investigator, reasonable efforts will be made to follow the subject through the end of study  
assessments . The reason for refusal will be documented on the eCRF. An y AEs experienced up 
to the point of discontinuation must be documented on the AE eCRF. If AEs are present when 
the subject withdraws from the study , the subject will be re -evaluated within 30 day s of 
withdrawal . All ongoing SAEs at the time of withdrawal will be followed until r esolution.
7.11 Other Study Procedures
7.11.1 Participation in Other Clinical Studies
Following enrollment, subjects in this study  will not be restricted from enrolling in another 
clinical study  that involves the use of investigational product . The status of a subject’s 
participation in such studies will be re corded (ie, yes/no) . If a subject is enrolled in such a study, 
additional parameters will be recorded, including the masking status of the study , the identity  of 
the investigational product being evaluated in the study , and the subject’s treatment assignment 
in the study  (if possible) . 
7.12 Appropriateness of Measurements
Overall, the primary  and secondary  efficacy  and safet y measures being employed in this study 
are considered appropriate for the follow -up of preterm infants. The validated tools being used to 
assess neurodevelopment, phy sical development, and health economic research outcomes in this 
pediatric population are widely used and recognized.
In some cases tools were designed specifically  for use in th is study . 
These are the pulmonary  
morbidity  assessment and the cerebral palsy  assessment . In these cases, the tools are either based 
on validated tools or the current state of knowledge in the literature . For example, the cerebral 
palsy  assessment is based on the Amiel -Tison neurological examination framework29and the 
pulmonary  assessment is based on published research in a similar pediatric population .39,40
For non-commercial use only
Shire CONFIDENTIAL Page 39
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
8 STUDY ACTIVITIES
The timing of the visits in this study  is based on subjects’ corrected age (CA). 
8.1 Initial Study Visit (40 weeks CA [term equivalent])
The Initia l Visit will occur at 40 weeks CA (ie, term equivalent) or upon discontinuation from 
Study  ROPP -2008- 01, Section D or any  time up to the visit at 3 months CA . 
For subjects enrolled between the ages of 9 months CA and 2 y ears +3 months CA, missed 
procedures such as neurocognitive assessments, abdominal ultrasounds, and echocardiograms are 
not required.
At the I nitial Visit, informed consent will be obtained followed by  an assessment of study  
eligibility  criteria and collection of demographic data.
The following AE d ata, collected as part of Study  ROPP -2008- 01 (Section D) will be recorded :
Ongoing targeted medical events regardless of causality
Ongoing stud y drug -related AEs, including SAEs
SAEs ,as outlined in Section 7.9.1.1 and Section 7.9.1.2, that the subject experiences between the 
ROPP -2008- 01 end-of
-study  visit and the time of informed consent for the SHI P-
607-201 study  
will be reported b y the Investigator ,pending permission for subject’s parent or legally  authorized 
representative(s) ,as doc umented on the informed consent form.
8.2 Study Visits
Study  visits for follow -up outcome assessments will take place at the following time points in 
CA:
3 months (±2 weeks) –conducted by  telephone
6 months (±1 month) –clinical site visit
12 months (±3 month s) –clinical site visit
20 month s (-1 months) 
–clinical site visit
24 months (±3 months) –clinical site visit
30 months (±3 months) –conducted b y telephone
3 years (±3 months) – conducted by  telephone
3.5 y ears (±3 months) – conducted by  telephone
4 years (±3 month) –conducted by  telephone
4.5 y ears (±3 month) – conducted by  telephone
4.75 y ears (- 1 months) – clinical site visit
5 years (+6 months) –clinical site visit
For non-commercial use only
Shire CONFIDENTIAL Page 40
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
In addition, there will be 2 visits that must occur at least 1 month prior to the 24-month and 
5-year CA stud y visits to assess the need for corrective lenses . The timing of these 2 visits 
(20months [ -1 month] and 4.75 y ears [- 1 month]) was set to ensure that any  prescribed 
corrective lenses would be worn for at least 1 month prior to the visual assessments at the 
24-month and 5- year study visits CA.
The activities at the study  visits are described in Sections 8.2.1 and 8.2.2.
8.2.1 Outcome Assessment Visits Conducted by Telephone
Visits at 3 months, 30 months, 3 y ears, 3.5 y ears, 4 years, and 4.5 y earsCA will be conducted b y 
telephone . The following outcome assessments will be conducted at each of these 6 visits, unless 
otherwise indicated:
HRQoL (3-month, 3 -year, and 4- year visits)
HCRU (3-month, 3 -year, and 4- year visits) 
HSCS -PS (3- year and 4 -year visits)
Pulmonary  morbidity  assessment (30 -month, 3 -year, 3.5 -year, 4-year, and 4.5 -year 
visits)
Medications (3-month, 3 -year, and 4
-year visits)
Survival assessment (3-month, 3 -year, and 4 -year visits)
Assessment of participation in other clin ical studies (3-month, 3 -year, and 4 -year 
visits) 
Adverse events , including targeted medical events (3-month, 3 -year, and 4 -year visits) 
8.2.2 Clinical Site Visits
8.2.2.1 Outcome Assessment Site Visits
The following clinical site visits (in CA) to capture follow- up 
outcome data will occur at the 
clinical site:
6 months (±1 month)
12 months (±3 months) 
20 months ( -1 month)
24 months (±3 months)
4.75 y ears (- 1 months)
5 years (+6 months)
The following assessments will be performed at the 6 -month visit:
Visual acuity
Refraction with cy cloplegia
For non-commercial use only
Shire CONFIDENTIAL Page 41
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Length
Weight
Head circumference
VABS -II
Physical examination (including tonsil examination)
Hearing Assessment History  (Historical hearing test data may  be recorded at any  time 
prior to the 6- month visit) 
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Abdominal ultrasound
Echoc ardiogram
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at the 12 -month visit:
Visual acuity
Corrective lens determination (including refract ion with cy cloplegia)
Ocular alignment and motility
Length
Weight
Head circumference
BSID-III
VABS -II
Physical examination (including tonsil examination)
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
For non-commercial use only
Shire CONFIDENTIAL Page 42
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medica l events)
The following assessments will be performed at the 20 -month visit:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
Assessment of participation in other clinical studies
The following assessments will be perform ed at the 24- month visit:
Visual acuity
Ocular alignment and motility
Length
Weight
Head circumference
BSID-III
CBCL
VABS -II
Physical examination (including tonsil examination)
Cerebral Pals y assessment
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HSCS -PS (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
For non-commercial use only
Shire CONFIDENTIAL Page 43
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
The following assessments will be performed at 4.75- year visit:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
The following assessments will be performed at the 5 -year visit:
Visual acuity
Ocular alignment and motility
Stereoacuit y
Height
Weight
WPPSI
CBCL
VABS -II
ADHD -RS
SCQ
Physical examination (including ton sil examination)
Blood pressure, heart rate, and respiratory  rate
Pulmonary  morbidity  assessment
Hearing assessment history
Survival assessment

Cerebral MRI
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HSCS -PS (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
For non-commercial use only
Shire CONFIDENTIAL Page 44
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
8.2.2.2 Visits Dedicated to Corrective Lens Determination
The following clinical site visits are dedicated solely  to corrective lens determination in 
preparation for the outcome assessment visits at 24- months and 5- years CA:
20months ( -1 month) 
4.75 y ears (- 1 month) 
At these visits, the following will be performed:
Visual acuity
Corrective lens determination (includes refraction with cy cloplegia)
The 20- month visit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 month prior 
to the 24-month and 5- year visits, respectivel y. Any prescribed corrective lenses must be worn 
for at least 1 month prior to the 24 month and 5 y ear assessments.
8.3 Assessments upon Discontinuation
If asubject discontinues prior to the 5 -year CA visit, every attempt will be made to complete the 
assessments scheduled for the subject’s next visit. 
For non-commercial use only
Shire CONFIDENTIAL Page 45
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
9 QUALITY CONTROL AND ASSURANCE
Training will occur at an Investigator meeting or at the site initiation visit or both, and instruction 
manuals will be provided to aid consistency  in data collection and reporting across sites.
Clinical sites will be monitored by  the Sponsor or its designee to ensure the accuracy  of data 
against source documents. The required data will be captured in a validated clinical data 
management s ystem that is compliant with the FDA 21 Code of Federal Regulations ( CFR )Part 
11 Guidance . The clinical trial database will include an audit trail to document any  evidence of 
data processing or act ivity on each data field by  each user . Users will be trained and given 
restricted access, based on their role(s) in the study, through a password -protected environment.
Data entered in the s ystem will be reviewed manually  for validity  and completeness agai nst the 
source documents by  a clinical monitor from the Sponsor or its designee . If necessary , the study  
site will be contacted for corrections or clarifications; all missing data will be accounted for.
Serious adverse event information captured in the cli nical trial database will be reconciled with 
the information captured in the Pharmacovigilance and Risk Management database.
For non-commercial use only
Shire CONFIDENTIAL Page 46
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
10 STATISTICAL AN ALYSES
10.1 General Methodology
Details regarding the statistical methods and definitions will be provided in the Statisti cal 
Analy sis Plan (SAP) . The SAP will be finalized prior to database lock. All statistical analy ses 
will be performed b y the Biometrics department at Shire. Statistical analy ses will be performed 
using Version 9.1 or higher of SAS®(SAS Institute, Cary , NC 27513).
Continuous variables will be summarized using descriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categorical variables will be summarized using frequencies and percentages.
As referred to in descriptions of summary  statistics, t reatment groups refer to the 2 possible 
treatment assignments in the antecedent study ,ROPP-2008- 01, Section D ( rhIGF-1/rhIGFBP -3
or standard neonatal care) .
For analysis purposes, baseline is defined as the first assessment either in the antecedent study  
(ROPP -2008- 01) or in this study  (SHP -607-201). As necessary , relevant data from Study  
ROPP -
2008- 01 may  be extracted and summarized with the data from this study  (SHP -
607-201).
For c onsented patients, additional biomarker analy sis may  be performed on prior collected blood 
samples from Study  ROPP -2008-01.
10.2 Determination of Sample Size
No formal sample size calculation wasperformed for this study  because this is a follow -up study  
to Sec tion D of Study  ROPP -2008- 01. Any  subjects enrolled in Study  ROPP -
2008- 01 are 
eligible to enroll in this study . There are up to 120 subjects who will be eligible to enroll in this 
long-term developmental outcome study .
10.3 Method of Assigning Study Subjects to Treatment Groups
Not applicable.
10.4 Population Description
10.4.1 Analysis Populations
Enrolled Population - the Enrolled Population will consist of all subjects for whom written 
informed consent has been provided for this study . 
Safety  Population- the Safety  Popul ation will consist of the subjects in the Enrolled Population
who have safet y follow
-up data in this long -term outcome study .
For non-commercial use only
Shire CONFIDENTIAL Page 47
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
10.4.2 Subject Disposition
Subjects who complete the study  and subjects who prematurel y discontinue from the stud y will 
be summarized by treatment group using descriptive statistics. I n addition, for subjects who 
prematurel y discontinue from the study, the reasons for discontinuation will be summarized by 
treatment group.
10.4.3 Protocol Violations and Deviations
Protocol violations and deviations will be listed. Details of the criteria for deviations and 
violations will be provided in the SAP.
10.4.4 Demographics and Baseline Characteristics
Descriptive summaries of demographic and baseline characteristics will be presented b y 
treatment group for the E nrolled Population . 
Demographics and baseline characteristics will be exami ned to assess the comparability  of the 
treatment group s. Continuous variables such as age (including corrected age) , weight, and 
length/height will be summarized using number of ob servations, mean, standard deviation, 
median, minimum and maximum values. Categorical variables, like gender and race, will be 
summarized using number of observations and percentages.
Medical history ,including maternal and perinatal history , (as obtained from the antecedent 
study , ROPP -2008- 01) will be summarized by  treatment group using the number of observations 
and percentages of subjects reporting each category .
10.5 Efficacy Analysis
All efficacy  analy ses will be performed using the Enrolled Population .
10.5.1 P rimary Efficacy Analysis
The primary  efficacy  endpoints consist of the following:
Visual Acuity :  Visual acuity  will be categorized as the following: 
onormal (measurable acuity ≥20/40), 
obelow normal (20/200≤ measurable acuit y <20/40), 
opoor (measurable acuity ≤20/200)
oblind/low vision (onl y the ability  to detec t the 2.2 cm wide stripes on the 
low-vision Teller acuit y card and at an y location in the visual field). 
The number and proportion of patients within each category  listed above will be 
summarized by treatment group and visit. I n addition, a cuity  results in the normal and 
below normal categories will be classified as favorable outcomes, and acuity  results in 
the poor and blind/low- vision categories will be classified as unfavorable outcomes. 
Tabular summaries b y trea tment group and visit will include the frequency  and the 
percentage for each visual acuity  category . 
For non-commercial use only
Shire CONFIDENTIAL Page 48
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Inaddition, shift tables offavorable outcomes from baseline (first assessment during 
this study ) to each of the subsequent assessments, including the last assessment , will 
be presented bytreatment group .
Ocular Alignment and Oculomotor Exam (Motility) :  Findings from the ocular 
motility  assessmen t will be either presence or absence of strabismus (esotropia, 
exotropia, hy pertropia, or hy potropia). Tabular summaries by treatment group and 
visit will include the frequency  and the percentage in each category . In addition, shift 
tables from baseline (first assessment during this study ) to the last assessment will be 
provided b y treatment group.
Nystagmus :  Presence or absence of ny stagmus will be summarized by  treatment 
group and visit
Refraction with C ycloplegia :  Findings from the refraction wit h cycloplegia will be 
summarized by  treatment group and visit
Stereoacuit y:  Presence or absence of stereopsis will be sum marized by  treatment 
group and visit
10.5.2 Secondary Efficacy Analysis
Growth Parameters (b ody weight, body  length [and height], and head circumference) :  
A standard Z- score, utilizing WHO child growth standards, will be calculated for each 
assessment by  adjusting age -and sex - matched means and standard deviations (norm). 
The descriptive statistics of the Z -score for each of these parameters will be 
summarized at each assessment and the corresponding change from baseline. When 
appropria te, a 95% CI for the corresponding mean change within each group and the 
difference in the mean change between the 2 treatment groups and the corresponding 
95% CI  will be presented as appropriate. If the parametric assumption for the 
distribution of the ab ove endpoints cannot be justified, a non -parametric approach will 
be utilized to estimate the treatment difference (ie, median difference or 
Hodges -Lehmann estimator and the corresponding confidence intervals)
BSID-III and WPPSI :  The raw score for each domain within each questionnaire will 
be summarized by  treatment group and visit using descriptive statistics.
ADHD -RS:  ADHD -RS total score and subscales (Hy peractivity /Impulsivity  and 
Inattentiveness) will be summarized by  treatment group and visit using descriptive 
statistics.
SCQ :  The SCQ subscales (communication and social) will be summarized by  
treatment group and visit using descriptive statistics
VABS -II:  The raw score for each domain of the scale will be summarized by  
treatment group and visit usi ng descriptive statistics.
CBCL :  The raw score and change from baseline for each domain of the scale will be 
summarized by  treatment group and visit using descriptive statistics.
For non-commercial use only
Shire CONFIDENTIAL Page 49
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Pulmonary  morbidity  assessment :  The binary  response of each question will b e by 
treatment group and visit using descriptive statistics.
Survival :  For subjects who have an event (ie, death), the event time will be calculated 
as the length of time from the subject’s date of birth to death during the study  due to 
any cause . Subjects who do not have an event (ie, death) during the stud y will be 
censored at the end of the study . The survival endpoint will be analy zed by treatment 
group using Kaplan- Meier methods.
10.5.3 Subset Analyses
Subgroup anal yses may  be explored based on factors that may  have influence on the efficacy  or 
safet y endpoints. Subgroup anal yses will be specified in the SAP.
10.5.4 Exploratory Analyses
10.6 Health Economics and Outcomes Research Analyses
For PedsQL, descriptive statistics will be provided for summary  scores by  treatment group and at 
each time point.
The HUI 2/3 s ystem contains a number of attributes/domains to classify  the level of health status. 
Each attribute or domain (eg, mobi lity, cognition, emotion or pain) is rated on a 5- point ordinal 
scale to indicate the severity  level, ranging from 1 to 5 (higher numbers indicating a more severe 
level). Summary  statistics will be provided by  treatment group and at each time point.
For HC RU the utilization for each resource -item (eg, hospital day s, phy sician visits) reported at 
each time point will be reported descriptivel y by treatment group.
10.7 Analysis of Safety
Safety  summaries will be based on all assessments post -baseline. The safet y data will be 
assessed b y AE monitoring, change in cardiac size, and kidney  and spleen size over time. 
Adverse events will be summarized by  system organ class and preferred term for each treatment 
group and overall, the number and percentage of subjects havi ng an y AE, having an AE in each 
body  system and having each individual AE. In addition, those events which resulted in death, or 
were otherwise classified as serious will be presented in a separate listing. In addition, the 
summary  of AEs will be presented by severit y and relationship to trial medication. 
The change in cardiac size, and size of kidney  and spleen will be assessed at the 6 -month CA 
visit via echocardiogram and abdominal ultrasound, respectivel y.  These data will be anal yzed as 
a binary  respo nse (ie, normal/abnormal) and summarized using frequency  count.  The number 
and proportion of patients with each category (ie, normal/abnormal) for each of these safet y 
endpoints will be summarized by  treatment group.  
For non-commercial use only
Shire CONFIDENTIAL Page 50
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Inaddition, the2-sided 95% CIforthe proportion of patients with a normal status for each of the 
endpoints will be estimated by  treatment group.
Physical examinations findings will be summarized descriptivel y. 
10.8 Statistical/Analytical Issues
10.8.1 Adjustment for Covariates
If any baseline data ar e imbalanced and are considered to be clinically  relevant, between -group 
comparisons for efficacy  outcomes will be adjusted for covariates and detailed in the SAP. 
10.8.2 Handling of Dropouts or Missing Data
Handling of missing data rules will be described in the SAP.
10.8.3 Interim Analyses and Data Monitoring
Aninterim anal ysis will be performed after all data from all enrolled subjects in this study  have 
either completed 2 -year follow -up (24- month visit) assessments or have prematurely  withdrawn 
from the study  (before completing 2 y ears of follow -up) has been entered i nto the database, 
queried and discrepancies resolved . A full 2- year study  report based on these data, including 
efficacy  and safet y endpoint analy ses,will be completed.
Additionally , descriptive anal yses of the data at other time points before study  completion may  
be performed for safet y monitoring, regulatory  reporting or general planning purposes.
10.8.4 Multiple Comparisons/Multiplicity
Not applicable.
10.8.5 Sensitivity Analyses
Sensitivity  analy ses for the eff icacy  outcomes will be detailed in the SAP, as necessary .
For non-commercial use only
Shire CONFIDENTIAL Page 51
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
11 ADMINISTRATIVE CONSIDERATIONS
11.1 Investigators and Study Administrative Structure
Before initiation of the study , the Investigators must provide the Sponsor with a completed Form 
FDA 1572 and Investig ator Agreement. Curriculum vitae must be provided for the Investigators 
and sub- investigators listed on Form FDA 1572 or I nvestigator Agreement . 
The Investigator should ensure that all persons assisting with the study  are adequatel y informed 
about the pro tocol, an y amendments to the protocol, and their study related duties and functions . 
The Investigator must maintain a list of sub -investigators and other appropriately  qualified 
persons to whom he or she has delegated significant study  related duties.
11.2 Institutional Review Board or Independent Ethics Committee Approval
Before initiation of the study , the Investigator must provide the Sponsor with a copy  of the 
written I RB/IEC/REB approval of the protocol and the informed consent form . This approval 
must refe r to the informed consent form and to the study  title, study  number, and version and 
date of issue of the stud y protocol, as given by the Sponsor on the cover page of the protocol.
Status reports must be submitted to the I RB/IEC/REB at least once per year. The IRB/IEC/REB 
must be notified of completion of the study . Within 3 months of study  completion or termination, 
a final report must be provided to the I RB/IECREB . A cop y of these reports will be sent to the 
study  clinical monitor . The Investigators must maintain an accurate and complete record of all 
submissions made to the IRB/IEC, including a list of all reports and documents submitted . 
AEs 
which are reported to the US (FDA or other Regulatory  agencies (Safet y Reports) must be 
submitted promptly  to the IRB/IEC/REB.
11.3 Ethical Conduct of the Study
The procedures set out in this study  protocol, pertaining to the conduct, evaluation, and 
documentation of this study , are designed to ensure that the Sponsor and Investigators abide by  
good clinical practice (GCP) as described in the 21 CFR Parts 50, 56, and 312 and the 
International Conference on Harmonization (I CH) GCP Guidelines Compliance with these 
regulations and guidelines also constitutes compliance with the ethical principles described in the 
Declarat ion of Helsinki.
11.4 Subject Information and Consent
Before enrolling in the clinical study , the subject or the subject’s parent(s) or legally  authorized 
representative(s) must consent to participate after the nature, scope, and possible consequences 
of the cl inical study  have been explained in a form understandable to him or her.
An informed consent form (assent form if applicable) that includes information about the study  
will be prepared and given to the subject or the subject’s parent(s) or legally authoriz ed 
representative(s) . This document will contain all FDA and ICH -required elements. The informed 
consent (or assent) form must be in a language understandable to the subject or the subject’s 
For non-commercial use only
Shire CONFIDENTIAL Page 52
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
parent(s) or legall y authorized representative(s) and must specif y who informed the subject, the 
subject’s parent(s), or the subject’s legall y authorized representative(s).
After reading the informed consent document, the subject or the subject’s parent(s) or legall y 
authorized representative(s) must give consent in wri ting. Consent must be confirmed at the time 
of consent b y the personally  dated signature of the subject, the subject’s parent(s) or the subject’s 
legally  authorized representative(s) and by  the personally  dated signature of the person 
conducting the inform ed consent discussions.
If the subject or the subject’s parent(s) or legally  authorized representative(s) is unable to read, 
oral presentation and explanation of the written informed consent form and information to be 
supplied must take place in the presen ce of an impartial witness. Consent must be confirmed at 
the time of consent orall y and by the personally dated signature of the subject or by a local 
legally  recognized alternative (eg, the subject’s thumbprint or mark) or by  the personall y dated 
signatur e of the subject’s parent(s) or the subject’s legally  authorized representative . The witness 
and the person conducting the informed consent discussions must also sign and personall y date 
the informed consent document . It should also be recorded and dated i n the source document that 
consent was given.
A cop y of the signed and dated consent document(s) must be given to the subject or the subject’s 
parent(s) or legal representative(s). The original signed and dated consent document will be 
retained b y the Investigator.
The Investigator will not undertake any  measures specificall y required solely for the clinical 
study  until valid consent has been obtained.
A model of the informed consent form to be used in this study  will be provided to the sites 
separately  from this protocol.
11.5 Subject Confidentiality
Subject names will not be supplied to the Sponsor . Only  the subject number - will be recorded in 
the eCRF, and if the subject name appears on an y other document, it must be obliterated before a 
copy  of the document is supplied to the Sponsor . Study  findings stored on a computer will be 
stored in accordance with local data protection laws . 
The subjects will be told that 
representatives of the Sponsor, a designated CRO, the I RB/IEC/REB, or regulatory  authorities 
may inspect their medical records to verify  the information collected, and that all personal 
information made available for inspection will be handled in strictest confidence and in 
accordance with local data protection laws . The Investigator will maintain a per sonal subject 
identification list (subject numbers with the corresponding subject names) to enable records to be 
identified.
11.6 Study Monitoring
Monitoring procedures that comply  with current Good Clinical Practice (GCP) guidelines will be 
followed. 
Review of the eCRFs for completeness and clarit y, cross -checking with source 
documents, and clarification of administrative matters will be performed.
For non-commercial use only
Shire CONFIDENTIAL Page 53
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
The study  will be monitored by  the Sponsor or its designee . Monitoring will be performed by  a 
representative of th e Sponsor (Clinical Study  Monitor) who will review the eCRFs and source 
documents . The site monitor will ensure that the investigation is conducted according to protocol 
design and regulatory  requirements by  frequent site visits and communications (letter, telephone, 
and facsimile).
11.7 Case Report Forms and Study Records
11.7.1 Case Report Forms
Electronic case report forms (eCRFs) are provided for each subject . All forms must be filled out 
by authorized study  personnel. All corrections to the original eCRF entry  mus t indicate the 
reason for change . The Investigator is required to sign the eCRF after all data have been captured 
for each subject . If corrections are made after review and signature b y the Investigator, he or she 
must be made aware of the changes, and his or her awareness documented by  resigning the 
eCRF.
11.7.2 Critical Documents
Before the Sponsor initiates the trial (ie, obtains informed consent from the first subject), it is the 
responsibility  of the Investigator to ensure that the following documents are ava ilable to Sponsor 
or their designee:
Completed FDA Form 1572 (Statement of Investigator), signed, dated, and accurate
Curricula vitae of Investigator and sub-investigator(s) (current, dated and signed 
within 12 months of study initiation)
Copy  of Investiga tor and sub- investigator(s) current medical license (indicating 
license number and expiration date)
Signed and dated agreement of the final protocol
Signed and dated agreement of an y amendment(s), if applicable
Approval/favorable opinion from the IRB/IEC/REB clearl y identifying the documents 
reviewed b y name, number and date of approval or re approval :  protocol, any  
amendments, Subject Information/I nformed Consent Form, and any  other written 
information to be provided regarding subject recruitmen t procedures
Copy  of IRB/IEC/REB approved Subject Information/I nformed Consent Form/any  
other written information/advertisement (with IRB approval stamp and date of 
approval)
Current list of I RB/IEC/REB Committee members/constitution (dated within 
12months prior to study  initiation)
Financial Disclosure Form signed b y Investigator and sub- investigator(s)
Current laboratory  reference ranges (if applicable)
Certification/QA scheme/other documentation (if applicable)
For non-commercial use only
Shire CONFIDENTIAL Page 54
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Regulatory approval and notification as required must also be available; these are the 
responsibility  of Shire.
11.8 Data Monitoring Committee
Given that an y long -term safet y signal observed in this study  could impact the safet y profile of 
rhIGF -1/rhIGFBP -3 as administered in premature neonates b eing enrolled in the antecedent 
study  (ROPP -2008- 01, Section D), the Data Monitoring Committee (DMC) for Study  
ROPP -2008- 01 will review safet y data from this long -term outcome study .
11.9 Protocol Violations/Deviations
The Investigator will conduct the study  incompliance with the protocol . The protocol will not be 
initiated until the I RB/IEC/REB and the appropriate regulatory  authorities, where applicable, 
have given approval/favorable opinion . Modifications to the protocol will not be made without 
agreement of the Sponsor . Changes to the protocol will require written IRB/I EC/REB 
approval/favorable opinion prior to implementation, except when the modification is needed to 
eliminate an immediate hazard(s) to subjects . The IRB/IEC/REB may  provide, if applicable 
regulatory  authorities permit, expedited review and approval/favorable opinion for minor 
change(s) in ongoing studies that have the approval/favorable opinion of the I RB/IEC/REB . 
The 
Sponsor will submit all protocol modifications to the regulatory  authoritie s, where applicable, in 
accordance with the governing regulations.
A record of subjects screened, but not entered into the study , is also to be maintained . No 
protocol exemption will be granted for this study .
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to 
subjects, the Investigator will contact the Sponsor or its designee, if circumstances permit, to 
discuss the planned course of action . Any departures from the protocol must be fully documented 
as a protocol deviation . Protocol deviations will need to be reviewed b y the medical monitor and 
may also be required to be submitted to the I RB/IEC/REB.
Protocol modifications will only  be initiated by  the Sponsor and must be approved by  the 
IRB/IEC/REB and submitted to the FDA or other applicable international regulatory  authorit y 
before initiation, if applicable.
11.10 Premature Closure of the Study
If the Sponsor, Investigator, or regulatory  authorities discover conditions arising during the stud y 
which indicate that the cl inical investigation should be halted due to an unacceptable subject risk, 
the study  may  be terminated after appropriate consultation between the Sponsor and the 
Investigator(s) . In addition, a decision on the part of the Sponsor to suspend or discontinue 
development of the investigational product may  be made at any  time . Conditions that may  
warrant termination of the study
 or site include, but are not limited to:
For non-commercial use only
Shire CONFIDENTIAL Page 55
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
The discovery  of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the study
Failure of the Investigator to comply  with pertinent global regulations
Submission of knowingly  false information from the study  site to the Sponsor or other 
pertinent regulatory  authorities
Insufficient adherence b y the I nvestigator to protocol requirements
11.11 Access to Source Documentation
Regulatory  authorities, the I RB/IEC/REB, or the Sponsor may  request access to all source 
documents, eCRFs, and other study  documentation for onsite audit or inspection. Direct access to 
these documents must be g uaranteed by  the Investigator, who must provide support at all times 
for these activities. Monitoring and auditing procedures that compl y with current GCP guidelines 
will be followed . On-site review of the eCRFs for completeness and clarit y, crosschecking with 
source documents, and clarification of administrative matters may  be performed.
11.12 Data Generation and Analysis
The clinical database will be developed and maintained b y a contract research organization or an 
electronic data capture technology  provider as designated by  the Sponsor . The Sponsor or its 
designee will be responsible for performing study  data management activities. 
Adverse events will be coded using Medical Dictionary  for Regulatory  Activities (MedDRA) . 
Concomitant medication will be coded u sing WHO -Drug Dictionary  (WHO -DD). Central reads 
will be employ ed as described in the study  manual to aid in consistent measurement of 
abdominal ultrasound and echocardiogram parameters . 
11.13 Retention of Data
Essential documents should be retained until at least 2 y ears after the last approval of a 
marketing application and until there are no pending or contemplated marketing applications or 
at least 2 y ears have elapsed since the formal discontinuation of clinical development of the 
investigational product. The Sponsor will notify  the Investigator if these documents must be 
retained for a longer period of time . It is the responsibility  of the Sponsor to inform the 
Investigator or institution as to when these documents no longer need to be retained.
11.14 Financial Disclosure
The Investigator should disclose an y financial interests in the Sponsor as described in 21 CFR 
Part 54 prior to beginning this study . The appropriate form will be provided to the I nvestigator 
by the Sponsor, which will be signed and dated b y the Investigator, prior to the start of the study . 
For non-commercial use only
Shire CONFIDENTIAL Page 56
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
11.15 Publication and Disclosure Policy
All information concerning the stud y material, such as patent applications, manufacturing 
processes, basic scientific data, and formulation information supplied by  the Spon sor and not 
previously  published are considered confidential and will remain the sole propert y of the 
Sponsor . The Investigator agrees to use this information only  in accomplishing this study  and 
will not use it for other purposes.
It is understood by  the Investigator that the information developed in the clinical study  may  be 
disclosed as required to the authorized regulatory  authorities and governmental agencies . In 
order to allow for the use of the information derived from the clinical studies, it is und erstood 
that there is an obligation to provide the Sponsor with complete test results and all data 
developed in the stud y in a timely manner.
The Investigator and an y other clinical personnel associated with this study  will not publish the 
results of the study , in whole or in part, at an y time, unless they  have consulted with the Sponsor, 
provided the Sponsor a copy  of the draft document intended for publication, and obtained the 
Sponsor’s written consent for such publication . All information obtained during the conduct of 
this study  will be regarded as confidential. 
For non-commercial use only
Shire CONFIDENTIAL Page 57
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
12 LIST OF REFERENCES
1.Maida JM, Mathers K, Alley  CL. Pediatric ophthalmology  in the developing world. Current 
opinion in ophthalmology  2008;19:403 -8.
2.O'Connor AR, Stephenson TJ, Johnson A, et al. Visual function in low birthweight children. 
The British journal of ophthalmology 2004;88:1149-53.
3.Keith CG, Kitchen WH. Ocular morbidit y in infants of very low birth weight. The British 
journal of ophthalmology 1983;67:302 -5.
4.Laws D, Shaw DE, Robinson J, Jones HS, Ng YK, Fielder AR. Retinopathy  of prematurit y: a 
prospective stud y. Review at six months. Ey e (London, England) 1992;6:477-83.
5.O'Connor AR, Stephenson T, Johnson A, et al. L ong-term ophthalmic outcome of low b irth 
weight children with and without retinopathy  of prematurity . Pediatrics 2002;109:12-8.
6.Schaffer DB, Quinn GE, Johnson L . Sequelae of arrested mild retinopathy  of prematurit y. 
Archives of ophthalmology  1984;102:373-6.
7.Cats BP, Tan KE. Prematures with and without regressed retinopathy  of prematurity : 
comparison of long -term (6 -10 years) ophthalmological morbidity . Journal of pediatric 
ophthalmology  and strabismus 1989;26:271 -
5.
8.Chard T. Insulin- like growth factors and their binding proteins in normal and abnormal 
human fetal growth. Growth Regul 1994;4:91- 100.
9.Hansen -Pupp I, Lofqvist C, Polberger S, et al. Influence of insulin-like growth factor I and 
nutrition during phases of postnatal growth in very preterm infants. Pediatric r esearch 
2011;69:448 -53.
10.Ohkawa N, Shoji H, Kitamura T, et al. IGF -I, leptin and active ghrelin levels in very low 
birth weight infants during the first 8 weeks of life. Acta paediatrica (Oslo, Norway  : 1992) 
2010;99:37
-41.
11.Lofqvist C, Hellgren G, Niklasson A, Engstrom E, L ey D, Hansen- Pupp I. Low postnatal 
serum IGF -I levels are associated with bronchopulmonary  dysplasia (BPD). Acta paediatrica 
(Oslo, Norway  : 1992) 2012;101:1211-6.
12.Ishii DN, Glazner GW, Whalen LR. Regulation of peripheral ne rve regeneration by  insulin -
like growth factors. Annals of the New York Academy  of Sciences 1993;692:172-82.
13. Lewis ME, Neff NT, Contreras PC, et al. Insulin- like growth factor -I: potential for treatment 
of motor neuronal disorders. Experimental neurol ogy 1993;124:73-88.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 59
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
26.DuPaul G, Power T, Anastopoulos A, Reed R. The ADHD rating scale IV: checklists, norms 
and clinical interpretation. New York: Guilford Press; 1998.
27.Rutter M, Bailey  A, Lord C. Manual for the Social Communication Questionnaire2003.
28. Chandler S, Charman T, Baird G, et al. Validation of the social communication questionnaire 
in a population cohort of children with autism spectrum disorders. Journal of the American 
Academ y of Child and Adolescent Psychiatry 2007;46:1324 -32.
29.Gosselin J, Amiel -Tison C. Neurological A ssessment from Birth to 6 Years. 2nd ed. 
Montreal: CHU Sainte- Justine; 2011.
30.Matza L S, Swensen AR, Flood EM, Secnik K, Leidy  NK. Assessment of health -related 
quality  of life in children: a review of conceptual, methodological, and regulatory  issues. V alue 
in health : the journal of the International Society  for Pharmacoeconomics and Outcomes 
Research 2004;7:79-92.
31.Varni JW, Burwinkle TM, L ane MM. Health- related quality  of life measurement in pediatric 
clinical practice: an appraisal and precept fo r future research and application. Health and qualit y 
of life outcomes 2005;3:34.
32.Constitution of the World Health Organization: basic document. Geneva, Switzerland: World 
Health Organization; 1948.
33.Varni JW, L imbers CA. The pediatric quality  of life inventory : measuring pediatric health -
related qualit y of life from the perspective of children and their parents. Pediatric clinics of North 
America 2009;56:843 -63.
34.Varni JW, L imbers CA, Neighbors K, et al. The PedsQL Infant Scales: feasibility , internal 
consistency  reliability , and validity  in health y and ill infants. Quality  of life research : an 
international journal of quality  of life aspects of treatment, care and rehabilitation 2011;20:45 -55.
35.Varni JW, Seid M, Kurtin PS. PedsQL  4.0: rel iability  and validity  of the Pediatric Quality  of 
Life Inventory version 4.0 generic core scales in healthy  and patient populations. Medical care 
2001;39:800 -12.
36.
Saigal S, Rosenbaum P, Stoskopf B, et al. Development, reliability  and validity  of a new 
measure of overall health for pre -school children. Quality  of life research : an international 
journal of quality  of life aspects of treatment, care and rehabilitation 2005;14:243 -57.
37.Rosenbaum DM, Korngold E, Teele RL. Sonographic assessment of renal length in normal 
children. AJR Am J Roentgenol 1984;142:467-9.
For non-commercial use only
Shire CONFIDENTIAL Page 60
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
38.Rosenberg HK, Markowitz RI , Kolberg H, Park C, Hubbard A, Bellah RD. Normal splenic 
size in infants and children: sonographic measurements. AJR Am J Roentgenol 1991;157:119 -
21.
39.Steve ns TP, Finer NN, Carlo WA, et al. Respiratory  Outcomes of the Surfactant Positive 
Pressure and Oximetry  Randomized Trial (SUPPORT). The Journal of pediatrics 2014;165:240 -
9.e4.
40.Zivanovic S, Peacock J, Alcazar -Paris M, et al. Late outcomes of a randomi zed trial of high -
frequency  oscillation in neonates. The New England journal of medicine 2014;370:1121 -30.
For non-commercial use only
Shire CONFIDENTIAL Page 61
Clinic al Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
13 APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 62
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Appendix 1 Study Schedule of Events
ProceduresInitial Study 
Visite Months (CA) Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 
wks6 
± 1mth12
± 3 
mths20 
-1 mthg24
± 3mth30
± 3mth3f
± 
3mths3.5
± 
3mth4f
± 3mths4.5
± 3mth4.75
-1 mthg5
+ 6 
mths
Informed Consent •
Eligibility Criteria •
Dem ographics •
Visual acuitya• • • • • •
Corrective lens determinationh• •g•g
Ocular alignment and motility • • •
Refraction with cycloplegiah•
Stereoacuity •
Length • • •
Height •
Weight • • • •
Head Circumference • • •
BSID -III • •
WPPSI •
CBCL • •
VABS -II • • • •
ADHD -RS •
SCQ •
Physical Examination including 
tonsil examination • • • •
Blood Pressure , Heart Rate , and 
Respiratory Rate•
Cerebral Palsy Assessment •
Hearing Assessment Historyb• •
Pulmonary Morbidity Assessment 
1• •
Pulmonary Morbidity Assessment 
2  (clinical site visit)• •
Pulmonary Morbidity Assessment 
(phone interview)• • • • •
For non-commercial use only
Shire CONFIDENTIAL Page 63
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
ProceduresInitial Study 
Visite Months (CA) Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 
wks6 
± 1mth12
± 3 
mths20 
-1 mthg24
± 3mth30
± 3mth3f
± 
3mths3.5
± 
3mth4f
± 3mths4.5
± 3mth4.75
-1 mthg5
+ 6 
mths
Survival assessment • • • • • • •
Cerebral MRI •
HRQoLc• •i•i•i• • •i
HCRU • •i•i•i• • •i
HSCS -PS •i• • •i
Abdominal Ultrasound •
Echocardiogram •
Assessment of Participation in 
Other Clinical Studies• • • • • • •
Medications • • • • • • •
Adverse eventsd•j• • • • • • •
Abbreviations:  ADHD -RS=Attention -Deficit/Hyperactivity Disorder Rating Scale; BSID- III=Bayley Scales of Infant and Toddler Development -Third 
Edition, CBCL =Child Behavior Checklist; CA =corrected age; HCRU = health care resource use; HRQoL = health -related quality of life; HSCS -PS = Health 
Status Classification System; mth(s) =months; ; PedsQL =Pediatric Quality of Life Inventory; SCQ =Social 
Communication Questionnaire; VABS -II=Vineland Adaptive Behavior Scales, Second Edition; wks =weeks; WPPSI =Wechsler Preschool and Primary 
Scale of Intelligence
aThe tools used t o assess visual acuity will change as the subject ages during their participation in the study. The tools that w ill be used i n this study and are 
summarized by applicable study visit in Table 13-1.
bHistorical hearing test data may be recorded at any time d uring the study prior to the 6 -month visit.
cHRQoL will be assessed via the validated PedsQL™  scales appropriate for the child’s age of development as specified in the S tudy Operations Manual 
dAdverse event collection will include an assessment of the specified targeted medical events 
eThe Initial Visit may be performed prior to 40 weeks CA for any subject who discontinued from Study ROPP -2008- 01 and, for all subjects, any time after 
40 w eeks CA , up to the study visit to occur at 3 months CA.
fVisits at 3 months, 3 years, and 4 years CA will be conducted by telephone.
gThe 20 -month visit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 month prior to the 24 -month and 5 -year visits, respectively. Any 
prescribed corrective lenses must be w orn for at least 1 month prior to the 24 -month and 5 -year assessments.
hRefraction with cycloplegia will be performed as part of the corrective lens determination procedure.
iThe HRQoL, HCRU, and HSCS -PS assessments for the 6 -month, 12 -month, 24 -month and 5 -year vi sits may be performed through clinical site staff if 
there are time constraints during the on -site visit. At the 3 -month, 3 -year, and 4 -year visits, these assessme nts will be performed through clinical site staff 
and may be performed at any time within the visit window .
For non-commercial use only
Shire CONFIDENTIAL Page 64
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
ProceduresInitial Study 
Visite Months (CA) Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 
wks6 
± 1mth12
± 3 
mths20 
-1 mthg24
± 3mth30
± 3mth3f
± 
3mths3.5
± 
3mth4f
± 3mths4.5
± 3mth4.75
-1 mthg5
+ 6 
mths
jThe follow ing, collected as part of the ROPP -2008- 01 study, w ill be used as part of this study (SHP -607-201):  any ongoing targeted medical events 
regardless of causality and an y ongoing study drug -related AEs, including SAEs.
For non-commercial use only
Shire CONFIDENTIAL Page 65
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Table 13-1 Summary of Visual Acuity Assessments 
Visual Acuity Assessment 
ToolDescription Unit of M easure Applicable 
Age/Study Visit 
(CA)
Teller acuity cardsResolution acuity –discrimination 
of a grating optotype from a 
background with the same mean 
luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity -tests 
recognition of 4 optotypesSnellen fraction
(eg, 20/20)24 monthsa
LEA Symbols (ETDRS -style) 
chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be made to assess visual acuity by the LEA Symbols Test 
and LEA Symbols Chart, respectively . If during this attempt, the examiner determines that it w ill not be 
possible to perform an accurate assessment with the relevant LEA tool, visual acuity should be assessed with 
the Teller acuity cards.
For non-commercial use only
Shire CONFIDENTIAL Page 66
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Appendix 2Pulmonary Morbidity Assessment ( Clinical Site Visits at 6 and 12 Months
CA)
Subject Name Subject Number
The SHP -607-201 Protocol refers to a “Pulmonary Morbidity Questionnaire” however; there is no formal 
questionnaire for the pulmonary morbidity assessment. These questions are built into the pulmonary 
morbidity eCRF page, which will be completed after obtai ning this information at the 6mo, 12movisits.  The 
data will be captured in EDC, not through MedAvante and will not scored in any way.  
To assist with capturing these data, Pulmonary Morbidity Assessment Site Source Document has been 
developed for your us e.
1.Was the Pulmonary Morbidity Assessment done?    
If NO, please explain why not:
2.Date of 
Examination: Month Day Year
FAMILY HISTORY
3.Does anyone living in the same home with subject smoke?
4.Have any immediate family members (parents or siblings) of the subject 
been diagnosed with asthma or wheezing?
5.Have the parents/family of the subject had to change their plans because 
the subject’s breathing problems or pulmonary health in the last six 
months?
PATIENT DA TA
6.Has the subject had asthma, wheezing, or bronchopulmonary  dysplasia 
(BPD) exacerbation or flare -up in the last six months?
If YES, how many episodes in the last six months? 
7.Has the subject had bronchiolitis, bronchitis, or pneumonia diagnosed in 
the last six months?
If YES, how many episodes in the last six months? 
8.Has the subject had to use oxygen at home during the last six months?
If YES, how many days did the subject use oxygen in the last month?
9.Has the subject had to visit an emergency room or urgent care for 
respirator y or pulm onary problems in the last six months?
If YES, how many times in the last six months? 
10.Has the subject had to stay in a hospital overnight for respirator y or 
pulm onary problems in the last six months?
If yes, how many  overnights has the subject spent in the hospital? 
 
  
For non-commercial use only
Shire CONFIDENTIAL Page 67
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Appendix 3Pulmonary Morbidity Assessment 2 ( Clinical Site Visits at 24 Months and 5 
Years CA)
Subject Name Subject Number
The SHP -607-201 Protocol refers to a “Pulmonary Morbidity Assessment –In Person Interview”. These 
questions are built into the pulmonary morbidity assessment in person interview eCRF page. It will be 
completed at M24 and Year 5. The questions will be administrated to the child caregive r during study visit by 
site personnel. The data will be captured in EDC on eCRF pages, no scoring is required.
1.Was the Pulmonary Morbidity Assessment done?    
If NO, please explain why not:
2.Date of Examination: Month Day Year
3.This questionnaire was administered to:
4.Was this questionnaire administered to the same responder as last time?
5.Has the child been with this caregiver during the six months
HOM E ENVIRONMENT
6.Does anyone living in the same home with subject smoke?
7.If YES, which of the following three statements best describes the situation regarding smoking in the 
child’s home?
Smoking is allowed in any common room of the home
Smoking is limited to part of the house where the child rarely goes
There is no smoking inside
Are there any exceptions to this situation?               
If YES, under what circumstances are the exceptions allowed?
8.Which of the following five statement best describes the situation regarding smoking in the car the child 
usually rides in? (check only one below)
Do not have a car
Smoking is usually or always allowed
Smoking is sometimes allowed
Smoking occurs in the car only when the child is not inside
There is no smoking inside the car
 
 
For non-commercial use only
Shire CONFIDENTIAL Page 68
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
9.How often has the baby’s mother or primary  caretaker smoked since the child was born
Never Occasionally Daily Don’t know
10.Altogether, how many people who live in the child’s home smoke, even if they 
smoke outside?
11.Approximately how many hours per week does the child spend at a baby sitters 
home or daycare hours
12.Is smoking permitted at the child’s daycare facility 
How frequent is t hesmoke exposure at the babysitter or day care?
Never Occasionally Daily Don’t know
Approximately how many children beside your child are in the daycare?
13.How many children under 12 live in the house? (including subject)
14.Is there a pet inside the home
If YES, how many dogs?
How many cats?
How many other pets?
Specif y other pets
PATIENT MEDICA L HISTORY DA TA
15.Has the child had any medical office visit during the past six month
If YES, how many visit in the last six months? 
If YES, how many of these visits were because of wheezing or breathing 
problems?
16.For what other reason did the child have a medical visit?
17.Has the child visited the urgent care during the past six months?
If YES, is this urgent care part of your doctor’s office?
If YES, how many visit in the last six months?
If YES, how many of these visits were because of wheezing or breathing 
problems?
18.Has the child visited the emergency room during the past six months?
If YES, how many visit in the last six months?
If YES, how many of these visits were because of wheezing or breathing 
problems?
    
    
   
  
  
   
For non-commercial use only
Shire CONFIDENTIAL Page 69
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
19.Has the child stayed in the hospital during the past six months?
If YES, how many visit in the last six months?
If YES, how many of these visits were because of wheezing or breathing 
problems?
If YES, what was the diagnosis?
20.How many colds has the child had in the last six months
21.Has the child's breathing sounded wheezy or whistling in the last six months?
If YES, has this occurred with colds?
22.During what month did your child’s chest first sound wheezy or whistling?
January February March April May June
July August September October November December
Not Sure Don’t Know Year:
23.On average how often has your child’s chest sounded wheezy or whistling during the day time? (check 
only one below)
Never Twice a week or lessMore than two times a 
week but not ever y day
Every day but not all the time Everyday all the time Don’t know
During night time? (check only one below)
Neveronce ever y two weeks or 
less Once a week
Two or more times a weekMore than three nights a 
week/ Frequently Don’t know
During the worst two week period, how often has your child’s chest sounded wheezy or whistling during 
the daytime? (check only one below)
Never Twice a week or lessMore than two times a 
week but not ever y day
Every day but not all the time Everyday all the time Don’t know
24.Has your child been diagnosed with wheezing by a doctor?
25.Has your child had a cough for more than three days when he/she did not have a 
cold?
What tim e of the day has this cough usually occurred?
In the morning shortly after rising Later in the day
During the night No relation to time of day
26.Has your child coughed on most days for as much as 2 to 3 months?
 
 
  
   
For non-commercial use only
Shire CONFIDENTIAL Page 70
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
During what month did your child first develop the cough? (Check only one below)
January February March April May June
July August September October November December
Not Sure Don’t Know Year:
27.Has your child’s chest ever sounded wheezy or whistling with episodes of 
coughing?
28.On average how often has your child had coughing during the daytime in the past six months? (check 
only one below)
Don’t know Twice a week or less More than two times a week but not ever y day
Never Everyday all the time Every day but not all the time
During the worst two week period, how often has your child’s had coughing during the daytime in the 
past six month? (check only one below)
Don’t know Twice a week or less More than two times a week but not ever y day
Never Everyday all the time Every day but not all the time
29.Has your child ever had breathing problems that has caused you to change your 
plans and stay home with your child?
On average, how many days per month did you have to change your daytime or evening plans 
becauase of your child’s breathing problems? (check only one below)
none, we never had to change plans 7 or more days 3-6 days
More than none but less than 3 day s Don’t know
During the worst two week period, how many days did you have to change your daytime or evening 
plans because of your child’s breathing problems? (check only one below)
none, we never had to change plans 7 or more days 3-6 days
More than none but less than 3 day s Don’t know
30.Has the child had any of the following diagnosed by a doctor in the past six month? (check all that 
apply)
AsthmasReactive airway 
disease BPD flare -up Bronchiolitis
Bronchitis Pneumonia Croup
31.Does the child have other medical problems?
If YES, list other medical problems
32.Please mark any medications your child is taking
Brochiodilators Inhaled Steriods Oral Steriods Antibiotics
Diuretics Synagis Other, specify
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
   
 
 
 
   
 
 
 
 
 
 
 
     
  
   
 
 
 
  
 
For non-commercial use only
Shire CONFIDENTIAL Page 71
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
33.Has the child ever had shots to prevent Respirator y Synsytial Virus (palivizxumab, 
or RSV shot)?
34.Has the child had a flu shot?
35.Has the child had to use oxygen therapy at home during the last six months?
If YES, how many days did the child use ox ygen in the last month?
Is the ox ygen administered by nasal canula?
If YES, what is the FiOxmmHg
Liter per minutes (LPM)?: (check only one below)
< 0.25 0.25 0.5 0.75 1 1.25
2 2.25 2.5 2.75 3 >3
36.Is your baby in an ox ygen hood or tent?
37.Is your baby on a ventilator or CPAP?
If YES, what are the ventilator settings?
38.Has the child taken any medication during the past six months?
Albuterol Proventil Serevent Ventolin Volmax Xopenex
Cromolyn (Intal) Flovent Advair Aerobid Azmacort Beclovent
Nedocromil (Tilade) Vanceril Pulmicort Decadron Prednison e Prednisolone
Accolate Diuril Lasix Aldactixide Aldactone Nebulizer
Theophylline Singulair
Does your child take that medicine every day, sometimes or only when sick? (check all that apply 
below)
Every Day Medication: 
Sometimes Medication:
Only when sickMedication:
PATIENT FA MILY DATA
39.Have the parents/family of the child had to change their plans because the child’s 
breathing problems or pulmonary health in the last six months?
40.Did m other smoke during pregnancy?
41.Did father smoke during pregnancy?
 
  
 
  
 
 
 
  
 
   
 
   
  
      
   
 
   
   
  
  
   
 
 
  
   
  
   
 
   
   
   
For non-commercial use only
Shire CONFIDENTIAL Page 72
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
42.Family history of atopy: (Check all that apply below)
Mother Asthma EczemaSeasonal Allergies
Father Asthma EczemaSeasonal Allergies
Siblings Asthma EczemaSeasonal Allergies
43.Does your child frequently have a stuffy  nose or runny nose?
If YES, how many infections has your child had for which antibiotics were 
prescribed since the last interview six months ago.
What area of the body was infected? (check all that apply below)
Nose Lungs Throat EyeSkin
Mouth Genitals urinar y tract Other, (Specify)
44.Does your child take a daily vitamin?
45.Does your child take daily iron (separate or in the vitamin)?
 
 
 
For non-commercial use only
Shire CONFIDENTIAL Page 73
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Appendix 4 Pulmonary Morbidity Assessment (Phone Interviews at 30 Months, 3 Years, 
3.5 Years, 4 Years, and 4.5 Years CA )
Subject Name Subject Number
The SHP -607-201 Protocol refers to a “Pulmonary Morbidity Assessment -phone interview”. These questions 
are built into the pulmonary morbidity eCRF page. It will be completed every 6 months after the M24 visit. The 
questions are administered to the child’s caregiver over the phone by site personnel. The data will be captured 
in EDC, no scoring is required.  
1.Was the Pulmonary Morbidity Assessment done?    
If NO, please explain:
2.Date of Examination: Month Day Year
3.This questionnaire was administered to:
4.Was this questionnaire administered to the same responder as last time?
5.Has the child been with this caregiver during the six months
6.Since the last contact, has the smoking status of anyone in the child’s home or 
the child’s day care provider changed?
If YES, please explain:
PATIENT DA TA
7.Has the child had any medical office visit during the past six month
If YES, how many visit in the last six months? 
If YES, were any of these visits for respirator y symptoms?
(Cold, wheezing or other breathing problems)
If YES, what was the diagnosis?
If YES, did the doctor prescribe any medication
If YES, what was the medication
8.Has the child visited an urgent care facility in the past six month?
If YES, were any of these visits related to respiratory sy mptoms?
(colds, wheezing or other breathing problems?) 
If YES, what was the diagnosis?
If YES, did the doctor prescribe any medication
 
  
For non-commercial use only
Shire CONFIDENTIAL Page 74
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
If YES, what was the medication
9.Has the child visited the emergency room facility in the past six months?
If YES, is this urgent care part of the doctor’s office?
If YES, were any of these visits related to respiratory sy mptoms?
(colds, wheezing or other breathing problems?) 
If YES, what was the diagnosis?
If YES, did the doctor prescribe any medication
If YES, what was the medication
10.Has the child had to stay in a hospital overnight in the last six months?
If YES, how many overnights in the last six months 
If YES, were any of these visits related to respiratory sy mptoms?
(colds, wheezing or other breathing problems)
If YES, what was the diagnosis?
11.Has the child had a flu shot?
12.Has the child had to use oxygen therapy at home during the last six months?
If YES, how many days did the child use ox ygen in the last month?
Is the ox ygen administered by nasal canula?
If YES, what is the FiO 2
Liter per minutes (LPM)?: (check only one below)
< 0.25 0.25 0.5 0.75 1 1.25
2 2.25 2.5 2.75 3 >3
13.Is your child in an oxygen hood or tent?
14.Is your child on a ventilator or CPAP?
If YES, what are the ventilator settings?
15.Has your child taken any medication during the past six months?
Albuterol Proventil Serevent Ventolin Volmax Xopenex
Cromolyn (Intal) Flovent Advair Aerobid Azmacort Beclovent
Nedocromil (Tilade) Vanceril Pulmicort Decadron Prednison e Prednisolone
Accolate Diuril Lasix Aldactixide Aldactone Nebulizer
Theophylline Singulair
 
  
 
   
 
 
 
 
For non-commercial use only
Shire CONFIDENTIAL Page 75
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 21 Feb 2017
Appendix 5Summary of Changes
Description ofChange Section(s)
Added pulmonary  morbidity  assessments which will be conducted during 
phone interviews at the 30 -month, 3-year, 3.5-year, 4-year, and 4.5- year 
CA visits.
Provided the pulmonary  morbidity  assessments at clinical site visits
(Appendix 2 for the 6- month and 12 -month CA visits; Appendix 3 for the 
24-month and 5- year CA visits ) and phone interviews ( Appendix 4 for 
the 30- month, 3 -year, 3.5 -year, 4-year, and 4.5 -year CA visits ).Section 4.1,
Figure 4-
1
Section 7.6.5
Section 8.2
Section 8.2.1
Appendix 1
Appendix 2
Appendix 3
Appendix 4
Added cerebral magnetic resonance imaging (MRI) to the 5 -year CA 
visit.Section 7.6.6
Section 8.2.2.1
Appendix 1
Added hearing assessment history  at the 5- year CA visits.Section 7.6.2
Section 8.2.2.1
Appendix 1
Added blood pressure , heart rate, and respiratory rate measurements at 
the 5- year CA visit.Section 7.7.4
Section 8.2.2.1
Appendix 1
Clarified that if informed consent is not obtained at or before the 3 -month 
visit in Study  ROPP -2008 -01 for inclusion in this study  (SHP607- 201), 
the subject may  still be enrolled until they  turn 2 y ears +3 months CA.Section 7.2
Clarified that for subjec ts enrolled between the ages of 9 months CA and 
2 years +3 months CA, missed procedures such as neurocognitive 
assessments, abdominal ultrasounds, and echocardiograms are not 
required.Section 8.1
Clarified that for consented patients, additional biomarker anal ysis may  
be performed on prior collected blood samples from Study  
ROPP -2008-01.Section 10.1
For non-commercial use only
For non-commercial use only
 
Appendix 6 Protocol Signature Page 
Study Title:  Long -term Outcome of Children Enrolled in Study ROPP -2008 -01 
Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of 
Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal 
Care  
Study Number:  SHP-607-201 
Final Date:  21 February 2017  
Version  Amendment 2 
I have read the protocol described above. I agree to comply with all applicable regulations and to 
conduct the study as described in the protocol.  
Signatory:    
   
   
Investigator    
 Signature  Date  
   
   
 Printed Name   
 
I have read and approve the protocol described above. 
Signatory:    
   
   
Shire Medical 
Monitor  
 
 Signature  Date  
   
 , MD, MPH   
 Printed Name   
 Shire  CONFIDENTIAL Page 77 
Clinical Trial Protocol: SHP-607-201 
Mecasermin rinfabate (rhIGF-1/rhIGFBP-3)  21 Feb 2017 
 
  
  
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 2
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
SYNOPSIS
Sponsor:
Premacure AB, A Member of the Shire Group of Companies
Name of Finished Product:
Mecasermin rinfabate (rhIGF -1/rhIGFBP -3)
Study Title:
Long- term Outcome of Children Enrolled in Study ROPP -2008- 01 Previously Treated with
rhIGF -1/rhI GFBP -3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received 
Standard Neonatal Care
Study Number:
SHP-607-201
Study Phase :  II
Investigational Product, Dose, and Mode of Administration:
Not applicable.
Primary Objectives
The primary objectives of this study are:
To evaluate the long -term efficacy outcomes following short -term exposure to 
rhIGF -1/rhI GFBP -3 versus standard neonatal care in Study ROPP -2008- 01 (Section D) 
as assessed by ROP associated visual outcomes
To evaluate the long -term safety outcomes following short -term exposure to 
rhIGF -1/rhI GFBP -3 versus standard neonatal care in Study ROPP -2008- 01 (Section D)
Secondary Objectives
The secondary objectives of this study are to evaluate the effect following shor t-term exposure to 
rhIGF -1/rhI GFBP -3 versus standard neonatal care in Study ROPP -2008- 01 (Section D) on:
Growth parameters
Cognitive development
Physical development
Child behavior
Pulmonary morbidity
Survival
Health -related quality of l ife (HRQoL)
Health utility
Health care resource u se (HCRU)
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 5
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Efficacy Assessments:
Efficacy will be assessed by visual outcom es, growth parameters, cognitive development, physical 
development, child behavior, p ulmonary morbidity, and survival.
Safety Assessments:
Safety will be assessed by physical examination (including tonsil examination), AEs (as
specified ), echocardiogram, and abdominal ultrasound.
Statistical Methods
Details regarding the statistical methods and definitions will be provided in the Statistical Analysis 
Plan (SAP) . The SAP will be finalized prior to database lock. All statistical analyses will be 
performed by the sponsor or CRO after the database is locked . Statistical analyses will be 
performed using Version 9.1 or higher of SAS®(SAS Institute, Cary, NC 27513).
Continuous variables will be summarized using descriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categorical variables will be summarized using frequencies and percentages.
As referred to in descriptions of summary statistics, treatment groups refer to the 2 possible 
treatment assignments in the antecedent study, ROPP -2008- 01, Section D (rhIGF -1/rhI GFBP -3 or 
standard neonatal care).
For analysis purposes, baseline is defined as the first assessment either in the antecedent study 
(ROPP-2008- 01) or in this study (SHP -607-201)
. As necessary , relevant data from Study 
ROPP -2008
-01 may be summarized with the data from this study (SHP -607
-201).
Date of Original Protocol :  27August 2014
Date of Amendment 1: 19 February 2016
Date of Amendment 2: 21 February 2017
Date of Amendment 3: 11May 2017
For non-commercial use only
Shire CONFIDENTIAL Page 6
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
TABLE OF  CONTENTS
SYNOPSI S.......................................................................................................................................2
LIST OF IN -TEXT TABLES ........................................................................................................10
LIST OF IN -TEXT FIGURES .......................................................................................................10
LIST OF APPENDICES ................................................................................................................10
LIST OF ABBREVIATION S................................
........................................................................11
1INTRODUCTION ..................................................................................................................13
2STUDY OBJECTIVES ..........................................................................................................15
2.1 Primary  Objectives ...................................................................................................15
2.2 Secondary  Objectives ...............................................................................................15
2.3 Exploratory  Objective ................................
..............................................................15
3STUDY ENDPOINTS ............................................................................................................16
3.1 Efficacy  Endpoints ...................................................................................................16
3.1.1 Primary  Efficacy  Endpoints ...................................................................................16
3.1.2 Secondary  Efficacy  Endpoints ...............................................................................16
3.2 Health Economic Outcome Research Endpoints ......................................................17
3.3 Safety  Endpoints ......................................................................................................17
3.4 Exploratory  Endpoints ..............................................................................................17
4INVESTIGATIONAL PLAN .................................................................................................18
4.1 Overall Study  Design and Plan ................................................................................18
4.2 Rationale for Study  Design ......................................................................................19
4.3 Study  Duration .........................................................................................................20
5STUDY POPUL ATION SEL ECTION ..................................................................................21
5.1 Study  Population ................................
......................................................................21
5.2 Inclusion Criteria
......................................................................................................21
5.3 Exclusion Criteria .....................................................................................................21
6STUDY TREATMENT ..........................................................................................................22
6.1 Description of Treatment .........................................................................................22
6.2 Treatments Administered .........................................................................................22
6.3 Selection and Timing of Dose for Each Subject ......................................................22
6.4 Method of Assigning Subjects to Treatment Groups ...............................................22
6.5 Masking................................
....................................................................................22
6.6 Medications ..............................................................................................................22
6.7 Restrictions ................................ ................................ ................................ ............... 22
6.7.1 Prior Therap y ................................ ................................ ................................ ......... 22
6.7.2 Other Restrictions ................................ ................................ ................................ ..22
For non-commercial use only
Shire CONFIDENTIAL Page 7
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
6.7.3 Treatment Compliance ...........................................................................................22
6.7.4 Packaging and Labeling .........................................................................................22
6.8 Storage and Accountability ......................................................................................22
7 STUDY PROCEDURES........................................................................................................23
7.1 Informed Consent .....................................................................................................23
7.2 Study  Entrance Criteria and Eligibility ....................................................................23
7.3 Study  Enrollment ......................................................................................................23
7.4 Demographics ...........................................................................................................23
7.5 Growth Parameters:  Length (and Height), Weight, and Head Circumference .......23
7.5.1 Length and Height ................................
..................................................................23
7.5.2 Body Weight ..........................................................................................................24
7.5.3 Head Circumference ..............................................................................................24
7.6 Efficacy  Assessments ...............................................................................................24
7.6.1 Visual Assessments ................................................................................................24
7.6.1.1 Visual Acuity ..........................................................................................24
7.6.1.2
Corrective Lens Determination ..............................................................25
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility )..................25
7.6.1.4 Refraction with C ycloplegia ...................................................................26
7.6.1.5 Stereoacuit y............................................................................................26
7.6.1.6
7.6.2 Hearing Assessment History ..................................................................................27
7.6.3 Behavioral Assessments .........................................................................................27
7.6.3.1 Bayley Scales of Infant and Toddler Development, Third Edition ........27
7.6.3.2 Wechsler Preschool and Primary  Scale of Intelligence (WPPSI ) ..........27
7.6.3.3 Child Behavior Checklist (CBCL) .........................................................28
7.6.3.4
Vineland Adaptive Behavior Scales, Second Edition ............................28
7.6.3.5 Attention- Deficit/Hy peractivity  Disorder Rating Scale .........................28
7.6.3.6 Social Communication Questionnaire –Lifetime Form ........................29
7.6.4 Cerebral Pals y Assessment ....................................................................................29
7.6.5 Pulmonary  Morbidit y Assessment .........................................................................29
7.6.6
Optional Cerebral Magnetic Resonance Imaging..................................................29
7.6.7 Survival Assessment ..............................................................................................30
7.6.8 Health Economic Outcome Research Assessments...............................................30
7.6.8.1 Health Related Quality  of L ife...............................................................30
7.6.9 Health Care Resource Use .....................................................................................30
7.6.9.1 Health Status Classification Sy stem -Preschool ......................................30
7.7 Safety  Assessments ................................ ................................ ................................ ..31
7.7.1 Abdominal ultrasound................................ ................................ ............................ 31
For non-commercial use only
Shire CONFIDENTIAL Page 8
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
7.7.2 Echocardiogram .....................................................................................................31
7.7.3 Physical Examination .............................................................................................31
7.7.4 Blood Pressure, Heart Rate, and Respiratory  Rate ................................................32
7.8 Medication Assessment ............................................................................................32
7.9 Adverse Events Assessments ...................................................................................32
7.9.1 Definitions of Adverse Events, Serious Adverse Events, and Suspected 
Unexpected Serious Adverse Reactions ................................................................32
7.9.1.1 Adverse Event ........................................................................................32
7.9.1.2 Serious Adverse Event ...........................................................................33
7.9.1.3 Suspected Unexpected Serious Adverse Reaction .................................34
7.9.1.4 Targeted Medical Events ........................................................................34
7.9.2 Classification of Adverse Events and Serious Adverse Events .............................34
7.9.3 Clarification between Serious and Severe .............................................................35
7.9.4 Relatedness of Adverse Events and Serious Adverse Events ................................35
7.9.5 Procedures for Recording and Reporting Adverse Events ....................................35
7.9.5.1 Adverse Event Monitoring and Period of Observation
..........................35
7.9.5.2 Reporting Serious Adverse Events .........................................................36
7.9.5.3 Regulatory  Agency , Institutional Review Board, Ethics Committee, 
and Site Reporting................................
..................................................37
7.10 Removal of Subjects from the Trial .........................................................................37
7.11 Other Study  Procedures ............................................................................................38
7.11.1 Participation in Other Clinical Studies ..................................................................38
7.12 Appropriateness of Measurements ...........................................................................38
8STUDY ACTIVIT IES................................
............................................................................39
8.1 Initial 
Study  Visit (40 weeks CA [term equivalent]) ...............................................39
8.2 Study  Visits ..............................................................................................................39
8.2.1 Outcome Assessment Visits Conducted by
 Telephone .........................................40
8.2.2 Clinical Site Visits .................................................................................................40
8.2.2.1 Outcome Assessment Site Visits............................................................40
8.2.2.2 Visits Dedicated to Corrective Lens Determination ............................... 44
8.3 Assessments upon Discontinuation ..........................................................................44
9QUALITY CONTROL AND ASSURANCE ........................................................................45
10STATI STICAL ANALYSES .................................................................................................46
10.1 General Methodology ...............................................................................................46
10.2 Determination of Sample Size ................................ ................................ .................. 46
10.3 Method of Assigning Study  Subjects to Treatment Groups ................................ .....46
10.4 Population Description................................ ................................ ............................. 46
10.4.1 Analy sis Populations ................................ ................................ .............................. 46
For non-commercial use only
Shire CONFIDENTIAL Page 9
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
10.4.2 Subject Disposition ................................................................................................47
10.4.3 Protocol Violations and Deviations .......................................................................47
10.4.4 Demographics and Baseline Characteristics..........................................................47
10.5 Efficacy  Anal ysis.....................................................................................................47
10.5.1 Primary  Efficacy  Anal ysis.....................................................................................47
10.5.2 Secondary  Efficacy  Analy sis.................................................................................48
10.5.3 Subset Analy ses................................................................
.....................................49
10.5.4 Exploratory  Anal yses.............................................................................................49
10.6 Health Economics and Outcomes Research Anal yses.............................................49
10.7 Analy sis of Safet y ................................
....................................................................49
10.8 Statistical/Analy tical Issues ................................
......................................................50
10.8.1 Adjustment for Covariates .....................................................................................50
10.8.2 Handling of Dropouts or Missing Data ..................................................................50
10.8.3 Interim Anal yses and Data Monitoring..................................................................50
10.8.4 Multiple Comparisons/Multiplicity ................................
.......................................50
10.8.5 Sensitivity  Anal yses...............................................................................................50
11ADMINISTRATIVE CONSI DERATIONS ................................
..........................................51
11.1 Investigators and Study  Administrative Structure ...................................................51
11.2 Institutional Review Board or Independent Ethics Committee Approval................51
11.3 Ethical Conduct of the Study ...................................................................................51
11.4 Subject I nformation and Consent .............................................................................51
11.5 Subject Confidentiality ................................
.............................................................52
11.6 Study  Monitoring .....................................................................................................53
11.7 Case Report Forms and Study  Records ....................................................................53
11.7.1 Case Report Forms .................................................................................................53
11.7.2 Critical Documents ................................
................................................................53
11.8 Data Monitoring Committee ................................
....................................................54
11.9 Protocol Violations/Deviations ................................................................................54
11.10 Premature Closure of the Study ...............................................................................55
11.11 Access to Source Documentation.............................................................................55
11.12 Data Generation and Analy sis................................
..................................................55
11.13 Retention of Data .....................................................................................................55
11.14 Financial Disclosure .................................................................................................56
11.15 Publication and Disclosure Policy ............................................................................56
12LIST OF REFERENCES ........................................................................................................57
For non-commercial use only
Shire CONFIDENTIAL Page 10
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
LIST OF IN -TEXT TABLES
Table 7-1 Summary  of Visual Acuity  Assessments ......................................................25
Table 7-2 Assessments for Phy sical Examinations .......................................................32
Table 7-3 Adverse Event Severit y .................................................................................35
Table 7-4 Adverse Event Relatedness ...........................................................................35
LIST OF IN -TEXT FIGURES
Figure 4-
1 Overview of Study  Design, Study  SHP -607-
201 ................................ .......... 19
LIST OF APPENDICES
Appendix 1 Study  Schedule of Events ..............................................................................60
Appendix 2 Summary  of Changes ....................................................................................64
Appendix 3 Protocol Signature Page ................................................................................65
For non-commercial use only
Shire CONFIDENTIAL Page 11
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
LIST OF ABBREVI ATIONS
Abbreviation Definition
AAO American Academy of Ophthalmology
ADHD attention -deficit hyperactivity disorder
ADHD -RS Attention -Deficit/ Hypera ctivity Disorder Rating Scale
AE adverse event
ASD Autism Spectrum Disorder
BSID -III Bayley Scales of Infant and Toddler Development, Third Edition
CBCL Child Behavior Checklist (1 ½ to 5)
CFR Code of Federal Regulations
CA corrected age
CI confidence interval
CRF case report form (electronic)
CRO contract research organization
DMC data monitoring committee
eCRF electronic case report form
EOS end of study
ETDRS Early Treatment of Diabetic Retinopathy Study
ER emergency room
EU European Union
FDA Food and Drug Administration
GCP Good Clinical Practice
GH grow th horm one
HRQoL health -related quality of l ife
HSCS -PS Health Status Classification System -Preschool
ICH International Conference on Harmonisation
IEC independent ethics committee
IGF insulin -like growth factor
IGFBP -3 insulin -like growth factor binding protein -3
IND Investigational New Drug application
IRB institutional review board
LV left ventricle
MedDRA Medical Dictionary for Regulatory Activities 
MRI magnetic resonance imaging
For non-commercial use only
Shire CONFIDENTIAL Page 12
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Abbreviation Definition
OD right eye
OS left eye
OU both eyes
PedsQL Pediatric Quality of Life Inventory 
REB research ethics board
ROP retinopathy of prematurity
SAE serious adverse event
SAP statistical analysis plan
SAS Statistical Analysis System©
SCQ Social Communication Questionnaire
SD standard deviation
SOE schedule of events
SUSAR suspected unexpected serious adverse reaction
UK United Kingdom
US United States
VABS -II Vineland Adaptive Behavior Scales, Second Edition
VLBW very low birth weight
WHO World Health Organization
WHO -DD World Health Organization Drug Dictionary
WPPSI Wechsler Preschool and Primary Scale of Intelligence
For non-commercial use only
Shire CONFIDENTIAL Page 13
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
1 INTRODUCTION
Retinopathy  of prematurity  (ROP) is a rare disorder of the developing retinal blood vessels and 
retinal neurons of the preterm infant and is one of the leading causes of preventable blindness in 
children.1
Visual acuity  is decreased in infants with a history  of ROP.2In addition to acuity , other aspects 
of ey e health are also significantly  impacted by  ROP . Strabismus and my opia are clearly  
increased in patients with a history  of ROP.3-6  Additionally , more than half of patients at 6 to 
10years of age with a history  of Stage 1 and Stage 2 ROP were reported to have ongoing visual 
issues.7
When preterm infants are deprived of their natural intrauterine environment, they  lose important 
factors normally  found in utero, such as proteins, growth factors and cy tokines . It has been 
demonstrated that IGF -1 is one such factor . During fetal life, IGF -1 is available through placental 
absorption and ingestion from amniotic fluid .8Deprivation of such factors is likely  to cause 
inhibition or improper stimulation of important pathway s, which in the ey e may  cause abnormal 
retinal vascular development, the hallmark of RO P.
The finding in both a mouse model of ROP and preterm infants that development of ROP is 
associated with low levels of IGF -1 after premature birth, indicates a possible role for 
replacement of IGF -1 to levels found in utero as a strategy  to potentially  decrease abnormal 
retinal vascularization and abnormal retinal neural development, and ultimately , ROP . 
Mecasermin rinfabate (rhIGF -1/rhIGFBP -3) is the human recombinant form of the naturall y 
occurring protein complex of I GF-1 and insulin-
like growth factor binding protein
-3 (IGFBP -3). 
rhIGF -1/rhIGFBP -3 was developed to enhance the sy stemic exposure of administered rhIGF -1 
and to improve the safety profile of rhIGF -1 therapy . rhIGF-1/rhIGFBP -3 was approved by  the 
Food and Drug Administration ( FDA )
in 2005 for the treatment of growth failure in children 
with severe primary  IGF-1 deficiency  or with growth hormone (GH) gene deletion who have 
developed neutralizing antibodies to GH . 
The pharmacokinetics and safet y of rh IGF-1/rhIGFBP -3 have been evalua ted in a Phase I study  
(ROPP -
2005- 01) and pharmacokinetics, safet y, and efficacy are being evaluated in the ongoing 
phase II stud y (ROPP -2008 -01). Sections A -C of the ROPP -2008- 01 study  are complete . 
Section D of the ROPP -2008- 01 study  is currentl y being c onducted to assess pharmacokinetics, 
safet y and efficacy of rhIGF -1/rhIGFBP -
3 for the prevention of ROP in premature infants (up to 
a corrected age [CA] of 40 weeks [± 4 day s]). Subjects in Study  ROPP -2008- 01 are randoml y 
assigned to receive rhIGF -1/rhIGFBP -3 or standard neonatal care . The target dose of 
rhIGF -1/rhIGFBP -3 for Study  Section D is 250 μg/kg/24 hours to be administered via 
continuous infusion starting on Study  Day  0 (day  of birth) and continuing through postmenstrual 
age (gestational age + time elapsed from birth) 29 weeks + 6 day s.
For non-commercial use only
Shire CONFIDENTIAL Page 14
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Although the rh IGF-1/rhIGFBP -3 therap y in Section D of the Phase II study 
(Study ROPP -2008- 01) represents a short -term exposure (< 2 months for each subject), 
rhIGF -1/rhIGFBP -3 may have long -lasting effects on visual outcomes as well as other potential 
outcomes related to complications of prematurit y such as neurodevelopment, pulmonary  
function, and growth . In addition, it is critical to understand an y long term safety effects from 
short term exposure to rhIGF -1/rhIGFB P-3. 
The long- term outcomes assessed in this study  will require utilization of different assessment 
tools than are utilized in the Phase II stud y, ROPP -2008- 01 Section D, given the changes in 
physical and cognitive development that will occur in the subje cts as they  age during their 
participation in this study . 
Please refer to the current edition of the I nvestigator’s Brochure for further information 
concerning the safet y and clinical development of rhIGF -1/rhIGFBP -3.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 16
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
3 STUDY E NDPOINTS
3.1 Efficacy Endpoints
3.1.1 Primary Efficacy Endpoints
Visual acuity  as assessed by  an age -appropriate method
Ocular alignment and ocular motor examination in primary  gaze and in as many  of 
9positions of gaze as possible as assessed b y corneal light reflex and b y the cover test
Assessment of n ystagmus by  observation
Refraction as assessed b y retinoscop y with cycloplegia
Stereoacuit y as assessed with the Lang Stereotest
3.1.2 Secondary Efficacy Endpoints
Growth parameters including bod y weight, bod y length (or height), and head 
circumference
Cognitive development as assessed b y the following standardized, age -appropriate 
tools:
oBayley Scales of Infant and Toddler Development, Third Edition (BSID- III)
oWechsler Pre school and Primary  Scale of Intelligence (WPPSI )
Physical development as assessed by  standardized, age appropriate tools including 
physical exam ination , neurological examination for assessment of cerebral palsy , and 
hearing assessment
Child behavior as assessed by  the following:
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
oChild Behavior Checklist (CBCL ;1 ½ to 5)
oAttention- Deficit/ Hyperactivity  Disorder Rating Scale (ADHD -RS) for the 
assessment of s ymptoms of attention -deficit/ hyperactivity  disorder (ADHD)
oSocial Communication Questionnaire (SCQ) for screening of Autism Spectrum 
Disorder (ASD)
Pulmonary  morbidity  data (eg, hospitalizations, emergency  room [ER] visits, 
pulmonary  medications)
Survival as assessed b y death during the study due t o any  cause
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 18
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
4 INVESTIGATIONAL PLAN
4.1 Overall Study Design and Plan
This is a Phase II, multicenter, long- term developmental outcome study  enrolling subjects who 
were ra ndomized in Section D of Study  ROPP -2008-01 to receive either rhIGF -1/rhIGFBP -3
(treated) or standard neonatal care (control) . Enrolled subjects in this study  will be 
followed through age 5 years CA. This study  will enroll both subjects who were in the 
treated (received rh IGF-1/rhIGFBP -3) and control (received standard neonatal care) groups of 
Study  ROPP -2008- 01 (Section D) to enable assessment of rhIGF -1/rhIGFBP -3 long -term 
efficacy  and safet y outcomes versus standard neonatal care. 
No investigational product will be
administered in this study . 
In this stud y, the Initial Visit will occur at 40 weeks CA (ie, term equivalent) or upon 
discontinuation from Study  ROPP -2008- 01 or may  occur any  time u p to the visit at 3 months 
CA. Subjects in Study  ROPP -2008-
01 are premature infants enrolling at gestational age of 
23weeks + 0 day s to 27 weeks + 6 days.
Time points for assessments have been chosen based on standard premature infant follow -
up 
periods and represent important developmental ages for premature infant f ollow -up. Both 
telephone and clinical site visits are included to help maintain contact with subjects throughout 
the 5- year duration of the study .
Subjects will be evaluated at appropriate follow
-up site locations with expertise in the 
assessment of the de velopmental outcomes of premature infants . Pediatric ophthalmology  
expertise will also be required. 
See Appendix 1for the Study  Schedule of Events 
table.
The overall study  design is outlined in Figure 4-1
.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 20
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Insulin -like g rowth factor -1 (IGF -1) mediates its primary  actions b y binding to its specific 
receptor, the insulin- like growth factor 1 receptor (IGF -1R), which is present on many  cell ty pes 
in many  tissues . Binding to its receptor initiates intracellular signaling incl uding via the AKT 
signaling pathway . This pathway  is involved in stimulation of cell division, growth and 
differentiation and inhibits programmed cell death
. Specificall y regarding premature infants, 
IGF-1 is an important mediator of fetal growth and has b een shown to play  a role in earl y 
postnatal growth following pre -term delivery .9,10
Insulin -like growth factor -1 (IGF -1) has also been shown to play  a role in pulmonary  
development11and neural development.12,13Given the potential role for IGF-1 in the 
development of multiple sy stems, this study  has been designed to evaluate the long -term effects 
of rhIGF -1/rhIGFBP -3, both from a safety  and efficacy  perspective, on the development of the 
premature infant.
4.3 Study Duration
Duration for an individual subject’s participation in the study will vary  depending upon age at 
enrollment, but subjects will not be followed beyond age 5.5 years CA .
For non-commercial use only
Shire CONFIDENTIAL Page 21
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
5 STUDY POPULATION SEL ECTION
5.1 Study Population
Subjects randomized in Study  ROPP -2008- 01, Section D are eligible to enroll in this study ; 
completion of Study  ROPP -2008- 01 Section D is not required. Subjects in Study  ROPP -2008-01 
are premature infants (gestational age of 23 weeks + 0 day sto 27 weeks + 6 day s) who are 
randomized to receive either treatment with rhIGF- 1/rhIGFBP -3 or standard neonatal care. Up to 
120 subjects are planned to be randomized in Study ROPP -2008- 01 Section D.
5.2 Inclusion Criteria
Each subject must meet the following criteria to be enrolled in this study .
1.Subje ct was randomized in Study  ROPP -2008- 01, Section D
2.Subject’s parent or legally  authorized representative(s) must provide written informed 
consent prior to performing an y stud y-related activities. Study -related activities are an y 
procedures that would not have been performed during normal management of the subject.
5.3
Exclusion Criteria
Subjects who meet an y of the following criteria will be excluded from the study.
1.Any other condition or therapy  that, in the Inves tigator’s opinion, may  pose a risk to the 
subject or interfere with the subject’s ability  to be compliant with this protocol or interfere 
with the interpretation of results
2.The subject or subject’s parent or legally  authorized representative(s) is unable t o comply  
with the protocol as determined by  the Investigator
For non-commercial use only
Shire CONFIDENTIAL Page 22
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
6 STUDY TREATMENT
6.1 Description of Treatment
No investigational product will be administered in this study .
6.2 Treatments Administered
Not applicable.
6.3 Selection and Timing of Dose for Each Subject
Not applicable.
6.4 Method of Assigning Subjects to Treatment Groups
Not applicable.
6.5 Masking
Not applicable.
6.6 Medications
Any medications administered to the subjects will be collected from the time of informed 
consent through the 5 -year CA visit (or until the subj ect withdraws or is discontinued). An y 
investigational product received b y subjects will be recorded separatel y as part of an assessment 
of subjects’ participation in other clinical studies (Section 7.11.1).
6.7 Restrictions 
6.7.1 Prior Therapy
There are no restric tions related to prior therapy .
6.7.2 Other Restrictions
There are no restrictions related to fluid or food intake, or subject activity .
6.7.3 Treatment Compliance
Not applicable.
6.7.4 Packaging and Labeling
Not applicable.
6.8 Storage and Accountability
Not applicable
For non-commercial use only
Shire CONFIDENTIAL Page 23
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
7 STUDY P ROCEDURES
Detailed descriptions of subject procedures and evaluations required for this protocol are 
described in this section . These evaluations will be performed during the indicated day s and 
weeks of the stud y (see Schedule of Events in Appendix 1). 
All data collected are to be recorded on the subject’s appropriate eCRF . 
Details for stud y procedures are described in the Operations Manual for this study.
7.1 Informed Consent
Prior to conducting an y study -related procedures, written informed consent must be obtained 
from the subject’s parent(s) or legall y authorized representative(s).
The nature, scope, and possible consequences, including risks and benefits, of the study will be 
explained to the subject, the subject’s parent(s), or the subject’s legall y authorized representative 
by the Investigator or designee in accordance with the guidelines described in Section 11.4. 
Documentation and filing of informed consent documents should be completed according to 
Section 11.4.
7.2 Study Entrance Criteria and Eligibil ity
At the I nitial Visit , each subject will be reviewed for eligibility  against the study  entrance 
criteria . Subjects who do not meet the study  entrance criteria will not be allowed to participate in 
the study . The reason(s) for the subject’s ineligibility for the stud y will be documented . No 
exemptions will be allowed.
If informed consent is not obtained at or before the 3 -month visit in Study  ROPP -2008- 01 for 
inclusion in this study  (SHP607 -201), the subject may  still be enrolled until they  turn 2 years C A
+3 months . Subjects are no longer eligible to participate in this study  after they  turn 2 y ears CA
+3 months
. 
7.3 Study Enrollment
Subjects will be considered enrolled in the stud y once written informed consent has been 
obtained from the subject’s parent(s) or legally  authorized representative(s).
7.4 Demographics
Subject demographic information including gender, date of birth , and race will be recorded.
7.5 Growth Parameters :  Length (and Height), Weight, and Head Circumference
7.5.1 Length and Height
Body length (supin
e measurement) will be collected when subjects are 24 -months CA or 
younger . For the length measurement, the subject will be placed on his or her back so that the 
For non-commercial use only
Shire CONFIDENTIAL Page 24
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
subject is ly ing straight and the shoulders and buttocks are flat against the measuring surfac e. 
The subject's ey es should be looking straight up and care should be taken that the head is in a 
neutral position (neither being flexed nor extended at the neck). Both legs should be fully  
extended and the toes should be pointing upward with feet perpend icular to the measuring 
surface.
Height (standing measure) will be collected when subjects are older than 24 -months CA. A 
stadiometer should be utilized for measurement of height . The subject should remove shoes.
For the measurement of standing height, the child is instructed to stand erect (stand up straight 
and look straight ahead) with the child’s head positioned in a horizontal plane . The moveable 
headpiece is brought onto the upper most (superior) point on the head with sufficient pressure to 
compress the hair. 
For height and length, 2 measures should take place and both will be recorded . If the 2 measures 
are discrepant b y >2 cm, the measures should be repeated. All measures should be recorded in 
metric units and measurement should be recorded to the nearest tenth centimeter (0.1 cm). 
7.5.2 Body Weight
Body weight will be collected . Calibrated scales should be utilized for body  weight measures 
(type of scale will depend upon subject’s age) . Care should be taken to remove any  extraneous 
clothing prior to measures and shoes should be removed.
The measure should be recorded to the nearest 0.1 kg.
7.5.3 Head Circumference
Head circumference will be measured for all subjects. An accurate head circumference 
measure ment is obtained with a “lasso” -type, non -stretchable me asuring tape such as the Lasso-o 
tape. Head circumference or occipital frontal circumference is measured over the occiput and just 
above the supraorbital ridge, which is the largest circumference of the head.
7.6 Efficacy Assessments
7.6.1 Visual Assessments
After c orrective lens determination has occurred (Section 7.6.1.2), all visual assessments should 
be conducted with best -corrected vision, ie, with corrective lenses in place (if required); this 
applies to 24
-month and 5- year visits.
7.6.1.1 Visual Acuity
Visual acuity  is a measure of how well a subject sees at different distances . 
It will be assessed by  
the methods summarized in Table 7-1; the method employ ed will be selected based on the 
subject’s age (CA) at the time of the study  visit . Visual acuity  measurements will be measured 
and recorded for the left (OS), right (OD) ey e, and both ey es (OU).
For non-commercial use only
Shire CONFIDENTIAL Page 25
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
At ages 6 months and 12 months CA, visual acuity will be assessed with Teller acuit y cards . At 
ages 24 months and 5 years CA an attempt should be made to assess visual acuity  by the LEA 
Symbols Test and LEA Sy mbols Chart, respectively . If during this attempt, the examiner 
determines that it will not be possible to perform an accurate assessment with the relevant LEA 
tool, visual a cuity  should be assessed with the Teller acuit y cards. 
The visual acuit y assessments should be performed by an optometrist or ophthalmologist trained 
in pediatrics. 
Table 7-1 Summary of Visual Acuity Assessments 
Visual Acuity 
Assessment ToolDescription Unit of Measure Applicable 
Age/Study 
Visit (CA)
Teller acuity cardsResolution acuity –
discrimination of a grating 
optotype from a background with 
the same mean luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity -tests 
recognition of 4 optotypesSnellen fraction
(eg, 20/20)24 monthsa
LEA Symbols 
(ETDRS -style) chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be made to assess visual acuity by the LEA 
Symbols Test and LEA Symbols Chart, respectively . If during this attempt, the examiner determines 
that it wi ll not be possible to perform an accurate assessment w ith the relevant LEA tool, visual acuity 
should be assessed with the Teller acuity cards.
7.6.1.2 Corrective Lens Determination
An assessment to determine if the subject requires vision correction with corrective lenses will 
be performed. This is being performed to ensure the accuracy  of subjects’ subsequent visual 
acuity  assessments (at the 24-month and 5- year visits) . The corrective lens determination will be 
performed according to the guidelines publi shed by the American Academy  of Ophthalmology  
(AAO).14
This assessment should be performed b y an optometrist or ophthalmologist trained in pediatrics . 
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility)
Ocular alignment will be assessed in primary  gaze by  comparing the position of the corneal light 
reflection in OS and OD (corneal light reflection assessment). Presence or absence of strabismus 
will be recorded in primary  gaze and in as many  of the 9 positions of gaze as feasible with the 
cover test assessme nt of refixation mo vement. Extraocular muscle over -action or deficiency  will 
be recorded. The assessment will be performed according to the AAO guidelines .14
Presence or absence of ny stagmus as observed during the ocular alignment assessments will also 
be recorded.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 27
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
7.6.2 Hearing Assessment History
Results of previously  completed hearing assessments will be recorded at the 6-month CA and 
5-year CA visits;hearing tests are not being performed as part of this study . 
7.6.3 Behavioral Assessments
7.6.3.1 Bayley Scales of Infant and Toddler Development, Third Edition
The BSID -III will be used to assess cognitive, motor, and language skills, and is applicable to 
children aged 1 to 42 months. 
The BSID-IIIis an assessment tool designed to measure a y oung child's skills in the 3 core areas 
of development :  cognitive, language, and motor. There are 5 subscales, the cognitive subscale 
stands alone while the 2 languag e subscales ( expressive and receptive) combine to make a total 
language score and the 2 motor subtests (fine and gross motor) form a combined motor scale. 
The tool is engaging, with colorful props and visual stimuli that capture the attention of the child . 
The individual test items are short, limiting the amount of attention required for each item. The 
test administration is flexible in that items can be administered out of order, provided the 
assessor adheres to the specific guide lines in the examiner's m anual.
The BSID -III will be administered to the subject ,with participation of the subject’s parent(s) or 
legally  authorized representative(s) ,by a trained professional. Scores to be recorded are detailed 
in the Study  Operations Manual.
7.6.3.2 Wechsler Preschool and Primary Scale of Intelligence (WPPSI)
The WPPSI is a measure of general cognitive development in children that has components of 
both verbal and nonverbal tasks.19  It is applicable to preschoolers and young children aged 
2years + 6 months to 7 years + 7 months, and is a direct assessment of a child’s cognitive skills.
It is composed of the following 5 scales:
Verbal
Performance
Processing Speed
Full Scale
Language
It not onl y applies to healthy children, but in the course of the scale’s standardization20special 
group validity  studies were performed, in cluding, but not limited to, groups of children with 
developmental risk factors, autistic disorder, and intellectual disability . Scores may  be 
interpreted in the context of provided norms, which reflect inclusion of the special groups.
The WPPSI will be ad ministered to the subject by a trained professional . Scores to be recorded 
are detailed in the Study  Operations Manual.
For non-commercial use only
Shire CONFIDENTIAL Page 28
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
7.6.3.3 Child Behavior Checklist (CBCL)
The CBCL (1 ½ to 5) is a parent -reported outcome measure used to assess behavioral, emotional, 
and socia l functioning of toddlers and preschool children aged 18 to 60 months .21It is composed 
of 99 items that are rated on a L ikert scale and includes the following 7 s yndrome scales 
arranged under 2 domains (ie, Internalizing and Externalizing Problems) :22
Internalizing Problems
Emotionally  Reactive
Anxious/Depressed
Somatic Complaints
Withdrawn
Sleep Problems
Attention Problems
Aggressive Behavior
The questionnaire is widely  used and has been employ ed to assess long- term behavioral 
outcomes in children born prematurel y, aged similarly to the subjects expected in this study  
population.22-24It is associated with well -established normative data;25norms may  be selected to 
aid in interpretation of the scale scores.
The CBCL (1 ½ to 5) is a questionnaire that will be administered to the subject’s parent(s) or 
legally  authorized representative(s) by  a trained professional. Scores to be recorded are detailed 
in the Study  Operations Manual.
7.6.3.4 Vineland Adaptive Behavior Scales, Second Edition
The VABS -II Expanded Interview Form will be used to measure the personal and social skills of 
subjects seriall y over time; these scales are organized within a 3 -domain structure :  
Communication, Daily  Living, and Socialization. In addition, the VABS -II offers a Motor Skills 
Domain and an optional Maladaptive Be havior Index. The VABS -II Expanded Interview Form 
assesses what a subject actually does, rather than what he or she is able to do. 
The VAB S-II Expanded Interview Form will be administered to the sub ject’s parent(s) or legall y 
authorized representative(s) b y a trained professional . Scores to be recorded are detailed in the 
Study  Operations Manual.
7.6.3.5 Attention -Deficit/Hyperactivity Disorder Rating Scale
The ADHD -RS was developed to measure the behaviors of children with ADHD. The 
ADHD -
RS consists of 18 items designed to reflect current s ymptomatology of ADHD based on 
DSM -IV criteria. Each item is scored from a range of 0 (reflecting no s ymptoms) to 3 (reflecting 
severe s ymptoms) with total scores ranging from 0 -54. 
For non-commercial use only
Shire CONFIDENTIAL Page 29
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
The18items aregrouped into2subscales :  hyperactivity -impulsivity  (even numbered items 
2-18) and inattention (“inattentivene ss”) (odd numbered items 1 -17).
The ADHD -RS,26will be completed b y the subject’s parent(s) or legally  authorized 
representat ive(s) .Scores to be recorded are detailed in the Study  Operations Manual.
7.6.3.6 Social Communication Questionnaire – Lifetime Form
The SCQ is a brief instrument that helps evaluate communication skills and social functioning in 
children27that can be used for screening for autism or autism spectrum disorders in the general 
population .28
The SCQ will be completed by  the subject’s parent(s) or legall y authorized representative(s). The 
investigator or designee should review the assessment for completeness and to con firm all 
responses . Scores to be recorded are detailed in the Study  Operations Manual.
7.6.4 Cerebral Palsy Assessment
Comprehensive neurological examination for the diagnosis of cerebral palsy (CP) will be 
conducted . The Amiel -Tison neurological examination fra mework29will be utilized for this 
assessment and conducted by  trained medical professionals.
7.6.5 Pulmonary Morbidity Assessment
Pulmonary  morbidity  will be assessed with questions related to famil y history and smoking 
status as well as diagnosis of select pulmonary  symptoms, conditions and related 
hospitalizations. The assessment will be administered to the subject’s parent(s) or legall y 
authorized representative(s). Assessments will be performed as outlined in the Schedule of 
Events (see Appendix 1).Questionnaires that will be used for these assessments at clinic al site
visits are provided in the Study  Operations Manual for the 6- month ,12-month 24 -month ,and 
5-year CA visits .The q uestionnaire that will be used for these assessments during phone 
interviews at the 30- month, 3 -year, 3.5 -year, 4 -year, and 4.5- year CA visits isprovided in the 
Study  Operations Manual .
7.6.6 Optional Cerebral M agnetic R esonance 
Imaging
Participation inthe MRI  assessment is optional and has no impact on participating in the main 
study .  If consented to, magnetic r esonance imaging ( MRI )of the brain will be performed. 
The MRI  may  
be performed with or without sedation. I f the scan is 
performed without sedation 
and the first attempt is unsuccessful, a second attempt should be made . Volumetric anal yses of 
the cortical gray  matter, cortical white matter, corpus callosum, frontal lobes , cerebellum, and 
total volume will be analyzed for the purposes of this study . 
The nature, scope, risks
,benefit s, and potential sedation associated with the procedure will be 
explained to the subject and subject’s parent(s) or legally  authorized representative(s) by  the 
Investigator or a designated trained study personnel . Subject’s parent(s) or legally  authorized 
representative(s) will be asked to separatel y opt in or decline participation inthis part of the 
study  in the informed consent document.     
For non-commercial use only
Shire CONFIDENTIAL Page 30
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
7.6.7 Survival Assessment
Survival status will be assessed and recorded.
7.6.8 Health Economic Outcome Research Assessments
7.6.8.1 Health Related Quality of Life
Health-related qualit y of l ife (HRQoL) is an important outcome towards improving the health 
care of pediatric patients as it is that part of a person’s overall qualit y of life that is determined 
primarily  by their health status and which can be influenced by  clinical interventions . It is an 
important concept, which is also used in determining the value of health care services in this 
population .30,31It is a multidimensional construct whose content is guided by the World Health 
Organization ;32minimally it includes ph ysical, psy chological (including emotional and 
cognitive), and social health dimensions .
In this stud y, HRQoL will be assessed via the validated Pediatric Quality of L ife Inventory  
(PedsQL™) Scales appropriate for the child’s a ge of development.33-35  The development of the 
PedsQL  was based on the delineations of the World Health Organization ( WHO )and is a 
modular approach to assessing HRQoL in the pediatric population. Initially , the PedsQL  Generic 
Scales were developed and continue to be used in children aged 2 to 18 years. 
More recently  
Infant Scales have been developed that appl y to ages 1 to 24 months.34
The following scales will be used in this study :
Infant Scale for ages 1 -12 months (36 I tems)
Infant Scale for ages 13 –24 months (45 I tems)
Toddler Scale for 2 -4 years of age (21 Items)
Young Child Scale for 5 -7 years of age (23 Items)
The PedsQL will be administered to the subject’s parent and ma y be conducted via telephone by 
clinical site staff . The scale(s) to be administered at each visit will be specified in the Study  
Operations Manual.
7.6.9 Health Care Resource Use
To understand the value of the investigational product administered in Study  ROPP -2008-01 
(Section D), the resource use associated with inpatient visits, outpatient visits, and medical and 
pharmacy utilization in this study  will be recorded. 
This assessment may  be conducted via telephone by clinical site staff .
7.6.9.1 Health Status Classifica tion System- Preschool
Health status (eg, health u tility ) will be measured by  the Health Status Classification 
System -Preschool (HSCS -PS), which is a validated instrument adapted for use via parent prox y 
within the pediatric population age 2.5 to 5 (adapted from the validated Health Utilities I ndex 
Mark 2 and 3 [HUI 2/3]).36  Validity  of the HSCS -PS concepts has not been established for ages 
younger than 2.5 y ears.
For non-commercial use only
Shire CONFIDENTIAL Page 31
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
The HSCS- PS was developed to provide a consistent measure of health status in preschool- aged 
children who had been born prematurely .36The sy stem is applicable to children with special 
needs as may  be included in this study ; validation cohorts for the s ystem incl uded children with 
very low birth weight (VLBW), which is congruent with this study  population.
The instrument is composed of 12 dimensions (Vision, Hearing, Speech, Mobility , Dexterity , 
Self-care, Emotion, Learn/remember, Think/problem solve, Pain, Genera l Health, and Behavior) 
intended to provide a comprehensive assessment of a child’s health status as it pertains to 
health- related quality  of life . The individual domains of the instrument will be scored as a mean 
score, representing the overall state for each concept individually . The global score will be 
recorded as well as the scores for each of the dimensions.
The HSCS- PS is a questionnaire that will be administered to the subject’s parent(s) or legall y 
authorized representative(s) and may  be conducted via telephone by clinical site staff .
7.7 Safety Assessments
7.7.1 Abdominal ultrasound
An abdominal ultrasound will be performed to assess the size of the spleen and kidney s. The 
spleen will be measured in the coronal longitudinal plane and the longest longitudinal length will 
be measured for each kidney  (left and right) .37Ultrasound results will be assessed by a central 
reader.
Organ size will be interpreted in the context of reference values established for children .37,38
7.7.2 Echocard iogram
Echocardiographic examination (conventional M- mode recording of the left ventricle [L V] 
parasternal long axis view) will be performed for the evaluation of cardiac size, assessed by  
measuring the following:
interventricular septal thickness (during end diastole)
LV posterior wall thickness
LV intracavit y volume (both in end diastole and end systole)
Echocardiogram results will be assessed by a central reader.
7.7.3 Physical Examination
Physical examinations will include a review of the subject’s general appearance, neurological 
examination, as well as a tonsillar examination ( Table 7-
2). An y abnormal change in findings 
will b e recorded as an AE
. 
For non-commercial use only
Shire CONFIDENTIAL Page 32
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Table 7-2 Assessments for Physical Examinations
Assessment Assessment
General appearance Endocrine
Head and neck Cardiovascular
Eyes Abdomen
Ears Genitourinary
Nose Skin
Throat Musculoskeletal
Chest and lungs Neurological
Tonsils
7.7.4 Blood Pressure , Heart Rate , and Respiratory Rate
Blood pressure ,heart rate , and respiratory will be measured at the 5- year CA visit.
7.8 Medication Assessment
All medications received by  study  subjects will be collected from the time of enrollment through 
the 5- year CA visit (or upon discontinuation) . Any investigational product received b y subjects 
will be recorded separately  as part of an assessment of subjects’ participation in other clinical 
studies (Section 7.11.1).
7.9 Adverse Events Assessments
7.9.1 Defin itions of Adverse Events, Serious Adverse Events , and Suspected 
Unexpected Serious Adverse Reactions
7.9.1.1 Adverse Event
An AE is an y noxious, pathologic, or unintended change in anatomical, physiologic, or 
metabolic function as indicated b y physical signs, sy mptoms, or laboratory  changes occurring in 
any phase of a clinical study , whether or not considered investigational product-related. This 
includes an exacerbation of a pre -existing condition . 
Adverse events include:
Worsening (change in nature, severit y, or frequency) of conditions present at the onset 
of the study
Intercurrent illnesses
Drug interactions
Events related to or possibly  related to concomitant medications
Abnormal laboratory values (this includes significant shifts from baseline within the 
range of normal that the Investigator considers to be clinically  important)
Clinically  significant abnormalities in phy sical examination, vital signs, and weight
For non-commercial use only
Shire CONFIDENTIAL Page 33
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
In this long -term outcome study  in follow -up to Study  ROPP -2008- 01 (Section D), no 
investigational product is being administered. However, the relationship to th e investigational 
product (rhIGF -1/rhIGFBP -3) as administered in Study  ROPP -2008- 01 (Section D) will be 
assessed . 
For the purposes of this study  only the following a dverse events will be collected:  
those considered related to investigational product (rhIGF- 1/rhIGFBP -3 as 
administered in Study  ROPP -2008- 01, Section D)
those considered related to procedures performed in this study  (Study  SHP -607-201)
specified targeted medical events (Section 7.9.1.3) regardless of causality
Throughout the stud y, the Investigator must record AEs on the AE electronic case report form 
(eCRF), regardless of the severit y. The Investigator should treat subjects with AEs appropriatel y 
and observe them at suitable intervals until the events stabilize or resolve . Adverse events may  
be discovered through observation or examination of the subject, questioning of the subject, 
complaint by  the subject, or by  abnormal clinical laboratory  values.
In addition, AEs may  also include la boratory  values that become significantly  out of range . In 
the event of an out -of-range value, the laboratory  test should be repeated until it returns to 
normal or can be explained and the subject’s safety is not at risk. 
Additional illnesses present at t
he time when informed consent is given are regarded as AEs and 
will be documented on the appropriate pages of the eCRF . Illnesses first occurring or detected 
during the stud y, and worsening of a concomitant illness during the stud y, are to be regarded as 
AEs and must be documented as such in the eCRF.
7.9.1.2 Serious Adverse Event
An SAE is any  AE that results in any  of the following outcomes:
Death
Is life -threatening
Requires hospitalization
Requires prolongation of existing hospitalization
A persistent or significant disability  or incapacity  
A congenital anomal y or birth defect
Important medical events that may  not result in death, be life -threatening, or require 
hospitalization may  be considered an SAE when, based upon appropriate medical judgment, they  
may jeopardize the subject and may  require medical or surgical intervention to prevent one of the 
outcomes listed in this definition . 
For non-commercial use only
Shire CONFIDENTIAL Page 34
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Alife-threatening AEisdefined as an AEthatplaced thesubject, in the view of the initial 
reporter, at immediate risk of death from the AE as it occurred (ie, it does not include an AE that, 
had it occurred in a more severe form, might have caused death).
For the purposes of this study  only SAE listed in the following will be collected:
fatal SAEs regardle ss of causality
SAEs related to ROP
SAEs related to congenital malformations not identified at birth which may impact 
neurocognitive development 
7.9.1.3 Suspected Unexpected Serious Adverse Reaction
Suspected unexpected serious adverse reactions (SUSAR) are suspected adverse reaction s related 
to an investigational product (investigational products and comparators [if applicable]), which 
occur in the concerned study , and that are both serious and unexpected according to the current 
Investigator’s Brochure .
7.9.1.4 Targeted Medical Events
If it is determined that any of the following targeted medical events have been experienced b y a 
subject, they will be recorded as AEs or SAEs, as appropriate, regardless of relationship to 
investigational product ( rhIGF-1/rhIGFBP -3as administered in Study  ROPP -2008-01, 
Section D):
intracranial hy pertension
any abnormalit y of glucose metabolism (eg, h ypogl ycemia, h ypergl ycemia, and 
diabetes)
tonsillar hy pertrophy  (based on tonsil exam [part of the phy sical exam])
increased kidney  size 
increased cardiac size
increased spleen size
7.9.2 Classification of Adverse Events and Serious Adverse Events
The severit y of AEs will be assessed b y the Investigator based on the definition indicated in 
Table 7-3
. The severit y of all AEs/SAEs should be recorded on the appropriate eCRF page to a 
severit y of mild, moderate, or severe.
For non-commercial use only
Shire CONFIDENTIAL Page 35
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Table 7-3 Adverse Event Severity
Severity Definition
Mild No limitation of usual activities.
Moderate Some limitation of usual activities.
Severe Inability to carry out usual activities.
7.9.3 Clarification between Serious and Severe
The term “severe” is often used to describe the intensity  (severit y) of a specific event (as in mild, 
moderate, or severe m yocardial infarction); the event itself, however, may  be of relatively  minor 
medical significance (such as severe headache) . This is not the same as “serious,” which is based 
on the outcome or action criteria usually associated with events that pose a threat to life or 
functioni ng. Seriousness (not severity) and causality serve as a guide for defining regulatory 
reporting obligations.
7.9.4 Relatedness of Adverse Events and Serious Adverse Events
Relationship of an AE or SAE to investigational product (rhIGF- 1/rhIGFBP -3 as administered in 
Study  ROPP -2008- 01, Section D) is to be determined by  the Investigator based on the following 
definitions (See Table 7-4).
Table 7-4 Adverse Event Relatedness
Relationship to Product Definition
Not Related Unrelated to investigational product
Possibly Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, but which could 
also be explained by concurrent disease or other drugs o r chemicals.
Probably Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, unlikely to be 
attributable to concurrent disease or other drugs and chemicals and 
which follows a clini cally  reasonable response on de- challenge . The 
association of the clinical event or laboratory abnormality must also 
have some biologic plausibility, at least on theoretical grounds.
Definitely related The event follows a reasonable temporal sequence from administration 
of the investigational product, follows a known or suspected response 
pattern to the investigational product, is confirmed by improvement 
upon stopping the investigational product (de -challenge), and 
reappears upon repeated exposure (re -challenge) . Note that this is not 
to be construed as requiring re -exposure of the subject to 
investigational product; however, the determination of definitely 
related can only be used when recurrence of event is observed.
7.9.5 Procedures for Recording and Report ing Adverse Events
7.9.5.1 Adverse Event Monitoring and Period of Observation
Adverse events will be monitored throughout the study . 
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 38
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
If a subject or the subject’s parent(s) or the subject’s legally  authorized representative(s) acting 
on behalf of the subject, discontinues participation in the study , or the subject is discontinued by  
the Investigator, reasonable efforts will be made to follow the subject through the end of study  
assessments . The reason for refusal will be documented on the eCRF. An y AEs experienced up 
to the point of discontinuation must be documente d on the AE eCRF . If AEs are present when 
the subject withdraws from the study , the subject will be re -evaluated within 30 day s of 
withdrawal . All ongoing SAEs at the time of withdrawal will be followed until resolution.
7.11 Other Study Procedures
7.11.1 Participatio n in Other Clinical Studies
Following enrollment, subjects in this study  will not be restricted from enrolling in another 
clinical study  that involves the use of investigational product . The status of a subject’s 
participation in such studies will be re corded (ie, yes/no) . If a subject is enrolled in such a study, 
additional parameters will be recorded, including the masking status of the study , the identity  of 
the investigational product being evaluated in the study, and the subject’s treatment assignme nt 
in the study  (if possible) . 
7.12 Appropriateness of Measurements
Overall, the primary  and secondary  efficacy  and safet y measures being employed in this study 
are considered appropriate for the follow -up of preterm infants. The validated tools being used to 
assess neurodevelopment, phy sical development, and health economic research outcomes in this 
pediatric population are widely used and recognized.
In some cases tools were designed specifically  for use in this study . These are the pulmonary  
morbidity  assess ment and the cerebral palsy  assessment . In these cases, the tools are either based 
on validated tools or the current state of knowledge in the literature . For example, the cerebral 
palsy  assessment is based on the Amiel -Tison neurological examination frame work29and the 
pulmonary  assessment is based on published rese arch in a similar pediatric population39,40.
For non-commercial use only
Shire CONFIDENTIAL Page 39
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
8 STUDY ACTIVITIES
The timing of the visits in this study  is based on subjec ts’ corrected age (CA). 
8.1 Initial Study Visit (40 weeks CA [term equivalent])
The Initial Visit will occur at 40 weeks CA (ie, term equivalent) or upon discontinuation from 
Study  ROPP -2008- 01, Section D or any  time up to the visit at 3 months CA . 
For subje cts enrolled between the ages of 9 months CA and 2 y ears +3 months CA, missed 
procedures such as neurocognitive assessments, abdominal ultrasounds, and echocardiograms are 
not required.
At the I nitial Visit, informed consent will be obtained followed by  anassessmen t of study  
eligibility  criteria and collection of demographic data.
The following AE d ata, collected as part of Study  ROPP -2008- 01 (Section D) will be recorded :
Ongoing targeted medical events regardless of causality
Ongoing stud y drug -related AE s, including SAEs
SAEs , as outlined in Section 7.9.1.1 and Section 7.9.1.2 ,that the subject experiences between the 
ROPP -2008- 01 end
-of
-study  visit and the time of informed consent for the SHI P-
607-201 study  
will be reported b y the Investigator ,pending permission for subject’s parent or legally  authorized 
representative(s) ,as documented on the informed consent form.
8.2 Study Visits
Study  visits for follow -up outcome assessments will take place at the following time points in 
CA:
3 months (±2 weeks) –conducted by  telephone
6 months (±1 month) –clinical site visit
12 months (±3 months) –clinical site visit
20 month s
(-1 months) – clinical site visit
24 months (±3 months) –clinical site visit
30 months (±3 months) –conducted b y telephone
3 years (±3 months) – conducted by  telephone
3.5 y ears (±3 months) – conducted by  telephone
4 years (±3 month) – conducted by  telephone
4.5 y ears (±3 month) – conducted by  telephone
4.75 y ears (- 1 months) 
–clinical site visit
5 years (+6 months) –clinical site visit
For non-commercial use only
Shire CONFIDENTIAL Page 40
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
In addition, there will be 2 visits that must occur at least 1 month prior to the 24 -month and 
5-year CA stud y visits to assess the need for corrective lenses . The timing of these 2 visits 
(20months [ -1 month] and 4.75 y ears [- 1 month]) was set to e nsure that any  prescribed 
corrective lenses would be worn for at least 1 month prior to the visual assessments at the 
24-month and 5- year study visits CA.
The activities at the study  visits are described in Sections 8.2.1 and 8.2.2.
8.2.1 Outcome Assessment Visi ts Conducted by Telephone
Visits at 3 months, 30 months, 3 y ears, 3.5 y ears, 4 years, and 4.5 yearsCA will be conducted b y 
telephone . The following outcome assessments will be conducted at each of these 6 visits, unless 
otherwise indicated:
HRQoL (3-month , 3-year, and 4- year visits)
HCRU (3-month, 3 -year, and 4- year visits) 
HSCS -PS (3
-year and 4 -year visits)
Pulmonary  morbidity  assessment (30 -month, 3 -year, 3.5 -year, 4-year, and 4.5 -year 
visits)
Medications (3-month, 30 months, 3-year, 3.5 y ear,4-year and 4.5 year visits)
Survival assessment (3-month, 30 month, 3- year, 3.5 y ear,4-year and 4.5 y ear visits)
Assessment of participation in other clinical studies (3-month, 30 months, 
3-year, 3.5 
year, 4-year and 4.5 year visits) 
Adverse events , including t argeted medical events (3-month, 30 month, 3- year, 3.5 
year,4-year and 4.5 year visits) 
8.2.2 Clinical Site Visits
8.2.2.1 Outcome Assessment Site Visits
The following clinical site visits (in CA) to capture follow
-up outcome data will occur at the 
clinical site:
6 months (±1 month)
12 months (±3 months) 
20 months ( -1 month)
24 months (±3 months)
4.75 y ears (- 1 months)
5 years (+6 months)
For non-commercial use only
Shire CONFIDENTIAL Page 41
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
The following assessments will be performed at the 6 -month visit:
Visual acuity
Refraction with cy cloplegia
Length
Weight
Head circumference
VABS -II
Physical examination (including tonsil examination)
Hearing Assessment History  (Historical hearing test data may  be recorded at any  time 
prior to the 6- month visit) 
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be per formed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Abdominal ultrasound
Echocardiogram
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at the 12 -month visit:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
Ocular alignment and mot ility
Length
Weight
Head circumference
BSID-III
VABS -II
Physical examination (including tonsil examination)
Pulmonary  morbidity  assessment
For non-commercial use only
Shire CONFIDENTIAL Page 42
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will b e performed at the 20 -month visit:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
Assessment of participation in other clinical studies
The following assessments will be performed at the 24 -month visit:
Visual acuity
Ocular alignment and motility
Length
Weight
Head circumference
BSID-III
CBCL
VABS -II
Physical examination (including tonsil examination)
Cerebral Pals y assessment
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HSCS -PS (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
For non-commercial use only
Shire CONFIDENTIAL Page 43
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at 4.75- year visit:
Visual acuity
Corrective lens determination (including refraction w ith cy cloplegia)
The following assessments will be performed at the 5 -year visit:
Visual acuity
Ocular alignment and motility
Stereoacuit y
Height
Weight
WPPSI
CBCL
VABS -II
ADHD -RS
SCQ
Physical examination (including tonsil examination)
Blood pressure, heart rate, and respiratory  rate
Pulmonary  morbidity  assessment
Hearing assessment history
Survival assessment

Cerebral MRI
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HSCS -PS (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
For non-commercial use only
Shire CONFIDENTIAL Page 44
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Medications
Adverse events (i ncluding targeted medical events)
8.2.2.2 Visits Dedicated to Corrective Lens Determination
The following clinical site visits are dedicated solely  to corrective lens determination in 
preparation for the outcome assessment visits at 24- months and 5- years CA:
20months ( -1 month) 
4.75 y ears (- 1 month) 
At these visits, the following will be performed:
Visual acuity
Corrective lens determination (includes refraction with cy cloplegia)
The 20- month visit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 month prior 
to the 24-month and 5- year visits, respectivel y. Any prescribed corrective lenses must be worn 
for at least 1 month prior to the 24 month and 5 y ear assessments.
8.3 Assessments upon Discontinuation
If a subject discontinues prior to the 5 -year CA visit, every attempt will be made to complete the 
assessments scheduled for the subject’s next visit. 
For non-commercial use only
Shire CONFIDENTIAL Page 45
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
9 QUALITY CONTROL AND ASSURANCE
Training will occur at an Investigator meeting or at the site initiation visit or both, and instruction 
manuals will be provided to aid consistency  in data collection and reporting across sites.
Clinical sites will be monitored by  the Sponsor or its designee to ensure the accuracy  of data 
against source documents. The required data will be captured in a validated cl inical data 
management s ystem that is compliant with the FDA 21 Code of Federal Regulations ( CFR )Part 
11 Guidance . The clinical trial database will include an audit trail to document any  evidence of 
data processing or activity  on each data field by  each u ser. Users will be trained and given 
restricted access, based on their role(s) in the study, through a password -protected environment.
Data entered in the s ystem will be reviewed manually  for validity  and completeness against the 
source documents by  a clin ical monitor from the Sponsor or its designee . If necessary , the study  
site will be contacted for corrections or clarifications; all missing data will be accounted for.
Serious adverse event information captured in the clinical trial database will be reconciled with 
the information captured in the Pharmacovigilance and Risk Management database.
For non-commercial use only
Shire CONFIDENTIAL Page 46
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
10 STATISTICAL AN ALYSES
10.1 General Methodology
Details regarding the statistical methods and definitions will be provided in the Statistical 
Analy sis Plan (SAP) . The SAP w ill be finalized prior to database lock. All statistical analy ses 
will be performed b y the Biometrics department at Shire. Statistical analy ses will be performed 
using Version 9.1 or higher of SAS®(SAS Institute, Cary , NC 27513).
Continuous variables will be summarized using descriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categorical variables will be summarized using frequencies and percentages.
As referred to in descriptions of summary  statistics, t reatment groups refer to the 2 possible 
treatment assignments in the antecedent study ,ROPP-2008- 01, Section D ( rhIGF-1/rhIGFBP -3
or standard neonatal care) .
For analy sis purposes, baseline is defined as the first assessment either in the antecedent study  
(ROPP -2008- 01) or in this study  (SHP -607-201). As necessary , relevant data from Study  
ROPP -2008- 01 may  be extracted and 
summarized with the data from this study  (SHP -607- 201).
For consented patients, additional biomarker analysis m ay be performed on prior collected blood 
samples from Study  ROPP -
2008-01.
10.2 Determination of Sample Size
No formal sample size calculation wasperformed for this study  because this is a follow -up study  
to Section D of Study  ROPP -2008- 01. Any  subjects enrolle d in Study  ROPP -
2008- 01 are 
eligible to enroll in this study . There are up to 120 subjects who will be eligible to enroll in this 
long-term developmental outcome study .
10.3 Method of Assigning Study Subjects to Treatment Groups
Not applicable.
10.4 Population Descr iption
10.4.1 Analysis Populations
Enrolled Population - the Enrolled Population will consist of all subjects for whom written 
informed consent has been provided for this study . 
Safety  Population- the Safety  Population will consist of the subjects in the Enrolled Population
who have safet y follow
-up data in this long -term outcome study .
For non-commercial use only
Shire CONFIDENTIAL Page 47
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
10.4.2 Subject Disposition
Subjects who complete the study  and subjects who prematurel y discontinue from the stud y will 
be summarized by  treatment group using descriptive statistics. I n addition, for subjects who 
prematurel y discontinue from the study, the reasons for discontinuation will be summarized by 
treatment group.
10.4.3 Protocol Violations and Deviations
Protocol violations and deviations will be listed. Details of the criteria for dev iations and 
violations will be provided in the SAP.
10.4.4 Demographics and Baseline Characteristics
Descriptive summaries of demographic and baseline characteristics will be presented b y 
treatment group for the Enrolled Population . 
Demographics and baseline characteristics will be exami ned to assess the comparability  of the 
treatment group s. Continuous variables such as age (including corrected age) , weight, and 
length/height will be summarized using number of observations, mean, standard deviation, 
median, m inimum and maximum values. Categorical variables, like gender and race, will be 
summarized using number of observations and percentages.
Medical history ,including maternal and perinatal history , (as obtained from the antecedent 
study , ROPP -2008- 01) will b e summarized by  treatment group using the number of observations 
and percentages of subjects reporting each category .
10.5 Efficacy Analysis
All efficacy  analy ses will be performed using the Enrolled Population .
10.5.1 Primary Efficacy Analysis
The primary  efficacy  endpoints consist of the following:
Visual Acuity :  Visual acuity  will be categorized as the following: 
onormal (measurable acuity ≥20/40), 
obelow normal (20/200≤ measurable acuit y <20/40), 
opoor (measurable acuity ≤20/200)
oblind/low vision (onl y the ability  to detec t the 2.2 cm wide stripes on the 
low-vision Teller acuit y card and at an y location in the visual field). 
The number and proportion of patients within each category  listed above will be 
summarized by  treatment group and visit. I n addition, acuity  results in the normal and 
below normal categories will be classified as favorable outcomes, and acuity  results in 
the poor and blind/low- vision categories will be classified as unfavorable outcomes. 
Tabular summaries b y trea tment group and visit wil l include the frequency and the 
percentage for each visual acuity  category . 
For non-commercial use only
Shire CONFIDENTIAL Page 48
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Inaddition, shift tables offavorable outcomes from baseline (first assessment during 
this study ) to each of the subsequent assessments, including the last assessment , will 
be pre sented bytreatment group .
Ocular Alignment and Oculomotor Exam (Motility) :  Findings from the ocular 
motility  assessmen t will be either presence or absence of strabismus (esotropia, 
exotropia, hy pertropia, or hy potropia). Tabular summaries by  treatment gr oupand 
visit will include the frequency  and the percentage in each category . In addition, shift 
tables from baseline (first assessment during this study ) to the last assessment will be 
provided b y treatment group.
Nystagmus :  Presence or absence of ny stagmus will be summarized by  treatment 
group and visit
Refraction with C ycloplegia :  Findings from the refraction wit h cycloplegia will be 
summarized by  treatment group and visit
Stereoacuit y:  Presence or absence of stereopsis will be sum marized by  treatment 
group and visit
10.5.2 Secondary Efficacy Analysis
Growth Parameters (b ody weight, body  length [and height], and head circumference) :  
A standard Z- score, utilizing WHO child growth standards, will be calculated for each 
assessment by  adjusting age -and sex - matched means and standard deviations (norm). 
The descriptive statistics of the Z -score for each of these parameters will be 
summarized at each assessment and the corresponding change from baseline. When 
appropriate, a 95% CI for the corr esponding mean change within each group and the 
difference in the mean change between the 2 treatment groups and the corresponding 
95% CI  will be presented as appropriate. If the parametric assumption for the 
distribution of the above endpoints cannot be justified, a non -parametric approach will 
be utilized to estimate the treatment difference (ie, median difference or 
Hodges -Lehmann estimator and the corresponding confidence intervals)
BSID-III and WPPSI :  The raw score , age equivalent scores, and standard scores for 
each domain within each questionnaire will be summarized by  treatment group and 
visit using descriptive statistics.
ADHD -RS:  ADHD -RS total score and subscales (Hy peractivity /Impulsivity  and 
Inattentiveness) will be summarized by  treatment gro up and visit using descriptive 
statistics.
SCQ :  The SCQ subscales (communication and social) will be summarized by 
treatment group and visit using descriptive statistics
VABS -II:  The raw score, age equivalent scores, and standard scores for each domain 
of the scale will be summarized by  treatment group and visit using descriptive 
statistics.
CBCL :  The raw score and change from baseline for each domain of the scale will be 
summarized by  treatment group and visit using descriptive statistics.
For non-commercial use only
Shire CONFIDENTIAL Page 49
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Pulmonary  morbidity  assessment :  The binary  response of each question will be by  
treatment group and visit using descriptive statistics.
Survival :  For subjects who have an event (ie, death), the event time will be calculated 
as the length of time from the subject’s date of birth to death during the study  due to 
any cause . Subjects who do not have an event (ie, death) during the stud y will be 
censored at the end of the study . The survival endpoint will be analy zed by treatment 
group using Kaplan- Meier metho ds.
10.5.3 Subset Analyses
Subgroup anal yses may  be explored based on factors that may  have influence on the efficacy  or 
safet y endpoints. Subgroup anal yses will be specified in the SAP.
10.5.4 Exploratory Analyses
10.6 Health Economics and Outcomes Research Analyses
For PedsQL, descriptive statistics will be provided for summary  scores by  treatment group and at 
each time point.
The HUI 2/3 s ystem contains a number of attributes/domains to classif y the level of health status. 
Each attribute or domain (eg, mobility , cognition, emotion or pain) is rated on a 5- point ordinal 
scale to indicate the severity  level, ranging from 1 to 5 (higher numbers indicating a more severe 
level). Summary  statistics wi ll be provided by  treatment group and at each time point.
For HCRU the utilization for each resource -item (eg, hospital day s, phy sician visits) reported at 
each time point will be reported descriptivel y by treatment group.
10.7 Analysis of Safety
Safety  summari es will be based on all assessments post -baseline. The safet y data will be 
assessed b y AE monitoring, change in cardiac size, and kidney  and spleen size over time. 
Adverse events will be summarized by  system organ class and preferred term for each treatme nt 
group and overall, the number and percentage of subjects having an y AE, having an AE in each 
body  system and having each individual AE. In addition, those events which resulted in death, or 
were otherwise classified as serious will be presented in a sep arate listing. In addition, the 
summary  of AEs will be presented by  severit y and relationship to trial medication. 
The change in cardiac size, and size of kidney  and spleen will be assessed at the 6 -month CA 
visit via echocardiogram and abdominal ultrasou nd, respectivel y.  These data will be anal yzed as 
a binary  response (ie, normal/abnormal) and summarized using frequency  count.  The number 
and proportion of patients with each category (ie, normal/abnormal) for each of these safet y 
endpoints will be summa rized by  treatment group.  
For non-commercial use only
Shire CONFIDENTIAL Page 50
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Inaddition, the2-sided 95% CIfortheproportion of patients with a normal status for each of the 
endpoints will be estimated by  treatment group.
Physical examinations findings will be summarized descriptivel y. 
10.8 Statistical/Analytical Issues
10.8.1 Adjustment for Covariates
If any baseline data are imbalanced and are considered to be clinically relevant, between -group 
comparisons for efficacy  outcomes will be adjusted for covariates and detailed in the SAP. 
10.8.2 Handling of Dropouts or Missing Data
Handling of missing data rules will be described in the SAP.
10.8.3 Interim Analyses and Data Monitoring
Aninterim anal ysis will be performed after all data from all enrolled subjects in this study  have 
either completed 2 -year follow -up (24 -month visit) assessments or have prematurely  withdrawn 
from the study  (before completing 2 y ears of follow -up) has been entered i nto the database, 
queried and discrepancies resolved . A full 2- year study  report based on these data, including 
efficacy  and safet y endpoint analy ses,will be completed.
Additionally , descriptive anal yses of the data at other time points before study  completion may  
be performed for safet y monitoring, regulatory  reporting or general planning purposes.
10.8.4 Multiple Comparisons/Multi plicity
Not applicable.
10.8.5 Sensitivity Analyses
Sensitivity  analy ses for the efficacy  outcomes will be detailed in the SAP, as necessary .
For non-commercial use only
Shire CONFIDENTIAL Page 51
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
11 ADMINISTRATIVE CONSIDERATIONS
11.1 Investigators and Study Administrative Structure
Before initiation of the study , the Investigators must provide the Sponsor with a completed Form 
FDA 1572 and Investigator Agreement . Curriculum vitae must be provided for the Investigators 
and sub- investigators listed on Form FDA 1572 or I nvestigator Agreement . 
The Investigator should ensu re that all persons assisting with the study  are adequatel y informed 
about the protocol, an y amendments to the protocol, and their study related duties and functions . 
The Investigator must maintain a list of sub -investigators and other appropriately  qualif ied 
persons to whom he or she has delegated significant study  related duties.
11.2 Institutional Review Board or Independent Ethics Committee Approval
Before initiation of the study , the Investigator must provide the Sponsor with a copy  of the 
written I RB/IEC/R EB approval of the protocol and the informed consent form. This approval 
must refer to the informed consent form and to the study  title, study  number, and version and 
date of issue of the stud y protocol, as given b y the Sponsor on the cover page of the pro tocol.
Status reports must be submitted to the I RB/IEC/REB at least once per year. The IRB/IEC/REB 
must be notified of completion of the study . Within 3 months of study  completion or termination, 
a final report must be provided to the I RB/IECREB . A cop y ofthese reports will be sent to the 
study  clinical monitor . The Investigators must maintain an accurate and complete record of all 
submissions made to the IRB/IEC, including a list of all reports and documents submitted . 
AEs 
which are reported to the US (FD A or other Regulatory  agencies (Safet y Reports) must be 
submitted promptly  to the I RB/IEC/REB.
11.3 Ethical Conduct of the Study
The procedures set out in this study  protocol, pertaining to the conduct, evaluation, and 
documentation of this study , are designed to ensure that the Sponsor and Investigators abide b y 
good clinical practice (GCP) as described in the 21 CFR Parts 50, 56, and 312 and the 
International Conference on Harmonization (I CH) GCP Guidelines Compliance with these 
regulations and guidelines also constitutes compliance with the ethical principles described in the 
Declaration of Helsinki.
11.4 Subject Information and Consent
Before enrolling in the clinical study , the subject or the subject’s parent(s) or legally  
authorized representative(s) must consen t to participate after the nature, scope, and 
possible consequences of the clinical study  have been explained in a form understandable to 
himor her.
An informed consent form (assent form if applicable) that includes information about the study  
will be pre pared and given to the subject or the subject’s parent(s) or legally  authorized 
representative(s) . This document will contain all FDA and ICH -required elements
. 
For non-commercial use only
Shire CONFIDENTIAL Page 52
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Theinformed consent (or assent) form must be in a language understandable to the subject or th e 
subject’s parent(s) or legally  authorized representative(s) and must specify who informed the 
subject, the subject’s parent(s), or the subject’s legall y authorized representative(s).
After reading the informed consent document, the subject or the subject ’s parent(s) or legall y 
authorized representative(s) must give consent in writing. Consent must be confirmed at the time 
of consent b y the personally  dated signature of the subject, the subject’s parent(s) or the subject’s 
legally  authorized representative (s) and b y the personally  dated signature of the person 
conducting the informed consent discussions.
If the subject or the subject’s parent(s) or legally  authorized representative(s) is unable to read, 
oral presentation and explanation of the written informed consent form and information to be 
supplied must take place in the presence of an impartial witness . Consent must be confirmed at 
the time of consent orall y and by the personally dated signature of the subject or by a local 
legally  recognized alternati ve (eg, the subject’s thumbprint or mark) or b y the personall y dated 
signature of the subject’s parent(s) or the subject’s legally  authorized representative . The witness 
and the person conducting the informed consent discussions must also sign and personal ly date 
the informed consent document . It should also be recorded and dated in the source document that 
consent was given.
A cop y of the signed and dated consent document(s) must be given to the subject or the subject’s 
parent(s) or legal representative(s). The original signed and dated consent document will be 
retained b y the Investigator.
The Investigator will not undertake any  measures specificall y required solely for the clinical 
study  until valid consent has been obtained.
A model of the informed conse nt form to be used in this study  will be provided to the sites 
separately  from this protocol.
11.5 Subject Confidentiality
Subject names will not be supplied to the Sponsor . Only  the subject number - will be recorded in 
the eCRF, and if the subject name appears on an y other document, it must be obliterated before a 
copy  of the document is supplied to the Sponsor . Study  findings stored on a computer will be 
stored in accordance with local data protection laws . The subjects will be told that 
representatives of the Sponsor, a designated CRO, the I RB/IEC/REB, or regulatory  authorities 
may inspect their medical records to verify  the information collected, and that all personal 
information made available for inspection will be handled in strictest confidence and in 
accordance with local data protection laws. The Investigator will maintain a personal subject 
identification list (subject numbers with the corresponding subject names) to enable records to be 
identified.
For non-commercial use only
Shire CONFIDENTIAL Page 53
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
11.6 Study Monitoring
Monitoring procedures that comply  with current Good Clinical Practice (GCP) guidelines will be 
followed. Review of the eCRFs for completeness and clarit y, cross -checking with source 
documents, and clarification of administrative matters will be performed.
The study  will be monitored by  theSponsor or its designee . Monitoring will be performed by  a 
representative of the Sponsor (Clinical Study  Monitor) who will review the eCRFs and source 
documents . The site monitor will ensure that the investigation is conducted according to protocol 
design and regulatory requirements by  frequent site visits and communications (letter, telephone, 
and facsimile).
11.7 Case Report Forms and Study Records
11.7.1 Case Report Forms
Electronic case report forms (eCRFs) are provided for each subject . All forms must be filled out 
by authorized study  personnel. All corrections to the original eCRF entry  must indicate the 
reason for change . The Investigator is required to sign the eCRF after all data have been captured 
for each subject . If corrections are made after review and sig nature by  the Investigator, he or she 
must be made aware of the changes, and his or her awareness documented by  resigning the 
eCRF.
11.7.2 Critical Documents
Before the Sponsor initiates the trial (ie, obtains informed consent from the first subject), it is the 
responsibility  of the Investigator to ensure that the following documents are available to Sponsor 
or their designee:
Completed FDA Form 1572 (Statement of Investigator), signed, dated, and accurate
Curricula vitae of Investigator and sub
-investigator(s) ( current, dated and signed 
within 12 months of study initiation)
Copy  of Investigator and sub -investigator(s) current medical license (indicating 
license number and expiration date)
Signed and dated agreement of the final protocol
Signed and dated agreement of an y amendment(s), if applicable
Approval/favorable opinion from the IRB/IEC/REB clearl y identifying the documents 
reviewed b y name, number and date of approval or re approval :  protocol, any  
amendments, Subject Information/I nformed Consent Form, and a ny other written 
information to be provided regarding subject recruitment procedures
Copy  of IRB/IEC/REB approved Subject Information/I nformed Consent Form/any  
other written information/advertisement (with IRB approval stamp and date of 
approval)
For non-commercial use only
Shire CONFIDENTIAL Page 54
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Current l ist of I RB/IEC/REB Committee members/constitution (dated within 
12months prior to study  initiation)
Financial Disclosure Form signed b y Investigator and sub- investigator(s)
Current laboratory  reference ranges (if applicable)
Certification/QA scheme/other documentation (if applicable)
Regulatory  approval and notification as required must also be available; these are the 
responsibility  of Shire.
11.8 Data Monitoring Committee
Given that an y long -term safet y signal observed in this study  could impact the safet y profile of 
rhIGF -1/rhIGFBP -3 as administered in premature neonates being enrolled in the antecedent 
study  (ROPP -2008- 01, Section D), the Data Monitoring Committee (DMC) for Study  
ROPP -2008- 01 will review safet y data from this long -term outcome study .
11.9 Protoc ol Violations/Deviations
The Investigator will conduct the study  in compliance with the protocol. The protocol will not be 
initiated until the I RB/IEC/REB and the appropriate regulatory  authorities, where applicable, 
have given approval/favorable opinion . Modifications to the protocol will not be made without 
agreement of the Sponsor . Changes to the protocol will require written IRB/I EC/REB 
approval/favorable opinion prior to implementation, except when the modification is needed to 
eliminate an immediate h azard(s) to subjects. 
The IRB/IEC/REB may  provide, if applicable 
regulatory  authorities permit, expedited review and approval/favorable opinion for minor 
change(s) in ongoing studies that have the approval/favorable opinion of the I RB/IEC/REB . The 
Sponsor will submit all protocol modifications to the regulatory  authorities, where applicable, in 
accordance with the governing regulations.
A record of subjects screened, but not entered into the study , is also to be maintained . No 
protocol exemption will be gra nted for this study .
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to 
subjects, the Investigator will contact the Sponsor or its designee, if circumstances permit, to 
discuss the planned course of action . Any departures from the protocol must be fully  documented 
as a protocol deviation. 
Protocol deviations will need to be reviewed b y the medical monitor and 
may also be required to be submitted to the I RB/IEC/REB.
Protocol modifications will only  be initiated by  the Sponsor and must be approved by  the 
IRB/IEC/REB and submitted to the FDA or other applicable international regulatory  authorit y 
before initiation, if applicable.
For non-commercial use only
Shire CONFIDENTIAL Page 55
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
11.10 Premature Closure of the Study
If the Sponsor, Investigator, or regulatory  authorities disc over conditions arising during the stud y 
which indicate that the clinical investigation should be halted due to an unacceptable subject risk, 
the study  may  be terminated after appropriate consultation between the Sponsor and the 
Investigator(s) . In addition, a decision on the part of the Sponsor to suspend or discontinue 
development of the investigational product may  be made at any  time . Conditions that may  
warrant termination of the study or site include, but are not limited to:
The discovery  of an unexpec ted, significant, or unacceptable risk to the subjects 
enrolled in the study
Failure of the Investigator to comply  with pertinent global regulations
Submission of knowingly  false information from the study  site to the Sponsor or other 
pertinent regulatory  authorities
Insufficient adherence b y the I nvestigator to protocol requirements
11.11 Access to Source Documentation
Regulatory  authorities, the I RB/IEC/REB, or the Sponsor may  request access to all source 
documents, eCRFs, and other study  documentation for onsite audit or inspection. Direct access to 
these documents must be guaranteed b y the Investigator, who must provide support at all times 
for these activities. Monitoring and auditing procedures that compl y with current GCP guidelines 
will be followed . On-site review of the eCRFs for completeness and clarit y, crosschecking with 
source documents, and clarification of administrative matters may  be performed.
11.12 Data Generation and Analysis
The clinical database will be developed and maintained b y a contract research organization or an 
electronic data capture technology  provider as designated by  the Sponsor . The Sponsor or its 
designee will be responsible for performing study  data management activities. 
Adverse events will be coded using Medical Dictionary  for R egulatory  Activities (MedDRA) . 
Concomitant medication will be coded using WHO- Drug Dictionary  (WHO -DD). 
Central reads 
will be employ ed as described in the study  manual to aid in consistent measurement of 
abdominal ultrasound and echocardiogram parameters . 
11.13 Retention of Data
Essential documents should be retained until at least 2 y ears after the last approval of a 
marketing application and until there are no pending or contemplated marketing applications or 
at least 2 y ears have elapsed since the formal disc ontinuation of clinical development of the 
investigational product. 
The Sponsor will notify  the Investigator if these documents must be 
retained for a longer period of time . It is the responsibility  of the Sponsor to inform the 
Investigator or institution as to when these documents no longer need to be retained.
For non-commercial use only
Shire CONFIDENTIAL Page 56
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
11.14 Financial Disclosure
The Investigator should disclose an y financial interests in the Sponsor as described in 21 CFR 
Part 54 prior to beginning this study . The appropriate form will be provided to th e Investigator 
by the Sponsor, which will be signed and dated b y the Investigator, prior to the start of the study . 
11.15 Publication and Disclosure Policy
All information concerning the stud y material, such as patent applications, manufacturing 
processes, basi c scientific data, and formulation information supplied by  the Sponsor and not 
previously  published are considered confidential and will remain the sole propert y of the 
Sponsor . 
The Investigator agrees to use this information only  in accomplishing this study  and 
will not use it for other purposes.
It is understood by  the Investigator that the information developed in the clinical study  may  be 
disclosed as required to the authorized regulatory  authorities and governmental agencies . In 
order to allow for t he use of the information derived from the clinical studies, it is understood 
that there is an obligation to provide the Sponsor with complete test results and all data 
developed in the stud y in a timely manner.
The Investigator and an y other study  personnel associated with this study  will not publish the 
results of the study , in whole or in part, at an y time, unless they  have consulted with the Sponsor, 
provided the Sponsor a copy  of the draft document intended for publication, and obtained the 
Sponsor’s w ritten consent for such publication . All information obtained during the conduct of 
this study  will be regarded as confidential. 
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 59
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
32.Constitution of the World Health Organization:  basic document. Geneva, Switzerland :  
World Health Organization; 1948.
33.Varni JW, L imbers CA. The pediatric quality  of life inventory :  measuring pediatric health -
related qualit y of life from the perspective of children and their parents. Pediatr Clin North 
Am 2009;56:843-63.
34.Varni JW, L imbers CA, Neighbors K, et al. The PedsQL Infant Scales :  feasibility , internal 
consistency  reliability , and validity  in health y and ill infants. Quality  of life research :  an 
international journal of quality  of life aspects of treatment, care and rehabilitation 
2011;20:45-55.
35.Varni JW, Seid M, Kurtin PS. PedsQL  4.0:  reliability  and validity  of the Pediatric Qualit y of 
Life Inventory  version 4.0 generic core scales in healthy  and patient populations. Medical 
care 2001;39:800-12.
36. Saigal S, Rosenbaum P, Stoskopf B, et al. Development, reliability  and validity  of a new 
measure of overall health for pre -school children. Quality  of life resear ch :  an international 
journal of quality  of life aspects of treatment, care and rehabilitation 2005;14:243 -57.
37. Rosenbaum DM, Korngold E, Teele RL. Sonographic assessment of renal length in normal 
children. Am J Roentgenol 1984;142:467 -9.
38.Rosenberg HK, Mar kowitz RI , Kolberg H, Park C, Hubbard A, Bellah RD. Normal splenic 
size in infants and children :  sonographic measurements. Am J Roentgenol 1991;157:119
-21.
39.Stevens TP, Finer NN, Carlo WA, et al. Respiratory  Outcomes of the Surfactant Positive 
Pressure and Oximetry  Randomized Trial (SUPPORT). J Pediatr 2014;165:240- 9.e4.
40.Zivanovic S, Peacock J, Alcazar -Paris M, et al. Late outcomes of a randomized trial of high -
frequency  oscillation in neonates. N Engl J Med 2014;370:1121 -30.
For non-commercial use only
Shire CONFIDENTIAL Page 60
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Appendix 1 Study Schedule of Events
ProceduresInitial Study 
Visite Months (CA)Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 
wks6 
± 1mth12
± 3 
mths20 
-1 mthg24
± 3mth30f
± 3mth3f
± 
3mths3.5f
± 
3mth4f
± 3mths4.5f
± 3mth4.75
-1 mthg5
+ 6 
mths
Informed Consent •
Eligibility Criteria •
Dem ographics •
Visual acuitya• • • • • •
Corrective lens determinationh• •g•g
Ocular alignment and motility • • •
Refraction with cycloplegiah•
Stereoacuity •
Length • • •
Height •
Weight • • • •
Head Circumference • • •
BSID -III • •
WPPSI •
CBCL • •
VABS -II • • • •
ADHD -RS •
SCQ •
Physical Examination including 
tonsil examination • • • •
Blood Pressure , Heart Rate , and 
Respiratory Rate•
Cerebral Palsy Assessment •
Hearing Assessment Historyb• •
Pulmonary Morbidity Assessment 
1• •
Pulmonary Morbidity Assessment 
2  (clinical site visit)• •
Pulmonary Morbidity Assessment 
(phone interview)• • • • •
For non-commercial use only
Shire CONFIDENTIAL Page 61
Clinical Trial Protocol: SHP -607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
ProceduresInitial Study 
Visite Months (CA)Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 
wks6 
± 1mth12
± 3 
mths20 
-1 mthg24
± 3mth30f
± 3mth3f
± 
3mths3.5f
± 
3mth4f
± 3mths4.5f
± 3mth4.75
-1 mthg5
+ 6 
mths
Survival assessment • • • • • • • • • •
Cerebral MRI •
HRQoLc• •i•i•i• • •i
HCRU • •i•i•i• • •i
HSCS -PS •i• • •i
Abdominal Ultrasound •
Echocardiogram •
Assessment of Participation in 
Other Clinical 
Studies• • • • • • • • • •
Medications • • • • • • • • • •
Adverse eventsd
•j• • • • • • • • • •
Abbreviations:  ADHD -RS=Attention -Deficit/Hyperactivity Disorder Rating Scale; BSID- III=Bayley Scales of Infant and Toddler Development -Third 
Edition, CBCL =Child Behavior Checklist; CA =corrected age; HCRU = health care resource use; HRQoL = health -related quality of life; HSCS -PS = Health 
Status Classification System; mth(s) =months; ; PedsQL =Pediatric Quality of Life Inventory; SCQ =Social 
Communication Questionnaire; VABS -II=Vineland Adaptive Behavior Scales, Second Edition; wks =weeks; WPPSI =Wechsler Preschool and Primary 
Scale of Intelligence
aThe tools used to assess visual acuity will change as the subject ages during their participation in the study. The tools tha t will be used in this study and are 
summarized by applicable study visit in Table A1 .
bHistorical hearing test data may be recorded at any time during the study prior to the 6 -month visit.
cHRQoL will be assessed via the validated PedsQL™ scales appropriate for the child’s age of development as specified in the Study Operations Manual.
dAdverse event collection will include an assessment of the specified targeted medical events .
eThe Initial Visit may be performed prior to 40 w eeks CA for any subject who discontinued from Study ROPP -2008- 01 and, for all subjects, any time after 
40 w eeks CA, up to the study visit to occur at 3 months CA.
fVisits at 3 months, 30 m onths, 3 years, 3.5 y ears, 4 years, and 4 .5years CA will be conducted by telephone.
gThe 20 -monthvisit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 month prior to the 24 -month and 5 -year visits, respectively. Any 
prescribed corrective lenses must be w orn for at least 1 month prior to the 24 -month and 5 -year assessments.
hRefractio n with cycloplegia will be performed as part of the corrective lens determination procedure.
For non-commercial use only
Shire CONFIDENTIAL Page 62
Clinical Trial Protocol: SHP -607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
ProceduresInitial Study 
Visite Months (CA)Years (CA)
40 weeks
(CA)/term  
equivalent3f
± 2 
wks6 
± 1mth12
± 3 
mths20 
-1 mthg24
± 3mth30f
± 3mth3f
± 
3mths3.5f
± 
3mth4f
± 3mths4.5f
± 3mth4.75
-1 mthg5
+ 6 
mths
iThe HRQoL, HCRU, and HSCS -PS assessments for the 6 -month, 12 -month, 24 -month and 5 -year vi sits may be performed through clinical site staff if 
there are time const raints during the on -site visit. At the 3 -month, 3 -year, and 4 -year visits, these assessme nts will be performed through clinical site staff 
and may be performed at any time within the visit window .
jThe follow ing, collected as part of the ROPP -2008- 01 study , will be used as part of this study (SHP -607-201):  any ongoing targeted medical events 
regardless of causality and any ongoing study drug -related AEs, including SAEs.
For non-commercial use only
Shire CONFIDENTIAL Page 63
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Table A1 Summary of Visual Acuity Assessments 
Visual Acuity 
Assessment ToolDescription Unit of Measure Applicable 
Age/Study 
Visit (CA)
Teller acuity cardsResolution acuity –
discrimination of a grating 
optotype from a background with 
the same mean luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity -tests 
recognition of 4 optotypesSnellen fraction
(eg, 20/20)24 monthsa
LEA Symbols 
(ETDRS -style) chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be made to assess visual acuity by the LEA 
Symbols Test and LEA Symbols Chart, respectively . If during this attempt , the examiner determines 
that it will not be possible to perform an accurate assessment w ith the relevant LEA tool, visual acuity 
should be assessed with the Teller acuity cards.
For non-commercial use only
Shire CONFIDENTIAL Page 64
Clinical Trial Protocol: SHP- 607-201
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 11 May 2017
Appendix 2Summary of Changes
Description ofChange Section(s) Affected
Added hearing assessment history  to the 6- month CA visit. Section 7.6.2
Added language explaining that cerebral magnetic resonance 
imagining (MRI) procedures are optional.  Language was also 
added explaining that the nature, scope, risks, benefits, and potential 
sedation associated with cerebral MRI will be explained to the 
subject and subject’s parent(s) or legally  authorized 
representative(s).Section 7.6.6
Added cerebral MRI to the 5 -year CA visit.Section 7.6.6
Section 8.2.2.1
Appendix 1
Added medications, survival assessment, assessment of 
participation in other clinical studies and adverse e vents, including 
targeted medical events to the 30 months, 3.5 y ears, 4.5 y ears CA 
visits co nducted by  telephone.Section 8.2.1
Appendix 1
Clarified that age equivalent scores and standard scores will be 
summarized for Bayley Scales of Infant and Toddler Development, 
Third Edition (BSID- III), Wechsler Preschool and Primary  Scale of 
Intelligence (WPPSI ), and Vineland Adaptive Behavior Scales, 
Second Edition (VABS -II).Section 10.5.2
Removed the pulmonary  morbidity  assessments from the 
appendices as they  will be provided in the Study  Operations 
Manual.Section 7.6.5
(formerl y)Appendix 2,
(formerl y)Appendix 3, 
(formerl y)Appendix 4
Administrative errors were corrected throughout the protocol. All sections
For non-commercial use only
Appendix 3 Protocol Signature Page  
Study Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 
Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of 
Retinopathy of Prematurity (ROP) or Who Received Standard Neona tal 
Care 
Study Number: SHP-607-201 
Final Date: 11 May 2017 
Version  Amendment 3 
I have read the protocol described above. I agree to comply with all applicable regulations and to 
conduct the study as described in the protocol.  
Signatory: 
Investigator 
Signature Date 
Printed Name 
I have read and approve the protocol described above. 
Signatory: 
Shire Medical 
Monitor  
Signature Date 
 MD, MPH 
Printed Name
 .BZShire  CONFIDENTIAL Page 65 
Clinical Trial Protocol: SHP-607-201 
Mecasermin rinfabate (rhIGF-1/rhIGFBP-3) 11 May 2017 
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 3
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018

Study Endpoints
The primary efficacy endpoints ofthis study are :
Visual acuity as assessed by an age appropriate method
Ocular alignment and ocular motor examination in primary gaze and in as many of 
9positions of gaze as possible as assessed by corneal light reflex and by the cover test
Assessment of nystagmus by observation
Refraction as assessed by retinoscopy with cycloplegia
Stereoacuity as assessed with the Lang Stereotest
The secondary efficacy endpoints of this study are :
Growth parameters including body weight, body length (or height), and head 
circumference
Cognitive development as assessed by the following standardized, age- appropriate 
tools:
oBayley Scales of Infant and Toddler Development, Third E dition (BSID -III)
oWechsler Preschool and Primary Scale of Intelligence (WPPSI )
Physical development as assessed by the following standardized, age appropriate tools :
oPhysical exam
oNeurological examination for assessment of cere bral palsy
oHearing assessment
oBlood pressure, heart rate, and respiratory rate
Child behavior as assessed by the following:
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
oChild Behavior Checklist (CBCL; 1 ½ to 5)
oAttention Deficit/Hyperactivit y Disorder Rating Scale (ADHD RS) for the 
assessment of symptoms of attention deficit/hyperactivity disorder (ADHD)
oSocial Communication Questionnaire (SCQ) for screening of Autism 
Spectrum Disorder (ASD)
Pulmonary morbidity data (eg, hospitalizations, eme rgency room [ER] visits, 
pulmonary medications)
Survival as assessed by death during the study due to any cause
The exploratory efficacy endpoints of this study are:


The health economic outcome research endpoints of this study are:
Health- related quality of l ife (HRQoL) will be assessed by the Pediatric Quality of Life 
Inventory (PedsQL™) Scales appropriate for the child's age of development with the 
For non-commercial use only
Shire CONFIDENTIAL Page 4
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Total Scale Score and 5 domains within Physical Health (Physical Functioning and 
Physical Symptoms) and Psychosocial Health Scores (Emotional, Social, and 
Cognitive Functioning, respectively)
Health status (eg, health u tility) will be measured by the Health Status Classification 
System -Preschool (HSCS- PS) and the Health Utilities Index Mark 2 (HUI2) and Mark 
3 (HUI3)
Resource use associated with inpatient visits, outpatient visits, medical utilization and  
pharmacy utilization w ill be assessed 
The safety endpoints of this study are:
Physical examination including tonsil examination
Adverse events (AEs), as follows :  
othose considered related to rhIGF -1/rhI GFBP -3(as administered in Study 
ROPP -2008- 01, Section D)
othose considered related to procedures performed in this study (Study 
SHP-607-201)
ospecified targeted medical events regardless of causality
ofatal SAEs regardless of causality
Cardiac size as assessed by echocardiogram 
Kidney and spleen size and any other gross abnormalities as assessed by abdominal 
ultrasound
Study Population :  
Subjects randomized in Study ROPP -2008- 01, Section D are eligible to enroll in this study; 
completion of Study ROPP -
2008- 01 Section D is not required. Subjects in Study ROPP -2008-01 
are premature infants (gestational age of 23 weeks + 0 days to 27 weeks +6 days) who are 
randomized to receive either treatment with rhIGF -1/rhIGFBP -3 or standard neonatal care. Up to 
120 subjects are planned to be randomized in toStudy ROPP -2008-01 Section D.
Study Design:
This is a Phase II, multicenter, long -term developmental outcome study enrolling subjects who 
were randomized in Section D of Study ROPP -2008- 01. Enrolled subjects in this study will be 
followed through age 5 years corrected age (CA) . This study will enroll both subjects who were in 
the treated (received rhIGF -1/rhI GFBP -3) and control (received standard neonatal care) groups of 
Study ROPP -2008- 01 (Section D) to enable asses sment of rhIGF -1/rhIGFBP -3 long -term efficacy 
and safety outcomes ve rsus standard neonatal care . No investigational product will be 
administered in this study . 
Study Duration:
Duration for an individual subject’s participation in the study will vary depending upon age at 
enrollment, but subjects will not be followed beyo nd age 5.5 years corrected age ( CA).
Study Inclusion and Exclusion Criteria:
Subjects randomized in Study ROPP -2008-01, Section D are eligible to enroll in this study . 
Subjects will not be excluded from participating in other clinical studies.
For non-commercial use only
Shire CONFIDENTIAL Page 5
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Efficacy Assessments:
Efficacy will be assessed by visual outcomes, growth parameters, cognitive development, physical 
development, child behavior, p ulmonary morbidity, and survival.
Safety Assessments:
Safety will be assessed by physical examination (including tonsil examination), AEs (as
specified ), echocardiogram, and abdominal ultrasound.
Statistical Methods
Details regarding the statistical methods and definitions will be provided in the Statistical Analysis 
Plan (SAP) . The SAP will be finalized prior to database lock. All statistical analyses will be 
performed by the sponsor or CRO after the database is locked . Statistical analyses will be 
performed using Version 9.1 or higher of SAS®(SAS Institute, Cary, NC 27513).
Continuous variables will be summarized using descriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categorical variables will be summarized using frequencies and percentages.
As referred to in descriptions of summary sta tistics, treatment groups refer to the 2 possible 
treatment assignments in the antecedent study, ROPP -2008- 01, Section D (rhIGF -1/rhI GFBP -3 or 
standard neonatal care).
For analysis purposes, baseline is defined as the first assessment either in the anteced ent study 
(ROPP-2008- 01) or in this study (SHP -607-
201). As necessary , relevant data from Study 
ROPP -2008
-01 may be summarized with the data from this study (SHP -607
-201).
Date of Original Protocol :  27August 2014
Date of Amendment 1: 19 February 2016
Date of Amendment 2: 21 February 2017
Date of Amendment 3: 11May 2017
Date of Amendment 4: 09 April 2018
For non-commercial use only
Shire CONFIDENTIAL Page 6
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
TABLE OF  CONTENTS
SYNOPSI S.......................................................................................................................................2
LIST OF IN -TEXT TABLES ........................................................................................................10
LIST OF IN -TEXT FIGURES .......................................................................................................10
LIST OF APPENDICES ................................................................................................................10
LIST OF ABBREVIATION S................................
........................................................................11
1INTRODUCTION ..................................................................................................................13
2STUDY OBJECTIVES ..........................................................................................................15
2.1 Primary  Objectives ...................................................................................................15
2.2 Secondary  Objectives ...............................................................................................15
2.3 Exploratory  Objectives ................................
.............................................................15
3STUDY ENDPOINTS ............................................................................................................16
3.1 Efficacy  Endpoints ...................................................................................................16
3.1.1 Primary  Efficacy  Endpoints ...................................................................................16
3.1.2 Secondary  Efficacy  Endpoints ...............................................................................16
3.1.3 Exploratory  Efficacy  Endpoints .............................................................................16
3.2 Health Economic Outcome Research Endpoints ......................................................17
3.3 Safety  Endpoints ......................................................................................................17
4INVESTIGATIONAL PLAN .................................................................................................18
4.1 Overall Study  Design and Plan ................................................................................18
4.2 Rationale for Study  Design ......................................................................................19
4.3 Study  Duration .........................................................................................................20
5STUDY POPUL ATION SEL ECTION ..................................................................................21
5.1 Study  Population ......................................................................................................21
5.2 Inclusion Criteria................................
......................................................................21
5.3 Exclusion Criteria .....................................................................................................21
6STUDY TREATMENT ..........................................................................................................22
6.1 Description of 
Treatment .........................................................................................22
6.2 Treatments Administered .........................................................................................22
6.3 Selection and Timing of Dose for Each Subject ......................................................22
6.4 Method of Assigning Subjects to Treatment Groups ...............................................22
6.5
Masking....................................................................................................................22
6.6 Medications ..............................................................................................................22
6.7 Restrictions ...............................................................................................................22
6.7.1 Prior Therap y
................................ ................................ ................................ ......... 22
6.7.2 Other Rest rictions ................................ ................................ ................................ ..22
For non-commercial use only
Shire CONFIDENTIAL Page 7
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
6.7.3 Treatment Compliance ...........................................................................................22
6.7.4 Packaging and Labeling .........................................................................................22
6.8 Storage and Accountability ......................................................................................22
7STUDY PROCEDURES ........................................................................................................23
7.1 Informed Consent .....................................................................................................23
7.2 Study  Entrance Criteria and Eligibility ....................................................................23
7.3 Study  Enrollment ......................................................................................................23
7.4 Demographics ...........................................................................................................23
7.5
Growth Parameters:  Length (and Height), Weight, and Head Circumference .......23
7.5.1 Length and Height ..................................................................................................23
7.5.2 Body Weight ..........................................................................................................24
7.5.3 Head Circumference ..............................................................................................24
7.6 Efficacy  Assessments ...............................................................................................24
7.6.1 Visual Assessments ................................................................
................................24
7.6.1.1 Visual Acuity ..........................................................................................24
7.6.1.2 Corrective Lens Determination ..............................................................25
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility )..................25
7.6.1.4 Refraction with C ycloplegia ...................................................................26
7.6.1.5 Stereoacuit y............................................................................................26
7.6.2 Hearing Assessment History ..................................................................................26
7.6.3 Behavioral Assessments .........................................................................................26
7.6.3.1 Bayley Scales of Infant and Toddler Development, Third Edition ........26
7.6.3.2 Wechsler Preschool and Primary  Scale of Intelligence (WPPSI ) ..........27
7.6.3.3 Child Behavior Checklist (CBCL) .........................................................27
7.6.3.4
Vine land Adaptive Behavior Scales, Second Edition ............................28
7.6.3.5 Attention- Deficit/Hy peractivity  Disorder Rating Scale .........................28
7.6.3.6 Social Communication Questionnaire –Lifetime Form ........................28
7.6.4 Cerebral Pals y Assessment ....................................................................................29
7.6.5 Pulmonary  Morbidit y Assessment ................................
.........................................29
7.6.6 ................................ ................................ ..........
7.6.7 ..................................................
7.6.8 Survival Assessment ..............................................................................................29
7.6.9 Health Economic Outcome Research Assessments...............................................30
7.6.9.1 Health Related Quality  of L ife...............................................................30
7.6.10 Health Care Resource Use ................................ ................................ ..................... 30
7.6.10.1 Health Utility ................................ ................................ .......................... 30
7.7 Safety  Assessments ................................ ................................ ................................ ..31
7.7.1 Abdominal ultrasound................................ ................................ ............................ 31
For non-commercial use only
Shire CONFIDENTIAL Page 8
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
7.7.2 Echocardiogram .....................................................................................................31
7.7.3 Physical Examination .............................................................................................32
7.7.4 Blood Pressure, Heart Rate, and Respiratory  Rate ................................................33
7.8 Medication Assessment ............................................................................................33
7.9 Adverse Events Assessments ...................................................................................33
7.9.1 Definitions of Adverse Events, Serious Adverse Events, and Suspected 
Unexpected Serious Adverse Reactions ................................................................33
7.9.1.1 Adverse Event ........................................................................................33
7.9.1.2 Serious Adverse Event ...........................................................................34
7.9.1.3 Suspected Unexpected Serious Adverse Reaction .................................35
7.9.1.4 Targeted Medical Events ................................
........................................35
7.9.2 Classification of Adverse Events and Serious Adverse Events .............................35
7.9.3 Clarification between Serious and Severe .............................................................36
7.9.4 Relatedness of Adverse Events and Serious Adverse Events ................................36
7.9.5 Procedures for Recording and Reporting Adverse Events ....................................36
7.9.5.1 Adverse Event Monitoring and Period of Observation
..........................36
7.9.5.2 Reporting Serious Adverse Events .........................................................37
7.9.5.3 Regulatory  Agency , Institutional Review Board, Ethics Committee, 
and Site Reporting..................................................................................38
7.10 Removal of Subject s from the Trial
.........................................................................38
7.11 Other Study  Procedures ............................................................................................39
7.11.1 Participation in Other Clinical Studies ..................................................................39
7.12 Appropriateness of Measurements ................................
...........................................39
8STUDY ACTIVIT IES............................................................................................................40
8.1 Initial Study  Visit (40 weeks CA [term equivalent]) ...............................................40
8.2 Study  Visits ................................
..............................................................................40
8.2.1 Outcome Assessment 
Visits Conducted by  Telephone .........................................41
8.2.2 Clinical Site Visits ................................................................
.................................41
8.2.2.1 Outcome Assessment Site Visits................................ ............................ 41
8.2.2.2 Visits Dedicated to Corrective Lens Determin ation...............................45
8.3 Assessments upon Discontinuation ..........................................................................45
9QUALITY CONTROL AND ASSURANCE ........................................................................46
10STATI STICAL ANALYSES .................................................................................................47
10.1 General Methodology ................................ ................................ ............................... 47
10.2 Determination of Sample Size ................................ ................................ .................. 47
10.3 Method of Assigning Study  Subjects to Treatment Groups ................................ .....47
10.4 Population Description................................ ................................ ............................. 47
10.4.1 Analy sis Populations ................................ ................................ .............................. 47
For non-commercial use only
Shire CONFIDENTIAL Page 9
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
10.4.2 Subject Disposition ................................................................................................48
10.4.3 Protocol Violations and Deviations .......................................................................48
10.4.4 Demographics and Baseline Characteristics..........................................................48
10.5 Efficacy  Anal ysis.....................................................................................................48
10.5.1 Primary  Efficacy  Anal ysis.....................................................................................48
10.5.2 Secondary  Efficacy  Analy sis.................................................................................49
10.5.3 Subset Analy ses.....................................................................................................50
10.5.4 Exploratory  Anal yses................................
.............................................................50
10.6 Health Economics and Outcomes Research Anal yses.............................................50
10.7 Analy sisof Safety ................................................................
....................................51
10.8 Statistical/Analy tical Issues ......................................................................................51
10.8.1 Adjustment for Covariates .....................................................................................51
10.8.2 Handling of Dropouts or Missing Data ..................................................................51
10.8.3 Interim Anal yses and Data Monitoring..................................................................51
10.8.4 Multiple Comparisons/Multiplicity ................................
.......................................51
10.8.5 Sensitivity  Anal yses...............................................................................................51
11ADMINISTRATIVE CONSI DERATIONS ..........................................................................52
11.1 Investigators and Study  Administrative Structure ...................................................52
11.2
Institutional Review Board or Independent Ethics Committee Approval ................52
11.3 Ethical Conduct of the Study ...................................................................................52
11.4 Subject I nformation and Consent .............................................................................52
11.5 Subject Confidentiality .............................................................................................53
11.6 Study  Monitoring ................................
.....................................................................54
11.7 Case Report Forms and Study  Records ....................................................................54
11.7.1 Case Report Forms .................................................................................................54
11.7.2 Critical Documents ................................
................................................................54
11.8 Data Monitoring Committee ................................
....................................................55
11.9 Protocol Violations/Deviations ................................................................................55
11.10 Premature Closure of the Study ...............................................................................55
11.11 Access to Source Documentation.............................................................................56
11.12 D ata Generation and Analy sis..................................................................................56
11.13 Retention of Data .....................................................................................................56
11.14 Financial Disclosure .................................................................................................56
11.15 Publication and Disclosure Policy ............................................................................57
12LIST OF REFERENCES ................................ ................................ ................................ ........ 58
13APPENDI CES ................................ ................................ ................................ ........................ 61
For non-commercial use only
Shire CONFIDENTIAL Page 10
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
LIST OF IN -TEXT TABLES
Table 7-1 Summary  of Visual Acuity  Assessments ......................................................25
Table 7-2 Assessments for Phy sical Examinations .......................................................33
Table 7-3 Adverse Event Severit y .................................................................................36
Table 7-4 Adverse Event Relatedness ...........................................................................36
LIST OF IN -TEXT FIGURES
Figure 4-1 Overview of Study  Design, Study  SHP -
607-
201 ................................ .......... 19
LIST OF APPENDICES
Appendix 1 Study  Schedule of Events ..............................................................................62
Appendix 2 Summary  of Changes ....................................................................................66
Appendix 3 Protocol Signature Page ................................................................................68
For non-commercial use only
Shire CONFIDENTIAL Page 11
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
LIST OF ABBREVIATIONS
Abbreviation Definition
AAO American Academy of Ophthalmology
ADHD attention -deficit hyperactivity disorder
ADHD -RS Attention -Deficit/ Hypera ctivity Disorder Rating Scale
AE adverse event
ASD Autism Spectrum Disorder
BSID -III Bayley Scales of Infant and Toddler Development, Third Edition
CBCL Child Behavior Checklist (1 ½ to 5)
CFR Code of Federal Regulations
CA corrected age
CI confidence interval
CRF case report form (electronic)
CRO contract research organization
DMC data monitoring committee
eCRF electronic case report form
EOS end of study
ETDRS Early Treatment of Diabetic Retinopathy Study
ER emergency room
EU European Union
FDA Food and Drug Administration
FEV1 forced expiratory volume over 1 second
FVC forced vital capacity
GCP Good Clinical Practice
GH grow th horm one
HRQoL health -related quality of l ife
HSCS -PS Health Status Classification System -Preschool
HUI Health Utilities Index
HUI2/3 Health Utilities Index Mark 2 and Mark 3
ICH International Conference on Harmonisation
IEC independent ethics committee
IGF insulin -like growth factor
IGFBP -3 insulin -like growth factor binding protein -3
IND Investigational New Drug application
IRB institutional review board
LV left ventricle
For non-commercial use only
Shire CONFIDENTIAL Page 12
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Abbreviation Definition
MedDRA Medical Dictionary for Regulatory Activities 
MRI magnetic resonance imaging
OD right eye
OS left eye
OU both eyes
PedsQL Pediatric Quality of Life Inventory 
REB research ethics board
ROP retinopathy of prematurity
SAE serious adverse event
SAP statistical analysis plan
SAS Statistical Analysis System©
SCQ Social Communication Questionnaire
SD standard deviation
SOE schedule of events
SUSAR suspected unexpected serious adverse reaction
UK United Kingdom
US United States
VABS -II Vineland Adaptive Behavior Scales, Second Edition
VLBW very low birth weight
WHO World Health Organization
WHO -DD World Health Organization Drug Dictionary
WPPSI Wechsler Preschool and Primary Scale of Intelligence
For non-commercial use only
Shire CONFIDENTIAL Page 13
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
1 INTRODUCTION
Retinopathy  of prematurity  (ROP) is a rare disorder of the developing retinal blood vessels and 
retinal neurons of the preterm infant and is one of the leading causes of preventable blindness in 
children.1
Visual acuity  is decreased in infants with a history  of ROP.2In addition to acuity, other aspects 
of ey e health are also significantly  impacted by  ROP . Strabismus and my opia are cle arly 
increased in patients with a history  of ROP.3-6  Additionally , more than half of patients at 
6-10 years of age with a history  of Stage 1 and Stage 2 ROP were reported to have ongoing 
visual issues.7
When preterm infants are deprived of their natural intrauterine environment, they  lose important 
factors normally  found in utero, such as proteins, growth factors and cy tokines . It has been 
demonstrated that IGF -1 is one such factor . During fetal life, IGF -1 is available through placental 
absorption and in gestion from amniotic fluid.8Deprivation of such factors is likely  to cause 
inhibition or improper stimulation of important pathway s, which in the ey e may  cause abnormal 
retinal vascular development, the hallmark of ROP.
The finding in both a mouse model of ROP and preterm infants that development of ROP is 
associated with low levels of IGF -1 after premature birth, indicates a possible role for 
replacement of IGF -1 to levels found in utero as a strategy  to potentially  decrease abnormal 
retinal vascularization and abnormal retinal neural development, and ultimately , ROP . 
Mecasermin rinfabate (rhIGF -1/rhIGFBP -3) is the human recombinant form of the naturall y 
occurring protein complex of I GF-1 and insulin-like growth factor binding protein
-3 (IGFBP -3). 
rhIGF -1/rhIGFBP -3 was developed to enhance the sy stemic exposure of administered rhIGF -1 
and to improve the safety profile of rhIGF -1 therapy . rhIGF-1/rhIGFBP -3 was approved by  the 
Food and Drug Administration ( FDA )
in 2005 for the treatment of growth failure i n children 
with severe primary  IGF-1 deficiency  or with growth hormone (GH) gene deletions who have 
developed neutralizing antibodies to GH . 
The pharmacokinetics and safet y of rh IGF-1/rhIGFBP -3 have been evaluated in a Phase I study  
(ROPP -2005- 01) and pha rmacokinetics, safet y, and efficacy were evaluated in the P hase II stud y 
(ROPP -2008-01). Section D of the ROPP -2008- 01 study  was conducted to assess 
pharmacokinetics, safet y
,and efficacy  of rhIGF -1/rhIGFBP -3 for the prevention of ROP in 
premature infants (up to a c orrected age [CA] of 40 weeks [± 4 day s]). Subjects in Study  
ROPP -2008-01 were randomly  assigned to receive rhIGF -1/rhIGFBP -3 or standard neonatal 
care. The target dose of rhIGF -1/rhIGFBP -3 for Study  Section D 
was 250 μg/kg/24 hours to be 
administered via continuous infusion starting on Study  Day  0 (day  of birth) and continuing 
through postmenstrual age (gestational age + time elapsed from birth) 29 weeks + 6 day s.
For non-commercial use only
Shire CONFIDENTIAL Page 14
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Although the rh IGF-1/rhIGFBP -3 therap y in Section D of the Phase II study 
(Study ROPP-2008- 01) represented a short -term exposure (<2 months for each subject), 
rhIGF -1/rhIGFBP -3 may have long -lasting effects on visual outcomes as well as other potential 
outcomes related to complications of prematurit y such as neurodevelopment, pulmonary  
function, and growth . In addition, it is critical to understand an y long term safety effects from 
short term exposure to rhIGF -1/rhIGFBP -3. 
The long- term outcomes assessed in this study  will require utilization of different assessment 
tools than were utilized in the Phase II study , ROPP -2008- 01 Section D, given the changes in 
physical and cognitive development that will occur in the subjects as they  age during their 
participation in this study . 
Please refer to the current edition of the I nvestigator’s Brochure for further information 
concerning the safet y and clinical development of rhIGF -1/rhIGFBP -3.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 16
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
3 STUDY E NDPOINTS
3.1 Efficacy Endpoints
3.1.1 Primary Efficacy Endpoints
Visual acuity  as assessed by  an age -appropriate method
Ocular alignment and ocular motor examination in primary  gaze and in as many  of 
9positions of gaze as possible as assessed b y corneal light reflex and b y the cover test
Assessment of n ystagmus by  observation
Refraction as assessed b y retinoscop y with cycloplegia
Stereoacuit y as assessed with the Lang Stereotest
3.1.2 Secondary Efficacy Endpoints
Growth parameters including bod y weight, bod y length (or height), and head 
circumference
Cognitive development as assessed b y the following standardized, age -appropriate 
tools:
oBayley Scales of Infant and Toddler Development, Third Edition (BSID -III)
oWechsler Preschool and Primary  Scale of Intelligence (WPPSI )
Physical development as assessed by  standardized, age appropriate tools including 
physical exam ination , neurological examination for assessment of cerebral palsy , and 
hearing assessment
Child behavior as assessed by  the following:
oVineland Adaptive Behavior Scales, Second Edition (VABS -II)
oChild Behavior Checklist (CBCL ;1 ½ to 5)
oAttention- Deficit/ Hyperactivity  Disorder Rating Scale (ADHD -RS) for the 
assessment of sy mptoms of attention -deficit/ hyperactivity  disorder (ADHD)
oSocial Communication Questionnaire (SCQ) for screening of Autism Spectrum 
Disorder (ASD)
Pulmonary  morbidity  data (eg, hospitalizations, emergency  room [ER] visits, 
pulmonary  medications)
Survival as assessed b y death during the study  due to any  cause
3.1.3 Exploratory Efficacy Endpoints


For non-commercial use only
Shire CONFIDENTIAL Page 17
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
3.2 Health Economic Outcome Res earch Endpoints
Health Related Quality  of L ife (HRQoL) will be assessed by  the Pediatric Quality  of 
Life Inventory  (PedsQL™) Scales appropriate for the child’s age of development with 
the Total Scale Score and 5 domains within Phy sical Health (Phy sical Functioning and 
Physical S ymptoms) and Psy chosocial Health Scores (Emotional, Social, and 
Cognitive Functioning, respectivel y)
Health status (eg, health u tility ) will be measured by  the Health Status Classification 
System -Preschool (HSCS -PS) and the Health Ut ilities I ndex Mark 2 (HUI2) and Mark 
3 (HUI3).
Resource use associated with inpatient visits, outpatient visits, medical utilization and  
pharmacy  utilization will b e assessed
3.3 Safety Endpoints
Physical examination including tonsil examination
Adverse events (AEs), as follows :  
othose considered related to rhIGF -1/rhIGFBP -3 (as administered in Study  
ROPP -2008- 01, Section D)
othose considered related to procedures performed in this study  (SHP-607- 201)
ospecified targeted medical events regardless of causality
ofatal serious adverse events ( SAEs )regardless of causality
Cardiac size as assessed by  echocardiogram 
Kidney  and spleen size and any  other gross abnormalities as assessed by  abdominal 
ultrasound
For non-commercial use only
Shire CONFIDENTIAL Page 18
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
4 INVESTIGATIONAL PLAN
4.1 Overall Study Design and Plan
This is a Phase II, multicenter, long -term developmental outcome study  enrolling subjects who 
were randomized in Section D of Study  ROPP -2008-01 to receive either rhIGF -1/rhIGFBP -3
(treated) or standard neonatal care (control) . Enrolled subjects in this study  will be 
followed through age 5 years CA. This study  will enroll both subjects who were in the 
treated (received rh IGF-1/rhIGFBP -3) and control (received standard neonatal care) groups of 
Study  ROPP -2008- 01 (Section D) to enable assessment of rhIGF -1/rhIGFBP -3 
long-term 
efficacy  and safet y outcomes versus standard neonatal care. No investigational product will be
administered in this study . 
In this stud y, the Initial Visit will occur at 40 weeks CA (ie, term equivalent) or upon 
discontinuation from Study  ROPP -2008- 01, or may  occur any  time until 2 y ears CA +3 months. 
Subjects are no longer eligible to participate in this study  after they  turn 2 years CA +3 months.
Subjects in Study  ROPP -
2008-01 are premature infants enrolling at gestational age of 23 weeks 
+0 days to 27 weeks +6 day s.
Time points for assessments have been chosen based on standard premature infant follow -
up 
periods and represent important developmental ages for premature infant follow -up. Both 
telephone and clinical site visits are included to help maintain contact with subjects throughout 
the 5
-year duration of the study .
Subjects will be evaluated at appropriate follow- up site locations with expertise in the 
assessment of the developmental outcomes of premature infants . 
Pediatric ophthalmology  
expertise will also be required. 
See Appendix 1for the Study  Schedule of Events 
table.
The overall study  design is outlined in Figure 4-
1.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 20
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Insulin -like growth factor -1 (IGF -1) mediates its primary  actions b y binding to its specific 
receptor, the insulin- like growth factor 1 receptor (IGF -1R), which is present on many  cell ty pes 
in many  tissues . Binding to its receptor initiates intra cellular signaling including via the AKT 
signaling pathway . This pathway  is involved in stimulation of cell division, growth and 
differentiation and inhibits programmed cell death. Specificall y regarding premature infants, 
IGF-1 is an important mediator of fetal growth and has been shown to play  a role in earl y 
postnatal growth following pre -term delivery .9,10
Insulin -like growth factor -1 (IGF -1) has also been shown to play  a role in pulmonary  
development11and neural development.12,13Given the potential role for IGF-1 in the 
development of multiple sy stems, this study  has been designed to evaluate the long -term effects 
of rhIGF -1/rhIGFBP -3, both from a safety  and efficacy  perspective, on the development of the 
premature infant.
4.3 Study Duration
Duration for an individual subject’s participation in the study will vary  depending upon age at 
enrollment, but subjects will not be followed beyond age 5.5 years CA .
For non-commercial use only
Shire CONFIDENTIAL Page 21
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
5 STUDY POPULATION SEL ECTION
5.1 Study Population
Subjects randomized in Study  ROPP -2008- 01, Section D are eligible to enroll in this study ; 
completion of Study  ROPP -2008- 01 Section D is not required. Subjects in Study  ROPP -2008-01 
are premature infants (gestational age of 23 weeks +0 day s to 27 weeks +6 day s) who are 
randomized to receive either treatment with rhIGF- 1/rhIGFBP -3 or standard neonatal care. A 
total of 121subjects were randomized in Study ROPP -2008- 01 Section D.
5.2 Inclusion Criteria
Each subject must meet the following criteria to be enrolled in this study .
1.Subje ct was randomized in Study  ROPP -2008- 01, Section D
2.Subject’s parent or legally  authorized representative(s) must provide written informed 
consent prior to performing an y stud y-related activities. Study -related activities are an y 
procedures that would not have been performed during normal management of the subject.
5.3 Exclusion Criteria
Subjects who meet an y of the following criteria will be excluded from the study.
1.Any other condition or therapy  that, in the Investigator’s o pinion, may  pose a risk to the 
subject or interfere with the subject’s ability  to be compliant with this protocol or interfere 
with the interpretation of results
2.The subject or subject’s parent or legally  authorized representative(s) is unable to comply  
with the protocol as determined by  the Investigator
For non-commercial use only
Shire CONFIDENTIAL Page 22
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
6 STUDY TREATMENT
6.1 Description of Treatment
No investigational product will be administered in this study .
6.2 Treatments Administered
Not applicable.
6.3 Selection and Timing of Dose for Each Subject
Not applicable.
6.4 Method of Assigning Subjects to Treatment Groups
Not applicable.
6.5 Masking
Not applicable.
6.6 Medications
Any medications administered to the subjects will be collected from the time of informed 
consent through the 5 -year CA visit (or until the subject withdra ws or is discontinued). Any  
investigational product received b y subjects will be recorded separatel y as part of an assessment 
of subjects’ participation in other clinical studies (Section 7.11.1).
6.7 Restrictions 
6.7.1 Prior Therapy
There are no restrictions relat ed to prior therap y.
6.7.2 Other Restrictions
There are no restrictions related to fluid or food intake, or subject activity .
6.7.3 Treatment Compliance
Not applicable.
6.7.4 Packaging and Labeling
Not applicable.
6.8 Storage and Accountability
Not applicable
For non-commercial use only
Shire CONFIDENTIAL Page 23
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
7 STUDY PROCEDURES
Detailed descriptions of subject procedures and evaluations required for this protocol are 
described in this section . These evaluations will be performed during the indicated day s and 
weeks of the stud y (see Schedule of Events in Appendix 1). 
All data col lected are to be recorded on the subject’s appropriate eCRF . 
Details for stud y procedures are described in the Operations Manual for this study.
7.1 Informed Consent
Prior to conducting an y study -related procedures, written informed consent must be obtained 
from the subject’s parent(s) or legall y authorized representative(s).
The nature, scope, and possible consequences, including risks and benefits, of the study will be 
explained to the subject, the subject’s parent(s), or the subject’s legall y authorized rep resentative 
by the Investigator or designee in accordance with the guidelines described in Section 11.4. 
Documentation and filing of informed consent documents should be completed according to 
Section 11.4.
7.2 Study Entrance Criteria and Eligibility
At the I nitial Visit, each subject will be reviewed for eligibility  against the study  entrance 
criteria. Subjects who do not meet the study  entrance criteria will not be allowed to participate in 
the study . The reason(s) for the subject’s ineligibility  for the stud y will be documented. No 
exemptions will be allowed.
If the Initial Visit does not occur at or before 40 weeks CA , the subject may  still be enrolled until 
2 years CA +3 months . Subjects are no longer eligible to participate in this study  after they  turn 2 
years CA +3 months. 
7.3 Study Enrollment
Subjects will be considered enrolled in the stud y once written informed consent has been 
obtained from the subject’s parent(s) or legally  authorized representative(s).
7.4 Demographics
Subject demographic information inclu ding gender, date of birth , and race will be recorded.
7.5 Growth Parameters :  Length (and Height), Weight, and Head Circumference
7.5.1 Length and Height
Body length (supine measurement) will be collected when subjects are 24 -months CA or 
younger . For the length m easurement, the subject will be placed on his or her back so that the 
subject is ly ing straight and the shoulders and buttocks are flat against the measuring surface. 
For non-commercial use only
Shire CONFIDENTIAL Page 24
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
The subject's ey es should be looking straight up and care should be taken that the head i s in a 
neutral position (neither being flexed nor extended at the neck). Both legs should be fully  
extended and the toes should be pointing upward with feet perpendicular to the measuring 
surface.
Height (standing measure) will be collected when subjects are older than 24 -months CA. A 
stadiometer should be utilized for measurement of height . The subject should remove shoes.
For the measurement of standing height, the child is instructed to stand erect (stand up straight 
and look straight ahead) with the child’s head positioned in a horizontal plane . The moveable 
headpiece is brought onto the upper most (superior) point on the head with sufficient pressure to 
compress the hair. 
For height and length, 2 measures should take place and both will be recorded .If the 2 measures 
are discrepant b y >2 cm, the measures should be repeated. All measures should be recorded in 
metric units and measurement should be recorded to the nearest tenth centimeter (0.1 cm). 
7.5.2 Body Weight
Body weight will be collected . Calibrated scales should be utilized for body weight measures 
(type of scale will depend upon subject’s age) . Care should be taken to remove any  extraneous 
clothing prior to measures and shoes should be removed.
The measure should be recorded to the nearest 0.1 kg.
7.5.3 Head Circumference
Head circumference will be measured for all subjects. An accurate head circumference 
measure ment is obtained with a “lasso” -type, non -stretchable measuring tape such as the Lasso-o 
tape. Head circumference or occipital frontal circumfere nce is measured over the occiput and just 
above the supraorbital ridge, which is the largest circumference of the head.
7.6 Efficacy Assessments
7.6.1 Visual Assessments
After corrective lens determination has occurred (Section 7.6.1.2), all visual assessments shoul d 
be conducted with best -corrected vision, ie, with corrective lenses in place (if required); this 
applies to 24-
month and 5- year visits.
7.6.1.1 Visual Acuity
Visual acuity  is a measure of how well a subject sees at different distances . It will be assessed by  
themethods summarized in Table 7-
1; the method employ ed will be selected based on the 
subject’s age (CA) at the time of the study  visit . 
Visual acuity  measurements will be measured 
and recorded for the left (OS), right (OD) ey e, and both ey es (OU).
At ages 6 months and 12 months CA, visual acuity will be assessed with Teller acuit y cards . At 
ages 24 months and 5 years CA an attempt should be made to assess visual acuity  by the LEA 
For non-commercial use only
Shire CONFIDENTIAL Page 25
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Symbols Test and LEA Sy mbols Chart, respectively . If during this attempt, the e xaminer 
determines that it will not be possible to perform an accurate assessment with the relevant LEA 
tool, visual acuity  should be assessed with the Teller acuit y cards. 
The visual acuit y assessments should be performed by an optometrist or ophthalmolo gist trained 
in pediatrics. 
Table 7-1 Summary of Visual Acuity Assessments 
Visual Acuity 
Assessment ToolDescription Unit of Measure Applicable 
Age/Study 
Visit (CA)
Teller acuity cardsResolution acuity –
discrimination of a grating 
optotype from a background with 
the same mean luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity -tests 
recognition of 4 optotypesSnellen fraction
(eg, 20/20)24 monthsa
LEA Symbols 
(ETDRS -style) chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be made to assess visual acuity by the LEA 
Symbols Test and LEA Symbols Chart, respectively . If during this attempt, the examiner determines 
that it will not be possible to perform an accurate assessment w ith the relevant LEA tool, visual acuity 
should be assessed with the Teller acuity cards.
7.6.1.2 Corrective Lens Determination
An assessment to determine if the subject requires vision correction with corrective lenses will 
be performed. This is being performed to ensure the accuracy  of subjects’ subsequent visual 
acuity  assessments (at the 24-month and 5- year visits) . The corrective lens determination will be 
performed according to the guidelines published by the American Academy of Ophthalmology  
(AAO).14
This assessment should be performed b y an optometrist or ophthalmologist trained in pediat rics. 
7.6.1.3 Ocular Alignment and Oculomotor Examination (Motility)
Ocular alignment will be assessed in primary  gaze by  comparing the position of the corneal light 
reflection in OS and OD (corneal light reflection assessment). Presence or absence of strabismus 
will be recorded in primary  gaze and in as many  of the 9 positions of gaze as feasible with the 
cover test assessment of refixation mo vement. Extraocular muscle over -action or deficiency  will 
be recorded. The assessment will be performed according to the AAO guidelines.14
Presence or absence of ny stagmus as observed during the ocular alignment assessments will also 
be recorded.
For non-commercial use only
Shire CONFIDENTIAL Page 26
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
The assessment will be performed b y a pediatric ophthalmologist or an ophthalmologist t rained 
in the care of pediatric subjects with a history of premature birth . Degree of adherence to the 
AAO guidelines will be at the discretion of the examining phy sician in consideration of the need 
for patient cooperation. 
Ocular motility  refers to ey e movements, which are governed b y the 6 extraocular muscles in 
each ey e. It will be assessed by  examiner observation of the subject’s ability  to abduct, adduct, 
supra, and inferoduct each ey e (to assess for strabismus). Any  observed misalignment 
(strabismus classifications) will be recorded:
esotropia
exotropia
hypertropia
hypotropia
The frequency (constant or intermittent) with which any  misalignment occurs and whether the 
turning ey e is alway s the same ey e or if it alternates between OS and OD, will be re corded. 
Extraocular muscle over -action or deficiency  will be recorded.
This assessment should be performed b y an optometrist or ophthalmologist trained in pediatrics . 
7.6.1.4 Refraction with Cycloplegia
Refraction is a measure of the lens power required for a foc used image on the retina. Refraction 
with cy cloplegia will be measured and recorded in diopters for each ey e individually  (OS and 
OD).
Cycloplegia may  be induced according to site standard practice.
This assessment should be performed b y an optometrist or ophthalmologist trained in pediatrics . 
7.6.1.5 Stereoacuity
Stereoacuit y is a measure of depth perception and will be assessed using the Lang Stereotest and 
performed b y certified personnel. The presence or absence of stereopsis will be recorded.
7.6.2 Hearing Assessme nt History
Results of previously  completed hearing assessments will be recorded at the 6-month CA and 
5-year CA visit s;hearing tests are not being performed as part of this study . 
7.6.3 Behavioral Assessments
7.6.3.1 Bayley Scales of Infant and Toddler Development, Third Edition
The BSID -III will be used to assess cognitive, motor, and language skills, and is applicable to 
children aged 1 -42 months. 
For non-commercial use only
Shire CONFIDENTIAL Page 27
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
The BSID-IIIis an assessment tool designed to measure a y oung child's skills in the 3 core areas 
of development :  cognitive, language, and motor. There are 5 subscales, the cognitive subscale 
stands alone while the 2 language subscales (expressive and receptive) combine to make a total 
language score and the 2 motor subtests (fine and gross motor) form a combined moto r scale. 
The tool is engaging, with colorful props and visual stimuli that capture the attention of the child. 
The individual test items are short, limiting the amount of attention required for each item. The 
test administration is flexible in that items can be administered out of order, provided the 
assessor adheres to the specific guide lines in the examiner's manual.
The BSID -III will be administered to the subject ,with participation of the subject’s parent(s) or 
legally  authorized representative(s) ,bya trained professional. Scores to be recorded are detailed 
in the Study  Operations Manual.
7.6.3.2 Wechsler Preschool and Primary Scale of Intelligence (WPPSI)
The WPPSI is a measure of general cognitive development in children that has components of 
both verbal and nonverbal tasks .15  It is applicable to preschoolers and young children aged 
2years +6 months to 7 years +7 months, and is a direct assessment of a child’s cognitive skills.
It is composed of the following 5 scales:
Verbal
Performance
Processing Speed
Full Scale
Language
It not onl y applies to healthy children, but in the course of the scale’s standardization16special 
group validity  studies were performed, including, but not limited to, groups of children with 
developmental risk factors, autistic dis order, and intellectual disability . Scores may  be 
interpreted in the context of provided norms, which reflect inclusion of the special groups.
The WPPSI will be administered to the subject by a trained professional. Scores to be recorded 
are detailed in th e Study  Operations Manual.
7.6.3.3 Child Behavior Checklist (CBCL)
The CBCL (1 ½ to 5) is a parent -reported outcome measure used to assess behavioral, emotional, 
and social functioning of toddlers and preschool children aged 18 -60 months .17It is composed 
of 99 i tems that are rated on a L ikert scale and includes the following 7 s yndrome scales 
arranged under 2 domains (ie, Internalizing and Externalizing Problems) :18
Internalizing Problems
Emotionally  Reactive
For non-commercial use only
Shire CONFIDENTIAL Page 28
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Anxious/Depressed
Somatic Complaints
Withdrawn
Sleep Problems
Attention Problems
Aggressive Behavior
The questionnaire is widely  used and has been employ ed to assess long- term behavioral 
outcomes in children born prematurel y, aged similarly to the subjects expected in this study  
population.18-20It is associated with well -established normative data;21norms may  be selected to 
aid in interpretation of the scale scores.
The CBCL (1 ½ to 5) is a questionnaire that will be administered to the subject’s parent(s) or 
legally  authorized representative(s) by  a trained professional. Scores to be recorded are detailed 
in the Study  Operations Manual.
7.6.3.4 Vineland Adaptive Behavior Scales, Second Edition
The VABS -II Expanded Interview Form will be used to measure the personal and social skills of 
subjects seriall y over time; these scales are organized within a 3 -domain structure :  
Communication, Daily  Living, and Socialization. In addition, the VABS -II offers a Motor Skills 
Domain and an optional Maladaptive Be havior Index. The VABS -II Expanded Interview Form 
assesses what a subject actually does, rather than what he or she is able to do. 
The VAB S-II Expanded Interview Form will be administered to the s ubject’s parent(s) or legall y 
authorized representative(s) b y a trained professional . Scores to be recorded are detailed in the 
Study  Operations Manual.
7.6.3.5 Attention -Deficit/Hyperactivity Disorder Rating Scale
The ADHD -RS was developed to measure the behavior s of children with ADHD. The 
ADHD -RS consists of 18 items designed to reflect current s ymptomatology of ADHD based on 
DSM -IV criteria. Each item is scored from a range of 0 (reflecting no s ymptoms) to 3 (reflecting 
severe s ymptoms) with total scores rangin g from 0 -54. 
The18items aregrouped into2subscales :  hyperactivity -impulsivity  (even numbered items 
2-
18) and inattention (“inattentivene ss”) (odd numbered items 1 -17).
The ADHD -RS,22will be completed b y the subject’s parent(s) or legally  authorized 
representat ive(s) . Scores to be recorded are detailed in the Study  Operations Manual.
7.6.3.6 Social Communication Questionnaire – Lifetime Form
The SCQ is a brief instrument that helps evaluate communication skills and social functioning in 
children23that can be used for screening for autism or autism spectrum disorders in the general 
population .24
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 30
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
7.6.9 Health Economic Outcome Research Assessments
7.6.9.1 Health Related Quality of Life
Health-related qualit y of l ife (HRQoL) is an important outcome towards improving the health 
care o f pediatric patients as it is that part of a person’s overall qualit y of life that is determined 
primarily  by their health status and which can be influenced by  clinical interventions . It is an 
important concept, which is also used in determining the value of health care services in this 
population .26,27It is a multidimensional construct whose content is guided by the World Health 
Organization;28minimally it includes ph ysical, psy chological (including emotional and 
cognitive), and social health dimensions .
In this stud y, HRQoL will be assessed via the validated Pediatric Quality of L ife Inventory  
(PedsQL™) Scales appropriate for the child’s age of development .29-31The development of the 
PedsQL  was based on the delineations of the World Health Organization (WHO )and is a 
modular approach to assessing HRQoL in the pediatric population. Initially , the PedsQL  Generic 
Scales were developed and continue to be used in children aged 2 -18 years. More recentl y Infant 
Scales have been developed that appl y to ages 1 -24 months.30
The following scales will be used in this study :
Infant Scale for ages 1 -12 months (36 I tems)
Infant Scale for ages 13 –24 months (45 I tems)
Toddler Scale for 2 -4 years of age (21 Items)
Young Child Scale for 5 -7 years of age (23 Items)
The PedsQL will be administered to the subject’s parent and may  be conducted via telephone by 
clinical site staff . The scale(s) to be administered at each visit will be specified in the Study  
Operations Manual.
7.6.10 Health Care Resource Use
To understand the va lue of the investigational product administered in Study  ROPP -
2008-01 
(Section D), the resource use associated with inpatient visits, outpatient visits, and medical and 
pharmacy utilization in this study  will be recorded. 
This assessment may  be conducted via telephone by clinical site staff .
7.6.10.1 Health Utility
Health Status Classification Sy stem -Preschool
Health status (eg, health u tility ) will be measured by  the Health Status Classification 
System -Preschool (HSCS -PS), which is a validated instrument adapted f or use via parent proxy  
within the pediatric population age 2.5- 5 (adapted from the validated Health Utilities I ndex Mark 
2 and 3 [HUI 2/3]).32  Validity  of the HSCS -PS concepts has not been established for ages 
younger than 2.5 y ears.
For non-commercial use only
Shire CONFIDENTIAL Page 31
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
The HSCS- PS was devel oped to provide a consistent measure of health status in preschool -aged 
children who had been born prematurely .32The sy stem is applicable to children with special 
needs as may  be included in this study ; validation cohorts for the s ystem included children with 
very low birth weight (VLBW), which is congruent with this study  population.
The instrument is composed of 12 dimensions (Vision, Hearing, Speech, Mobility , Dexterity , 
Self-care, Emotion, Learn/remember, Think/problem solve, Pain, General Health, and Behavior) 
intended to provide a comprehensive assessment of a child’s health status as it pertains to 
health- related quality  of life . The individual domains of the instrument will be scored as a mean 
score, representing the overall state for each concept individually . The global score will be 
recorded as well as the scores for each of the dimensions.
The HSCS- PS is a questionnaire that will be administered to the subject’s parent(s) or legall y 
authorized representative(s) and may  be conducted via telephone by clinical site staff .
Health Utilities I ndex
The Health Utilities Index (HUI ) is a famil y of generic health profiles and preference -based 
systems used for measuring health status, reporting HRQoL, and producing utility  scores. The 
HUI2/3 each include a generic comprehensive health status classification system and a generic 
HRQoL  utility  scoring s ystem.33The HUI 2/3 will be administered to the subject’s parent(s) or 
legally  authorized representative(s) and may  be conducted in person at clinic visits or v ia 
telephone b y clinical site staff at 5 years CA as specified in the Schedule of Events.
7.7 Safety Assessments
7.7.1 Abdominal ultrasound
An abdominal ultrasound will be performed to assess the size of the spleen and kidney s. The 
spleen will be measured in the cor onal longitudinal plane and the longest longitudinal length will 
be measured for each kidney  (left and right) .35Ultrasound results will be assessed by a central 
reader.
Organ size will be interpreted in the context of reference values established for children.34,35
7.7.2 Echocardiogram
Echocardiographic examination (conventional M- mode recording of the left ventricle [L V] 
parasternal long axis view) will be performed for the evaluation of cardiac size, assessed by  
measuring the following:
interventricular se ptal thickness (during end diastole)
LV posterior wall thickness
LV intracavit y volume (both in end diastole and end systole)
Echocardiogram results will be assessed by a central reader.
For non-commercial use only
Shire CONFIDENTIAL Page 32
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
7.7.3 Physical Examination
Physical examinations will include a review of the subject’s general appearance, neurological 
examination, as well as a tonsillar examination ( Table 7-2). Adverse events will be collected as 
described in Section 7.9.1.1 .
For non-commercial use only
Shire CONFIDENTIAL Page 33
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Table 7-2 Assessments for Physical Examinations
Assessment Assessment
General appearance Endocrine
Head and neck Cardiovascular
Eyes Abdomen
Ears Genitourinary
Nose Skin
Throat Musculoskeletal
Chest and lungs Neurological
Tonsils
7.7.4 Blood Pressure , Heart Rate , and Respiratory Rate
Blood pressure ,heart rate , and respiratory will be measured at the 5- year CA visit.
7.8 Medication Assessment
All medications received by  study  subjects will be collected from the time of enrollment through 
the 5- year CA visit (or upon discontinuation) . Any i nvestigational product received by  subjects 
will be recorded separately  as part of an assessment of subjects’ participation in other clinical 
studies (Section 7.11.1).
7.9 Adverse Events Assessments
7.9.1 Defin itions of Adverse Events, Serious Adverse Events , and Su spected 
Unexpected Serious Adverse Reactions
7.9.1.1 Adverse Event
An AE is an y noxious, pathologic, or unintended change in anatomical, physiologic, or 
metabolic function as indicated b y physical signs, sy mptoms, or laboratory  changes occurring in 
any phase of a clinical study , whether or not considered investigational product-related. This 
includes an exacerbation of a pre -existing condition . 
Adverse events include:
Worsening (change in nature, severit y, or frequency) of conditions present at the onset 
of the st udy
Intercurrent illnesses
Drug interactions
Events related to or possibly  related to concomitant medications
Abnormal laboratory values (this includes significant shifts from baseline within the 
range of normal that the Investigator considers to be clinically  important)
Clinically  significant abnormalities in phy sical examination, vital signs, and weight
For non-commercial use only
Shire CONFIDENTIAL Page 34
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
In this long -term outcome study  in follow -up to Study  ROPP -2008- 01 (Section D), no 
investigational product is being administered. However, the relat ionship to the investigational 
product (rhIGF -1/rhIGFBP -3) as administered in Study  ROPP -2008- 01 (Section D) will be 
assessed . 
For the purposes of this study  only the following a dverse events will be collected:  
Those considered related to investigationa l product (rhIGF -1/rhIGFBP -3 as 
administered in Study  ROPP -2008- 01, Section D)
Those considered related to procedures performed in this study  (Study  SHP -607-201)
AEs related to ROP
AEs related to congenital malformations not identified at birth which may  impact 
neurocognitive development 
Additional illnesses present at the time when informed consent is given are to be 
regarded as AEs
Specified targeted medical events (Section 7.9.1.4 ) regardless of causality
Throughout the stud y, the Investigator must rec ord these AEs or an y AEs resulting in death in 
the eCRF , regardless of the severit y or causalit y.The Investigator should treat subjects with AEs 
appropriatel y and observe them at suitable intervals until the events stabilize or resolve . Adverse 
events may be discovered through observation or examination of the subject, questioning of the 
subject, complaint by  the subject, or by  abnormal clinical laboratory  values.
7.9.1.2 Serious Adverse Event
An SAE is any  AE that results in any  of the following outcomes:
Death
Is life -threatening
Requires hospitalization
Requires prolongation of existing hospitalization
A persistent or significant disability  or incapacity  
A congenital anomal y or birth defect
Important medical events that may  not result in death, be 
life-threatening, or require 
hospitalization may  be considered an SAE when, based upon appropriate medical judgment, they  
may jeopardize the subject and may  require medical or surgical intervention to prevent one of the 
outcomes listed in this definition .
Alife-threatening AEisdefined as an AEthatplaced thesubject, in the view of the initial 
reporter, at immediate risk of death from the AE as it occurred (ie, it does not include an AE that, 
had it occurred in a more severe form, might have caused deat h).
For non-commercial use only
Shire CONFIDENTIAL Page 35
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
For the purposes of this study  only the SAEs listed below will be collected:
Fatal SAEs regardless of causality
SAEs considered related to investigational product (rhIGF -1/rhIGFBP -3 as 
administered in Study  ROPP -2008- 01, Section D)
SAEs considered rela ted to procedures performed in this study  (Study  SHP -607-201)
SAEs related to ROP
SAEs related to congenital malformations not identified at birth which may impact 
neurocognitive development
SAEs related to additional illnesses present at the time when inf ormed consent is given
Specified targeted medical events (Section 7.9.1.4 ) regardless of causality
7.9.1.3 Suspected Unexpected Serious Adverse Reaction
Suspected unexpected serious adverse reactions (SUSAR) are suspected adverse reactions related 
to an investiga tional product (investigational products and comparators [if applicable]), which 
occur in the concerned study , and that are both serious and unexpected according to the current 
Investigator’s Brochure .
7.9.1.4 Targeted Medical Events
If it is determined that any of the following targeted medical events have been experienced b y a 
subject, they will be recorded as AEs or SAEs, as appropriate, regardless of relationship to 
investigational product ( rhIGF-1/rhIGFBP -3 as administered in Stud y ROPP-2008-
01, 
Section D):
intracranial hy pertension
any abnormalit y of glucose metabolism (eg, h ypogl ycemia, h ypergl ycemia, and 
diabetes)
tonsillar hy pertrophy  (based on tonsil exam [part of the phy sical exam])
increased kidney  size 
increased cardiac si ze
increased spleen size
7.9.2
Classification of Adverse Events and Serious Adverse Events
The severit y of AEs will be assessed b y the Investigator based on the definition indicated in 
Table 7-3. The severity of all AEs/SAEs should be recorded on the appropriat e eCRF page to a 
severit y of mild, moderate, or severe.
For non-commercial use only
Shire CONFIDENTIAL Page 36
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Table 7-3 Adverse Event Severity
Severity Definition
Mild No limitation of usual activities.
Moderate Some limitation of usual activities.
Severe Inability to carry out usual activities.
7.9.3 Clarification between Serious and Severe
The term “severe” is often used to describe the intensity  (severit y) of a specific event (as in mild, 
moderate, or severe m yocardial infarction); the event itself, however, may be of relatively  minor 
medical significance (such as severe headache) . This is not the same as “serious,” which is based 
on the outcome or action criteria usually associated with events that pose a threat to life or 
functioning. Seriousness (not sever ity) and causality  serve as a guide for defining regulatory  
reporting obligations.
7.9.4 Relatedness of Adverse Events and Serious Adverse Events
Relationship of an AE or SAE to investigational product (rhIGF- 1/rhIGFBP -3 as administered in 
Study  ROPP -2008- 01, Se ction D) is to be determined by  the Investigator based on the following 
definitions (See Table 7-4).
Table 7-4 Adverse Event Relatedness
Relationship to Product Definition
Not Related Unrelated to investigational product
Possibly Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, but which could 
also be explained by concurrent disease or other drugs or chemicals.
Probably Related A clinical event or laboratory abnormality with a reasonable time 
sequence to administration of investigational product, unlikely to be 
attributable to concurrent disease or other drugs and chemicals and 
which follows a clinically reasonable response on de- challenge . The 
association of the clinical event or laboratory abnormality must also 
have some biologic plausibility, at least on theoretical grounds.
Definitely related The event follows a reasonable temporal sequence from administratio n 
of the investigational product, follows a known or suspected response 
pattern to the investigational product, is confirmed by improvement 
upon stopping the investigational product (dechallenge), and reappears 
upon repeated exposure (rechallenge) . Note th at this is not to be 
construed as requiring re- exposure of the subject to investigational 
product; how ever, the determination of definitely related can only be 
used when recurrence of event is observed.
7.9.5 Procedures for Recording and Reporting Adverse Events
7.9.5.1 Adverse Event Monitoring and Period of Observation
Adverse events will be monitored throughout the study . 
For non-commercial use only
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 39
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
If a subject or the subject’s parent(s) or the subject’s legally  authorized representative(s) acting 
on behalf of the subject, discontinues participation in the study , or the subject is discontinued by  
the Investigator, reasonable efforts will be made to follow the subject through the end of study  
assessments . The reason for refusal will be documented on the eCRF. An y AEs experienced up 
to the point of discontinuation must be documente d on the AE eCRF . If AEs are present when 
the subject withdraws from the study , the subject will be re -evaluated within 30 day s of 
withdrawal . All ongoing SAEs at the time of withdrawal will be followed until resolution.
7.11 Other Study Procedures
7.11.1 Participatio n in Other Clinical Studies
Following enrollment, subjects in this study  will not be restricted from enrolling in another 
clinical study  that involves the use of investigational product . The status of a subject’s 
participation in such studies will be re corded (ie, yes/no) . If a subject is enrolled in such a study, 
additional parameters will be recorded, including the masking status of the study , the identity  of 
the investigational product being evaluated in the study, and the subject’s treatment assignme nt 
in the study  (if possible) . 
7.12 Appropriateness of Measurements
Overall, the primary  and secondary  efficacy  and safet y measures being employed in this study 
are considered appropriate for the follow -up of preterm infants. The validated tools being used to 
assess neurodevelopment, phy sical development, and health economic research outcomes in this 
pediatric population are widely used and recognized.
In some cases tools were designed specifically  for use in this study . These are the pulmonary  
morbidity  assess ment and the cerebral palsy  assessment . In these cases, the tools are either based 
on validated tools or the current state of knowledge in the literature . For example, the cerebral 
palsy  assessment is based on the Amiel -Tison neurological examination frame work25and the 
pulmonary  assessment is based on published research in a similar pediatric population .36,37
For non-commercial use only
Shire CONFIDENTIAL Page 40
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
8 STUDY ACTIVITIES
The timing of the visits in this study  is based on subjects’ corrected age (CA). 
8.1 Initial Study Visit (40 weeks CA [term equivalent ])
The Initial Visit will occur at 40 weeks CA (ie, term equivalent) or upon discontinuation from 
Study  ROPP -2008- 01, Section D or any  time up to the visit at 3 months CA . 
For subjects enrolled between the ages of 9 months CA and 2 y ears +3 months CA, missed 
procedures such as neurocognitive assessments, abdominal ultrasounds, and echocardiograms are 
not required.
At the I nitial Visit, informed consent will be obtained followed by  an assessment of study  
eligibility  criteria and collection of demographic data.
The following AE d ata, collected as part of Study  ROPP -2008- 01 (Section D) will be recorded :
Ongoing targeted medical events regardless of causality
Ongoing stud y drug -related AEs, including SAEs
Serious adver se events, as outlined in Section 7.9.1 .1and Section 7.9.1.2, that the subject 
experiences between the ROPP-
2008- 01 end-of- study  visit and the time of informed consent for 
Study SHP-
607-201 will be reported b y the Investigator ,pending permission for subject’s parent 
or legally  authorized repr esentative(s) ,as documented on the informed consent form.
8.2 Study Visits
Study  visits for follow -up outcome assessments will take place at the following time points in 
CA:
3 months (±2 weeks) –conducted by  telephone
6 months (±1 month) –
clinical site visit
12 months (±3 months) –clinical site visit
20 month s (-1 months) 
–clinical site visit
24 months (±3 months) –clinical site visit
30 months (±3 months) –conducted b y telephone
3 years (±3 months) – conducted by  telephone
3.5 y ears (±3 months) – conducted by  telephone
4 years (±3 month) – conducted by  telephone
4.5 y ears (±3 month) – conducted by  telephone
For non-commercial use only
Shire CONFIDENTIAL Page 41
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
4.75 y ears (- 1 months) – clinical site visit
5 years (+6 months) –clinical site visit
Multiple visits and/or phone contacts are allowed to complete all assessments, if needed. In 
addition, there will be 2 visits that must occur at least 1 month prior to the 24-month and 5- year 
CA study  visits to assess the need for corrective lenses. The ti ming of these 2 visits (20 months [ -
1 month] and 4.75 y ears [- 1 month]) was set to ensure that an y prescribed corrective lenses 
would be worn for at least 1 month prior to the visual assessments at the 24 -month and 5- year 
study  visits CA.
The activities at the study  visits are described in Sections 8.2.1 and 8.2.2.
8.2.1 Outcome Assessment Visits Conducted by Telephone
Visits at 3 months, 30 months, 3 y ears, 
3.5 y ears, 4 years, and 4.5 yearsCA will be conducted b y 
telephone . The following outcome assessments wil l be conducted at each of these 6 visits, unless 
otherwise indicated:
HRQoL (3-month, 3 -year, and 4- year visits)
HCRU (3-month, 3 -year, and 4- year visits) 
HSCS -PS (3
-year and 4 -year visits)
Pulmonary  morbidity  assessment (30 -month, 3 -year, 3.5 -year, 4-year, and 4.5 -year 
visits)
Medications (3-month, 30 months, 3-year, 3.5 y ear,4-year and 4.5 year visits)
Survival assessment (3-month, 30 month, 3- year, 3.5 y ear,4-year and 4.5 y ear visits)
Assessment of participation in other clinical studies (3-month, 30months, 
3-year, 
3.5year, 4-year and 4.5 year visits) 
Adverse events , including targeted medical events (3-month, 30 month, 3- year, 
3.5year,4-year and 4.5 year visits) 
8.2.2 Clinical Site Visits
8.2.2.1 Outcome Assessment Site Visits
The following clinical site visits (in CA) to capture follow -up outcome data will occur at the 
clinical site:
6 months (±1 month)
12 months (±3 months) 
20 months ( -1 month)
24 months (±3 months)
For non-commercial use only
Shire CONFIDENTIAL Page 42
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
4.75 y ears (- 1 months)
5 years (+6 months)
The following assessments will be performed at the 6 -month visit:
Visual acuity
Refraction with cy cloplegia
Length
Weight
Head circumference
VABS -II
Physical examination (including tonsil examination)
Hearing Assessment History  (Historical hearing test data may  be recorded at any  time 
prior to the 6- month visit) 
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical sit e visit)
Abdominal ultrasound
Echocardiogram
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at the 12 -month visit:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
Ocular alignment and motility
Length
Weight
Head circumference
BSID-III
For non-commercial use only
Shire CONFIDENTIAL Page 43
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
VABS -II
Physical examination (including tonsil examination)
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adver se events (including targeted medical events)
The following assessments will be performed at the 20 -month visit:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
Assessment of participation in other clinical studies
Thefollowing assessments will be performed at the 24- month visit:
Visual acuity
Ocular alignment and motility
Length
Weight
Head circumference
BSID-III
CBCL
VABS -II
Physical examination (including tonsil examination)
Cerebral Pals y assessment
Pulmonary  morbidity  assessment
Survival assessment
HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
For non-commercial use only
Shire CONFIDENTIAL Page 44
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
HSCS -PS (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
The following assessments will be performed at 4.75- year visit:
Visual acuity
Corrective lens determination (including refraction with cy cloplegia)
The following assessments will be performed at the 5 -year visit:
Visual acuity
Ocular alignment and motility
Stereoacuit y
Height
Weight
WPPSI
CBCL
VABS -II
ADHD -RS
SCQ
Physical examination (including tonsil examination)
Blood pressure, heart rate, and respiratory  rate
Pulmonary  morbidity  assessment
Hearing assessment history
Survival assessment


HRQoL  (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HCRU (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
HSCS -PS (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
For non-commercial use only
Shire CONFIDENTIAL Page 45
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
HUI2/3 (may  be performed by  telephone if there are time constraints during this 
clinical site visit)
Assessment of participation in other clinical studies
Medications
Adverse events (including targeted medical events)
8.2.2.2 Visits Ded icated to Corrective Lens Determination
The following clinical site visits are dedicated solely  to corrective lens determination in 
preparation for the outcome assessment visits at 24- months and 5- years CA:
20months ( -1 month) 
4.75 y ears (- 1 month) 
At these visits, the following will be performed:
Visual acuity
Corrective lens determination (includes refraction with cy cloplegia)
The 20- month visit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 month prior 
to the 24-month and 5- year visits, respectivel y. Any prescribed corrective lenses must be worn 
for at least 1 month prior to the 24 month and 5 y ear assessments.
8.3 Assessments upon Discontinuation
If a subject discontinues prior to the 5 -year CA visit, every attempt will be made to complete the 
assessments scheduled for the subject’s next visit. 
For non-commercial use only
Shire CONFIDENTIAL Page 46
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
9 QUALITY CONTROL AND ASSURANCE
Training will occur at an Investigator meeting or at the site initiation visit or both, and instruction 
manuals wil l be provided to aid consistency  in data collection and reporting across sites.
Clinical sites will be monitored by  the Sponsor or its designee to ensure the accuracy  of data 
against source documents. The required data will be captured in a validated clini cal data 
management s ystem that is compliant with the FDA 21 Code of Federal Regulations ( CFR )Part 
11 Guidance . The clinical trial database will include an audit trail to document any  evidence of 
data processing or activity  on each data field by  each user . Users will be trained and given 
restricted access, based on their role(s) in the study, through a password -protected environment.
Data entered in the s ystem will be reviewed manually  for validity  and completeness against the 
source documents by  a clinica l monitor from the Sponsor or its designee. If necessary , the study  
site will be contacted for corrections or clarifications; all missing data will be accounted for.
Serious adverse event information captured in the clinical trial database will be reconcil ed with 
the information captured in the Global Drug Safety database.
For non-commercial use only
Shire CONFIDENTIAL Page 47
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
10 STATISTICAL AN ALYSES
10.1 General Methodology
Details regarding the statistical methods and definitions will be provided in the Statistical 
Analy sis Plan (SAP) . The SAP will be finalized prior to database lock. All statistical analy ses 
will be performed b y the Biometrics department at Shire. Statistical analy ses will be performed 
using Version 9.1 or higher of SAS®(SAS Institute, Cary , NC 27513).
Continuous variables will be summarized using d escriptive statistics including the number of 
observations, mean, standard deviation (SD), median, minimum, and maximum values.
Categorical variables will be summarized using frequencies and percentages.
As referred to in descriptions of summary  statistics , treatment groups refer to the 2 possible 
treatment assignments in the antecedent study ,ROPP-2008- 01, Section D ( rhIGF-1/rhIGFBP -3
or standard neonatal care) .
For analy sis purposes, baseline is defined as the first assessment either in the antecedent study  
(ROPP -2008- 01) or in this study  (SHP -607-201). As necessary , relevant data from Study  
ROPP -2008- 01 may  be extracted and 
summarized with the data from this study  (SHP -607- 201).
For consented patients, additional biomarker analysis may  be performed on 
prior collected blood 
samples from Study  ROPP -2008-01.
10.2 Determination of Sample Size
No formal sample size calculation wasperformed for this study  because this is a follow -up study  
to Section D of Study  ROPP -
2008- 01. Any  subjects enrolled in Study  ROPP -2008- 01 are 
eligible to enroll in this study . There are up to 120 subjects who will be eligible to enroll in this 
long-term developmental outcome study .
10.3 Method of Assigning Study Subjects to Treatment Groups
Not applicable.
10.4 Population Description
10.4.1 Analysis Pop ulations
Enrolled Population - the Enrolled Population will consist of all subjects for whom written 
informed consent has been provided for this study . 
Safety  Population- the Safety  Population will consist of 
the subjects in the Enrolled Population
who have safet y follow- up data in this long -term 
outcome study .
For non-commercial use only
Shire CONFIDENTIAL Page 48
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
10.4.2 Subject Disposition
Subjects who complete the study  and subjects who prematurel y discontinue from the stud y will 
be summarized by  treatment group using descriptive statistics. I n addition, f or subjects who 
prematurel y discontinue from the study, the reasons for discontinuation will be summarized by 
treatment group.
10.4.3 Protocol Violations and Deviations
Protocol violations and deviations will be listed. Details of the criteria for deviations and
violations will be provided in the SAP.
10.4.4 Demographics and Baseline Characteristics
Descriptive summaries of demographic and baseline characteristics will be presented b y 
treatment group for the Enrolled Population . 
Demographics and baseline characteristics will be exami ned to assess the comparability  of the 
treatment group s. Continuous variables such as age (including corrected age) , weight, and 
length/height will be summarized using number of observations, mean, standard deviation, 
median, m inimum and maximum values. Categorical variables, like gender and race, will be 
summarized using number of observations and percentages.
Medical history ,including maternal and perinatal history , (as obtained from the antecedent 
study , ROPP -2008- 01) will b e summarized by  treatment group using the number of observations 
and percentages of subjects reporting each category .
10.5 Efficacy Analysis
All efficacy  analy ses will be performed using the Enrolled Population .
10.5.1 Primary Efficacy Analysis
The primary  efficacy  endpoints consist of the following:
Visual Acuity :  Visual acuity  will be categorized as the following: 
onormal (measurable acuity ≥20/40), 
obelow normal (20/200≤ measurable acuit y <20/40), 
opoor (measurable acuity ≤20/200)
oblind/low vision (onl y the abilit y to detec t the 2.2 cm wide stripes on the 
low-vision Teller acuit y card and at an y location in the visual field). 
The number and proportion of patients within each category  listed above will be 
summarized by  treatment group and visit. I n addition, a cuity results in the normal and 
below normal categories will be classified as favorable outcomes, and acuity  results in 
the poor and blind/low- vision categories will be classified as unfavorable outcomes. 
Tabular summaries b y trea tment group and visit will incl ude the frequency and the 
percentage for each visual acuity  category . 
For non-commercial use only
Shire CONFIDENTIAL Page 49
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Inaddition, shift tables offavorable outcomes from baseline (first assessment during 
this study ) to each of the subsequent assessments, including the last assessment , will 
be presented bytreatment group .
Ocular Alignment and Oculomotor Exam (Motility) :  Findings from the ocular 
motility  assessmen t will be either presence or absence of strabismus (esotropia, 
exotropia, hy pertropia, or hy potropia). Tabular summaries by treatment group and 
visit will include the frequency  and the percentage in each category . In addition, shift 
tables from baseline (first assessment during this study ) to the last assessment will be 
provided b y treatment group.
Nystagmus :  Presence or absence of ny stagmus wi ll be summarized by  treatment 
group and visit
Refraction with C ycloplegia :  Findings from the refraction wit h cycloplegia will be 
summarized by  treatment group and visit
Stereoacuit y:  Presence or absence of stereopsis will be sum marized by  treatment 
group and visit
10.5.2 Secondary Efficacy Analysis
Growth Parameters (b ody weight, body  length [and height], and head circumference) :  
A standard Z- score, utilizing WHO child growth standards, will be calculated for each 
assessment by  adjusting age -and sex -matched means and standard deviations (norm). 
The descriptive statistics of the Z -score for each of these parameters will be 
summarized at each assessment and the corresponding change from baseline. When 
appropriate, a 95% CI for the corresponding mean change with in each group and the 
difference in the mean change between the 2 treatment groups and the corresponding 
95% CI  will be presented as appropriate. If the parametric assumption for the 
distribution of the above endpoints cannot be justified, a non -parametric approach will 
be utilized to estimate the treatment difference (ie, median difference or 
Hodges -Lehmann estimator and the corresponding confidence intervals)
BSID-III and WPPSI :  The raw score, age equivalent scores, and standard scores for 
each domain wi thin each questionnaire will be summarized by  treatment group and 
visit using descriptive statistics.
ADHD -RS:  ADHD -RS total score and subscales (Hy peractivity /Impulsivity  and 
Inattentiveness) will be summarized by  treatment group and visit using descrip tive 
statistics.
SCQ :  The SCQ subscales (communication and social) will be summarized by 
treatment group and visit using descriptive statistics
VABS -II:  The raw score, age equivalent scores, and standard scores for each domain 
of the scale will be summar ized by  treatment group and visit using descriptive 
statistics.
CBCL :  The raw score and change from baseline for each domain of the scale will be 
summarized by  treatment group and visit using descriptive statistics.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 51
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
10.7 Analysis of Safety
Safety  summaries will be based on all assessments post -baseline. The safet y data will be 
assessed b y AE monitoring, change in ca rdiac size, and kidney  and spleen size over time. 
Adverse events will be summarized by  MedDRA system organ class (SOC) and preferred term 
for each treatment group and overall, the number and percentage of subjects having any  AE, 
having an AE in each SOC and having each individual AE. In addition, those events which 
resulted in death, or were otherwise classified as serious will be presented in a separate listing. In 
addition, the summary  of AEs will be presented by  severit y and relationship to trial medica tion. 
The change in cardiac sizeand size of kidney  and spleen will be assessed at the 6 -month CA visit 
via echocardiogram and abdominal ultrasound, respectively .  These data will be analy zed as a 
binary  response (ie, normal/abnormal) and summarized using frequency  count.  The number and 
proportion of patients with each category  (ie, normal/abnormal) for each of these safety  
endpoints will be summarized by  treatment group.  
Inaddition, the2-sided 95% CIfortheproportion of patients with a normal status for each of the 
endpoints will be estimated by  treatment group.
Physical examinations findings will be summarized descriptivel y. 
10.8 Statistical/Analytical Issues
10.8.1 Adjustment for Covariates
If any baseline data are imbalanced and are considered to be clinical ly relevant, between -group 
comparisons for efficacy  outcomes will be adjusted for covariates and detailed in the SAP. 
10.8.2 Handling of Dropouts or Missing Data
Handling of missing data rules will be described in the SAP.
10.8.3 Interim Analyses and Data Monitoring
Nointerim anal ysis is planned. However, a snapshot of the data will be reviewed after all data 
from all enrolled subjects in this study  (after eit her completed 2 -year follow -up [24 -month visit]
assessments or have premat urely withdrawn from the study  [before completing 2 years of follow 
up]) has been entered into the database, queried, and discrepancies resolved. A selective 
descriptive analy sis of the data for this interim review may  be performed and used to understand 
the progress of the study , comple tion of the data, safet y monitoring, regulatory communication, 
or general planning purposes.
10.8.4 Multiple Comparisons/Multiplicity
Not applicable.
10.8.5 Sensitivity Analyses
Sensitivity  analy ses for the efficacy  outcomes will be detailed in the SAP, as necessary .
For non-commercial use only
Shire CONFIDENTIAL Page 52
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
11 ADMINISTRATIVE CONSIDERATIONS
11.1 Investigators and Study Administrative Structure
Before initiation of the study , the Investigators must provide the Sponsor with a completed Form 
FDA 1572 and Investigator Agreement . Curriculum vitae must be provided for the I nvestigators 
and subinvestigators listed on Form FDA 1572 or Investigator Agreement . 
The Investigator should ensure that all persons assisting with the study  are adequatel y informed 
about the protocol, an y amendments to the protocol, and their study relat ed duties and functions. 
The Investigator must maintain a list of sub -investigators and other appropriately  qualified 
persons to whom he or she has delegated significant study  related duties.
11.2 Institutional Review Board or Independent Ethics Committee Approval
Before initiation of the study , the Investigator must provide the Sponsor with a copy  of the 
written I RB/IEC/REB approval of the protocol and the informed consent form . This approval 
must refer to the informed consent form and to the study  title, study number, and version and 
date of issue of the stud y protocol, as given by the Sponsor on the cover page of the protocol.
Status reports must be submitted to the I RB/IEC/REB at least once per year. The IRB/IEC/REB 
must be notified of completion of the study . Within 3 months of study  completion or termination, 
a final report must be provided to the I RB/IEC /REB . A cop y of these reports will be sent to the 
study  clinical monitor . 
The Investigators must maintain an accurate and complete record of all 
submissions made to the IRB/IEC, including a list of all reports and documents submitted . AEs 
which are reported to the US (FDA or other Regulatory  agencies (Safet y Reports) must be 
submitted promptly  to the I RB/IEC/REB.
11.3 Ethical Conduct of the Study
The procedures se t out in this study  protocol, pertaining to the conduct, evaluation, and 
documentation of this study , are designed to ensure that the Sponsor and Investigators abide by  
good clinical practice (GCP) as described in the 21 CFR Parts 50, 56, and 312 and the 
International Conference on Harmonization (I CH) GCP Guidelines Compliance with these 
regulations and guidelines also constitutes compliance with the ethical principles described in the 
Declaration of Helsinki.
11.4 Subject Information and Consent
Before enrollin g in the clinical study , the subject or the subject’s parent(s) or legally  
authorized representative(s) must consent to participate after the nature, scope, and 
possible consequences of the clinical study  have been explained in a form understandable to 
himor her.
An informed consent form (assent form if applicable) that includes information about the study  
will be prepared and given to the subject or the subject’s parent(s) or legally authorized 
representative(s) . This document will contain all FDA and ICH -required elements
. 
For non-commercial use only
Shire CONFIDENTIAL Page 53
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Theinformed consent (or assent) form must be in a language understandable to the subject or the 
subject’s parent(s) or legally  authorized representative(s) and must specify who informed the 
subject, the subject’s parent(s), or the subject’s legall y authorized representative(s).
After reading the informed consent document, the subject or the subject’s parent(s) or legall y 
authorized representative(s) must give consent in writing. Consent must be confirmed at the time 
of consent b y the personally  dated signature of the subject, the subject’s parent(s) or the subject’s 
legally  authorized representative(s) and by  the personally  dated signature of the person 
conducting the informed consent discussions.
If the subject or the subject’s parent (s) or legally  authorized representative(s) is unable to read, 
oral presentation and explanation of the written informed consent form and information to be 
supplied must take place in the presence of an impartial witness . Consent must be confirmed at 
the time of consent orall y and by the personally dated signature of the subject or by a local 
legally  recognized alternative (eg, the subject’s thumbprint or mark) or by  the personall y dated 
signature of the subject’s parent(s) or the subject’s legally  authoriz ed representative . The witness 
and the person conducting the informed consent discussions must also sign and personall y date 
the informed consent document . It should also be recorded and dated in the source document that 
consent was given.
A cop y of the signed and dated consent document(s) must be given to the subject or the subject’s 
parent(s) or legal representative(s). The original signed and dated consent document will be 
retained b y the Investigator.
The Investigator will not undertake any  measures specificall y required solely for the clinical 
study  until valid consent has been obtained.
A model of the informed consent form to be used in this study  will be provided to the sites 
separately  from this protocol.
11.5 Subject Confidentiality
Subject names will not be supplied to the Sponsor . Only  the subject number - will be recorded in 
the eCRF, and if the subject name appears on an y other document, it must be obliterated before a 
copy  of the document is supplied to the Sponsor . Study  findings stored on a compu ter will be 
stored in accordance with local data protection laws . The subjects will be told that 
representatives of the Sponsor, a designated CRO, the I RB/IEC/REB, or regulatory  authorities 
may inspect their medical records to verify  the information collec ted, and that all personal 
information made available for inspection will be handled in strictest confidence and in 
accordance with local data protection laws . The Investigator will maintain a personal subject 
identification list (subject numbers with the 
corresponding subject names) to enable records to be 
identified.
For non-commercial use only
Shire CONFIDENTIAL Page 54
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
11.6 Study Monitoring
Monitoring procedures that comply  with current Good Clinical Practice (GCP) guidelines will be 
followed. Review of the eCRFs for completeness and clarit y, cross -checking with source 
documents, and clarification of administrative matters will be performed.
The study  will be monitored by  the Sponsor or its designee . Monitoring will be performed by  a 
representative of the Sponsor (Clinical Study  Monitor) who will review the eCRFs and source 
documents . The site monitor will ensure that the investigation is conducted according to protocol 
design and regulatory  requirements by  frequent site visits and communications (letter, telephone, 
and facsimile).
11.7 Case Report Forms and Study Reco rds
11.7.1 Case Report Forms
Electronic case report forms (eCRFs) are provided for each subject . All forms must be filled out 
by authorized study  personnel. All corrections to the original eCRF entry  must indicate the 
reason for change . The Investigator is requir ed to sign the eCRF after all data have been captured 
for each subject . If corrections are made after review and signature b y the Investigator, he or she 
must be made aware of the changes, and his or her awareness documented by  resigning the 
eCRF.
11.7.2 Critical Documents
Before the Sponsor initiates the trial (ie, obtains informed consent from the first subject), it is the 
responsibility  of the Investigator to ensure that the following documents are available to Sponsor 
or their designee:
Completed FDA Form 1572 (Statement of Investigator), signed, dated, and accurate
Curricula vitae of Investigator and subinvestigator(s) (current, dated and signed within 
12months of study  initiation)
Copy  of Investigator and subinvestigator(s) current medical license (indicatin g license 
number and expiration date)
Signed and dated agreement of the final protocol
Signed and dated agreement of an y amendment(s), if applicable
Approval/favorable opinion from the IRB/IEC/REB clearl y identifying the documents 
reviewed b y name, number and date of approval or re approval :  protocol, any  
amendments, Subject Information/I nformed Consent Form, and any  other written 
information to be provided regarding subject recruitment procedures
Copy  of IRB/IEC/REB approved Subject Information/I nformed Consent Form/any  
other written information/advertisement (with IRB approval stamp and date of 
approval)
Current list of I RB/IEC/REB Committee members/constitution (dated within 
12months prior to study  initiation)
For non-commercial use only
Shire CONFIDENTIAL Page 55
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Financial Disclosure Form signed b y Investigator and sub- investigator(s)
Current laboratory  reference ranges (if applicable)
Certification/QA scheme/other documentation (if applicable)
Regulatory  approval and notification as required must also be available; these are the 
responsibility  of S hire.
11.8 Data Monitoring Committee
Given that an y long -term safet y signal observed in this study  could impact the safet y profile of 
rhIGF -1/rhIGFBP -3 as administered in premature neonates being enrolled in the antecedent 
study  (ROPP -2008- 01, Section D), the Data Monitoring Committee (DMC) for Study  
ROPP -2008- 01 will review safet y data from this long -term outcome study .
11.9 Protocol Violations/Deviations
The Investigator will conduct the study  in compliance with the protocol. The protocol will not be 
initiate d until the I RB/IEC/REB and the appropriate regulatory  authorities, where applicable, 
have given approval/favorable opinion . Modifications to the protocol will not be made without 
agreement of the Sponsor . Changes to the protocol will require written IRB/I EC/REB 
approval/favorable opinion prior to implementation, except when the modification is needed to 
eliminate an immediate hazard(s) to subjects . The IRB/IEC/REB may  provide, if applicable 
regulatory  authorities permit, expedited review and approval/favor
able opinion for minor 
change(s) in ongoing studies that have the approval/favorable opinion of the I RB/IEC/REB . The 
Sponsor will submit all protocol modifications to the regulatory  authorities, where applicable, in 
accordance with the governing regulation s.
A record of subjects screened, but not entered into the study , is also to be maintained . No 
protocol exemption will be granted for this study .
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to 
subjects, the Investigator will contact the Sponsor or its designee, if circumstances permit, to 
discuss the planned course of action . Any departures from the protocol must be fully documented 
as a protocol deviation. 
Protocol deviations will need to be reviewed b y the me dical monitor and 
may also be required to be submitted to the I RB/IEC/REB.
Protocol modifications will only  be initiated by  the Sponsor and must be approved by  the 
IRB/IEC/REB and submitted to the FDA or other applicable international regulatory  authorit y 
before initiation, if applicable.
11.10 Premature Closure of the Study
If the Sponsor, Investigator, or regulatory  authorities discover conditions arising during the stud y 
which indicate that the clinical investigation should be halted due to an unacceptable sub ject risk, 
the study  may  be terminated after appropriate consultation between the Sponsor and the 
Investigator(s) . In addition, a decision on the part of the Sponsor to suspend or discontinue 
For non-commercial use only
Shire CONFIDENTIAL Page 56
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
development of the investigational product may  be made at any  time. Conditions that may  
warrant termination of the study or site include, but are not limited to:
The discovery  of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the study
Failure of the Investigator to comply  with pertinent g lobal regulations
Submission of knowingly  false information from the study  site to the Sponsor or other 
pertinent regulatory  authorities
Insufficient adherence b y the I nvestigator to protocol requirements
11.11 Access to Source Documentation
Regulatory  authorit ies, the I RB/IEC/REB, or the Sponsor may  request access to all source 
documents, eCRFs, and other study  documentation for onsite audit or inspection. Direct access to 
these documents must be guaranteed b y the Investigator, who must provide support at all t imes 
for these activities. Monitoring and auditing procedures that compl y with current GCP guidelines 
will be followed . On-site review of the eCRFs for completeness and clarit y, crosschecking with 
source documents, and clarification of administrative matte rs may  be performed.
11.12 Data Generation and Analysis
The clinical database will be developed and maintained b y a contract research organization or an 
electronic data capture technology  provider as designated by  the Sponsor . The Sponsor or its 
designee will be responsible for performing study  data management activities. 
Adverse events will be coded using Medical Dictionary  for Regulatory  Activities (MedDRA) . 
Concomitant medication will be coded using WHO- Drug Dictionary  (WHO -DD). Central reads 
will be employ ed as described in the study  manual to aid in consistent measurement of 
abdominal ultrasound and echocardiogram parameters . 
11.13 Retention of Data
Essential documents should be retained until at least 2 y ears after the last approval of a 
marketing application and until there are no pending or contemplated marketing applications or 
at least 2 y ears have elapsed since the formal discontinuation of clinical development of the 
investigational product. 
The Sponsor will notify  the Inv estigator if these documents must be 
retained for a longer period of time . It is the responsibility  of the Sponsor to inform the 
Investigator or institution as to when these documents no longer need to be retained.
11.14 Financial Disclosure
The Investigator sho uld disclose any  financial interests in the Sponsor as described in 21 CFR 
Part 54 prior to beginning this study . The appropriate form will be provided to the I nvestigator 
by the Sponsor, which will be signed and dated b y the Investigator, prior to the sta rt of the stud y. 
For non-commercial use only
Shire CONFIDENTIAL Page 57
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
11.15 Publication and Disclosure Policy
All information concerning the stud y material, such as patent applications, manufacturing 
processes, basic scientific data, and formulation information supplied by  the Sponsor and not 
previously  published are considered confidential and will remain the sole propert y of the 
Sponsor . The Investigator agrees to use this information only  in accomplishing this study  and 
will not use it for other purposes.
It is understood by  the Investigator that the informatio n developed in the clinical study  may  be 
disclosed as required to the authorized regulatory  authorities and governmental agencies . In 
order to allow for the use of the information derived from the clinical studies, it is understood 
that there is an obligation to provide the Sponsor with complete test results and all data 
developed in the stud y in a timely manner.
The Investigator and an y other study  personnel associated with this study  will not publish the 
results of the study , in whole or in part, at an y time, unless they  have consulted with the Sponsor, 
provided the Sponsor a copy  of the draft document intended for publication, and obtained the 
Sponsor’s written consent for such publication . All information obtained during the conduct of 
this study  will be regarded as confidential. 
For non-commercial use only
Shire CONFIDENTIAL Page 58
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
12 LIST OF REFERENCES
1.Maida JM, Mathers K, Alley  CL. Pediatric ophthalmology  in the developing world. Current 
opinion in ophthalmology  2008;19:403 -8.
2.O'Connor AR, Stephenson TJ, Johnson A, et al. Visual function in low birthweight children. 
The British journal of ophthalmology 2004;88:1149-53.
3.Keith CG, Kitchen WH. Ocular morbidit y in infants of very low birth weight. The British 
journal of ophthalmology 1983;67:302 -5.
4.Laws D, Shaw DE, Robinson J, Jones HS, Ng YK, Fielder AR. Retinopathy of prematurit y:  
a prospective stud y. Review at six months. Ey e 1992;6:477 -83.
5.O'Connor AR, Stephenson T, Johnson A, et al. L ong-term ophthalmic outcome of low birth 
weight children with and without retinopathy  of prematurity . Pedi atr 2002;109:12 -8.
6.Schaffer DB, Quinn GE, Johnson L . Sequelae of arrested mild retinopathy  of prematurit y. 
Archives of ophthalmology  1984;102:373-6.
7. Cats BP, Tan KE. Prematures with and without regressed retinopathy  of prematurity :  
comparison of long -term (6-10 years) ophthalmological morbidity . Journal of pediatric 
ophthalmology  and strabismus 1989;26:271 -5.
8.Chard T. Insulin
-like growth factors and their binding proteins in normal and abnormal 
human fetal growth. Growth Regul 1994;4:91- 100.
9.Hansen -Pupp I, Lofqvist C, Polberger S, et al. Influence of insulin-like growth factor I and 
nutrition during phases of postnatal growth in very preterm infants. Pediatr Res 2011;69:448 -
53.
10.Ohkawa N, Shoji H, Kitamura T, et al. IGF -I, leptin and active ghrelin levels in very low 
birth weight infants during the first 8 weeks of life. Acta Paediatr 2010;99:37 -41.
11.Lofqvist C, Hellgren G, Niklasson A, Engstrom E, L ey D, Hansen- Pupp I. Low postnatal 
serum IGF -I levels are associated with bronchopulmonary  dysplasia (BPD). Acta Paediatr 
2012;101:1211-6.
12.Ishii DN, Glazner GW, Whalen L R. Regulation of peripheral nerve regeneration by  insulin -
like growth factors. Annals of the New York Academy  of Sciences 1993;692:172-82.
13. Lewis ME, Neff NT, Contreras PC, et al. Insulin- like growth factor -I:  potential for treatment 
of motor neuronal disorders. Experimental neurology  1993;124:73-88.
14.Pediatric Ophthalmology/Strabismus Preferred Practice Pattern Development Process and 
Participants. Pediatric Eye Evaluations :  American Academ y of Ophth almology Pediatric 
Ophthalmology /Strabismus Preferred Practice Pattern Panel; 2012.
15.Wechsler D. Wechsler preschool and primary  scale of intelligence 4th ed. Bloomington, MN :  
Pearson; 2012.
16.Wechsler D. Technical and I nterpretive Manual Supplement :  Special Group Validity  Studies 
With Other Measures 2012.
For non-commercial use only
Shire CONFIDENTIAL Page 59
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
17.Achenbach T, Rescorla L. Manual for the ASEBA preschool forms and profiles. Burlington, 
VT:  University of Vermont; 2000.
18.Vinall J, Miller SP, Sy nnes AR, Grunau RE. Parent behaviors moderate the relationship
between neonatal pain and internalizing behaviors at 18 months corrected age in children 
born very  prematurel y. Pain 2013;154:1831 -9.
19.Scott MN, Tay lor HG, Fristad MA, et al. Behavior disorders in extremely  preterm/extremel y 
low birth weight children in ki ndergarten. J Dev Behav Pediatr 2012;33:202 -13.
20. Wu YC, Leng CH, Hsieh WS, et al. A randomized controlled trial of clinic- based and home -
based interventions in comparison with usual care for preterm infants :  Effects and mediators. 
Res Dev Disabil 2014;35:2384-93.
21. Ebesutani C, Bernstein A, Nakamura BJ, Chorpita BF, Higa- McMillan CK, Weisz JR. 
Concurrent Validity  of the Child Behavior Checklist DSM -Oriented Scales :  Correspondence 
with DSM Diagnoses and Comparison to Sy ndrome Scales. Journal of psychopatholog y and 
behavioral assessment 2010;32:373-84.
22.DuPaul G, Power T, Anastopoulos A, Reed R. The ADHD rating scale IV:  checklists, norms 
and clinical interpretation. New York :  Guilford Press; 1998.
23.Rutter M, Bailey  A, Lord C. Manual for the Social Communication Questionnaire2003.
24.
Chandler S, Charman T, Baird G, et al. Validation of the social communication questionnaire 
in a population cohort of children with autism spectrum disorders. Journal of the American 
Academ y of Child and Adolescent Psychiatry 2007;46:1 324-32.
25.Gosselin J, Amiel -Tison C. Neurological Assessment from Birth to 6 Years. 2nd ed. 
Montreal :  CHU Sainte -Justine; 2011.
26.Matza L S, Swensen AR, Flood EM, Secnik K, Leidy  NK. Assessment of health -related 
quality  of life in children :  a review of concep tual, methodological, and regulatory  issues. 
Value Health 2004;7:79-92.
27.Varni JW, Burwinkle TM, L ane MM. Health- related quality  of life measurement in pediatric 
clinical practice :  an appraisal and precept for future research and application. Health Qual 
Life Outcomes 2005;3:34.
28.Constitution of the World Health Organization:  basic document. Geneva, Switzerland :  
World Health Organization; 1948.
29.Varni JW, L imbers CA. The pediatric quality  of life inventory :  measuring pediatric health -
related qualit y of life from the perspective of children and their parents. Pediatr Clin North 
Am 2009;56:843-
63.
30.Varni JW, L imbers CA, Neighbors K, et al. The PedsQL Infant Scales :  feasibility , internal 
consistency  reliability , and validity  in health y and ill infants. Qual ity of life research :  an 
international journal of quality  of life aspects of treatment, care and rehabilitation 
2011;20:45-55.
31.Varni JW, Seid M, Kurtin PS. PedsQL  4.0:  reliability  and validity  of the Pediatric Qualit y of 
Life Inventory  version 4.0 gener ic core scales in healthy  and patient populations. Medical 
care 2001;39:800-12.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 61
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
13 APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 62
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Appendix 1 Study Schedule of Events
ProceduresInitial Study 
Visite Months (CA)kYears (CA)k
40 weeks
(CA)/term  
equivalent3f
± 2 
wks6 
± 1mth12
± 3 
mths20 
-1 mthg24
± 3mth30f
± 3mth3f
± 
3mths3.5f
± 
3mth4f
± 3mths4.5f
± 3mth4.75
-1 mthg5
+ 6 
mths
Informed Consent •
Eligibility Criteria •
Dem ographics •
Visual acuitya• • • • • •
Corrective lens determinationh• •g•g
Ocular alignment and motility • • •
Refraction with cycloplegiah•
Stereoacuity •
Length • • •
Height •
Weight • • • •
Head Circumference • • •
BSID -III • •
WPPSI •
CBCL • •
VABS -II • • • •
ADHD -RS •
SCQ •
Physical Examination including 
tonsil examination • • • •
Blood Pressure , Heart Rate , and 
Respiratory Rate•
Cerebral Palsy Assessment •
Hearing Assessment Historyb• •
Pulmonary Morbidity Assessment 
1• •
Pulmonary Morbidity Assessment 
2  (clinical site visit)• •
Pulmonary Morbidity Assessment 
(phone interview)• • • • •
For non-commercial use only
Shire CONFIDENTIAL Page 63
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
ProceduresInitial Study 
Visite Months (CA)kYears (CA)k
40 weeks
(CA)/term  
equivalent3f
± 2 
wks6 
± 1mth12
± 3 
mths20 
-1 mthg24
± 3mth30f
± 3mth3f
± 
3mths3.5f
± 
3mth4f
± 3mths4.5f
± 3mth4.75
-1 mthg5
+ 6 
mths
Survival assessment • • • • • • • • • •
HRQoLc• •i•i•i• • •i
HCRU • •i•i•i• • •i
HSCS -PS •i• • •i
HUI2/3 •
Abdominal Ultrasound •
Echocardiogram •
Assessment of Participation in 
Other Clinical 
Studies• • • • • • • • • •
Medications • • • • • • • • • •
Adverse eventsd
•j• • • • • • • • • •
Abbreviations:  ADHD -RS=Attention -Deficit/Hyperactivity Disorder Rating Scale; BSID- III=Bayley Scales of Infant and Toddler Development -Third 
Edition, CBCL =Child Behavior Checklist; CA =corrected age; HCRU = health care resource use; HRQoL = health -related quality of life; HSCS -PS = Health 
Status Classification Sys tem; HUI2/HUI3=Health Utilities Index Mark 2 and Mark 3; mth(s) =months; PedsQL =Pediatric Quality of Life Inventory; 
SCQ =Social Communication Questionnaire; VABS -II=Vineland Adaptive Behavior Scales, Second Edition; wks =weeks; WPPSI =Wechsler Preschool and 
Primary Scale of Intelligence
aThe tools used to assess visual acuity will change as the subject ages during their participation in the study. The tools tha t will be used in this study and are 
summarized by applicable study visit in Table A1 .
bHistorical hearing test data may be recorded at any time during the study prior to the 6 -month visit.
cHRQoL will be assessed via the validated PedsQL™ scales appropriate for the child’s age of development as specified in the St udy Operations Manual .
dAdverse event collection will include an assessment of the specified targeted medical events .
eThe Initial Visit may be performed prior to 40 weeks CA for any subject who discontinued from Study ROPP -2008- 01 and, for all subjects, any time after 
40 w eeks CA. If the Initial Visit does not occur at or before 40 w eeks CA, the subject may still be enrolled until 2 years CA +3 m onths. Subjects are no 
longer eligible to participate in this study after they turn 2 years CA +3 months.
fVisits a t 3 m onths, 30 m onths, 3 years, 3.5 y ears, 4 years, and 4 .5years CA will be conducted by telephone.
gThe 20 -month visit and the 4.75 -year (4 years, 9 months) visit must occur at least 1 month prior to the 24 -month and 5 -year visits, respectively. Any 
prescribed corrective lenses must be w orn for at least 1 month prior to the 24 -month and 5 -year assessments.
For non-commercial use only
Shire CONFIDENTIAL Page 64
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
ProceduresInitial Study 
Visite Months (CA)kYears (CA)k
40 weeks
(CA)/term  
equivalent3f
± 2 
wks6 
± 1mth12
± 3 
mths20 
-1 mthg24
± 3mth30f
± 3mth3f
± 
3mths3.5f
± 
3mth4f
± 3mths4.5f
± 3mth4.75
-1 mthg5
+ 6 
mths
hRefraction with cycloplegia will be performed as part of the corrective lens determination procedure.
iThe HRQoL, HCRU, and HSCS -PS assessments for the 6 -month, 12 -month, 24 -month and 5 -year vi sits may be performed through clinical site staff if 
there are time constraints during the on -site visit. At the 3 -month, 3 -year, and 4 -year visits, these assessme nts will be performed through clinical site staff 
andmay be performed at any time within the visit window .
jThe follow ing, collected as part of the ROPP -2008- 01 study, w ill be used as part of this study (SHP -607-201):  any ongoing targeted medical events 
regardless of causality and any ongoing study drug -related AEs, including SAEs.
kMultiple visits and/or phone contacts are allowed to complete all assessments, if needed.
For non-commercial use only
Shire CONFIDENTIAL Page 65
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Table A1 Summary of Visual Acuity Assessments 
Visual Acuity 
Assessment ToolDescription Unit of Measure Applicable 
Age/Study 
Visit (CA)
Teller acuity cardsResolution acuity –
discrimination of a grating 
optotype from a background with 
the same mean luminancecycles per degree6 months
12 months
LEA Symbols Test Recognition acuity -tests 
recognition of 4 optotypesSnellen fraction
(eg, 20/20)24 monthsa
LEA Symbols 
(ETDRS -style) chartDistance visual acuity testSnellen fraction
(eg, 20/20)5 yearsa
Abbreviations :  CA=corrected age; ETDRS =Early Treatment of Diabetic Retinopathy Study
aAt ages 24 months and 5 years CA an attempt should be made to assess visual acuity by the LEA 
Symbols Test and LEA Symbols Chart, respectively . If during this attempt, the examiner determines 
that it will not be possible to perform an accurate assessment with the relevant LEA tool, visual acuity 
should be assessed with the Teller acuity cards.
For non-commercial use only
For non-commercial use only
Shire CONFIDENTIAL Page 67
SHP -607-201 Protocol Am endment 4
Mecaserm in rinfabate (rhIGF -1/rhIGFBP -3) 09 Apr 2018
Description ofChange Section(s) Affected by
Clarified that multiple visits and/or phone contacts are allowed 
to complete all assessments, if needed.Section 8.2
Appendix 1
A description of the Health Status Classification 
System -Preschool (HSCS -PS) statistical analy sis was added.Section 10.6
Removed language stating that a full 2- year clinical study report 
based on the data at the interim anal ysis will be completed.Section 10.8.3
Administrative errors were corrected throughout the protocol. All sections
For non-commercial use only
For non-commercial use only